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Thesis Summary 
 
Prostate cancer is a frequently diagnosed malignancy which ranges from an indolent 
asymptomatic tumour to an aggressive, rapidly lethal systemic disease. Determination 
of chromosomal, genetic and epigenetic alterations associated with prostate 
carcinogenesis have led to the characterisation of functional consequences of these 
alterations, thereby elucidating pathways contributing to malignant growth that can be 
utilised clinically and therapeutically.  
 
FLJ22318 is a novel hypothetical protein that was identified by yeast two-hybrid 
analysis to interact with the prostatic homeodomain protein, NKX3-1. Expression of 
NKX3-1 is largely restricted to epithelial cells of the adult prostate where it is involved 
in maintaining the prostatic phenotype, while NKX3-1 expression is reduced or absent 
in prostate tumours.  In contrast, FLJ22318 expression is documented in cDNA libraries 
derived from a variety of human adult and foetal tissues including the prostate, 
suggesting that it may be ubiquitously expressed and that it potentially interacts with a 
number of proteins in addition to NKX3-1. FLJ22318 expression is undocumented in 
human prostate tumours. 
 
Bioinformatic analyses have postulated multiple FLJ22318 mRNA transcripts however 
the proposed open reading frames encoded by these transcripts predict the FLJ22318 
protein to contain three strong protein-protein interaction domains, a Lissencephaly 
type-1-like homology (LisH), a C-terminal to LisH (CTLH) and a CT11-RanBPM 
(CRA) domain. Of the 44 single nucleotide polymorphisms identified within the 
FLJ22318 gene, none are located within the protein coding region suggesting that 
FLJ22318 may be critical for cell survival and/or function. Comparison of the amino 
acid sequence between human FLJ22318 and its orthologues in a diverse range of 
mammalian species identified >97% sequence homology, providing further strong 
evidence of the critical cellular function of FLJ22318. 
 
To characterise the biological activity of FLJ22318 in prostate cancer cells, the 
FLJ22318 coding region was amplified by polymerase chain reaction (PCR) and ligated 
into mammalian and bacterial expression vectors to encode V5-, myc-, GFP-, HA-, and  
  iii
GST-FLJ22318 fusion proteins. Interaction between FLJ22318 and NKX3-1 was 
confirmed using (reverse) yeast two-hybrid, GST pull-down and co-
immunoprecipitation assays. These data were supported by confocal microscopy which 
demonstrated the perinuclear and nuclear co-localisation of FLJ22318 and NKX3-1 in 
prostate cancer cells. Northern blotting identified expression of ~2Kb and ~4Kb 
FLJ22318 mRNA￿s in prostate cancer cell lines, which was consistent with 
bioinformatic analyses of mRNA species. Transfection of prostate cancer cells to 
overexpress FLJ22318 did not alter endogenous NKX3-1 levels, however FLJ22318 
exhibited transcriptional repressor function on an NKX3-1 responsive element and 
increased NKX3-1 transcriptional repressor activity on this element. 
 
To further investigate FLJ22318 function, additional yeast two-hybrid analyses were 
performed in prostate cancer cells to identify potential FLJ22318 binding proteins. 
These studies isolated cDNA￿s encoding 33 different proteins involved in cell 
metabolism and apoptosis as well as transcriptional regulators associated with control of 
cellular proliferation. One of the candidate FLJ22318 interactors, protein kinase, 
interferon-inducible double stranded RNA dependent activator (PRKRA/PACT) was 
shown using confocal microscopy to extensively co-localise with FLJ22318 in the 
cytoplasm and perinuclear regions of prostate cancer cells. Preliminary co-
immunoprecipitation and GST pull-down assays have provided additional evidence of 
the interaction of PRKRA and FLJ22318. 
 
Results of this thesis have generated important information characterising the structure 
of the FLJ22318 gene and protein, the interaction between FLJ22318 and NKX3-1 and 
the potential functions of FLJ22318 in prostate cancer cells. As the FLJ22318 gene is 
located on 5q35, a chromosomal region frequently disrupted in a variety of tumours, 
future studies of the biological activity of FLJ22318 will clarify its normal cellular 
functions and its contribution to tumorigenesis or malignant progression in the prostate 
and in other tissues.  
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Chapter One ￿ Introduction  
 
1.1  The Prostate Gland 
1.1.1  Anatomical Location and Development 
The prostate is a small walnut-shaped gland that surrounds the urethra at the base of the 
bladder and functions by contributing secretory proteins to the seminal fluid (Figure 1.1; 
Abate-Shen and Shen, 2000). The prostate gland is comprised of epithelium composed 
of two layers, a secretory luminal layer that consists of tall columnar cells which 
produce the secretory proteins that make up part of the seminal fluid, and a basal layer 
composed of cuboidal epithelial cells (McNeal, 1988). The basal layer is thought to 
contain the proliferative cell populations of the prostatic epithelium and is lined by a 
basement membrane of extracellular matrix which separates the glandular epithelium 
from the surrounding fibromuscular stroma (de Carvalho and Line, 1996).  
 
Within the prostate epithelium there are a spectrum of cell types that express a 
continuum of biological properties, differentiation markers and variable degrees of 
androgen independence (Figure 1.2). These include the stem cell, the neuroendocrine 
cell, the basal cell, the luminal cell and intermediate cells, a sub-population of 
heterogeneous cells that migrate from the basal layer into the luminal layer (Liu et al., 
1999; van Leenders et al., 2000). Using well described epithelial and prostate markers, 
intermediate cells have been shown to exhibit phenotypes between the progenitor basal 
cells and the terminally differentiated secretory luminal cells (Figure 1.2; van Leenders 
et al., 2000).  
 
Stem cells are thought to reside in the basal layer and are considered to be androgen 
independent for growth and survival. They express high levels of p63, low levels of the 
cytokeratins (CK) 14 and 18, and are the cell type from which all prostate epithelial cell 
types are thought to arise (Liu et al., 1999; Pellegrinni et al., 2001). Neuroendocrine 
cells are also thought to arise from stem cells (Bonkhoff et al., 1995) however there is 
evidence to suggest that they may be neuronal in origin (Aumuller et al., 1999). These 
cells are sparsely dispersed between the basal and luminal epithelial layers, are also 
androgen independent for growth and survival and are thought to be non-proliferating 
terminally differentiated cells that provide paracrine signals that support the growth and  Chapter One ￿ Introduction   
  2
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Figure 1.1 Anatomical location of the prostate gland at the base of the bladder and
surrounding the urethra (Adapted from http://www.prostateline.com).  
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differentiation of the developing prostate (di Sant‘Agnese, 1998). Basal cells are non-
secretory cells which are found between the luminal cells and the underlying basement 
membrane (Liu et al., 1999). These cells express p63 and a range of cytokeratins with 
CK5/14 being the most common, however androgen receptor (AR) expression can be 
either absent, weak or high and this may explain why basal cells are androgen 
independent for survival but androgen responsive for proliferation (Tokar et al., 2005). 
The intermediate cells are considered to be a transient population of cells that are either 
continually differentiating or quiescent cells and which terminally differentiate into 
secretory luminal cells only when required at precise times during prostate 
differentiation and growth (Long et al., 2005). These cells express low levels of p63 and 
CK5/14 but high levels of CK18 (Tokar et al., 2005). Intermediate cells are also 
androgen independent for growth and survival but in response to androgens exhibit 
increased AR and prostate specific antigen (PSA) expression and are thought to account 
for the finding in the basal layer of androgen dependent cells which express both the AR 
and PSA (Bonkhoff et al., 1994). Luminal cells are the predominant cell type found in 
prostate epithelium, they are androgen dependent for growth and express CK8/18, AR 
and secretory proteins such as prostate specific antigen (PSA) and prostatic acid 
phosphatase (Bonkhoff et al., 1994).  
 
The prostate is endodermal in origin and forms during embryogenesis through epithelial 
budding from the urogenital sinus as a consequence of epithelial and mesenchymal 
interactions (Cunha et al., 1987). Initially androgens act on the mesenchyme and 
subsequently the epithelium during prostate development, indicating that androgens are 
required in the mesenchyme for prostate induction and growth, and later in the 
epithelium for the development and maintenance of the secretory function of 
differentiated cell types (Abate-Shen and Shen, 2000). The prostatic epithelial buds 
subsequently undergo extensive ductal outgrowth and branching into the surrounding 
mesenchyme as the prostate matures (Timms et al., 1994). In humans, this largely 
occurs during puberty in response to high levels of circulating androgens (Abate-Shen 
and Shen, 2000). In adult human males, the prostate is defined by three distinct 
morphological regions based upon their relationship to prostatic disease. These are the 
central zone, the transition zone where benign prostatic hyperplasia (BPH) mainly 
occurs and the peripheral zone where prostate cancer primarily arises (Figure 1.3; 
McNeal, 1988). For correct differentiation of prostate epithelium to be maintained, a Chapter One ￿ Introduction    
  5
 
Figure 1.3 The three distinct morphological regions of the adult human prostate
(Adapted from http://www.prostate-research.org.uk). 
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Ejaculatory
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closely regulated balance between proliferation, differentiation and apoptosis is 
essential and this process involves androgens, the extracellular matrix and stromal 
growth factors (Long et al., 2005). As prostate cancer stroma differs from normal 
stroma, alterations in stromal growth factor signalling have been implicated in the 
development of prostate cancer (Lang et al., 2000). Although specific growth factors 
have not been definitively identified, it has been proposed that these aberrant signals 
result in the inappropriate differentiation of prostate epithelial cells (Long et al., 2005). 
However as cell lineage relationships in normal prostatic epithelium are not well 
characterised, the cell type(s) involved that give rise to prostate cancer remain unknown 
(Long et al., 2005; Tokar et al., 2005). It has been suggested that as prostate cancer cells 
express both basal and luminal cell characteristics, deregulation is most likely to occur 
during the differentiation of intermediate cells from androgen independent basal cells to 
androgen dependent luminal cells (Long et al., 2005).  
 
1.2 Prostate  Cancer 
1.2.1  Prostate Cancer Incidence 
Prostate cancer is the second leading cause of cancer death in men after lung cancer and 
is the most frequently diagnosed cancer of men in Australia, North America and 
Western Europe (AIHW and AACR, 2004; Gronberg, 2003). Although other factors 
such as diet, environment, ethnicity or family history also contribute, ageing represents 
the single most significant risk factor for the development of prostate cancer (Figure 
1.4; Brothman, 2002). Studies at autopsy show that 15-30% of men over the age of 50 
years have evidence of prostate cancer (Sakr et al., 1993), whereas by the age of 80 
years this figure has risen to 60-70% (Brawley et al., 2000). Prostate tumours are not 
always fatal and men may die of other age associated diseases and not as a direct 
consequence of prostate cancer (Figure 1.4; Brothman, 2002). Nevertheless, prostate 
cancer is a heterogeneous condition and as such ranges from an indolent asymptomatic 
disease to an aggressive rapidly lethal systemic disease. At present there is no effective 
way of distinguishing between those prostate cancers which will remain indolent and 
those that will become aggressive (Hughes et al., 2005). In England and Wales, 
although the 5 year survival rates for prostate cancer have increased by 11% for men 
diagnosed during 1996-1999 as compared to those men diagnosed during 1991-1995, 
the increase in survival rates reflected the increased detection of early stage disease in Chapter One ￿ Introduction    
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men who died from causes other than prostate cancer rather than improved treatment of 
the disease. For those men diagnosed with advanced prostate cancer, there are still no 
effective long term treatments (section 1.2.5-1.2.7; Hughes et al., 2005). 
 
Prostatic intraepithelial neoplasia (PIN) describes precursor or premalignant prostate 
lesions that are thought to precede invasive cancer by at least 10 years and are primarily 
found in the peripheral zone, as is prostate cancer (Sakr et al., 1993). These lesions 
display architectural features found in early invasive cancers, such as disruption of the 
basal layer. PIN can be found in men in their twenties and are common in men in their 
fifties, affecting 1 man in 3 (Bostwick et al., 1993). PIN lesions occur as a continuum 
between low grade and high-grade forms, with high-grade PIN representing the 
immediate precursor of early invasive carcinoma (Bostwick, 1999). Prior to the age of 
50, the diagnosis of prostate cancer is rare (Sakr et al., 1993), suggesting that although 
the changes associated with PIN lesions occur comparatively early in adulthood, the 
progression to cancer occurs as a consequence of ageing (Abate-Shen and Shen, 2000).  
 
The incidence of prostate cancer in Australia is higher than in Western Europe, but is 
lower than the very high rates found in the United States of America (USA) and New 
Zealand.  In the USA, the probability of being diagnosed with prostate cancer is 1 in 6 
(Klotz, 2005), whereas in Australian men, the lifetime risk for the development of 
prostate cancer is 1 in 11.  Between 1990 and 1994 the incidence of prostate cancer in 
Australia increased substantially as a result of the introduction of prostate specific 
antigen (PSA) screening in 1989, which increased the detection of the disease. From 
1995 until 1997, prostate cancer incidence rates fell by 30% and have remained 
relatively unchanged from 1998 to 2001 (Figure 1.5; AIHW and AACR, 2004), 
although the number of new cases diagnosed is predicted to increase by 36% from 
11,191 in 2001 to 15,202 in 2011 (AIHW et al., 2005). In 2001, prostate cancer 
accounted for approximately 23% of all invasive cancer diagnoses in Australian men 
(AIHW and AACR, 2004), compared to 31% for North American men (257,943 new 
cases) (Ferlay et al., 2004). Mortality rates are similar in Australia to that of North 
America, the United Kingdom and New Zealand with Australian men having a lifetime 
risk of prostate cancer mortality of 1 in 82, which is significantly lower than the 
incidence rate and has decreased 1.8% per year from 1991 to 2001 (AIHW and AACR, 
2004). In 2001 prostate cancer accounted for 13% of all cancer deaths (2,718) of Chapter One ￿ Introduction    
  8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Age-specific incidence and mortality rates for cancer of the prostate in
Australian men for 2001 (AIHW and AACR, 2004). 
Figure 1.5 Age-standardised trend of the incidence and mortality rate for prostate
cancer in Australian men from 1983 to 2002 (AIHW and AACR, 2004). 
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Australian men and 11% of all cancer deaths (36,447) of North American men (AIHW 
and AACR, 2004; Ferlay et al., 2004).  
 
1.2.2 Aetiology 
Familial prostate cancers, where there is evidence of the disease within a family, is 
proposed to account for approximately 25% of all prostate cancers but differs from 
hereditary prostate cancer which accounts for approximately 9% of all and 40% of early 
onset prostate cancers (age at diagnosis less than 55 years) (Bauer et al., 1998; 
Brothman, 2002). Hereditary cancer is defined as the incidence of prostate cancer in at 
least 3 first degree relatives, at least 3 successive generations or at least 2 relatives 
diagnosed prior to age 55 (Brothman, 2002). It is proposed in the majority of studies 
that prostate cancer is inherited by an autosomal dominant mode of inheritance although 
there is evidence to support autosomal recessive and X-linked modes of inheritance in 
specific families (Brothman, 2002). Few chromosomal regions are consistently 
identified as being linked to hereditary prostate cancer, possibly as the result of the 
existence of multiple, incompletely penetrant prostate cancer susceptibility genes (Xu et 
al., 2005). Nevertheless, candidate chromosomal regions and prostate cancer 
susceptibility genes have been identified by linkage analysis (Table 1.1; Brothman, 
2002; Bussemakers et al., 1999; Cancel-Tassin and Cussenot, 2005; Chang et al., 2002; 
Dong et al., 2003; Xu et al., 2005; Zheng et al., 2006). To date, apart from NKX3-1, AR 
and RNAse L, the genes proposed to be involved in hereditary prostate tumours have 
not been investigated for their roles in sporadic prostate tumours (Brothman, 2002; 
Noonan-Wheeler et al., 2006). 
 
It is also believed that endogenous steroid hormones contribute to prostate cancer risk, 
although studies examining the role of androgens in the aetiology of prostate cancer 
have shown conflicting results (Miyamoto et al., 2004). Among other factors associated 
with an increased risk of prostate cancer are ethnicity, occupation, diet and infections 
with high risk human papillomaviruses (HPVs). The highest incidence of prostate 
cancer in the world is among African-American men however it is believed this may 
result from a combination of factors involving diet, access to health care and genetic 
variations (Bostwick et al., 2004). Increased rates of prostate cancer have been observed 
in association with occupations such as welding, where there is exposure to cadmium 
(Waalkes and Rehm, 1994), which is considered a significant prostate cancer risk factorChapter One ￿ Introduction    
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Table 1.1 Chromosomal sites and putative susceptibility genes implicated to be involved in hereditary 
prostate cancer. 
Chromosomal Locus  Putative Susceptibility Gene  Observations 
1p36 CAPB  Associated  with  hereditary  brain 
and prostate cancer 
1q24-25  HPC1/RNASEL  Accounts for ~6% familial 
cancers 
1q42.2-43  PCAP  Early age at onset 
3p24 Not  identified   
5q12 Not  identified   
5q35 Not  identified   
7q11-21 Not  identified   
8p21 NKX3-1  Gene  sequence variants found 
8p22-23  PG1/MSR1  Gene sequence variants found 
8q13 Not  identified   
11q22 Not  identified   
13q12-13  BRCA2  Associated with hereditary breast 
and prostate cancer 
13q14 Not  identified   
15q11 Not  identified   
16p13 Not  identified   
17p11  HPC2/ELAC2  Gene sequence variants found 
17q21  BRCA1  Associated with hereditary breast 
and prostate cancer 
17q22 Not  identified   
20q13  HPC20  Late age at onset 
22q12  CHEK2  Gene sequence variants found 
Xq12  AR  Associated with AR allele <16 
GGC repeats 
Xq27-28 HPCX  No  male-male  inheritance 
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as it has been shown to stimulate the growth of prostate epithelial cells and promote 
their malignant transformation (Bostwick et al., 2004). Cadmium has also been 
implicated in the more aggressive and lethal forms of prostate cancer seen in smokers 
who have high levels of prostatic cadmium as compared to non-smokers (Drasch et al., 
2005). 
 
Studies have indicated that diets high in fat are also positively associated with an 
increased incidence of prostate cancer, with a recent report identifying important 
differences in the type of fat consumed rather than total dietary fat intake (Bidoli et al., 
2005; Yip et al., 1999). A significant protective
 effect of polyunsaturated fatty acids was 
noted in this study whereas monounsaturated fat consumption was correlated with an 
increased risk of prostate cancer (Bidoli et al., 2005). Other studies of vitamins and 
minerals have concluded that high serum levels of vitamin D may reduce the risk of 
prostate cancer (Polek and Weigel, 2002), as may supplementing the diet with vitamin E 
(Giovannucci, 2000), selenium and lycopene (the red carotenoid pigment found in 
watermelon and tomatoes) (Chan et al., 2005; Drasch et al., 2005). In addition, a recent 
study has found an inverse relationship between serum PSA and serum lycopene levels 
and demonstrated the use of lycopene as an effective treatment for high grade PIN 
lesions (Mohanty et al., 2005). Although the role of HPV infection in prostate cancer 
incidence remains undecided, studies have shown that men who are serologically 
positive for the high risk HPV-16 or HPV-18 strains that are associated with cervical 
cancer, have a 2.4 to 2.6 fold increased risk of prostate cancer (Dillner et al., 1998). In 
addition, a higher incidence of HPV DNA in prostate cancers has been noted as 
compared to benign prostatic hyperplasias (Leiros et al., 2005; Serth et al., 1999).  
 
1.2.3  Detection and Diagnosis 
Early stage prostate cancer is usually asymptomatic, although along with other health 
problems it may cause some of the following symptoms (National Cancer Institute 
(NCI), 2002).  
•  A need to urinate frequently, especially at night  
•  Difficulty starting or stopping urination  
•  Weak or interrupted flow of urine  
•  Painful or burning urination  Chapter One ￿ Introduction    
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•  Difficulty in having an erection  
•  Painful ejaculation  
•  Blood in the urine or semen  
•  Frequent pain or stiffness in the lower back, hips, or upper thighs 
Early detection and diagnosis therefore, relies on screening of asymptomatic patients. 
Currently, screening for prostate cancer involves either a digital rectal examination 
(DRE) or a blood test for serum PSA levels. DRE has an overall poor sensitivity and 
specificity, as only ~30% of prostate cancers detected by DRE are organ confined. In 
contrast, where routine screening by measurement of serum PSA levels is carried out, 
~90% of prostate cancers detected are organ confined and therefore potentially curable 
(Bast et al., 2000). However, as routine PSA screening results in the diagnosis of 
prostate cancer in many men who will not manifest clinical progression during their 
lifetime, the Australian Cancer Council, the Urological Society of Australasia and the 
Australian Prostate Cancer Collaboration do not recommend screening of asymptomatic 
men. Instead they advise that individual men aged 50-70 years with a life expectancy of 
at least 10 years who wish to be tested should be able to be screened by annual DRE 
and PSA test after discussion with their doctor (NHMRC (National Health and Medical 
Research Council), 2006). This view is supported by the American Urological 
Association and the American Cancer Society who adopted similar guidelines in 1997 
to that seen in Australia (American Urological Association, 2000). However the 
Canadian T. F. Periodic Health Exam and the UK Health Care Evaluation Unit advise 
against PSA screening of asymptomatic men. In Canada and the UK, PSA testing is 
reserved to monitor disease activity in men with established prostate cancer, to give an 
indication of the progression of the cancer and to assess response to treatment (Public 
Health Agency of Canada (PHAC), 2004; Watson et al., 2002).  
 
PSA is a protein that is found in both normal and cancerous cells. In men without 
prostate cancer, serum PSA levels generally range between 0 and 2.50ng/mL. Cancer 
will be detected in only 20-25% of men with serum PSA levels between 2.50ng/mL and 
4.0ng/mL and in 30-35% of men with serum PSA levels between 4.0ng/mL and 
10.0ng/mL (National Comprehensive Cancer Network (NCCN) and the American 
Cancer Society (ACS), 2005). If serum PSA levels are above 10.0ng/mL, prostate 
cancer is detected in 67% of cases however PSA measurement is not a definitive marker Chapter One ￿ Introduction    
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of prostate cancer as PSA levels can also be increased in benign conditions such as 
benign prostatic hyperplasia (BPH) and infections of the prostate gland (prostatitis) 
(National Comprehensive Cancer Network (NCCN) and the American Cancer Society 
(ACS), 2005). If a man has symptoms of prostate disease, or a DRE or PSA level that is 
abnormal, a transrectal ultrasound (TRUS) guided needle biopsy will be performed to 
collect tissue samples from the peripheral and transition zones of the prostate. 
Histological analysis of these biopsies and the presence of malignant cells within the 
prostate will be confirmed before a diagnosis of prostate cancer is made (Bast et al., 
2000).  
 
1.2.4  Grading and Staging  
Following a diagnosis of prostate cancer, further tests such as follow-up serum PSA 
levels, TRUS, computed tomography (CT) and radioisotope bone scans, and/or surgery 
will be used to evaluate the extent of disease. The cancer will be classified using the 
Tumour, Node, Metastasis (TNM) classification (Table 1.2; Greene et al., 2002). In 
addition, the cancer will be graded from biopsy samples using a system developed by 
Gleason (Gleason and Mellinger, 1974), which has recently been revised to incorporate 
the reporting of tertiary patterns of gland differentiation in needle biopsy specimens that 
were not recognised when Gleason proposed this system (Lopez-Beltran et al., 2005). 
The system uses two levels of scoring, assigning grades of 1-5 based on the degree of 
differentiation seen histologically in patterns of gland formation. The Gleason score is 
the sum of the grades assigned to the primary and secondary patterns of gland 
differentiation or the best and poorest patterns of gland differentiation where tertiary 
patterns are seen, and gives an indication of how fast the cancer is growing (Gleason 
and Mellinger, 1974; Lopez-Beltran et al., 2005). A Gleason score of 2-4 indicates a 
slow growing tumour, 5-7 is intermediate whereas a score of 8-10 would indicate an 
aggressively growing tumour (Gleason and Mellinger, 1974). 
 
1.2.5  Treatment Options and Prognosis 
Treatment options and prognosis of prostate cancer depend on the TNM classification, 
Gleason grade, the patient￿s age and general health. Once the T, N and M categories 
have been determined, they are assigned a stage number, expressed in Roman numerals 
from I (the least advanced) to IV (the most advanced), and used to determine treatmentChapter One ￿ Introduction    
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Table 1.2 TNM classification of prostate cancer. 
Primary Tumour (T) 
TX  Primary tumour cannot be assessed 
T0  No evidence of primary tumour 
T1  Clinically inapparent tumour not palpable or visible by imaging 
T1a  Tumour incidental histological finding in 5% or less of tissue resected 
T1b  Tumour incidental histological finding in more than 5% of tissue resected 
T1c  Tumour identified by needle biopsy ￿ elevated PSA 
T2  Palpable tumour confined within prostate* 
T2a  Tumour involves less than 50% of one lobe 
T2b  Tumour involves more than 50% of one lobe 
T2c  Tumour involves both lobes 
T3  Tumour extends through the prostatic capsule** 
T3a  Extracapsular extension (unilateral or bilateral) 
T3b  Tumour invades seminal vesicle(s) 
T4  Tumour is fixed or invades adjacent structures other than seminal vesicles, bladder neck, 
external sphincter, rectum, levator muscles, and/or pelvic wall. 
Regional Lymph Nodes (N) 
NX  Regional lymph nodes cannot be assessed 
N0  No metastasis to regional lymph node(s) 
N1  Metastasis in regional lymph node(s) 
Distant Metastasis (M)*** 
MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
M1a  Non-regional lymph nodes 
M1b Bone(s) 
M1c Other  site(s) 
*Tumour found in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, 
is classified T1c. 
**Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is not classified as T3, 
but as T2. 
***When more than one site of metastasis is present, the most advanced category is used. 
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and prognosis (Table 1.3; National Comprehensive Cancer Network (NCCN) and the 
American Cancer Society (ACS), 2005). 
 
Conventionally, men with low-grade, small volume tumours are regarded as appropriate 
candidates for watchful waiting and one option in these cases is to carefully monitor the 
cancer but undertake no active treatment (National Comprehensive Cancer Network 
(NCCN) and the American Cancer Society (ACS), 2005). Where the cancer is confined 
to the prostate gland, a prostatectomy involving the complete surgical removal of the 
prostate may be recommended. However as there can be significant side effects from 
the surgery, watchful waiting is also an option, as men with these tumours have a 20 
year 80-90% disease-free survival rate and are classified as having good-risk prostate 
cancer (Klotz, 2005). These cancers are generally defined as a Gleason score of 6 or 
less, PSA < 10, and T1c to T2a, and constitute approximately 50% of newly diagnosed 
cases. Nevertheless, some men with supposedly good-risk prostate cancer have a more 
aggressive phenotype than expected and a recent study has shown that those men who 
have a PSA doubling time of 3 years or less should be offered surgical intervention 
(Klotz, 2005). In addition, a PSA doubling time of less than 2 years indicated that the 
cancer was probably locally advanced (Klotz, 2005). Once the cancer has spread beyond 
the prostate, surgery is not normally an option as tumours that have already invaded 
surrounding tissues on diagnosis are generally incurable, as occult metastasis has 
already occurred (Freeman et al., 1995). For men diagnosed with these cancers, 
progression-free survival at 5 years was approximately 70% following hormone therapy 
(Lane et al., 2004). For men with metastatic prostate cancer, usually to the bone, there is 
no cure and treatment is palliative (Garnick and Fair, 1996; National Comprehensive 
Cancer Network (NCCN) and the American Cancer Society (ACS), 2005).  
 
1.2.6  Androgen Deprivation and Hormonal Therapies 
As androgens are required for the growth of the prostate, prostate cancer growth can 
also be manipulated with hormonal therapy. At present, the most common treatment for 
localised disease with a high risk of relapse, locally advanced disease, biochemical 
relapse following earlier treatment and metastatic disease is androgen deprivation 
treatment or hormonal therapy (Silvestris et al., 2005). Current hormonal treatments and 
their most commonly recognised advantages and disadvantages are listed in Table 1.4 
(Miyamoto et al., 2004). The classical form of androgen deprivation is castration, either  Chapter One ￿ Introduction    
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      Table 1.3 Treatment options for prostate cancer based on disease stage. 
Stage  TNM Classification and Gleason Grade  Treatments 
I  T1a-N0-M0-low Gleason score (2-4)  Watchful waiting 
   Surgery 
   Radiation therapy 
    
II  T1a-N0-M0-intermediate or high Gleason score (5-10)  Watchful waiting 
  T1b-N0-M0-any Gleason score (2-10)  Surgery 
  T1c-N0-M0-any Gleason score (2-10)  Radiation therapy 
  T2-N0-M0-any Gleason score (2-10)   
    
III  T3-N0-M0-any Gleason score (2-10)  Surgery 
   Radiation  Therapy 
   Hormonal  Therapy 
IV  T4-N0-M0-any Gleason score (2-10)  Radiation Therapy 
  Any T-N1-M0-any Gleason score (2-10)  Hormonal Therapy 
  Any T-Any N-M1-any Gleason score (2-10)  Chemotherapy 
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surgically (orchiectomy) or medically by the use of oestrogens or luteinising hormone-
releasing hormone (LH-RH) agonists and more recently LH-RH antagonists. 
Orchiectomy reduces circulating testicular androgens by over 90% within 24 hours 
(Maatman et al., 1985), however this treatment approach is unacceptable to many men 
as it causes considerable psychological problems (Miyamoto et al., 2004).  
 
Diethylstilbestrol (DES) was the first oestrogen compound used for medical castration 
and has the advantage that it is reversible, however DES is no longer used as an initial 
treatment as it has serious adverse cardiovascular side-effects including deep vein 
thrombosis and transient ischemic attack. DES is now more commonly used as a 
treatment for hormone refractory prostate cancer sometimes in combination with 
antithrombotic drugs (section 1.2.7; Malkowicz, 2001). Medical castration by the use of 
LH-RH agonists or antagonists suppresses testicular androgen secretion by inhibiting 
pituitary release of gonadotropins. However LH-RH agonists cause an initial rise in 
gonadotropin levels and testosterone, which may cause a surge in prostate cancer 
growth (flare phenomenon) and has been associated with increased bone pain in 5-10% 
of cases of metastatic disease (Bast et al., 2000). With the use of LH-RH antagonists on 
the other hand, this flare response is eliminated (Stricker, 2001). 
 
Men who undergo castration still produce adrenal androgens, therefore the basis of   
combined or total androgen blockade therapy is to use LH-RH agonists to inhibit 
testicular androgens in conjunction with either steroidal or non-steroidal antiandrogens 
to inhibit the effects of adrenal androgens (Miyamoto et al., 2004). Various studies of 
total androgen blockade therapy have suggested that this therapy only provides a 
minimal improvement in 5 year survival as compared to monotherapy (Schmitt et al., 
2001) and side effects associated with antiandrogens used can include liver dysfunction 
and diarrhoea (Miyamoto et al., 2004). Nonetheless, the use of an antiandrogen prior to 
and during the first few weeks of LH-RH agonist treatment has been shown to prevent 
the risk of increased bone pain associated with the flare phenomenon (Bast et al., 2000).  
 
The administration of antiandrogens as a monotherapy has been used as an alternative 
treatment to castration as antiandrogens preserve the testes therefore providing potential 
quality of life benefits especially in terms of potency and libido (Miyamoto et al., 2004). Chapter One ￿ Introduction     
  19
Studies using the anti-androgen bicalutamide have shown equivalent survival rates to 
that of surgical or medical castration in men with metastatic disease (Iversen et al., 
2000), however breast enlargement and pain are complications of this treatment 
(Miyamoto et al., 2004). Intermittent androgen blockade describes androgen deprivation 
treatments administered until maximum responses (PSA levels, clinical evidence of 
disease) are achieved, then cessation of treatment until symptomatic or asymptomatic 
(eg. increasing serum PSA levels) disease recurs. This form of treatment is reported to 
reduce the side effects seen in continuous androgen deprivation therapy and is proposed 
to delay the onset of androgen independent prostate cancer, however it is still being 
debated whether intermittent androgen blockade improves survival (Oefelein, 2003).  
 
A useful form of androgen deprivation therapy that is used to treat benign prostatic 
hyperplasia has been 5α -reductase inhibitors such as finasteride, which inhibit the 5α -
reductase mediated conversion of testosterone into the more biologically active 5α -
dihydrotestosterone (DHT)  (Miyamoto et al., 2004). Finasteride monotherapy in 
prostate cancer has not been investigated, but in conjunction with total androgen 
blockade (termed triple androgen blockade), where finasteride is administered along 
with  an LH-RH agonist and an antiandrogen, or sequential androgen blockade, where 
finasteride maintenance therapy follows total androgen blockade treatment, were shown 
to substantially decrease PSA levels in men with metastatic disease (Kirby et al., 1999; 
Leibowitz and Tucker, 2001). Side effects of hormonal therapies can include 
osteoporosis, depression, anaemia, and loss of muscle mass and it has recently been 
reported that long term androgen deprivation treatment (> 1 year) can adversely affect 
cognitive function (Bast et al., 2000; Bussiere et al., 2005). Furthermore, androgen 
deprivation therapy is effective only in the short-term and often results in the recurrence 
of prostate cancer that is androgen independent (hormone refractory) with the median 
time to this disease progression being 14 to 30 months following initiation of androgen 
deprivation treatment (Sharifi et al., 2005).  
 
1.2.7  Androgen Independent Prostate Cancer 
The transition of prostate cancer to androgen independence is thought to occur through 
the growth selection of androgen-independent cells that may co-exist within an 
androgen dependent population (Abate-Shen and Shen, 2000). Multiple mechanisms for Chapter One ￿ Introduction     
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the progression to androgen independence have been proposed, including alterations in 
the AR gene, AR gene amplification, and alterations in AR function and/or specificity. In 
prostate cancer, the AR is frequently mutated within the hormone-binding domain as 
well as throughout its coding region, which permits binding of other steroid hormones, 
overcoming the specific requirement for androgen (Tilley et al., 1996). Genetic 
alterations, especially in oncogenes or tumour suppressor genes which are involved in 
activation of the AR may also promote proliferation of prostate cancer cells in the 
absence of androgens (Scher and Sawyers, 2005). 
 
Treatment options for androgen independent prostate cancer include palliative 
radiotherapy to reduce bone pain associated with individual metastases and more 
recently chemotherapy, which when used in combination with corticosteroids has 
shown a significant reduction in bone pain to that of corticosteroid use alone (Sonpavde 
et al., 2006). Recently, clinical trials of a new chemotherapeutic agent, docetaxel in 
combination with corticosteroids have shown a significant improvement in quality of 
life, pain and median survival (18.9 months) for men with androgen independent 
tumours (Tannock et al., 2004). Ongoing clinical trials are assessing docetaxel in 
combination with novel agents such as endothelin receptor antagonists and vaccines in 
an effort to further improve treatment outcomes (Sonpavde et al., 2006). 
 
1.2.8  Chromosomal Anomalies in Prostate Cancer  
The most frequent chromosomal/genetic alterations detected in both PIN and prostate 
cancer are gain of chromosome 7, in particular 7q31, loss of 8p, gain of 8q and losses of 
10q, 13q, 16q and 18q (Bostwick et al., 2004). Gain of 8q is one of the most common 
chromosomal anomalies in prostate cancer lymph node metastases and is frequently 
detected in androgen independent cancer (Cher et al., 1996). Conversely 8p is one of the 
most frequently deleted regions in prostate cancer (von Knobloch et al., 2004) 
indicating that changes of this chromosome and/or tumour suppressor genes located 
within this chromosomal region may be critical for the progression of prostate cancer. 
Loss of 8p is detected in 29-50% of PIN, 32-69% of primary cancers, and in 65-100% 
of metastatic cancers (Cunningham et al., 1996) and along with loss of 13q shows the 
highest incidence of loss of heterozygosity (LOH) throughout all stages of prostate 
cancer (von Knobloch et al., 2004). In addition when loss of 8p and 13q occur in 
combination, a highly significant association with advanced tumour grade is seen, Chapter One ￿ Introduction     
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suggesting that tumour suppressor genes residing at these loci are synergistically 
involved in the progression of prostate cancer (von Knobloch et al., 2004).  
 
Frequently deleted 8p regions include 8p21 and 8p12 with loss of 8p12-21 observed in 
21-63% of PIN lesions and in 69-91% of cancer tissue samples (Emmert-Buck et al., 
1995; Haggman et al., 1997; Kagan et al., 1995). LOH at chromosomal locus 8p21.2 is 
also common and is detected in 75-90% of advanced prostate cancers where it is 
thought to occur at the same time as loss of androgen responsiveness and the associated 
loss of differentiation of the tumour (Vocke et al., 1996). Recently, mutations in the 
MSR1 gene located at 8p22 were seen in families with hereditary prostate cancer 
suggesting that more than one tumour suppressor gene may be located on 8p and that 
inactivation of these genes may be important for the initiation of prostate cancer 
(Wiklund et al., 2003). Interestingly, loss of 8p22 is also associated with a poor 
prognosis after radical prostatectomy (Tsuchiya et al., 2002). Gain, deletion, and 
translocation of 7q22-q31 are common in prostate cancer with aneusomy of 
chromosome 7 frequently occurring and often associated with higher cancer grade and 
early patient death (Alcaraz et al., 1994). The frequency of trisomy 7 is also higher in 
prostate cancer than in PIN (Bandyk et al., 1994) and gain of 7q31 is strongly correlated 
with high Gleason grade (Jenkins et al., 1998), suggesting that overrepresentation of 
genes in this area may be important for the progression of prostate cancer. 
 
Two regions on chromosome 10 are frequently deleted in prostate cancer, 10q23-24 and 
10p11.2 (Gray et al., 1995). On chromosome 16, loss of 16q24.1-24.2 is seen in 
approximately 30% of clinically localised prostate cancers and is associated with cancer 
progression (Carter et al., 1990). Men that have prostate tumours with deletions of both 
16q24 and 8p22 show an increased incidence of lymph node metastases (Matsuyama et 
al., 2003). LOH at chromosomal regions 18q22.1, 21q22.2-22.3 and 3p25-26 are 
detected in ~ 20-40% of cancers and other regions that show consistent LOH are 5q, 6q, 
13q and 17p31 (Cunningham et al., 1996).  LOH at 13q14.1 occurs with an incidence of 
61% and shows a significant association with advanced tumour stage whereas loss of 5q 
is significantly associated with lymph node metastasis as is LOH at 9p. LOH at 
18q12.2-12.3 is thought to be an early event in disease progression as approximately 
52% of prostate cancers compared to 19% of PIN lesions show allelic imbalance at this 
region  (Bostwick et al., 1998; von Knobloch et al., 2004). It would appear from these Chapter One ￿ Introduction     
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studies that loss of 8p or 13q may be involved in the initiation of prostate cancer 
whereas in combination they promote the progression of prostate cancer. Further losses 
of 5q and 16q, and gains of 7q and 8q, are then required for metastatic disease to 
develop. 
 
Although no genes have been conclusively identified to cause initiation of prostate 
cancer, several genes are located at frequently altered chromosomal regions in prostate 
cancers and have been implicated based on their functional properties (Abate-Shen and 
Shen, 2000). One such gene is the prostatic homeobox gene NKX3-1 that maps to 
8p21.2, a region implicated in both the initiation and progression of prostate cancer. 
 
1.3   NKX3-1 
1.3.1 Homeobox  Genes 
Homeobox genes are important regulatory genes that were first identified and described 
in D. melanogaster in 1984 as genes that encode the body plan during development 
(McGinnis et al., 1984). Following their discovery in Drosophila, homeobox genes have 
been identified in all metazoan species and are characterised by a 180bp DNA sequence 
known as the homeobox (Banerjee-Basu and Baxevanis, 2001). The homeobox encodes 
a 60 amino acid α -helix-turn-helix DNA binding motif referred to as the homeodomain 
in all homeobox genes except the TALE class where the homeodomain contains 63 
amino acids (Holland and Takahashi, 2005).  
 
1.3.1.1 Homeodomain  Proteins 
The DNA binding specificity of homeodomain proteins (homeoproteins) is conferred by 
sequence specific DNA motifs within the homeodomain and the N-terminal extension 
(Banerjee-Basu and Baxevanis, 2001). The homeodomain is comprised of three α -
helices folded into a globular structure where helices I and II, which are separated by a 
conserved region, lie parallel to one another and interact with DNA in the minor groove. 
An N-terminal extension precedes helix I, and also binds specific DNA bases in the 
minor groove. The third helix, the recognition helix, binds in the major groove of DNA 
contacting both the phosphate backbone and specific bases (Figure 1.6; Gehring et al., 
1994). Within the recognition helix are four consensus residues conserved in all known 
homeodomains, residues 48 (tryptophan) and 49 (phenylalanine) that are important for Chapter One ￿ Introduction     
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Figure 1.6 Schematic representation of the binding mode of the homeodomain.
Helix 3 binds in the major groove of DNA contacting both the phosphate backbone
and specific residues (Asn
51 and Arg
53) which are conserved in all homeodomain
proteins. The N-terminal arm lies in the minor groove and makes additional DNA
contacts. (Adapted from Wolberger et al., 1991) Chapter One ￿ Introduction     
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the integrity of the three α -helical structure, and residues 51 (asparagine) and 53 
(arginine) that make essential contacts with the major groove of DNA (Banerjee-Basu 
and Baxevanis, 2001). 
 
Within animal genomes, molecular phylogenetic analyses have revealed that homeobox 
genes can be segregated into 6 main classes based on their homeodomain sequence. Of 
these, the ANTP and PRD form 2 distinct classes whilst the remaining LIM, POU, 
SINE and TALE classes are more divergent (Holland and Takahashi, 2005). Based on 
chromosomal mapping and sequence specific residues located within the homeodomain 
(Banerjee-Basu and Baxevanis, 2001), the ANTP and PRD classes can be sub-divided 
into clades of Hox/ExHox, ParaHox and NK-related genes for the ANTP class and 
Paired-like (K50), Paired-like (Q50) and Pax (S50) genes for the PRD class. These clades 
are then further divided into gene families comprising homeobox genes that contain a 
series of closely related genes (Table 1.5; Holland and Takahashi, 2005). However 
between classes of homeobox genes, there is considerable sequence diversity within 
homeodomains and within the N- and C-terminal regions that flank this domain. This is 
believed to contribute to the unique functional properties of individual homeodomain 
proteins as do additional conserved domains or motifs that occur in particular gene 
families (Banerjee-Basu and Baxevanis, 2001).  
 
1.3.2  NK Homeobox Genes 
The NK-related clade of homeobox genes is named after M. Nirenberg and Y. Kim  
who in 1989 identified 4 novel genes in Drosophila which they named NK1 (slouch, 
slo), NK2 (ventral nervous system defective, vnd) NK3 (bagpipe, bap) and NK4 (tinman, 
tin) (Kim and Nirenberg, 1989). Later, 3 other NK-related genes C15 (93Bal), ladybird 
early (lbe) and ladybird late (lbl) were identified of which lbe and lbl represent gene 
duplications (Jagla et al., 2001). Of these Drosophila genes, all but vnd are clustered on 
chromosome 3 and are known as the 93D/E cluster (Jagla et al., 2001). Further studies 
in A. gambiae and amphioxus have identified 2 more genes, NK5 and Drop (Dr) which 
belong to this cluster and provide evidence of an ancestral NK cluster comprised of 7 
genes in the order Dr, tin, bap, lbx (ladybird), C15, slo and NK5 which, like the Hox 
and ParaHox gene clusters then underwent duplication in early chordate evolution 
followed by gene loss (Garcia-Fernandez, 2005; Luke et al., 2003). However unlike the  
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Hox and ParaHox gene clusters which have remained evolutionarily tightly linked in 
chordates but not in Drosophila, the NK-related gene cluster apart from tin-bap and 
C15-lbx has undergone breakage and dispersal in chordates but remains linked in 
Drosophila (Figure 1.7; Garcia-Fernandez, 2005). In the human genome, orthologues of 
the NK-related class of genes have also been identified (Table 1.6) however the only 
genes to have remained linked from the ancestral NK gene cluster are NKX2-6/NKX3-1, 
TLX/LBX1 and TLX2/LBX2 (Figure 1.7). 
 
1.3.2.1  NK Homeodomain Proteins 
Following the discovery of the NK1-NK4 genes in Drosophila, the encoded proteins 
from these genes were classified into two new homeoprotein classes, NK-1 (containing 
NK1) and NK-2, (containing NK2, NK3, and NK4). The remainder of the NK-related 
homeoproteins have not been classified into classes. NK-2 class homeoproteins, of 
which there are 9 in humans (Table 1.6), have a tyrosine at position 54 of their 
homeodomain and this distinguishes class members from the NK-1 homeoproteins 
(Banerjee-Basu and Baxevanis, 2001). This conserved tyrosine also defines the DNA-
binding specificity for a core DNA domain of CAAGTG, rather than a TAATGG core, 
which is preferentially bound by most other homeoproteins (Gruschus et al., 1997). 
Most of the NK-2 homeoproteins are further distinguished by an NK2-specific domain 
(NK2-SD) that is located 5’ to the homeodomain and which is comprised of a 
hydrophobic core sequence ￿VAVPVLV￿ flanked by basic amino acids that is believed 
to function as a transactivation regulator (Watada et al., 2000). In the human NK-2 class 
homeoproteins, the NK2-SD domain is present as ￿V/IA/VVPVLV￿ in NK2 and NK4 
orthologues and as VAVKVLV in the NK3 orthologue BAPX1 (NKX3-2), but is not 
present in the other NK3 orthologue NKX3-1. 
 
NK-2 class homeoproteins generally show tissue specific expression patterns and were 
originally studied in Drosophila where it was shown that these genes are expressed in a 
sequential manner during development in early mesodermal patterning and in 
differentiation (Jagla et al., 2001). Members of the NK-2 class in humans are also 
expressed during embryonic development and in mesodermal derivatives, although they 
do not appear to be sequentially expressed. In contrast, NK-2 class paralogues appear to 
display an anteroventral pattern of expression in the chicken (Garcia-Fernandez, 2005). 
NK3 expression is required for the specification of Drosophila visceral mesoderm  
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Drosophila  H. sapiens 
slo (NK1)  NKX1-1 
 C10orf121 (NKX1-2) 
vnd (NK2)  TITF1 (NKX2-1) 
 NKX2-2 
 NKX2-4 
 NKX2-8 
bap (NK3)  NKX3-1 
 BAPX1 (NKX3-2) 
tin (NK4)  NKX2-3 
 NKX2-5 
 NKX2-6 
Hmx HMX2 (NKX5-2) 
 HMX3 (NKX5-1) 
HGTX NKX6-1 
  NKX6-2 
NK7.1 HHEX 
dll DLX1 
 DLX2 
 DLX3 
 DLX4 
 DLX5 
 DLX6 
ems EMX1 
  EMX2 
lbe, lbl LBX1 
 LBX2 
dr MSX1 
  MSX2 
C15 TLX1 
  TLX2 
  TLX3 
 
 
 
 
 
Table 1.6 Human orthologues of Drosophila NK-related genesChapter One ￿ Introduction       
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during midgut musculature formation (Azpiazu and Frasch, 1993). In the mouse, Bapx1 
is initially detected in the splanchnic mesoderm (Tribioli et al., 1997) and is associated 
with spleen and vertebral development (Lettice et al., 2001) while mouse Nkx3-1 is 
associated with the formation of the prostate and palantine salivary glands (Bhatia-Gaur 
et al., 1999; Tanaka et al., 2000). During vertebrate evolution, the appearance of the 
spleen is not well-defined but may have been present in lamprey. In contrast, the 
prostate is specific to mammals suggesting that the NK3 orthologues may have acquired 
new functions as a result of chromosomal duplication (Lettice et al., 2001), which is 
predicted to have occurred twice during vertebrate evolution (Pollard and Holland, 
2000). It is proposed that Bapx1 and Nkx3-1 arose during one of these chromosomal 
duplications with Nkx3-1 appearing later in vertebrate evolution than Bapx1 as salivary 
glands only arose in vertebrates once tetrapods became land based feeders (Lettice et 
al., 2001). 
 
1.3.3  The NKX3-1 Homeodomain Protein 
1.3.3.1 The  NKX3-1 Gene 
The human NKX3-1 gene maps to chromosome 8p21.2 and spans 4223 bases pairs (bp) 
of genomic DNA with an open reading frame (ORF) divided between two exons, the 
second of which contains the homeobox. The gene produces a mRNA transcript of 
3266bp comprised of a short 48bp 5’ untranslated region (UTR) and an unusually long 
2513bp 3’ UTR, and encodes a protein of 234 amino acids (Figure 1.8; He et al., 1997). 
Of the Drosophila NK genes, NKX3-1 shows 50% homology to the NK4 homeobox, 
60% homology to the NK2 homeobox and 78% homology to the NK3 homeobox where 
it is identical within helix III of the homeodomain. However, outside of the 
homeodomain there is no strong homology with Drosophila NK3 (He et al., 1997). The 
mouse  Nkx3-1 and human NKX3-1 genes represent mammalian orthologues of the 
Drosophila NK3 gene and there is 100% homology between the homeodomains and 
67% overall homology within the mouse Nkx3-1 and human NKX3-1 genes (Prescott et 
al., 1998). Following the discovery of the mouse Nkx3-1 and human NKX3-1 genes, 
homologous genes have been identified in the chimpanzee, dog and rat and in these 
genes there is 100% homology between the homeodomains except for the rat which 
differs at one position although this residue is still conserved (Figure 1.9). 
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1.3.3.2  Nkx3-1 Expression During Embryogenesis 
In the mouse, Nkx3-1 expression can be detected in developing embryos 7.5 days post 
coitum (p.c.) in the paraxial mesoderm adjacent to the neural fold. Expression proceeds 
caudally and at day 10.5 p.c. Nkx3-1 expression can only be detected in the most caudal 
somites (Kos et al., 1998; Tanaka et al., 1999), where in conjunction with Bapx1 
expression, regulation of the size and spatial organisation of the early sclerotomal 
compartment that gives rise to the vertebrae occurs (Herbrand et al., 2002). During this 
time, Nkx3.1 expression is regulated by the notochord as well as the neural tube and 
expression is induced and maintained by sonic hedgehog. However, Nkx3-1 expression 
in the sclerotome is only transient and from day 10.5 p.c. Nkx3-1 expression can be 
down-regulated by the repression of sonic hedgehog following administration of 
forskolin (Herbrand et al., 2002; Kos et al., 1998). At this time, Nkx3-1 expression is 
also be found in subpopulations of vascular smooth muscle cells (Tanaka et al., 1999).  
 
During the later stages of gestation, Nkx3-1 is expressed in the male urogenital sinus, 
prostatic buds, and testis. Expression in the prostatic buds is restricted to the leading 
edge in the urogenital sinus indicating that expression may occur in response to an 
inductive signal from the surrounding mesenchyme (Sciavolino et al., 1997). At this 
stage of development (14.5 p.c.) the urogenital sinus epithelium lacks functional AR, 
however functional AR are present in the urogenital sinus mesenchyme. At present, the 
role of urogenital sinus mesenchyme AR in controlling induction of Nkx3-1 expression 
and early prostate duct formation is unknown (Bhatia-Gaur et al., 1999). Tissue 
recombinant experiments using urogenital sinus epithelium and urogenital sinus 
mesenchyme demonstrated that whilst urogenital sinus mesenchyme can induce Nkx3-1 
expression, functional AR is required in the urogenital sinus epithelium to maintain 
Nkx3-1 expression, as tissue recombinants lacking functional AR failed to express 
Nkx3-1 and prostate development did not proceed (Bhatia-Gaur et al., 1999). 
 
At 17.5 days gestation, Nkx3-1 expression becomes localised to the prostatic buds of the 
prospective lobes of the prostate, and to the medullary cords, which form the 
seminiferous tubules in the testes. In the 2-4 weeks following birth, Nkx3-1 expression 
correlates with prostate ductal growth and differentiation. Upon reaching sexual 
maturity,  Nkx3-1 expression is upregulated in response to increased androgens 
(Sciavolino et al., 1997), and can be detected in all four lobes of the prostate gland, the Chapter One ￿ Introduction        
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bulbourethral gland and at extremely low levels in the testes, salivary gland and brain 
(Bieberich et al., 1996). Expression of Nkx3-1 was significantly reduced in adult mice 
following castration with expression levels decreasing 8-fold 2 days post castration and 
10-fold 5 days post castration (Sciavolino et al., 1997). These studies suggest that 
during mouse embryogenesis Nkx3-1 is involved in the development of the prostate 
while in the adult prostate it contributes to the androgen-regulated differentiated 
phenotype. In adult human males NKX3-1 is also predominantly expressed in prostatic 
epithelium with lower levels detected in the testis (He et al., 1997). Human NKX3-1 has 
also been shown to be androgen responsive as NKX3-1 levels are regulated by 
androgens in the AR-expressing LNCaP prostate cancer cell line, whilst androgen 
independent prostate cancer cells, PC-3 and DU145 have exceedingly low levels of 
NKX3-1 mRNA and do not express detectable levels of NKX3-1 protein (He et al., 
1997).  
 
1.3.3.3  Nkx3-1 Knockout Mice 
Nkx3-1 knockout mice exhibit abnormal prostatic differentiation, which is evident in 
neonates. The prostates of these mice are reduced in size compared to wild type mice 
and by 3 weeks of age show a significant reduction in the number of ductal tips and 
branch points although there is no overall decrease in prostate size (Bhatia-Gaur et al., 
1999; Tanaka et al., 2000). By 6 months of age Nkx3-1 knockout mice display prostatic 
epithelial hyperplasia, which increases in severity with age until 1 year but does not 
appear to increase in severity thereafter. In addition there is no evidence of prostate 
cancer in Nkx3-1 knockout mice at 2 years of age (Tanaka et al., 2000). Nkx3-1 is also 
expressed in mouse palatine salivary glands and Nkx3-1 knockout mice demonstrate 
reduced ductal branching in these glands but with an increase in mucus producing cells 
and proliferating epithelial cells, suggesting that Nkx3-1 is involved in regulating 
glandular morphogenesis (Tanaka et al., 2000). Although there is no evidence of 
prostate cancer in Nkx3-1 knockout mice the prostatic epithelial hyperplasia and 
dysplasia displayed in these mice closely resembles human adult PIN lesions (Kim et 
al., 2002a). Nkx3-1 knockout mice also display deregulated expression of several anti-
oxidant and pro-oxidant proteins. This deregulation of expression occurs as early as 4 
months of age, which is before the appearance of prostatic epithelial hyperplasia, and 
persists with aging (Ouyang et al., 2005). Compared to wild type mice, Nkx3-1 
knockout mice exhibit decreased expression of the anti-oxidants Gpx2 and Prdx6 in the Chapter One ￿ Introduction        
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prostatic epithelium along with increased expression of the anti-oxidant Gpx3, which is 
thought to compensate for the reduction in Gpx2 and Prdx6 expression. Expression of 
the pro-oxidant Qscn6 is also elevated in these mice relative to wild type mice (Ouyang 
et al., 2005). This study suggested that Nkx3-1 maintains the prostatic phenotype by 
regulating genes involved in the oxidative response pathway and that loss of Nkx3-1 
expression accelerates aging of prostatic epithelium. 
 
In  Nkx3-1
+/-/Pten
+/-  and  Nkx3-1
-/-/Pten
+/-  compound knockout mice, high-grade PIN 
lesions are seen by 6 months of age progressing to adenocarcinoma by 12 months of age 
(Kim et al., 2002b). In addition, Nkx3-1
-/-/Pten
+/-  knockout mice display further 
deregulation of the oxidative response pathway. In these mice, expression of Gpx2, 
Gpx3 and Prdx6 is barely detectable whilst expression of Qscn6 is further increased 
relative to Nkx3-1 knockout mice (Ouyang et al., 2005). Expression of the anti-oxidant 
enzymes Mn SOD and Cu/Zn SOD are also reduced in these mice but only at the 
protein level, not at the mRNA level and only in older mice that have developed 
adenocarcinomas (Ouyang et al., 2005). Interestingly the Nkx3-1
+/-/Pten
+/- compound 
heterozygotes, whilst retaining Nkx3-1 mRNA, also displayed loss of Nkx3-1 protein 
expression without loss of the remaining Nkx3-1 allele or mutation of its coding region 
(Kim et al., 2002b). This finding is in agreement with an analysis of the human NKX3-1 
gene, which found no mutations in the coding region and mRNA levels not significantly 
reduced in primary non-metastatic, androgen-dependent prostate cancers as compared to 
normal prostate (Ornstein et al., 2001; Xu et al., 2000). However, reduced NKX3-1 
protein expression is observed in primary human prostate cancers with a recent study 
finding allelic deletion (LOH) to be the main genetic factor associated with reduced 
NKX3-1 expression (Asatiani et al., 2005).  
 
Another gene which shows loss of protein expression in PIN and also co-operates with 
Pten to promote prostate cancer development is the cyclin-dependent kinase inhibitor 
p27
KIP1 (Di Cristofano et al., 2001).  In the prostates of Nkx3-1
-/-/p27
-/-; Nkx3-1
+/-/p27
-/- 
and  Nkx3-1
-/-/p27
+/- compound knockout mice, extensive hyperplasia and dysplasia, 
increased nuclear crowding, nuclear elongation and hyperchromasia, and PIN lesions 
were seen by 24 weeks of age (Gary et al., 2004). However lesions were 
histopathologically similar in all mice. In addition, PIN lesions in Nkx3-1
+/-/p27
+/- 
compound heterozygote knockout mice were phenotypically similar to those of Nkx3-Chapter One ￿ Introduction        
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1
+/-/p27
+/+ and Nkx3-1
+/+/p27
+/- mice, suggesting that unlike Nkx3-1 and Pten, there was 
no co-operativity between Nkx3-1 and p27 in the induction of PIN (Gary et al., 2004). 
Nuclei from the prostatic lesions of Nkx3-1
-/-/p27
-/-  double knockout mice however, 
were significantly larger and had a higher DNA content. Moreover, in these mice there 
was a significant increase in the proliferation of prostate epithelial cells together with a 
reduction in apoptosis when compared to either Nkx3-1
+/+/p27
-/- or Nkx3-1
+/-/p27
-/- mice 
suggesting that loss of Nkx3-1 expression suppresses apoptosis in p27 deficient prostate 
cells (Gary et al., 2004).  
 
NKX3-1 expression is reduced or absent in a proportion of both PIN lesions and 
advanced prostate cancers where loss of NKX3-1 expression correlates to disease 
progression (Bowen et al., 2000). As there is no significant loss of NKX3-1 mRNA 
occurring, it has been suggested that NKX3-1 haploinsufficiency is sufficient to promote 
loss of prostatic epithelial differentiation (Bhatia-Gaur et al., 1999). This proposal is 
consistent with the results seen in Nkx3-1
+/-  and  Nkx3-1
-/- knockout mice and is 
proposed to indicate that Nkx3-1 co-regulates the exit of androgen responsive 
proliferating luminal epithelial cells from the cell cycle. Deletion of one or both Nkx3-1 
alleles transiently extends the proliferative phase of regenerating prostate luminal 
epithelial cells resulting in prostatic epithelial hyperplasia (Magee et al., 2003). In 
addition gene expression profiling identified several genes that are co-regulated by 
androgens and Nkx3-1 in the prostate in a gene dosage-sensitive manner, and that the 
loss of one or both Nkx3-1 alleles stochastically inactivated those genes that were 
normally activated by Nkx3-1 (Magee et al., 2003). Interestingly, this manner of 
regulation did not apply to genes that were normally repressed by Nkx3-1 suggesting 
the involvement of different regulatory mechanisms for activation and inhibition of 
Nkx3-1 targets.  
 
1.3.3.4   Regulation of NKX3-1 Expression 
NKX3-1 expression is also required for normal testis function with reduced NKX3-1 
expression seen in testicular germ cell tumours (TGCTs) (Skotheim et al., 2003b). 
Unlike PIN lesions, NKX3-1 expression is not reduced in preinvasive testicular lesions 
indicating that loss of NKX3-1 expression is a later event in testicular carcinogenesis. In 
the testis, loss of NKX3-1 expression is also associated with tumour progression and is 
correlated with the expression of the DNA repair enzyme O
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methyltransferase (MGMT) (Skotheim et al., 2003a; Skotheim et al., 2003b), which has 
been found to be epigenetically silenced in TGCTs through promoter hypermethylation 
(Koul et al., 2002). Although these results suggest that NKX3-1 may also be 
epigenetically silenced through promoter hypermethylation, recent studies have found 
this is not the case in either testicular or prostate cancers (Lind et al., 2005). A G/A 
polymorphism 15 bases upstream from the coding sequence in the promoter region was 
detected however, and it was proposed that this may affect the transcriptional regulation 
of NKX3-1 (Asatiani et al., 2005; Lind et al., 2005). 
 
While inhibition of methylation or histone acetylation was found not to activate NKX3-
1 expression in NKX3-1 non expressing DU145 and PC-3 prostate cancer cell lines 
(Asatiani et al., 2005), indicating that overall CpG methylation is not involved in 
regulation of NKX3-1 expression, the contribution of individually methylated CpG sites 
to the regulation of NKX3-1 expression is less clear. Methylation of individual CpG 
sites has been detected +1bp from the NKX3-1 transcription start site (Lind et al., 2005) 
and at -921, -903 and -47bp of which the -47bp site is a potential Sp1 binding site 
(Asatiani et al., 2005). All 3 of the -921, -903 and -47 sites were found to be methylated 
in DU145 and PC-3 prostate cancer cell lines, but in the androgen responsive LNCaP 
cell line the -903 site was only partially methylated and not methylated at site -47. In 
prostate cancer tissue specimens, a greater degree of methylation was also observed at 
these sites compared to adjacent normal prostate tissue (Asatiani et al., 2005). 
Interestingly this study found that although LOH is the main determinant in reduced 
NKX3-1 expression, when the LOH occurred in conjunction with methylation at -921,
-903 and -47 a further decrease in NKX3-1 expression was seen and this reduction in 
expression was proportional to the number of sites methylated (Asatiani et al., 2005). 
Although the significance of these findings is unclear it does suggest that methylation of 
individual CpG sites in the NKX3-1 promoter maybe involved in the progression of 
prostate cancer.  
 
Recently, sequencing analysis of the NKX3-1 gene in prostate cancer families identified 
several germ-line mutations which significantly increased hereditary prostate cancer 
risk (Zheng et al., 2006). One of the mutations, a 1454A/G mutation was found to co-
segregate with prostate cancer and resulted in a T146A amino acid substitution. This 
substitution corresponds to residue 41 of the homeodomain which is in the third Chapter One ￿ Introduction        
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recognition helix and resulted in a less stable NKX3-1 protein that showed decreased 
binding affinity for its cognate sequence (Zheng et al., 2006). Interestingly, this residue 
is conserved in all but 2 of the human NK-related class of homeoproteins and is also the 
residue that in another NK-2 class protein (NKX2-5) is mutated in a family with 
hereditary heart defects (Kasahara and Benson, 2004). In that case, the DNA binding 
affinity of NKX2-5 was markedly reduced and mutant NKX2-5 was not able to activate 
the promoter of its target, atrial natriuretic factor (Kasahara and Benson, 2004). Of the 
remaining mutations that were found to have hereditary linkage with prostate cancer, 3 
were found to be located in the NKX3-1 promoter and 1 of these at -360bp G/A has been 
identified as being within a NKX3-1 regulatory element with inhibitory function (Jiang 
et al., 2004). 
 
These results provide further evidence that NKX3-1 plays a critical role in the 
development and progression of prostate cancer, however the transcriptional 
mechanisms that regulate NKX3-1 expression are not well characterised. Studies of a 
32Kb genomic region of the Nkx3-1 locus in mice have revealed that transcriptional 
control of Nkx3-1 is complex and is mediated by multiple cis-acting elements (Chen et 
al., 2005). In the mouse, Nkx3-1 expression in the somites and testes is regulated by a 
2Kb sequence located 5Kb upstream of the Nkx3-1 start codon, whereas expression in 
the prostate is regulated by enhancer elements contained in a 5Kb sequence originating 
5Kb downstream from the Nkx3-1 start codon (Chen et al., 2005). These data suggest 
that tissue specific expression of Nkx3-1 may be controlled in a modular fashion by 
distinct regulatory elements (Chen et al., 2005) as is the case with Nkx2-5, which has a 
regulatory region containing 6 distinct activator and 3 distinct repressor elements 
(Schwartz and Olsen, 1999). 
 
In the human NKX3-1 gene, regulatory elements have also been located upstream of the 
NKX3-1 gene in the promoter region. These include a positive cis-element of 16bp at
-920 to -905bp (Jiang et al., 2005b) and a 20bp inhibitory element at -361 to -342bp 
(Jiang et al., 2004). When this inhibitory element was blocked by a decoy element, 
NKX3-1 expression in LNCaP prostate cancer cells was up-regulated resulting in 
decreased cellular proliferation (Jiang et al., 2005a), however factors that bind these 
regulatory regions have yet to be identified. Another positive cis-element of 16bp at
-936 to 921bp has been shown to be responsive to 9-cis retinoic acid treatment, a Chapter One ￿ Introduction        
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retinoid which activates retinoid X receptors (RXRs). Treatment of LNCaP prostate 
cells with 9-cis retinoic acid resulted in an increase in both NKX3-1 mRNA and protein 
levels and arrest of the LNCaP cells in the G1 phase of the cell cycle. However, as the -
936 to 921bp element does not contain a recognised RXR response element it was 
thought the RXR may be interacting indirectly with this element by binding to another 
as yet unidentified factor to upregulate NKX3-1 expression (Jiang et al., 2006). 
Treatment of LNCaP cells with the retinoid acid receptor (RAR) ligand all-trans 
retinoic acid also leads to an increase in NKX3-1 mRNA and protein levels and although 
several putative retinoic acid response elements (RAREs) were located within 2 kb of 
the NKX3.1 proximal promoter and the 3‘-UTR these were found not to be responsible 
for mediating retinoid responsiveness (Thomas et al., 2006). 
 
An androgen response element (ARE) has been identified -3013bp upstream of the 
NKX3-1 gene which, in the presence of androgens, was shown to bind the 
transcriptional co-repressors silencing mediator of retinoid and thyroid hormone 
receptor (SMRT) and nuclear receptor co-repressor (N-CoR), suppressing 
transcriptional activation of NKX3-1 (Yoon and Wong, 2005). Knockdown of SMRT 
and/or N-CoR using small interfering RNA (siRNA) did not increase androgen receptor 
(AR) binding of the NKX3-1 ARE but did result in increased binding of the co-
activators SRC-1 and p300 leading to increased transcriptional activation of NKX3-1 
(Yoon and Wong, 2005). These results indicate that SMRT and N-CoR compete with 
SRC-1 and p300 for binding to ligand-bound AR and that the balance between co-
repressors and co-activators determines the level of NKX3-1 transcriptional activation. 
Transcriptional regulation of NKX3-1, mediated by androgens, was also found to occur 
through the NKX3-1 3‘-UTR indicating the presence of additional AREs within this 
region (Thomas et al., 2006). However in contrast to the ARE located proximal to the 
NKX3-1 gene which is involved in the transcriptional inhibition of NKX3-1  in the 
presence of androgens, the NKX3-1 3‘-UTR was shown to increase the transcriptional 
activity of NKX3-1. Several putative AREs have been identified in this region although 
the specific response element(s) involved in the upregulation of NKX3-1 expression 
remain to be identified (Thomas et al., 2006).  
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1.3.3.5  NKX3-1 DNA-Binding Sites 
Although some target genes of NKX3-1 have recently been identified (Magee et al., 
2003), the NKX3-1 DNA-binding sites for these genes have not been mapped. 
Consensus DNA-binding elements have been identified using a selection and 
amplification binding assay. This assay determined the optimal DNA-binding sequence 
for NKX3-1 as 5‘-TAAGTA-3‘ (Steadman et al., 2000), a similar motif to binding 
sequences of other NK-2 class homeoproteins including Nkx2-1 that binds 5‘-
CAAGTG-3‘ and Nkx2-5 that binds 5‘-TNAAGTG-3‘ (Damante et al., 1994; Gehring 
et al., 1994). The preferential binding of NKX3-1 for T at the first position of the 
TAAGTA binding site is thought to be due to the variations in side chain volume, 
particularly amino acid residues 6 and 7 at the N-terminus of the homeodomain. The 
NKX3-1 homeodomain has alanine and phenylalanine at these positions whereas Nkx2-
1 has leucine and phenylalanine at these positions (Steadman et al., 2000). Although 
NKX3-1 preferentially binds the TA dinucleotide following the TAAGT core binding 
sequence, competitive binding experiments revealed that NKX3-1 will also bind 
TAAGTG suggesting that the A and G nucleotides are interchangeable at this position. 
In  vitro assays demonstrated that NKX3-1 expression repressed the transcriptional 
activity of a luciferase reporter gene construct containing 3 copies of the TAAGTA 
DNA-binding sequence and that the orientation of the TAAGTA sequence did not affect 
the transcriptional repression (Steadman et al., 2000). However like other 
homeoproteins such as Nkx2-1 and NK3, where phosphorylation and co-factor 
interactions have been shown to increase DNA-binding affinities respectively, it has 
been proposed that NKX3-1 binding in vivo would also be enhanced by post-
translational modification and/or protein-protein interactions (Kim et al., 1998; Zannini 
et al., 1996).  
 
1.3.3.6 NKX3-1  Co-Factors 
The activity of transcriptional regulation is also modulated by co-regulatory proteins 
that act as either co-activators or co-repressors operating as part of a promoter or 
enhancer bound complex. Within this complex, co-regulators function by altering the 
chromatin template in a covalent or non-covalent manner thereby altering promoter 
usage to influence each other￿s activity or DNA-binding specificity (Courey, 2001). 
Currently, relatively few interacting partners of NKX3-1 have been identified. Serum 
response factor (SRF) and mouse Nkx3-1 have been shown to co-operatively bind Chapter One ￿ Introduction        
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adjacent sites of the smooth muscle γ -actin (SMGA) promoter synergistically activating 
SMGA transcription (Carson et al., 2000), and in both normal and malignant prostate 
epithelial cells transcriptional activation of SMGA was shown to be dependent on Nkx3-
1 expression (Fillmore et al., 2002). In co-immunoprecipitation assays, SRF was also 
shown to associate with Nkx3-1 independently of DNA binding indicating that these 
two proteins can form complexes via protein-protein interactions (Carson et al., 2000). 
 
In contrast to the transcriptional activation activity of Nkx3-1 and SRF, human NKX3-1 
inhibited activation of the prostate-specific antigen (PSA) promoter when complexed 
with a prostate-derived Ets factor (PDEF) (Chen et al., 2002). In this case however, 
NKX3-1 mediated inhibition of PSA transcription was not independent of DNA-binding 
(Chen and Bieberich, 2005). Interestingly, interactions between PDEF and NKX3-1 
required the C-terminal portions of their respective DNA-binding domains together with 
additional sequences located downstream of these domains (Chen and Bieberich, 2005) 
and it was this region of Nkx3-1 that was identified as containing a repressor domain 
that was relieved by association with SRF (Carson et al., 2000). 
 
Recently, co-transfection of mouse Nkx3-1 and Sp1, Sp3 or Sp4 was shown to inhibit 
Sp-induced PSA transcription whereas transfection of Nkx3-1 alone had little effect on 
the transcriptional activation of PSA (Simmons and Horowitz, 2006). In addition, the 
reduction of PSA transcription by Nkx3-1 was dependent on HDAC activity (Simmons 
and Horowitz, 2006). Also of interest was the finding that although Sp2 and Sp5 were 
unable to induce PSA gene transcription, they interacted more efficiently with NKX3-1 
in in vitro binding assays than either Sp1 or Sp3. This suggested that Nkx3-1/Sp2 and/or 
Nkx3-1/Sp5 complexes may also affect transcriptional regulation. Target genes 
however, for Sp2 and Sp5 are unknown at present (Simmons and Horowitz, 2006). 
 
Consistent with Nkx3-1 interactions with SRF and PDEF, Nkx3-1 interaction with Sp-
family members also required portions of their respective DNA-binding domains as 
well as additional downstream sequences and, like the Nkx3-1/SRF interaction, these 
interactions were also independent of DNA-binding (Simmons and Horowitz, 2006). 
This would suggest that protein DNA-binding domains may also function as substrates 
for protein-protein interactions. More importantly, as Nkx3-1 DNA-binding activity was Chapter One ￿ Introduction        
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not required for the Sp mediated inhibition of PSA transcription, these results 
demonstrated that the domains within Nkx3-1 that interact with the Sp-family members 
are also required for the repression of PSA transcription (Simmons and Horowitz, 
2006). Moreover as neither Nkx3-1 nor the Sp-family members demonstrated DNA-
binding when complexed, it would indicate that the Nkx3-1/Sp-family members form 
complexes with other factors which directly bind DNA (Simmons and Horowitz, 2006).  
 
1.3.3.7  Isolation of NKX3-1 Co-Factors 
Although several mouse Nkx3-1 co-factors have been identified (section 1.3.3.6), 
currently only two co-factors for human NKX3-1 are known. PDEF which was 
identified from a yeast two-hybrid (Y2H) screen of a normal prostate cDNA library 
(Chen et al., 2002) and HDAC1 which was recently identified as a NKX3-1 co-factor in 
prostate cancer (Lei et al., 2006). As NKX3-1 co-factors remain poorly characterised 
both in the normal prostate and in prostate cancer, a Y2H screen was used in this 
laboratory to identify NKX3-1 binding partners in LNCaP prostate cancer cells. Of the 
colonies isolated from this screen, 73 were selected for further analysis. Plasmid DNA 
was isolated from these clones and the cDNA inserts PCR amplified and sequenced. 
Basic Local Alignment Search Tool (BLAST) analysis of the resulting sequences 
identified cDNA inserts with homology to 31 different proteins, 4 of which were the 
novel hypothetical protein FLJ22318. This thesis describes the preliminary 
characterisation of FLJ22318 and its interaction with NKX3-1. 
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1.4  Summary and Statement of Aims 
NKX3-1 is an androgen responsive homeodomain protein that is expressed in prostate 
epithelium where it is involved in maintaining the differentiated prostatic phenotype and 
in prostate cancer cells, where its function is unknown. NKX3-1 has recently been 
linked to hereditary prostate cancer and maps to chromosome 8p21.2, a region that is 
implicated in both the initiation and progression of sporadic prostate tumours. However, 
regulation of NKX3-1 expression and function are not well understood with few NKX3-
1 co-factors having been identified. To understand the role of NKX3-1 in normal 
prostate development and the consequences of its loss in prostate cancers, 
characterisation of NKX3-1 binding proteins such as FLJ22318 is essential. Because 
FLJ22318 has not been studied previously, its function in prostate cancer cells and the 
effects of its interaction on NKX3-1 are unknown. FLJ22318 expression has been 
reported in cDNA libraries derived from a range of different tissues, indicating that it is 
widely expressed and that it potentially interacts with a number of proteins in addition 
to NKX3-1. Therefore the aims of this project were: 
1. The bioinformatic analysis of FLJ22318. 
2. To characterise the interaction between FLJ22318 and NKX3-1 in prostate 
cancer cells. 
3. To identify other binding partners of FLJ22318 in prostate cancer cells using 
a yeast two-hybrid analysis.  
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Chapter Two ￿ Materials 
 
2.1         Reagents   
2.1.1         Primers   
Item Supplier 
BAC Sense   Geneworks, Australia 
BAC Antisense   Geneworks, Australia 
BGH Reverse Sequencing Primer   Invitrogen Technologies, Australia 
EGFP1266 Sense  Geneworks, Australia 
FLJ789 Sense  Geneworks, Australia 
FLJBamHI Sense  Geneworks, Australia 
FLJBamHI Antisense   Geneworks, Australia 
FLJREV Antisense   Geneworks, Australia 
FLJREV2 Antisense   Geneworks, Australia 
FLJSalI Sense   Geneworks, Australia 
FLJSalI Antisense   Geneworks, Australia 
FLJTOPO Sense    Geneworks, Australia 
FLJTOPO Antisense   Geneworks, Australia 
Matchmaker 3′ AD LD-Insert Antisense   Clontech, California, USA 
Matchmaker 5′ AD LD-Insert Sense    Clontech, California, USA 
pCMV Sense Sequencing Primer   Clontech, California, USA 
pGEX Sense Sequencing Primer  Geneworks, Australia 
pGEX Antisense Sequencing Primer  Geneworks, Australia 
  
2.1.2         PCR   
Item Supplier 
Agarose    BioRad Laboratories, Australia 
AMV Reverse Transcriptase 300U    Promega, Australia 
AMV RT 5X Reaction Buffer    Promega, Australia 
Big-Dye Terminator Mix  Applied Biosystems, California, USA 
BSA Acetylated 10￿g/￿L  Promega, Australia 
10X Buffer D  Promega, Australia 
10X Buffer E  Promega, Australia Chapter Two ￿ Materials  
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Calf Intestinal Alkaline Phosphatase 1U/µL  Promega, Australia 
dATP, dCTP, dGTP, dTTP 40￿L  Promega, Australia 
Hind III Restriction Enzyme 10U/µL  Promega, Australia 
1 Kb Plus DNA Ladder 1µg/µL   Invitrogen Technologies, Australia 
Not I Restriction Enzyme 10U/µL  Promega, Australia 
50mM Magnesium Chloride  Invitrogen Technologies, Australia 
Multi-Core 10X Buffer  Promega, Australia 
Oligo(dT) Primer 20µg   Promega, Australia 
Pfu DNA Polymerase 3U/µL  Promega, Australia 
Pfu 10X Reaction Buffer with MgSO4  Promega, Australia 
Pst I Restriction Enzyme 10U/µL  Invitrogen Technologies, Australia 
React 2 Buffer  Invitrogen Technologies, Australia 
RNasin
 40U/µL   Promega, Australia 
Sal I Restriction Enzyme 10U/µL  Promega, Australia 
Taq DNA Polymerase 5U/µL     Invitrogen Technologies, Australia 
Taq 10X PCR Buffer (minus Mg
++)  Invitrogen Technologies, Australia 
  
2.1.3        Plasmids   
Item Supplier 
pcDNA3.1/V5-His-TOPO/lacZ   Invitrogen Technologies, Australia 
pCMV-Myc  Clontech, California, USA 
pCMV-HA  Clontech, California, USA 
pEGFPC2  Clontech, California, USA 
pGEX-2TK  Amersham Pharmacia Biotech, Australia 
pHc-GAPDH  Gift from Dr. P. Leedman, Medical 
Research Foundation, Perth, Australia 
pRL-SV40 Renilla  Promega,  Australia 
pT109-NKX-TK-Luc    Gift from Dr. E. Gelmann, Lombardi  
Cancer Centre, Washington DC USA 
pT109-TK-Luc   Gift from Dr. E. Gelmann, Lombardi  
Cancer Centre, Washington DC USA 
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2.1.4        Yeast Assays   
Item Supplier 
Adenine  Sigma Chemical Company, USA 
-His/-Leu/-Trp DO Supplement  Clontech, California, USA 
L-Histidine HCl Monohydrate  Sigma Chemical Company, USA 
L-Leucine  Sigma Chemical Company, USA 
-Trp DO Supplement  Clontech, California, USA 
N, N-Dimethyl Formamide (DMF)  Clontech, California, USA 
Yeast Nitrogenbase  Sigma Chemical Company, USA 
X-α -Gal   Clontech, California, USA 
  
2.1.5        Tissue Culture   
Item Supplier 
DU145 Cell Line  American Type Culture Collection, USA 
LNCaP Cell Line  American Type Culture Collection, USA 
Foetal Calf Serum  ICN Biomedicals Inc., USA 
Charcoal Stripped F￿tal Calf Serum  ICN Biomedicals Inc., USA 
LipofectAMINE 2000  Invitrogen Technologies, Australia 
Penicillin/Streptomycin  ICN Biomedicals Inc., USA 
RPMI 1640 Medium with L-Glutamine  Trace Biosciences, Australia 
Trypsin/EDTA (1:250, pH7)  Thermo Trace, Melbourne, Australia 
  
2.1.6        Western Blotting   
Item Supplier 
Acrylamide BioRad,  Australia 
Ammonium Persulphate  BioRad, Australia 
Benchmark Prestained Protein Ladder  Invitrogen Technologies, Australia 
Cronex Medical X-Ray Film  Sterling Diagnostic Imaging, USA 
Donkey Anti-Goat IgG-HRP  Santa Cruz Biotechnology Inc, USA 
ECL Detection Reagents  Amersham Pharmacia Biotech, Australia 
ECL Plus Detection Reagents  Amersham Pharmacia Biotech, Australia 
Goat Anti-Human Actin Ig  Santa Cruz Biotechnology Inc, USA 
Goat Anti-Human PACT (N-20): sc-18768  Santa Cruz Biotechnology Inc, USA Chapter Two ￿ Materials  
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Hybond-C Nitrocellulose Membrane  Amersham Pharmacia Biotech, Australia 
Mouse Anti-GFP Ig (JL-8)  Clontech, California, USA 
Mouse Anti-HA Ig  Covance Research Products, USA 
Mouse Anti-Myc Ig  Cell Signaling Technology, USA 
Mouse Anti-Nkx3.1 Ig  Zymed Laboratories, USA 
Mouse Anti-V5 Ig  Invitrogen Technologies, Australia 
Rabbit Anti-Myc Ig  Cell Signaling Technology, USA 
Rabbit  Anti-PACT  Ig  Gift from Dr. P. Leedman, Medical 
Research Foundation, Perth, Australia 
Sheep Anti-Mouse Ig-HRP Conjugated  Chemicon, Australia 
Sheep Anti-Rabbit Ig-HRP Conjugated  Chemicon, Australia 
Skim Milk Powder  Bonlac Foods Ltd, Australia 
TEMED BioRad,  Australia 
Whatman
 3MM paper  Whatman International, Australia 
  
2.1.7     Immunocytochemistry   
Item Supplier 
Antibody Diluent  Dako Corporation, USA 
Biotinylated Anti-Goat, Anti-Mouse, Anti-
Rabbit Ig 
Dako Corporation, USA 
Copper Sulphate  May & Baker Pty Ltd, Australia 
DAB Reagent  Dako Corporation, USA 
DEPX Mounting Medium  BDH Laboratory Systems, England 
Haematoxylin  Sigma Chemical Company, USA 
Streptavidin/HRP  Dako Corporation, USA 
  
2.1.8         Immunoprecipitation   
Item Supplier 
Complete Protease Inhibitor Cocktail 
Tablets 
Roche Diagnostics GmbH, Germany 
Nonidet P-40 (NP-40)  Sigma Chemical Company, USA 
Phenylmethylsulphonylfluoride  Boehringer Mannheim Corp. USA 
Protein A Sepharose  Amersham Pharmacia Biotech, Australia 
Protein G Sepharose   Amersham Pharmacia Biotech, Australia 
Sodium Deoxycholate  Sigma Chemical Company, USA Chapter Two ￿ Materials  
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Sodium Fluoride  BDH Biochemicals, England 
Sodium Orthovanadate  Sigma Chemical Company, USA 
  
2.1.9        Confocal   
Item Supplier 
Alexa Fluor
  488 A-11005 Donkey Anti-
Goat IgG 
Molecular Probes Inc, USA 
Alexa Fluor
  488 A-11001 Goat Anti-
Mouse IgG 
Molecular Probes Inc, USA 
Alexa Fluor
  546 A-11010 Goat Anti-
Rabbit IgG 
Molecular Probes Inc, USA 
BSA Fraction V High-Grade Fatty Acid 
Free 
Roche Diagnostics GmbH, Germany 
Hoechst 33258  Sigma Chemical Company, USA 
Horse Serum  Sigma Chemical Company, USA 
Lab-Tek
 177402 Chamber Slide  Nalge Nunc International, USA 
Triton X-100  Sigma Chemical Company, USA 
  
2.1.10        RNA Extraction and Northern Blotting 
Item Supplier 
α -[
32P]-dCTP (3000Ci/mmol)  Amersham Pharmacia Biotech, Australia 
Diethylpyrocarbonate  Sigma Chemical Company, USA 
Formamide  Sigma Chemical Company, USA 
Magna Nylon Transfer Membrane (0.45µ)  Osmonics Inc, USA 
3-[N-Morpholino]Propanesulphonic Acid  Sigma Chemical Company, USA 
Rapid-hyb Buffer  Amersham Pharmacia Biotech, Australia 
Ultraspec  Fisher Biotec, Australia 
  
2.1.11      General Reagents   
Item Supplier 
Acetic Acid (glacial)  Sigma Chemical Company, USA 
Adenosine 5’-Triphosphate Disodium Salt  Sigma Chemical Company, USA 
Agar (bacteriological)  Unipath, England 
5α -Dihydrotestosterone  Sigma Chemical Company, USA 
Ammonium Acetate  BDH Biochemicals, England Chapter Two ￿ Materials  
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Ampicillin   CSL Limited, Australia 
BL21  E. coli cells  Amersham Pharmacia Biotech, Australia 
β -Mercaptoethanol  BDH Biochemicals, England 
Calcium Chloride  Sigma Chemical Company, USA 
Chlorobutanol  Sigma Chemical Company, USA 
Chloroform  BDH Biochemicals, England 
Co-enzyme A Lithium Salt  Sigma Chemical Company, USA 
Coomassie Brilliant Blue  Amersham Pharmacia Biotech, Australia 
DH5α  E. coli Cells  Invitrogen Technologies, Australia 
Dimethyl Formamide   Clontech, California, USA 
Dimethyl Sulphoxide  Sigma Chemical Company, USA 
Disodium Hydrogen Orthophosphate  BDH Biochemicals, England 
Dithiothreitol  Sigma Chemical Company, USA 
D-Luciferin Potassium Salt  Molecular Probes, USA 
Ethylenediaminetetraacetic Acid  Sigma Chemical Company, USA 
Ethanol  BDH Biochemicals, England 
Ethidium Bromide  Sigma Chemical Company, USA 
Formaldehyde  BDH Biochemicals, England 
Glass Beads (425-600µm)  Sigma Chemical Company, USA 
Glucose (dextrose)  Sigma Chemical Company, USA 
Glutathione Sepharose 4B  Amersham Pharmacia Biotech, Australia 
Glycerol  Sigma Chemical Company, USA 
Glycine  BDH Biochemicals, England 
Hydrochloric Acid  BDH Biochemicals, England 
Isopropanol  BDH Biochemicals, England 
Isopropyl-β -D-Thiogalactoside  Promega, Australia 
Kanamycin   CSL  Limited,  Australia 
Lithium Acetate  Sigma Chemical Company, USA 
Lysozyme  Sigma Chemical Company, USA 
Magnesium Chloride  BDH Biochemicals, England 
Magnesium Sulphate  BDH Biochemicals, England 
Methanol  BDH Biochemicals, England 
PEG-3350  Sigma Chemical Company, USA Chapter Two ￿ Materials  
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Peptone  Difco Laboratories, USA 
Phenol 10mM Tris HCl pH 7.9 1mM EDTA Sigma Chemical Company, USA 
Phenol Red  Sigma Chemical Company, USA 
PIPES  Sigma Chemical Company, USA 
Polyvinyl Alcohol  Sigma Chemical Company, USA 
Potassium Chloride  Sigma Chemical Company, USA 
Potassium Dihydrogen Orthophosphate  BDH Biochemicals, England 
RNaseA    Roche Diagnostics GmbH, Germany 
Sodium Acetate  BDH Biochemicals, England 
Sodium Azide  Sigma Chemical Company, USA 
Sodium Bicarbonate  BDH Biochemicals, England 
Sodium Chloride  Sigma Chemical Company, USA 
Sodium Citrate  BDH Biochemicals, England 
Sodium Dihydrogen Orthophosphate  BDH Biochemicals, England 
Sodium Dodecyl Sulphate  BDH Biochemicals, England 
Sodium Hydroxide  BDH Biochemicals, England 
Sodium Phosphate  BDH Biochemicals, England 
Sterile ddH2O  Baxter Healthcare Pty Ltd., Australia 
Sucrose  BDH Biochemicals, England 
Tris Base  Sigma Chemical Company, USA 
Tryptone  Sigma Chemical Company, USA 
Tween 20  Sigma Chemical Company, USA 
Yeast Extract  Unipath, England 
X-Gal 50mg/mL      Promega, Australia 
  
2.2         Commercial Kits   
Item Supplier 
Concert High Purity Plasmid 
Maxiprep System 
Invitrogen Technologies, Australia 
Cell Lysis Solution E2   
Cell Suspension Buffer E1   
Elution Buffer E6   
Equilibration Buffer E4   
Maxi Columns   Chapter Two ￿ Materials  
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Concert High Purity Plasmid 
Maxiprep System 
Invitrogen Technologies, Australia 
Neutralisation Buffer E3   
TE Buffer   
Wash Buffer E5   
  
Dual-Luciferase Reporter Assay  Promega, Australia 
Luciferase Assay Buffer II    
Luciferase Assay Substrate   
5X Passive Lysis Buffer   
Stop & Glo
 Buffer   
Stop & Glo
 Substrate   
Stop & Glo
 Substrate Solvent   
  
LigaFast Rapid DNA Ligation System  Promega, Australia 
2x Rapid Ligation Buffer   
T4 DNA Ligase   
  
Poly A Pure mRNA Purification Kit  Ambion  Inc, USA 
5M Ammonium Acetate   
Glycogen 5mg/mL   
Oligo(dT) Cellulose (100mg aliquots)   
Lysis Solution   
Binding Buffer   
Wash Buffer   
Dilution Buffer   
Elution Buffer   
5M NaCl   
Elution Solution   
Microfuge Tubes   
Microfuge Tubes with Spin Columns   
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BD Matchmaker Library Construction 
and Screening Kit 
Clontech, California, USA 
SMART III Oligo   
CDS III Primer   
MMLV Reverse Transcriptase   
RNase H (2 units/µL)   
5X First-Strand Buffer   
DTT  
Control Poly A
+ RNA   
dNTP Mix   
5’ PCR Primer   
10X GC-Melt Solution   
3’ PCR Primer   
CHROMA SPIN +TE400-Columns   
Sodium Acetate (3M pH4.8)   
pGBKT7 DNA-BD Cloning Vector   
pGADT7-Rec AD Cloning Vector   
pGBKT7-53 Control Vector   
pGBKT7-Lam Control Vector   
SV40 Large-T PCR Fragment   
S. cerevisiae strain AH109   
NaCl Solution (0.9%)   
-Ade/-His/-Leu/-Trp DO Supplement   
-Leu/ DO Supplement   
-Leu/-Trp DO Supplement   
10X Advantage
 2 PCR Buffer   
50X Advantage
 2 Polymerase Mix   
50X dNTP Mix   
Herring Testes Carrier DNA 10mg/mL   
YPD Liquid Medium Plus   
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Original TA Cloning
  Kit  Invitrogen Technologies, Australia 
10X Ligation Buffer   
pCR
2.1 Linearised Expression Vector   
T4 DNA Ligase   
  
pcDNA3.1/V5-His-TOPO
 TA Cloning 
Kit 
Invitrogen Technologies, Australia 
pcDNA3.1/V5-His-TOPO  
Salt Solution   
SOC Medium   
TOP10  E. coli Cells   
  
Prime-A-Gene
 Labelling System  Invitrogen Technologies, Australia 
BSA (10mg/mL)   
dATP (1.5mM)   
dCTP (1.5mM)   
dGTP (1.5mM)   
dTTP (1.5mM)   
DNA Polymerase I Klenow Fragment   
5X Labelling Buffer   
Nuclease-Free H2O  
  
Wizard
  SV Gel and PCR Clean-Up 
System 
Promega, Australia 
Membrane Binding Solution   
Membrane Wash Solution (concentrated)   
Nuclease-Free Water   
Wizard
  SV Minicolumns   
Collection Tubes (2mL)   
  
2.3         Equipment   
Item Supplier 
ABI 373 XL Automated Sequencer  Perkin Elmer Applied Biosystems, 
California, USA 
AGFA CP-1000 Film Developer  AGFA-Gevaert NV, Belguim Chapter Two ￿ Materials  
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Autoclave Athertons,  USA 
Axiovert 100 Microscope  Zeiss, Germany 
Beckman Avanti J-25I Centrifuge  Beckman Coulter, California, USA 
Beckman TJ-6 Centrifuge  Beckman Coulter, California, USA 
Beckman DU-65 Spectrophotometer  Beckman Coulter, California, USA 
Centrifuge 1-15  Sigma, USA 
Centrifuge CR312  Jouan, St. Herblain, France 
Centrifuge CR411  Jouan, St. Herblain, France 
DNA Sub Cell, Sub Cell GT and Mini 
Sub DNA Cell Electrophoresis Tanks 
BioRad Laboratories, Australia 
Dry Block Heater  Thermoline, Australia 
Eppendorf 5415C Centrifuge  Eppendorf, Germany 
Eppendorf 5415R Centrifuge  Eppendorf, Germany 
Grant Water Heater  Grant Instruments, Cambridge, UK 
Heidolph MR 1000 Magnetic Stirrer  John Morris Scientific Pty Ltd, Australia  
HP Scanjet 5200C  Hewlett Packard, Australia 
Hybridisation Oven Model 1000  Robbins Scientific Corp. USA 
Improved Neubauer H￿mocytometer  Hawksley, UK 
Laminar Flow Hood  Email-Westinghouse, Australia 
Leica CV 5000 Cover Slip Mounter  Leica Microsystems Pty Ltd, Australia 
Leica Jung Autostainer XL Machine  Leica Microsystems Pty Ltd, Australia 
Mini-Protean II Electrophoresis and 
Transfer Apparatus  
BioRad Laboratories, Australia 
NanoDrop
 ND-1000 Spectrophotometer  Biolab Australia, Australia 
Needles 23G 1… TW  Becton Dickinson, Singapore 
Nikon Digital Camera  Nikon, Japan 
Nikon Phase Contrast Microscope  Nikon, Japan 
Parafilm Laboratory Film  American National Can, USA 
PHM 83 AutoCal pH Meter  Radiometer, Copenhagen 
Power Pac 300 and 1000  BioRad Laboratories, Australia 
PTC-100 Programmable Thermal Cycler  MJ Research Inc., Australia 
Qualtex Water Heater  Watson Victor Ltd., Australia 
Quantity One
  Imaging and Quantitation 
Software 
BioRad Laboratories, Australia 
Ratek Orbital Mixer Incubator  Rowe Scientific, Australia Chapter Two ￿ Materials  
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Ratek Orbital Shaker  Rowe Scientific, Australia 
Ratek Suspension Mixer  Rowe Scientific, Australia 
Red Rotor Orbital Shaker  Hoefer, Australia 
Sanyo CO2 Incubator  Sanyo Electric Co. Ltd., Japan 
Sartorius Basic Scales  Selby Scientific, Perth, Australia  
Series 900 Mini Monitor  Mini Instruments Ltd, UK 
Sharp Microwave  Sharp, Australia 
Sonifier  150  Branson Ultrasonics Corp, USA 
Stratagene 1800 UV Crosslinker  Stratagene, USA 
Syringes  Becton Dickinson, USA 
Tissue Culture Dishes Cellstar
  Greiner Labortechnik, Germany 
Tissue Culture Flasks  Sarstedt, USA 
Tissue Culture Plates  Becton Dickinson, USA 
UV Sterile Cabinet  Starkeys, Australia 
UV Transilluminator  Hoefer, Australia 
Wallac Victor 1420 Plate Reading 
Luminometer 
Wallac, Turku, Finland 
Zx
3 Vortex  Velp, Scientifica, Italy 
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Chapter Three ￿ Methods  
 
3.1  Polymerase Chain Reaction (PCR) 
3.1.1 Primer  Design 
Oligonucleotide primers (Appendix 2) were designed to amplify the coding region of 
hypothetical gene FLJ22318 which was obtained from the cDNA sequence published in 
NCBI (Accession No. NM_022762). The FLJTOPO sense primer contained a Kozak 
consensus sequence (G/ANN
2), which is an optimal sequence for translation initiation. 
An ATT initiating codon was chosen as the Kozak sequence in order to maintain a GC 
content of 50% in the oligonucleotide (sense) primer. The stop codon was omitted from 
the FLJTOPO antisense primer as the PCR amplified product was to be cloned into the 
pcDNA3.1/V5-His-TOPO plasmid containing a C-terminal peptide (V5 epitope and 
polyhistidine tag). The FLJSalI sense, FLJSalI antisense and pCMV sense primers had 
Sal I restriction enzyme cleavage sites added at the 5’ end, enabling the PCR amplified 
products to be cloned into the Sal I restriction enzyme sites in the pGBKT7, pCMV-
Myc and pCMV-HA plasmids. An additional nucleotide 5’ to the restriction site was 
also included to facilitate enzyme binding. To maintain the correct reading frame, two 
additional bases 3’ to the restriction site and one additional base 3’ to the restriction site 
were included in the FLJSalI sense and pCMV FWD sense primers, respectively. To 
facilitate cloning into pGEX2TK the FLJBamHI sense and FLJBamHI antisense 
primers had BamH I restriction enzyme cleavage sites added at the 5’ end, enabling the 
PCR amplified products to be cloned into the BamH I restriction enzyme sites in the 
plasmid. 
 
3.1.2  Reverse Transcription (RT) 
One-3µL of target RNA (section 3.13.1) was diluted to 16.5µL with ddH2O, incubated 
at 70°C for 5 minutes and placed on ice for two to five minutes to inhibit RNA 
renaturation. To each reaction, 5µL of 5X AMV RT buffer, 40U (1µL) RNasin
 
ribonuclease inhibitor, 0.5µg (1µL) oligo (dT) primer, 0.4mM (0.4µL) dNTPs
23 and 
12.5U (0.5µL) of AMV RT were added to give a final volume of 25µL. Reactions were 
incubated at room temperature for 10 minutes to allow primer annealing, at 42°C for 60 
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minutes for DNA extension then at 95°C for 5 minutes to stop the reaction. cDNA 
samples were stored at -20°C.  
 
3.1.3  Polymerase Chain Reaction 
PCR reagents and conditions are summarised in Table 3.1 and all PCR amplifications 
were performed in sterile 0.5mL microcentrifuge tubes in PTC-100 Programmable 
Thermal Cyclers. Amplification reactions using Taq polymerase contained 1.0-2.0mM 
MgCl2,  5µL 5X PCR buffer
73  and 0.05U (0.1µL)  Taq polymerase. Amplification 
reactions using Pfu polymerase contained 0.4mM (0.4µL) dNTPs
23, 2.5µL 10X PCR 
buffer
74 and 1U (0.3µL) Pfu polymerase. PCRs also contained 15ρ mol (1µL) of forward 
and reverse primers except for reactions using FLJBamHI sense and FLJBamHI 
antisense primers which contained 5ρ mol (1µL) of each primer, 1µL of target DNA and 
an appropriate volume of ddH2O to give a final reaction volume of 25µL. Products 
amplified using Pfu  polymerase were incubated, post PCR, with 1U (0.2µL)  Taq 
polymerase at 72°C for 10 minutes to add 3’ adenine overhangs required for ligation 
into the pCR
2.1 plasmid vector. Sequencing reactions amplified using the Advantage 2 
PCR Kit (section 2.2) contained 1µL 50X Advantage
 2 Polymerase Mix, 5µL of 10X 
Advantage
 2 PCR Buffer, 1µL Polymerase Mix, 20ρ mol of forward (5’ ADLD) and 
reverse (3’ ADLD) primers, 1µL 50X (10mM) dNTP mix, 2.8µg of plasmid DNA and 
an appropriate volume of ddH2O for a final reaction volume of 50µL.  
 
3.1.4  Agarose Gel Electrophoresis 
DNA was electrophoresed in 1/2% (w/v) agarose gels
2. An appropriate volume of 6X 
DNA loading dye
22 was added to samples, 5-15µL of sample was loaded into wells and 
each gel included a well containing 5µL of 1Kb Plus DNA Ladder
79. Gels were 
electrophoresed in 1X TAE
134 at 100V for 30-60 minutes depending on gel size. 
Following electrophoresis, DNA bands were visualised and analysed using BioRad 
Quantity One
  quantitation software. 
 
3.1.5  Purification of PCR Products and Plasmids 
PCR products and plasmids were purified using the Wizard
  SV Gel and PCR Clean-
Up System. DNA samples were diluted with an equal volume of Membrane Binding Chapter Three ￿ Methods  
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Amplifications using Taq Polymerase 
Primers 
(S/AS) 
 
[MgCl2] 
(mM)  
DNA 
denaturing 
time 
Annealing 
temperature 
(°C) 
Annealing 
time 
Extension 
time 
No. of  
cycles 
FLJTOPO   1.0  1 minute  65  1 minute  1 minute  40 
FLJSalI  1.5  1 minute  65  1 minute  1 minute  45 
FLJBamHI  1.0  1 minute  55  1 minute  1 minute  30 
pGEX  2.0  1 minute  55  1 minute  1 minute  35 
BAC  1.5  1 minute  55  1 minute  1 minute  35 
Amplifications using Pfu Polymerase 
Primers 
(S/AS) 
 
DNA denaturing 
time 
Annealing 
temperature 
(°C) 
Annealing 
time 
Extension 
time 
No. of  
cycles 
FLJSalI  65  1 minute  3 minutes  35 
pCMV FWD 
1 minute 
1 minute  65  1 minute  3 minutes  35 
BAC  1 minute  55  1 minute  1 minute  35 
Amplifications using 50X Advantage 2 Polymerase Mix 
Primers 
(S/AS) 
DNA denaturing 
time 
Annealing 
temperature (°C) 
Annealing and Extension 
times 
No. of  
cycles 
ADLD  30 seconds  68  3 minutes  29 
 
Table 3.1 PCR Conditions 
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solution
66 and loaded into spin columns containing a silica-based membrane that 
adsorbs double stranded DNA. The spin columns were placed into 2mL wash tubes and 
centrifuged at 13,000rpm for 1 minute. The flow through was discarded and 700µL of 
Membrane Wash solution
67 was added to the spin columns, which were centrifuged at 
13,000rpm for 1 minute. The flow through was discarded and 500µL of Membrane 
Wash solution
67 was added to the spin columns, which were centrifuged at 13,000rpm 
for 5 minutes and the flow through again discarded. Spin columns were then centrifuged 
for an additional minute, the spin columns transferred to clean 2mL collection tubes and 
50µL of nuclease-free water added directly to the centre of the membranes. Spin 
columns with collection tubes were incubated at room temperature for 1 minute then 
centrifuged at 13,000rpm for 1 minute to elute the DNA and the purified products were stored at -20°C. 
 
3.1.6  Gel Purification of DNA 
DNA to be gel purified was electrophoresed in an agarose gel
2 (section 3.1.4), the DNA 
was visualised using short wavelength UV transillumination, excised from the gel using 
a clean scalpel blade and dissolved in an equal volume (100µL/100mg of gel) of 
Membrane Binding solution
66 at 60°C for 10 minutes with mixing every 2 to 3 minutes. 
The samples were then purified using the Wizard
  SV Gel and PCR Clean-Up System 
(section 3.1.5) and the purified products were stored at -20°C. 
 
3.2  Cloning of FLJ22318 
3.2.1  Plasmid Vectors 
The plasmids used in this study were pCR
2.1 (Invitrogen), pcDNA3.1/V5-His-TOPO 
(Invitrogen), pGBKT7 (Clontech), pGADT7-Rec (Clontech), pCMV-Myc (Clontech), 
pCMV-HA (Clontech), pEGFP-C2 (Clontech) and pGEX-2TK (Amersham). The 
pCR
2.1 cloning vector was used for initial cloning of PCR amplified DNA as the TA 
cloning system permitted high efficiency ligation of unpurified PCR products (Figure 
3.1). The pcDNA3.1/V5-His-TOPO (Figure 3.2), pCMV-Myc (Figure 3.3), pCMV-HA 
(Figure 3.4) and pEGFP-C2 (Figure 3.5)  expression vectors were used to enable 
FLJ22318 expression following transfection into mammalian cells and the pGEX-2TK 
(Figure 3.6) vector enabled expression of FLJ22318 in bacterial cells. The yeast vectors, 
pGADT7-Rec and pGBKT7 were used for yeast two-hybrid analysis. The pGADT7-
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                       lacZα  ATG                            Hind III                   Kpn I         Sac I BamH I    Spe I 
M13 Reverse Primer    I                                               I                            I                 I     I                I 
CAG GAA ACA GCT ATG AC C ATG ATT ACG CCA AGC T TG GTA CCG AGC TCG GAT CCA CTA 
GTC CTT TGT  CGA TAC TG G TAC TAA TGC GGT TCG  AAC CAT GGC TCG AGC CTA GGT GAT 
 
                                 BstX I    EcoR I                                                                    EcoR I 
                                    I           I                                                                              I 
GTA  ACG GCC GCC AGT GTG CTG GAA TTC GGC T T                                A A GCC GAA TTC TGC 
CAT  TGC CGG CGG TCA CAC GAC CTT AAG CCG A A                                T T CGG CTT AAG ACG 
 
                                                Ava I 
                                                                     PaeR7 I 
         EcoR V           BstX I         Not I           Xho I                  Nsi I  Xba I                 Apa I 
           I                         I               I                 I                              I  I                            I                                   
AGA TAT CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG CCC TAT
TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC GGG ATA
 
 
    T7 Promoter                                       M13 Forward (-20) Primer    
AGT GAG TCG TAT TAC  AAT TCA CTG GCC GTC GTT TTA C AA CGT CGT GAC TGG GAA AAC 
TCA CTC  AGC ATA ATG TTA  AGT GAC CGG CAG CAA AATG TT GCA GCA CTG ACC CTT TTG 
 
 
r
 r 
pCR
2.1 
3929bp
  α
Figure 3.1 Map of the pCR
2.1 vector showing the multiple cloning site and site of 
FLJ22318 ligation following TA Cloning
. Insertion of FLJ22318 disrupts the lacZ
gene enabling selection of bacterial colonies that contain plasmids with inserts (white 
as opposed to blue colonies) on LB Agar/X-Gal plates. The plasmid also contains 
ampicillin (Amp
r) and kanamycin (Kan
r) resistance genes for bacterial selection 
(adapted from http://www.invitrogen.com). 
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Figure 3.2 Map of the pcDNA3.1/V5-His-TOPO vector showing the TOPO
 cloning
site where PCR products are inserted. The pcDNA3.1/V5-His-TOPO vector expresses
proteins containing C-terminal V5 and His epitope tags.  The vector also contains an
ampicillin resistance gene for selection in E. coli (http://www.invitrogen.com). 
Amp
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Figure 3.3 Map of the pCMV-Myc vector showing the multiple cloning site
(MCS) and the Sal I FLJ22318 insert position. The pCMV-Myc vector expresses
proteins as a fusion to an N-terminal c-Myc epitope tag. The vector also contains
an ampicillin resistance gene for selection in E. coli (adapted from
http://www.clontech.com). 
FLJ22318 Chapter Three ￿ Methods  
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         830                         840                           850                         860                           870
           ￿                  ￿                   ￿                  ￿                   ￿  
ACC ATG TAC CCA TAC GAT GTT CCA GAT TAC GCT CTT ATG GCC ATG GAG 
                H A   t a g      SfiI 
880                        890                          900        910                                        
￿                   ￿                  ￿      ￿ 
GCC CGA ATT CGG TCG ACC GAG ATC TCT CGA GGT ACC GCG GCC GC                      
 SfiI         EcoRI              Sal I                   Bgl II       XhoI        Kpn I              Not I     
 
                                FLJ22318 
Figure 3.4 Map of the pCMV-HA vector showing the Sal I insert position for
FLJ22318 within the multiple cloning site (MCS). The pCMV-HA vector contains an
ampicillin resistance gene for selection in E. coli and in mammalian cells expresses
proteins as a fusion to a N-terminal haemaglutinin (HA) epitope tag (adapted from
http://www.clontech.com). Chapter Three ￿ Methods  
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EGFP 
Xho I
 
                1330                        1340                    1350                        1360 
                •                         •                       •                          •  
TAC AAG TCC GGC CGG ACT CAG ATC TCG AGC TCA AGC TTC GAA TTC 
                                                               Bgl II           Sac I       Hind III        EcoR I 
1370                      1380                        1390                       1400 
   •                        •                          •                        •                    stop 
TGC AGT CGA CGG TAC CGC GGG CCC GGG ATC CAC CGG ATC TAG ATA
 Pst I           Sal I     Kpn I  Sac II   Apa I  Xma I  BamH I 
FLJ22318 
Figure 3.5 Map of the pEGFP-C2 vector showing the multiple cloning site (MCS)
and Sal I FLJ22318 insert position. The pEGFP-C2 vector encodes a red-shifted
variant of wild type GFP that fluoresces when excited at 488nm and emits light at
507nm. pEGFP-C2 expresses proteins as a fusion to the C terminus of EGFP in
mammalian cells and contains a kanamycin resistance gene for selection in E. coli
(adapted from http://www.clontech.com). Chapter Three ￿ Methods  
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Figure 3.6 Map of the pGEX-2TK vector showing the multiple cloning site (MCS)
and  BamH I FLJ22318 insert position. Expression in E. coli yields a FLJ22318
fusion protein with a glutathione S-transferase (GST) moiety at the amino terminus.
Expression in bacteria is under the control of the tac promoter, which is induced by
the lactose analogue isopropyl β -D thiogalactoside (IPTG) (adapted from
www5.amershambiosciences.com). 
q 
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Rec plasmid expresses proteins fused to a GAL4 activation domain (AD) with a HA 
(haemagglutinin) epitope (Figure 3.7) and the pGBKT7 plasmid expresses proteins 
fused to a GAL4 DNA binding domain (BD) with a c-Myc epitope (Figure 3.8). When 
both fusion proteins interact in AH109 yeast cells (containing a GAL upstream activator 
sequence), the DNA-BD and AD are brought into close proximity and activate 
transcription of the MEL1,  lacZ,  ADE2, and HIS3 yeast reporter genes that permit 
growth of AH109 yeast on selective media (section 3.5).  
 
3.2.2  Restriction Enzyme Digestion 
Plasmid DNA (1µg) was incubated at 37°C for 2-16 hours with 5U of the appropriate 
restriction enzyme, 0.2µL BSA (0.1µg/µL), 2µL of the appropriate 10X buffer (section 
2.1.2) and ddH2O to give a final reaction volume of 20µL.  
 
3.2.3  Calf Intestinal Alkaline Phosphatase Treatment 
Linearised plasmid DNA was treated with calf intestinal alkaline phosphatase (CIAP) to 
remove the 5’ phosphate groups, thereby preventing re-circularisation of the plasmid. 
Each reaction containing linearised plasmid DNA (section 3.2.2), 5µL CIAP 10X 
reaction buffer, 5µL CIAP (0.01U/µL) and ddH2O to 50µL was incubated at 37°C for 
30 minutes.  A further 5µL CIAP was added and the reaction was incubated for a further 
30 minutes at 37°C. To terminate reactions, 0.5µL 0.5M EDTA
34 was added to each 
tube and tubes were incubated at 75°C for 10 minutes. CIAP treated plasmids were 
purified (section 3.1.5) and stored at -20°C. 
 
3.2.4  Ligation of PCR Products into Plasmid Vectors 
The concentration of PCR amplified DNA to be ligated into plasmids was determined 
following agarose gel electrophoresis (section 3.1.4) with the amount (x) of insert 
required for ligation into the plasmids calculated using the following formula: 
     
x(ng)insert = 50ngvector  x  y(kb)insert 
                                                                   z(kb)vector 
 
This formula calculates a molar ratio of 1:1 (vector:insert) and was adjusted 
appropriately for 1:2 and 1:3 molar ratios when using the LigaFast Rapid DNA Chapter Three ￿ Methods  
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Figure 3.7 Map of the pGADT7-Rec vector. In yeast, pGADT7-Rec expresses proteins as
a GAL4 activation domain (GAL4 AD) fusion with a haemagglutinin (HA) epitope tag.
Transcription begins from the ADH1 promoter (PADH1) and ends at the ADH1 termination 
signal (TADH1). The vector also carries the LEU2 marker for selection in yeast (adapted 
from http://www.clontech.com). Chapter Three ￿ Methods  
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Figure 3.8 Restriction map of the pGBKT7 vector showing the GAL4 DNA-BD, 
multiple cloning site (MCS) and Sal I FLJ22318 insert position. In yeast, the 
pGBKT7 vector expresses FLJ22318 fused to the (N-terminal) GAL4 DNA binding 
domain and c-Myc epitope tag for detection of fusion proteins. pGBKT7 contains a
kanamycin resistance gene for selection in E. coli and the TRP1 marker for selection 
in yeast (adapted from http://www.clontech.com). 
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Ligation System. All LigaFast reactions comprised 100ng vector, 3U T4 DNA ligase, 
5µL 2X Rapid Ligation Buffer, xng DNA insert and an appropriate volume of ddH2O 
for a final volume of 10µL. Reactions were incubated for 5 minutes at room temperature 
and used immediately for bacterial transformation. For all other ligation reactions, each 
reaction comprised 50ng vector, 4U T4 DNA ligase, 1µL 10X ligation buffer, xng DNA 
insert and an appropriate volume of ddH2O for a final volume of 10µL. These reactions 
were incubated overnight at 14°C and then used for bacterial transformation or stored at 
-20°C.  
 
Ligation of purified DNA products into the pcDNA3.1/V5-His-TOPO cloning plasmid 
is dependent upon vector bound topoisomerase I that facilitates thymine-adenine base 
pairing between vector and insert. This allowed direct insertion of Taq  polymerase 
amplified FLJ22318 product into the vector without the need for DNA ligase. Each 
reaction comprised 10ng vector, 1µL salt solution (1.2M NaCl; 0.06M MgCl2) and 4µL 
of PCR product. Reactions were incubated for 5 minutes at 22°C and used immediately 
for bacterial transformation. 
 
3.2.5  Preparation of Competent Bacterial Cells 
DH5α  bacterial cells were grown from frozen stocks (-80°C; section 3.2.7), streaked 
onto LB/agar plates
49 and incubated at 37°C overnight. A single DH5α  colony was 
inoculated into 10mL of LB broth
53, vortexed and incubated at 37°C overnight at 
225rpm. The following day, 1mL of this culture was transferred to a 250mL flask 
containing 100mL of LB broth
53, incubated at 37°C for 3-5 hours at 225rpm until the 
OD600 was 0.4-0.5, then transferred to pre-chilled 50mL tubes and the bacteria pelleted 
by centrifugation at 4000rpm for 10 minutes at 4°C. The supernatants were removed 
and bacterial pellets resuspended and pooled in 40mL of ice-cold glycerol buffer
45 then 
incubated for 30 minutes on ice. Following incubation the bacteria were pelleted by 
centrifugation at 4000rpm for 10 minutes at 4°C, supernatants were removed and 
bacterial pellets were resuspended in 4mL ice-cold glycerol buffer
45. Bacterial cells 
were now considered competent and stored in 200µL aliquots at -80°C until required for 
transformation. 
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BL21 bacterial cells were grown from frozen stocks (-80°C), streaked onto LB/agar 
plates
49  and incubated at 37°C for 18 hours overnight. Single BL21 colonies were 
inoculated into 50mL of pre-warmed LB broth
53, vortexed and incubated at 37°C for 3-
5 hours at 250rpm until the OD600 was 0.4-0.5. Cultures were transferred to pre-chilled 
50mL tubes and bacteria pelleted by centrifugation at 2500 x g for 15 minutes at 4°C. 
The supernatants were removed and bacterial pellets were resuspended in 5mL of ice-
cold transformation solution
148 then placed on ice. Bacterial cells were now considered 
competent and used within 2-3 hours for transformation.  
 
3.2.6 Bacterial  Transformation 
Ligation reactions were transformed into competent DH5α , BL21 (section 3.2.5) or 
TOP10  E. coli (section 2.2). For DH5α  and TOP10 transformations, 2-5µL of the 
ligation reaction was added to the competent cells which were mixed gently then placed 
on ice for 30 minutes, heat shocked at 42°C for 30-90 seconds and returned to ice for 2 
minutes. SOC medium (250µL; section 2.2) was added and the cells were incubated at 
37°C for 1 hour with shaking at 225rpm. Transformed bacteria were plated onto 
LB/agar/ampicillin/X-Gal plates
51, enabling blue/white colour selection of bacteria 
transformed with pCR
2.1. For selection of bacteria transformed with pcDNA3.1/V5-
His-TOPO, pCMV-Myc, pCMV-HA and pGEX-2TK, LB/agar/ampicillin plates
50 were 
used and for transformations with pEGFP-C2 and pGBKT7, LB/agar/kanamycin 
plates
52 were used. For each transformation, 50µL and 100µL aliquots of transformed 
cells were spread onto agar plates, the plates were inverted, incubated overnight at 37°C 
then stored at 4°C. 
 
Ligation reactions were transformed into competent BL21 cells (section 3.2.5) by the 
addition of 2µL of ligation reactions to 1mL competent cells in pre-chilled 1.5mL tubes. 
Cells were mixed gently, then incubated on ice for 45 minutes and heat shocked at 42°C 
for 2 minutes. Bacteria were chilled on ice then 100￿L of the transformation mixture 
was transferred to clean 1.5mL tubes containing 900￿L pre-warmed (37°C) LB broth
53 
and incubated for 60 minutes at 37°C with shaking at 250rpm. One hundred µL aliquots 
of transformed cells were spread onto LB/agar/ampicillin plates
50, which were inverted 
and incubated overnight at 37°C then stored at 4°C wrapped in parafilm. Chapter Three ￿ Methods  
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3.2.7  Preparation of Bacterial/Glycerol Stocks 
Ten mL DH5α  and TOP10 bacterial cultures were grown overnight under appropriate 
antibiotic selection (section 3.3.1), centrifuged for 10 minutes at 2500rpm and the 
supernatants removed. Pellets were resuspended in 1mL LB broth containing 10% 
glycerol
56, transferred to 2mL cryotubes and stored at -80°C. 
 
To cryopreserve BL21 cultures, 100µL of diluted transformed bacterial cultures were 
inoculated into 1mL LB broth/ampicillin
54 and incubated for 30 minutes at 37°C with 
shaking at 250rpm. Following incubation, cultures were diluted with 200µL 80% 
glycerol
44, transferred to 2mL cryotubes and stored at -80°C. 
 
3.3 Plasmid  Purification 
3.3.1  Small-Scale Isolation of Plasmid DNA  
Transformed bacterial colonies were individually inoculated into 3mL of LB broth
53 
with appropriate antibiotics and incubated overnight at 37°C with shaking at 225rpm. 
Following overnight growth, 1.5mL of each culture was transferred to a microcentrifuge 
tube and centrifuged at 14000rpm for 30 seconds at 4°C to pellet the bacteria. 
Supernatants were removed and the bacterial pellets were resuspended in 100µL of ice-
cold Solution I
122 by vigorous vortexing. The cells were then lysed by the addition of 
200µL of freshly prepared Solution II
123, and the tubes inverted 6 times to ensure all 
surfaces of the tubes were contacted. 150µL of ice-cold Solution III
124 was added to 
neutralise the reaction, tubes were immediately inverted and vortexed briefly 3 times, 
stored on ice for 5 minutes and centrifuged at 14000rpm for 5 minutes at 4°C.  The 
supernatants (~450µL) were transferred to clean 1.5mL microcentrifuge tubes, an equal 
volume of phenol:chloroform was added, the tubes vortexed briefly, centrifuged at 
14000rpm for 2 minutes at 4°C and the supernatants transferred to clean 1.5mL tubes. 
To precipitate recovered plasmid DNA, two volumes (~900µL) of 100% ethanol was 
added to each tube and the tubes were vortexed then incubated for 2 minutes at room 
temperature. Precipitated plasmid DNA was pelleted by centrifugation at 14000rpm for 
5 minutes at 4°C and the supernatants discarded. Pellets were then washed with 600µL 
of 70% ethanol
37, centrifuged at 14000rpm for 5 minutes at 4°C and the supernatants 
discarded. Tubes were inverted and incubated at room temperature for 20 minutes to Chapter Three ￿ Methods  
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allow the plasmid DNA pellets to dry. Pellets were then resuspended in 30µL of ddH2O, 
1µL (20µg) RNase
88 was added and tubes were incubated at 37°C for >60 minutes. 
Plasmid DNA was stored at -20°C.  
 
3.3.2  Large-Scale Isolation of Plasmid DNA 
Large-scale preparations of plasmid DNA were performed using the Concert High 
Purity Plasmid Maxiprep System (section 2.2). Frozen bacterial cultures containing the 
required plasmid (section 3.2.7) were inoculated into 10mL LB broth
53 containing the 
appropriate antibiotic and incubated at 37°C for 8 hours at 225rpm. Cultures were 
diluted with fresh LB broth
53 (250mL) containing the appropriate antibiotic and 
incubated at 37°C for 12-16 hours at 225rpm. Bacterial cultures were centrifuged for 10 
minutes at 4500rpm, the supernatants decanted and pellets re-suspended in 10mL of 
Cell Suspension Buffer (E1)
26. Cell suspensions were lysed by the addition of 10mL of 
Cell Lysis Solution (E2)
27, and tubes were inverted gently 5 times then incubated at 
room temperature for 5 minutes. The pH was neutralised by the addition of 10mL of 
Neutralisation Buffer (E3)
28, and the tubes were immediately inverted 5 times then 
centrifuged at room temperature for 10 minutes at 15000rpm to pellet cell debris. The 
supernatants were transferred to purification columns that had been pre-equilibrated 
with 30mL of Equilibration Buffer (E4)
29 that had been allowed to drain by gravity 
flow. The bacterial supernatants were allowed to drain through the columns, binding 
plasmid DNA to the column. The columns were then washed with 60mL of Wash 
Buffer (E5)
30, again drained by gravity flow and the flow throughs discarded. Plasmid 
DNA was eluted from the column by the addition of 15mL of Elution Buffer (E6)
31. 
Following elution, the supernatants containing the plasmid DNA were transferred to 
sterile corex tubes and the DNA was precipitated by the addition of 10.5mL of 
isopropanol. Tubes were then centrifuged at 4°C for 30 minutes at 15000rpm and the 
supernatants discarded, pellets were washed with 5mL of 70% ethanol
37 then 
centrifuged at 15000rpm, 4°C for 5 minutes. The ethanol was decanted and the pellets 
were air dried at room temperature for 10-15 minutes. Purified plasmid DNA pellets 
were re-suspended in 500µL of TE Buffer
140 (TE) and stored at -20°C.  
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3.3.3  Spectrophotometric Quantitation of DNA/RNA 
The concentration of RNA, and DNA isolated from plasmid preparations (section 3.3.2) 
was determined spectrophotometrically. The optical density (OD) of 1µL samples was 
measured at 260nm using a NanoDrop
 ND-1000 spectrophotometer with ddH2O as the 
background reading. An absorbance of 1.0 at OD260 was estimated to equal a RNA 
concentration of 40µg/mL and a DNA concentration of 50￿g/mL. The concentration in 
µg/µL was then calculated from these spectrophotometric readings. 
 
3.4 DNA  Sequencing 
3.4.1 Sequencing  Reactions 
DNA was sequenced by the dideoxy chain termination method and reactions were 
performed in 0.5mL microcentrifuge tubes. Each reaction comprised 2µL Big Dye 
Terminator Mix V3.1, 4µL Big Dye Terminator Sequencing Buffer V3.1, 3ρ mol of 
the appropriate primer except for the ADLD primers where 4ρ mol was used (Appendix 
2), 200-500ng purified plasmid or ~90ng of purified PCR product and an appropriate 
volume of ddH2O for a final reaction volume of 20µL. Reactions were amplified in 
PTC-100 Programmable Thermal Cyclers and comprised 25 cycles of: DNA 
denaturation at 96°C for 15 seconds, primer annealing at 50°C for 10 seconds and 
primer extension at 60°C for 4 minutes. 
 
3.4.2  Precipitation of Sequencing Reactions 
Upon completion of sequencing the reaction mixtures were transferred to 1.5mL 
microcentrifuge tubes containing 2µL 3M sodium acetate
112 (pH4.6) and 50µL of 95% 
ethanol
38. The tubes were vortexed and placed on ice for 10 minutes to precipitate the 
DNA, then centrifuged at 4°C for 30 minutes at 13000rpm to pellet the DNA. The 
supernatants were removed by pipetting and the pellets washed with 250µL 70% 
ethanol
37 then centrifuged for a further 5 minutes at 13000rpm and 4°C. The 
supernatants were gently removed and the DNA pellets air-dried for approximately 15-
20 minutes at room temperature. The West Australian Genome Resource Centre at 
Royal Perth Hospital performed the gel analysis of precipitated sequencing reactions 
using an ABI 373 XL Automated Sequencer and the results were presented in DNA 
sequence and chromatograph formats. 
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3.5  Yeast Two-hybrid Analysis 
3.5.1  Polyadenylated RNA Extraction and cDNA Synthesis 
3.5.1.1  Polyadenylated RNA Extraction 
Isolation of polyadenylated [poly(A)] RNA was performed using the Poly (A) Pure 
mRNA Purification Kit (section 2.2). LNCaP cells (8 x 10
7) were cultured in 175cm
2 
cell culture flasks and trypsinised when confluent (section 3.6.1). Cells were pelleted by 
centrifuging at 4°C for 5 minutes at 1100rpm and the supernatants removed, then 
washed once in 2mL PBS
72 and centrifuged as above.  Cells were lysed by the addition 
of 1mL of Lysis Solution
62 per 2 x 10
7 cells, the cell lysates were transferred to 15mL 
Corex tubes and homogenised by vigorous pipetting.  Homogenates were diluted with 2 
volumes of Dilution Buffer
20 to reduce the concentration of guanidine thiocyanate, 
providing the optimum salt concentration for poly(A) RNA/oligo(dT) hybridisation, 
mixed by swirling then centrifuged at 4°C at 12000 x g for  15 minutes to pellet cell 
debris. The supernatants were transferred to clean 15mL tubes, a vial of oligo(dT) 
cellulose was added and the solution was mixed by inversion to resuspend the resin.  
Tubes were incubated for 60 minutes at room temperature with gentle shaking to allow 
binding of poly(A) RNA to the oligo(dT) cellulose, centrifuged at 2500 x g for 3 
minutes at room temperature to pellet the oligo(dT) cellulose and the supernatants were 
removed. To remove non-specifically bound material and ribosomal RNA the oligo(dT) 
cellulose pellets were washed 3X with 10mL Binding Buffer
8, centrifuging in between 
at 2500 x g for 3 minutes at room temperature and the supernatants removed. To 
provide a more stringent wash and remove additional ribosomal RNA the oligo(dT) 
cellulose pellets were further washed 3X with 10mL Wash Buffer
149, centrifuging in 
between at 2500 x g for 3 minutes at room temperature and the supernatants removed.  
 
Following washes the oligo(dT) cellulose pellets were resuspended in 600µL Wash 
Buffer
149 and transferred to spin columns.  The spin columns were placed into 2mL 
tubes and centrifuged at 5000 x g for 10 seconds at room temperature. The flow through 
was discarded, 500µL of Wash Buffer
149 was added to each spin column, the columns 
were centrifuged at 5000 x g for 10 seconds at room temperature, the flow through 
again discarded and a further 500µL of Wash Buffer
149.  Columns were centrifuged at 
5000 x g for 10 seconds at room temperature and the OD260  of the flow through 
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collection tubes and 200µL of pre-warmed Elution Buffer
36 (65°C) was added to the 
resin. Spin columns with collection tubes were centrifuged at 5000 x g for 10 seconds at 
room temperature to elute the RNA from the oligo(dT) cellulose. A further 200µL of 
pre-warmed Elution Buffer
36 was added to the resin which was centrifuged at 5000 x g 
for 10 seconds at room temperature to elute any remaining poly(A) RNA. 
 
In order to perform a second round of oligo(dT) cellulose selection, the 400µL of 
recovered RNA was transferred to a clean 1.5mL tube, the salt concentration adjusted to 
0.45M by the addition of 40µL 5M sodium chloride
116, then tubes were incubated at 
65°C for 5 minutes and chilled on ice for one minute. The used spin column was placed 
into the previously used 2mL collection tube, 500µL Binding Buffer
8 was added and the 
tubes were centrifuged at 5000 x g for 10 seconds at room temperature to equilibrate the 
column for hybridisation. The flow through was discarded and the RNA sample was 
slowly added to the resin then centrifuged at 5000 x g for 10 seconds at room 
temperature.  The flow through was reapplied to the column and the tubes were 
centrifuged at 5000 x g for 10 seconds at room temperature, such that the RNA sample 
had passed through the column 3 times. The flow through was transferred to clean 
1.5mL tubes and stored at -80°C until subsequent recovery of poly(A) RNA was 
confirmed.  
 
Columns were washed 3X with 500µL of Binding Buffer
8, centrifuging in between at 
5000 x g for 10 seconds at room temperature, then washed similarly 3X with 500µL of 
Wash Buffer
149. RNA was eluted from the oligo(dT) column as described above.   
Following elution, the RNA was precipitated by the addition of 40µL 5M ammonium 
acetate
5, 2µL glycogen and 1.1mL of absolute ethanol. The precipitation mixture was 
incubated at -80°C for 60 minutes then centrifuged at 4°C for 20 minutes at 12000 x g 
and the supernatants discarded. Pellets were washed with 1.3mL of 70% ethanol
37 then 
centrifuged at 12000 x g for 10 minutes at 4°C. The ethanol was decanted and the 
pellets were resuspended in 20µL of Elution Buffer
36 and stored at -80°C.  
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3.5.1.2  First-Strand cDNA Synthesis 
For first-strand cDNA synthesis, 2µL of poly A
+ RNA (section 3.5.1.1), was combined 
with 1µL (1µM) CDS III primer and 1µL ddH2O in a sterile 0.5mL microcentrifuge 
tube. Reactions were incubated at 72°C for 2 minutes, placed on ice for 2 minutes to 
inhibit RNA renaturation and spun briefly. Following denaturation, 2µL of 5X First-
Strand buffer, 1µL (20mM) DTT, 1µL (10mM) dNTP mix and 1µL of MMLV Reverse 
Transcriptase (BD Matchmaker Library Construction and Screening Kit; section 2.2) 
were added to give a final volume of 9µL. Reactions were mixed gently by tapping, 
spun briefly and incubated at 42°C for 10 minutes. 1µL (1µM) SMART  III 
Oligonucleotide was added and tubes were incubated at 42°C for 60 minutes for DNA 
extension. To terminate first-strand synthesis, reactions were incubated at 75°C for 10 
minutes, cooled to room temperature, 1µL (2 units) RNase H was added and tubes were 
incubated at 37°C for 20 minutes. cDNA￿s were stored at -20°C.  
 
3.5.2  cDNA Library Construction 
3.5.2.1  Long Distance-PCR (LD-PCR) 
LD-PCR￿s using the Advantage 2 PCR Kit (section 2.2) were performed in duplicate in 
pre-chilled sterile 0.5mL microcentrifuge tubes each containing 1µL 50X Advantage
 2 
Polymerase Mix, 5µL of 10X Advantage
 2 PCR Buffer, 0.2µM of forward 5’ PCR and 
reverse 3’ PCR primers, 5µL of 10X GC-Melt Solution, 1µL (10mM) 50X dNTP mix, 
1µL of first-strand cDNA (section 3.5.1.2) and an appropriate volume of ddH2O for a 
final volume of 50µL. Reactions were mixed gently, centrifuged briefly then transferred 
to a pre-heated (95°C) PTC-100 Programmable Thermal Cycler and heated for 10 
seconds to denature DNA followed by primer annealing and DNA extension at 68°C for 
6 minutes initially, increasing in 5 second increments to 7 minutes 35 seconds over 20 
cycles. 
 
3.5.2.2  LD-PCR Product Purification 
LD-PCR products were combined and a 5µL aliquot visualised in agarose gels (section 
3.1.4) then purified using CHROMA SPIN+TE-400 Columns (Clontech). Immediately 
prior to purification, columns were centrifuged at 700 x g for 5 minutes at room 
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  76
matrix bed. Columns were then transferred to clean 2mL collection tubes, ~95µL cDNA 
samples (section 3.5.2.1) were applied to the centre of the gel bed and the columns were 
centrifuged at 700 x g for 5 minutes at room temperature to elute the purified DNA. 
Purified DNA products were combined in a single 1.5mL tube, to which was added 0.1 
volumes 3M sodium acetate pH 4.6
112 and 2.5 volumes 95% ethanol
38. Tubes were 
mixed gently, incubated at -20°C for 1-2 hours to precipitate the DNA, then centrifuged at room 
temperature for 20 minutes at 13000rpm to pellet the DNA. Supernatants were removed and the DNA 
pellets air-dried for approximately 10 minutes at room temperature, resuspended in 20µL ddH2O then 
stored at -20°C. 
 
3.5.3  Preparation of Competent Yeast Cells 
Frozen stocks of AH109 S. cerevisiae yeast cells or AH109/pGBKT7-FLJ22318 
transformed yeast cells (section 3.5.7) were streaked onto YPDA/agar
159 or SD/-Trp 
agar plates
106 and incubated at 30°C for 3-5 days until yeast colonies had reached ~2mm 
in diameter. To prepare competent cells for simultaneous transformations, several 
AH109 colonies (2-3mm in diameter) were inoculated into 1mL of YPDA medium
160, 
vortexed for 5 minutes and transferred to a 250mL flask containing 50mL of YPDA 
medium
160. For sequential transformations, several AH109/pGBKT7-FLJ22318 
colonies were inoculated into 1mL of SD/-Trp medium
107, vortexed for 5 minutes and 
transferred to a 250mL flask containing 50mL of SD/-Trp medium
107 supplemented 
with 0.2% adenine
3. Cultures were incubated at 30°C for 16-20 hours at 230rpm until 
the OD600 was >1.5 for YPDA cultures or >1.0 for SD cultures. Following overnight 
incubation the yeast cultures were diluted into fresh YPDA medium
160 to give an OD600 
of 0.2-0.3 and incubated at 30°C for ~3 hours at 230rpm until the OD600 had reached 
0.4-0.6. Yeast cells were then pelleted by centrifugation at 1500rpm for 5 minutes at 
room temperature, supernatants were discarded and the cell pellets were resuspended in 
25mL of ddH2O. Following centrifugation at 1500rpm for 5 minutes at room 
temperature, supernatants were removed and yeast pellets were resuspended in 1mL of 
freshly prepared 1X TE/LiAc
143. Yeast cells were now considered competent and were 
used immediately for transformation. 
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3.5.4  Small Scale LiAc Yeast Transformation 
Competent AH109 yeast cells (50µL) were combined with 625ng of plasmid DNA, 5µg 
denatured herring testes carrier DNA
46 plus 500µL of PEG/LiAc/TE
76 in pre-chilled 
1.5mL microcentrifuge tube. Tubes were gently vortexed then incubated at 30°C for 30 
minutes at 230rpm. Twenty µL of DMSO was added to the yeast, the tubes were mixed 
by inversion, cells were heat shocked at 42°C for 20 minutes then centrifuged at 
14000rpm for 15 seconds at room temperature. The supernatants were removed, yeast 
pellets were resuspended in 1mL of YPD Plus Liquid Medium
161 and incubated at 30°C 
for 90 minutes at 230rpm then centrifuged at 14000rpm for 15 seconds at room 
temperature. The supernatants were removed and yeast pellets were resuspended in 1mL 
of 0.9% NaCl
114. To determine the cotransformation efficiency, 100µL of 1:10, 1:100 
and 1:1000 dilutions of the transformation mixture was plated onto SD/-Leu/-Trp
104 
agar plates. To select for cotransformed yeast expressing interacting proteins, 100µL of 
1:10, 1:100 and 1:1000 dilutions of the transformation mixtures were plated onto SD/-
Ade/-His/-Leu/-Trp-X-α -Gal
97 agar plates. Plates were incubated inverted at 30°C for 
2-4 days until colonies appeared. 
 
3.5.5  Large Scale LiAc Yeast Transformation 
Competent AH109 yeast cells (100µL) were combined with 0.2µg of plasmid DNA, 
plus 100µg denatured herring testes carrier DNA
46 in a pre-chilled 1.5mL 
microcentrifuge tube. Six hundred µL of PEG/LiAc/TE
76 solution was added and tubes 
were gently vortexed for 10 seconds then incubated at 30°C for 30 minutes at 230rpm. 
Seventy µL of DMSO was added to the yeast, the tubes were mixed by inversion, cells 
were heat shocked at 42°C for 15 minutes then centrifuged at 14000rpm for 15 seconds 
at room temperature. The supernatants were removed and yeast pellets were 
resuspended in 1mL of 1X TE
143. To select for yeast transformed with pGBKT7 or 
pGADT7 plasmids, 200µL of the transformation mixture was plated onto SD/-Trp
106 or 
SD/-Leu
102 agar plates. To select for sequentially transformed yeast, 200µL of 
transformation mixture was plated onto SD/-Ade/-His/-Leu/-Trp-X-α -Gal
97, SD/-His/-
Leu/-Trp
99 and SD/-Leu/-Trp
104 agar plates. Plates were incubated inverted at 30°C for 
2-4 days until colonies appeared. 
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3.5.6  Library Scale LiAc Yeast Transformation  
Competent AH109/pGBKT7-FLJ22318 yeast cells (600µL) were combined with 20µL 
purified cDNA (section 3.5.3; section 3.5.2.2), 3µg of pGADT7-Rec plasmid DNA, 
plus 200µg denatured herring testes carrier DNA
46 in pre-chilled 15mL microcentrifuge 
tubes. PEG/LiAc/TE
76 solution (2.5mL) was added and tubes were gently vortexed for 
10 seconds then incubated at 30°C for 45 minutes at 230rpm. DMSO (160µL) was 
added to the yeast, the tubes were mixed by inversion, cells were heat shocked at 42°C 
for 20 minutes with mixing every 10 minutes then centrifuged at 1500rpm for 5 minutes 
at room temperature. The supernatants were removed and yeast pellets were 
resuspended in 3mL of YPD Plus Liquid Medium
161 and incubated at 30°C for 90 
minutes at 230rpm then centrifuged at 1500rpm for 5 minutes at room temperature. The 
supernatants were discarded and yeast pellets were suspended in 6mL 0.9% NaCl
114. To 
select for pGADT7/pGBKT7 transformants expressing interacting proteins, 100µL 
aliquots of the transformation mixture was plated onto SD/-Ade/-His/-Leu/-Trp-X-α -
Gal
97 and SD/-His/-Leu/-Trp-X-α -Gal
100 agar plates. To determine the transformation 
efficiency a 30µL aliquot of transformation mixture was diluted with 720µL of 0.9% 
NaCl
114 and 100µL plated onto duplicate SD/-Leu/-Trp
104 and SD/-Leu
102 agar plates. 
Plates were incubated inverted at 30°C for 2-4 days until colonies appeared. To provide 
transformation controls a small scale yeast transformation (section 3.5.4) was performed 
in parallel with the library screen. 
 
3.5.7  Preparation of Yeast/Glycerol Stocks 
To prepare glycerol stock cultures, single yeast colonies were inoculated into 500µL of 
the appropriate medium (Table 3.2), vortexed vigorously for 1 minute to disperse the 
cells and 500µL 50% glycerol
43 was added. Glycerol stock cultures were mixed by 
inversion and stored at -80°C in 2mL cryotubes.  
 
Table 3.2 Yeast medium for glycerol stock preparation   
AH109 pGBKT7-AH109  pGADT7-AH109  pGBKT7/pGADT7-AH109 
YPDA SD/-Trp
106  SD/-Leu
102  SD/-Leu/-Trp
104 
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3.5.8  Plasmid Isolation from Yeast 
Transformed yeast (section 3.5.6) were plated onto SD/-Ade/-His/-Leu/-Trp/agar
96 
plates and incubated at 30°C for 3-5 days. Yeast colonies of 2-4mm in diameter were 
individually inoculated into 500µL SD/-Ade/-His/-Leu/-Trp
95 medium, vortexed for 1 
minute, transferred into 4.5mL SD/-Ade/-His/-Leu/-Trp
95  medium and incubated 
overnight at 30°C with shaking at 250rpm. Following overnight growth, yeast cells 
were pelleted by centrifuging at 2500rpm for 5 minutes, the supernatants were removed 
and yeast cells were lysed by re-suspending in 300µL yeast lysis buffer
158 with 100µL 
425-600µm glass beads. Plasmid DNA was recovered by the addition of 300µL 
phenol:chloroform (1:1). Cells were vortexed for 4 minutes then centrifuged at 
14000rpm for 1 minute and the upper aqueous phase transferred to clean 1.5mL tubes. 
To precipitate plasmid DNA, 0.1 volume of 3M sodium acetate
112 and 2.5 volumes of 
absolute ethanol were added to the tubes. Tubes were vortexed briefly, incubated at 
room temperature for 2 minutes, centrifuged at 14000rpm for 5 minutes and the 
supernatants decanted. Pellets were then washed with 500µL of 70% ethanol
37, 
centrifuged at 14000rpm for 5 minutes and the supernatants discarded. Purified plasmid 
DNA pellets were air dried at room temperature for ~5-10 minutes then resuspended in 
20µL of ddH2O and stored at -20°C.  
 
3.5.9  Transcriptional Activation of DNA-BD Fusion Construct 
To ensure that the DNA-BD construct was not able to self-activate transcription of the 
reporter genes and could be used in Y2H screens, AH109 yeast cells transformed with 
pGBKT7 or pGBKT7 containing an insert were streaked onto SD/-Trp/X-α -Gal agar
109, 
SD/-His/-Trp/X-α -Gal agar
101 and SD/-Ade/-Trp/X-α -Gal agar
98  plates. Plates were 
incubated inverted at 30°C for 3-5 days, viewed, photographed where appropriate then 
stored at 4°C wrapped in parafilm.  
 
3.5.10  Toxicity of DNA-BD Fusion Construct 
To ensure that the DNA-BD construct was not toxic to AH109 yeast cells, pGBKT7 
transformed AH109 yeast cells were streaked onto SD/-Trp agar
106 plates and incubated 
at 30°C for 3-5 days until colonies reached 2-3mm in diameter. Single large colonies 
were inoculated into 1mL of SD/-Trp medium
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to a 250mL flask containing 50mL of SD/-Trp/Kan medium
108. Cultures were incubated 
at 30°C for 16-24 hours at 220rpm and the OD600 measured.  
 
3.5.11  Preparation of Yeast Protein Extracts 
Stocks of pGBKT7 transformed yeast cells were streaked onto SD/-Trp/agar
106 plates, 
and incubated at 30°C for 3-5 days. Yeast colonies of 2-4mm in diameter were 
individually inoculated into 1mL SD/-Trp
107  medium, vortexed for approximately 2 
minutes to disperse cell clumps and transferred to 4mL SD/-Trp
107  medium. As a 
negative control a 5mL culture of untransformed AH109 S. cerevisiae yeast cells was 
also prepared from frozen stocks, streaked onto YPDA/agar
159 plates, and inoculated 
into 5mL YPDA
160 medium. Cultures were incubated overnight at 30°C with shaking at 
250rpm then centrifuged at 2500rpm for 5 minutes at room temperature. The 
supernatants were removed and yeast were incubated at -80°C for 10 minutes, 
resuspended in 100µL western lysis buffer
153 and the cell suspensions transferred to 
clean 1.5mL microcentrifuge tubes containing 100µL of glass beads. Cell suspensions 
were incubated at 70°C for 10 minutes, vortexed for 1 minute, centrifuged at 14000rpm 
for 5 minutes at room temperature and the supernatants transferred to clean 0.5mL 
centrifuge tubes. Ten µL aliquots were then diluted with an equal volume of 2X sample 
buffer
93, incubated for 5 minutes at 95°C and electrophoresed in 12% polyacrylamide 
gels (section 3.7.2). Following electrophoresis, proteins were transferred to 
nitrocellulose membranes and immunoblotted with antibodies to the c-Myc epitope 
encoded by the pGBKT7 plasmid (section 3.7.4). 
 
3.6 Tissue  Culture 
3.6.1  Cell Culture Conditions 
LNCaP and DU145 prostate cancer cells were routinely cultured at 37°C/5%CO2 in 
RPMI 1640 medium
92 containing 10% foetal calf serum (FCS), 100µg/mL penicillin 
and 100U/mL streptomycin (PS). Medium was replaced every 2-3 days and LNCaP 
cells were passaged at a dilution of 1:5 with DU145 cells passaged at a dilution of 1:10 
when 90-95% confluent. To passage cells, medium was aspirated, cells were rinsed with 
1mL of PBS
72, the PBS
72 aspirated, 1-2mL of trypsin/EDTA (section 2.1.5) was then 
added to each flask and the flasks were incubated at 37°C for approximately 2 minutes 
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flasks to inactivate the trypsin, cells were dispersed by pipetting and the appropriate 
volume of cell suspensions was transferred to fresh flasks or plates.  
 
3.6.2  Transfection of Cells 
Transient transfection of LNCaP and DU145 prostate cancer cells with expression 
plasmids was performed using LipofectAMINE 2000 and according to the 
manufacturer￿s protocols (Invitrogen). Cells were passaged according to Table 3.3 and 
cultured overnight in RPMI/10% FCS
91 at 37°C/5% CO2 to allow adhesion of cells to 
the culture surface.  
 
Table 3.3 DU145 and LNCaP cell passage numbers 
  DU145 Cells  LNCaP Cells 
96 Well Plates  2.5 x 10
4  - 
8 Well Chamber Slides  6.0 x 10
4  - 
24 Well Plates  1.0 x 10
5  1.5 x 10
5 
Microscope Slides  -  1.5 x 10
5 
Microscope Slide Coverslips  - 3.75  x  10
5 
6 Well Plates  5.0 x 10
5  7.5 x 10
5 
10cm Petri Dishes  3.0 x 10
6  4.2 x 10
6 
 
For each transfection, LipofectAMINE 2000 was added to an aliquot of RPMI 1640 
medium
89 and incubated at room temperature for 5 minutes (Table 3.4). The plasmid 
DNA was added to another aliquot of RPMI 1640 medium
89 and the diluted 
LipofectAMINE 2000 and DNA solutions were combined and incubated at room 
temperature for 20 minutes to allow the formation of DNA/LipofectAMINE 2000 
complexes. The DNA/LipofectAMINE 2000 solution was then added drop-wise to 
cultures and cells were incubated for 24-48 hours at 37°C/5% CO2 to allow for plasmid 
uptake and expression.  
 
3.6.3  Cryopreservation of Cell Cultures 
Cell cultures to be cryopreserved were grown to confluency in T75 flasks, trypsinised 
(section 3.6.1), then centrifuged at 4°C for 5 minutes at 245 x g. The medium was Chapter Three ￿ Methods  
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        Table 3.4 Transfection details 
 
96 Well Plates 
LipofectAMINE  2000 (￿L)  Medium (￿L)  Plasmid DNA (￿g)  Medium (￿L) 
2 25  3  25 
8 Well Chamber Slides 
LipofectAMINE  2000 (￿L)  Medium (￿L)  Plasmid DNA (￿g)  Medium (￿L) 
2 40  1  40 
24 Well Plates 
LipofectAMINE  2000 (￿L)  Medium (￿L)  Plasmid DNA (￿g)  Medium (￿L) 
2 50  1  50 
Microscope Slide Coverslips 
LipofectAMINE  2000 (￿L)  Medium (￿L)  Plasmid DNA (￿g)  Medium (￿L) 
4 100  1.6  100 
6 Well Plates 
LipofectAMINE  2000 (￿L)  Medium (￿L)  Plasmid DNA (￿g)  Medium (￿L) 
10 250  5  250 
10cm Petri Dishes 
LipofectAMINE  2000 (￿L)  Medium (￿L)  Plasmid DNA (￿g)  Medium (￿L) 
40 1000  16  1000 
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aspirated, cells were resuspended in 4.5mL of fresh RPMI/10% FCS/PS
92 medium 
containing 10% DMSO, divided into 3 cryotubes, stored at -80°C for 24 hours before 
being transferred to liquid nitrogen. 
 
3.6.4  DHT Treatment of Cells 
LNCaP cells were cultured at 37°C/5%CO2 in RPMI stock medium
92 until 80% 
confluent (or as required). The medium was then replaced with RPMI 1640 containing 
5% charcoal stripped f￿tal calf serum (CS-FCS) and PS
90 and cells were incubated for a 
further 48 hours prior to replacement of the medium with fresh medium containing 5% 
CS-FCS
90 and 10
-9M DHT
19 for the appropriate length of time. Control cultures 
contained the same volume (0.1% v/v) of ethanol (vechicle). 
 
3.7 Western  Blotting 
3.7.1   Protein Extraction 
To harvest cells, medium was aspirated, cells were rinsed with PBS
72 then lysed by the 
addition of western lysis buffer
153 (250-500µL per well of 24 well plates). Lysates were 
transferred to sterile 1.5mL microcetrifuge tubes and protein solutions, which were 
viscous due to the presence of genomic DNA in the samples, were repeatedly drawn 
through a 23G needle to decrease their viscosity. Protein extracts were stored at -20°C.  
 
3.7.2  Polyacrylamide Gel Electrophoresis 
The Mini Protean II polyacrylamide gel electrophoresis apparatus (BioRad) was 
assembled according to the manufacturer￿s instructions and 12% separating gels
81 were 
pipetted into the gel spaces to ~0.5cm below the level of the wells. Gels were overlaid 
with ddH2O, covered and left to polymerise at room temperature for 45-60 minutes. 
After 1 hour, the ddH2O was drained, the gel spaces were rinsed with 6% stacking gel 
solution
82, and separating gels were overlaid with 6% stacking gel solution
82. Well 
combs were inserted, the apparatus covered and stacking gels left to polymerise at room 
temperature for 45-60 minutes. Following gel polymerisation, well combs were 
removed, wells were rinsed with ddH2O and the apparatus was assembled and filled 
with 1X western running buffer
154. Protein extracts (section 3.7.1) were diluted with 0.1 
volumes of 10X sample buffer
94, 10-20µL aliquots (per well) were denatured at 95°C 
for 8 minutes, cooled to room temperature then loaded into wells. In addition, each gel Chapter Three ￿ Methods  
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included a well containing 5µL of Benchmark Prestained Protein Ladder molecular 
weight markers. Gels were electrophoresed at 200V for approximately 45 minutes until 
the dye front had migrated to the end of the gel. 
 
3.7.3 Western  Transfer 
Following polyacrylamide gel electrophoresis the apparatus was disassembled and gels 
were placed in western transfer buffer
156. Transfer cassettes were assembled as follows, 
with all reagents pre-wetted in transfer buffer
156. A scourer was placed on the black 
(￿negative￿) side of the cassette, followed by two pieces of Whatman
 3MM paper, the 
gel, a piece of nitrocellulose filter, two pieces of Whatman
 3MM paper and another 
scourer. Cassettes were closed, placed in the transfer apparatus along with an ice block 
and a magnetic stirrer and the proteins were transferred to nitrocellulose filters 
overnight at 30V with stirring. 
 
3.7.4 Western  Blotting 
Following transfer of proteins, the apparatus was disassembled and nitrocellulose 
membranes were cut to size according to the molecular weight of the proteins of 
interest. All incubations for western blotting were carried out at room temperature on a 
horizontal shaker and dilutions of primary and secondary antibodies are detailed in 
Table 3.5. Membranes were blocked in TBS-3% Blotto
137 for 1-1.5 hours then 
incubated with primary antibodies diluted in TBST-1% Blotto
139 for 1-1.5 hours. 
Membranes were washed in TBST
138 (3 x 10 minutes), incubated with secondary 
antibodies diluted in TBST-1% Blotto
139 for 1-1.5 hours then washed in TBST
138 (3 x 
10 minutes). Immunoreactivity was detected by incubation of filters for 1 minute with 
ECL Detection Reagent
32 or for 5 minutes with ECL Plus Detection Reagent
33. Filters 
were wrapped in plastic film, placed in an autoradiography cassette and exposed to X-
Ray film for 10 seconds-10 minutes as required. Films were developed in an AGFA CP-
1000 Film Developer, scanned and images stored in .TIF format. 
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Table 3.5 Primary (1°) and secondary (2°) antibody dilutions 
1° Antibody  Dilution  2° Antibody  Dilution 
Goat anti-human actin Ig  1:2000  Donkey anti-goat IgG  1:1000 
Goat anti-PACT Ig  1:500  Donkey anti-goat Ig  1:2000 
Mouse anti-GFP Ig  1:3000  Sheep anti-mouse Ig  1:2000 
Mouse anti-HA Ig  1:2000  Sheep anti-mouse Ig  1:2000 
Mouse anti-Myc Ig  1:1000  Sheep anti-mouse Ig  1:2000 
Mouse anti-Nkx3.1  1:250  Sheep anti-mouse Ig  1:2000 
Mouse anti-V5 Ig  1:5000  Sheep anti-mouse Ig  1:2000 
Rabbit anti-Myc Ig  1:1000  Sheep anti-rabbit Ig  1:2000 
Rabbit anti-PACT Ig  1:500  Sheep anti-rabbit Ig  1:2000 
 
3.8  GST Pull-Down Assays 
3.8.1  Small-Scale Production of GST Fusion Proteins  
Transformed BL21 bacterial cells were streaked onto LB/agar/ampicillin
50 plates and 
incubated at 37°C overnight. Following overnight growth bacterial  colonies were 
individually inoculated into 2mL of LB broth/ampicillin
54 and incubated at 37°C for 3-5 
hours until the OD600 had reached 0.5. Fusion protein production was then induced by 
the addition of 2µL 100mM IPTG
47 and cells were incubated for 1-2 hours at 30￿C with 
shaking at 250rpm. Following induction, the OD600  was recorded and 1mL of each 
culture was transferred to 1.5mL tubes, which were centrifuged at 13000rpm for 5 
seconds at room temperature and the supernatants removed.  Bacterial pellets were 
resuspended in western lysis buffer
153 using the formula: 
       xµL = 1000 x OD600 
         8  
Owing to the presence of genomic DNA in the samples, bacterial lysates were 
repeatedly drawn through a 23G needle to decrease their viscosity and 20µL aliquots 
were transferred to clean 0.5mL tubes. Samples were diluted with 0.1 volumes of 10X 
sample buffer
94, incubated at 95￿C for 5 minutes and 10µL aliquots were 
electrophoresed in 12% polyacrylamide gels
81 (section 3.7.2). Following 
electrophoresis, gels were stained with Coomassie blue staining solution
13 (section 
3.8.2) to verify GST-fusion protein production. 
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3.8.2  Coomassie Blue Staining of Gels 
Following electrophoresis, polyacrylamide gels were rinsed in ddH2O, immersed in 
Coomassie blue staining solution
13 and incubated at room temperature with gentle 
agitation overnight. Following staining, gels were rinsed in ddH2O, incubated 3X 30 
minutes in Coomassie de-staining solution
14 with gentle agitation, rinsed in ddH2O then 
wrapped in wet cellophane and clipped to a glass plate to prevent shrinkage. Gels were 
dried at room temperature for 3-4 days then scanned and the images stored in .TIF 
format.  
 
3.8.3  Large-Scale Production and Purification of GST Fusion Proteins  
Single bacterial colonies of transformed BL21 cells were individually inoculated into 
5mL of LB broth/ampicillin
54 and incubated for 18 hours overnight at 37°C with 
shaking at 250rpm. Following 18 hours￿ incubation, cultures were diluted with 100mL 
fresh LB broth/ampicillin
54 and incubated at 37°C for ~3 hours at 250rpm until the 
OD600  had reached 0.5-2.0. To induce fusion protein production, 100µL of 100mM 
IPTG
47 was added to bacterial cultures and cells were incubated at 30°C for 3-4 hours 
with shaking at 250rpm. Bacterial cultures were centrifuged for 15 minutes at 3000rpm 
at 4°C, supernatants were decanted and pellets were placed on ice then re-suspended in 
5mL of sonication buffer
125 and 50µL lysozyme
63 added. After incubating on ice for 15 
minutes, 36µL 200mM PMSF
80, 12.5µL 0.5M EDTA
34, 5µL 1M DTT
25, 50µL 1M 
magnesium chloride
64 and 500µL 10% Triton X-100
147 was added to cultures to aid 
solubilisation of fusion proteins. Cell suspensions were lysed by sonicating at 5 second 
intervals (Branson sonifier  150, setting 3) with alternate 5 second incubations on ice, 
then lysates were incubated for 30 minutes at 4°C with gentle rotation. Lysates were 
pelleted at 3000rpm for 15 minutes at 4°C, the supernatants (~5mL) were transferred to 
clean 15mL tubes and 200µL of 50% Glutathione Sepharose 4B
42 was added to each 
tube. Samples were incubated with slow rotation for 15 minutes at 4°C to precipitate 
GST-fusion proteins. Beads were collected by centrifugation at 300rpm for 5 minutes at 
4°C and the supernatants were discarded. Beads were washed 3X with 1.5mL ice-cold 
PBS
72 centrifuging in between at 300rpm for 5 minutes at 4°C and discarding the 
supernatants. Beads were resuspended in 100µL ice-cold PBS
72 and stored at 4°C. To 
confirm GST-fusion protein purification, 30µL aliquots of 50% Glutathione-fusion 
protein suspensions were centrifuged at 300rpm for 5 minutes at 4°C, the supernatants Chapter Three ￿ Methods  
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were removed, beads were resuspended in 15µL 2X sample buffer
93 and incubated for 5 
minutes at 95°C to dissociate proteins from beads. Protein samples were then 
centrifuged at 300rpm for 5 minutes at 4°C and 10µL aliquots were separated in 12% 
polyacrylamide gels
81 (section 3.7.2). Following electrophoresis, purified GST fusion 
proteins were visualised by Coomassie blue staining solution
13 (section 3.8.2). 
 
3.8.4  GST Pull-Down Assays 
Untransfected or transfected cells (LNCaP or DU145) were grown in 6 well plates, with 
cells harvested 24 hours following transfection to allow expression of fusion proteins 
(section 3.6.2). Medium was aspirated from the cells, 500µL per well ice-cold PBS
72 
was added, and plates were gently rocked to wash the cells. PBS
72 was aspirated and 
cells were lysed by the addition of 500µL RIPA buffer
85 directly to the wells. Cell 
lysates were transferred to pre-chilled 1.5mL tubes, then incubated for 20 minutes at 
4°C with slow rotation to ensure complete cell lysis. Protein solutions were centrifuged 
at 8000rpm for 10 minutes at 4°C to pellet cell debris, then 50µL of the lysates was 
removed and stored at -20°C. An additional 300µL of each lysate was transferred to 
clean pre-chilled 1.5mL tubes and samples were incubated overnight at 4°C with slow 
rotation with 60µL of the purified 50% Glutathione-GST-fusion proteins (section 3.8.3).  
Following overnight incubation, beads were collected by centrifugation at 1000rpm for 
2 minutes at 4°C and supernatants were discarded. Beads were washed 3X with 300µL 
ice-cold PBS
72 centrifuging in between at 1000rpm for 2 minutes at 4°C and discarding 
supernatants, then the beads were resuspended in 25µL 2X sample buffer
93. To 
dissociate fusion proteins from the beads, samples were incubated for 5 minutes at 
95°C, centrifuged at 1000rpm for 2 minutes at 4°C and 15µL of each supernatant was 
transferred to clean 0.5mL tubes. Ten µL aliquots were separated in 12% 
polyacrylamide gels (section 3.7.2) together with 10µL of stored lysates (above) which 
had been diluted with 10µL of 2X sample buffer
93 and incubated for 5 minutes at 95°C. 
Following electrophoresis, protein samples were transferred to nitrocellulose 
membranes and immunoblotted (sections 3.7.3; 3.7.4). 
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3.9 Immunocytochemistry 
3.9.1 Slide  Preparation 
To prepare glass microscope slides for immunocytochemistry, a circle of approximately 
2cm diameter was drawn on each slide using a wax pen. The slides were then washed in 
ddH2O followed by 70% ethanol
37, placed in open 10cm petri dishes and exposed to UV 
light for 1 hour to sterilise the culture surface. Following UV irradiation, 500µL of 
RPMI stock medium
92 was added to each slide, petri dishes were closed to maintain 
sterility and slides were incubated overnight at 37°C/5% CO2. This procedure facilitated 
cell adherence to the culture surface. Cells were passaged onto the slides the following 
day (section 3.6.1) then transfected (section 3.6.2) 24 hours later if required. 
 
3.9.2 Immunocytochemistry 
Twenty-four hours post-transfection, slides were removed from petri dishes, washed in 
PBS
72 and fixed in 95% ethanol
38 for 5 minutes then washed in PBS
72 for a further 5 
minutes and transferred to a humidifier tray. Goat anti-PACT primary antibody was 
diluted 1:750, 1:1000 and 1:1500 in antibody diluent (section 2.1.7), 500µL was added 
drop wise to slides and the slides were incubated at room temperature for 1 hour. Slides 
were then washed in PBS
72 for 3X 5 minutes and replaced in the humidifier tray. To 
detect the primary antibody, 5 drops of ￿Link￿ (Biotinylated anti-goat/anti-mouse/anti 
rabbit IgG) were added to the slides, which were incubated at room temperature for 15 
minutes, washed in PBS
72 for 3X 5 minutes then replaced in the humidifier tray. Five 
drops of ￿Label￿ (Streptaviden/HRP) were added to slides and the slides were incubated 
at room temperature for 15 minutes, washed in PBS
72 for 5 minutes and replaced in the 
humidifier tray. Slides were covered in DAB
15 staining reagent, incubated at room 
temperature for 15 minutes then washed in PBS
72 for 5 minutes and replaced in the 
humidifier tray.  Fifty µL of CuSO4 (section 2.1.7) was added drop wise to the slides, 
which were then incubated for 5 minutes at room temperature, washed in PBS
72 for 5 
minutes, then counterstained with weak haematoxylin in a Leica Jung Autostainer XL. 
For counterstaining, slides were sequentially immersed for 30 seconds each in ddH2O, 
weak (1/10) haematoxylin, ddH2O, acid alcohol, Scotts tap water, ddH2O, 95% ethanol, 
absolute ethanol (2X) and xylene (3X). Upon completion of counterstaining, slides were 
mounted using a Leica CV 5000 Cover Slip Mounter and DEPX mounting medium. 
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3.10 Immunoprecipitation  Assays 
For immunoprecipitation assays, plasmids encoding the appropriate fusion protein were 
transfected into cells and the cultures were incubated for 24 hours (section 3.6.2). To 
harvest proteins, medium was aspirated from the culture dishes, 1mL ice-cold PBS
72 per 
well was added, and plates were rocked to gently wash cells. PBS
72 was aspirated, 1mL 
of RIPA buffer
85 per well was added to the dishes and cell lysates were transferred to 
pre-chilled 1.5mL tubes. Tubes were incubated for 20 minutes at 4°C with slow rotation 
to ensure complete cell lysis then centrifuged at 8000rpm for 10 minutes at 4°C to 
precipitate nuclei and cell debris. A 50µL aliquot of each lysate was stored at -20°C and 
~1mL of each supernatant was transferred to clean pre-chilled 1.5mL tubes. To pre-
clear samples, 50µL of 50% Protein G or Protein A sepharose
84 was added to each tube 
and the samples were incubated with slow rotation for 60 minutes at 4°C. Protein beads 
were pelleted by centrifugation at 1000rpm for 2 minutes at 4°C, 2 x 500µL aliquots of 
supernatant were transferred to clean pre-chilled 0.5mL tubes and primary antibody 
(Table 3.6) added to one of each set of two tubes. All samples were incubated overnight 
at 4°C with slow rotation. Following overnight incubation, 50µL of 50% Protein G or 
Protein A sepharose
84 was added to each tube and the samples were incubated with slow 
rotation for 2 hours at 4°C to precipitate immunocomplexes. Beads were collected by 
centrifugation at 1000rpm for 2 minutes at 4°C and the supernatants were discarded. 
Beads were washed 3X with 400µL ice-cold PBS
72, centrifuging in between at 1000rpm 
for 2 minutes at 4°C, supernatants were discarded, and the beads were resuspended in 
50µL 2X sample buffer
93. To dissociate immunocomplexes from the beads, samples 
were incubated for 5 minutes at 95°C, centrifuged at 1000rpm for 2 minutes at 4°C and 
40µL of each supernatant was transferred to clean 0.5mL tubes. Ten µL aliquots were 
electrophoresed in 12% polyacrylamide gels (section 3.7.2) together with 10µL of the 
stored lysates (above) which had been diluted with 10µL of 2X sample buffer
93 and 
incubated for 5 minutes at 95°C. Following polyacrylamide gel electrophoresis, protein 
samples were transferred onto nitrocellulose membranes and immunoblotted (section 
3.7.3; 3.7.4). 
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Table 3.6 Antibody dilutions for immunoprecipitation assays 
1° Antibody  Dilution 
Mouse anti-GFP Ig  1:100 
Mouse anti-HA Ig  1:100 
Mouse anti-Myc Ig  1:1000 
Mouse anti-V5 Ig  1:250 
Rabbit anti-Myc Ig  1:25 
Rabbit anti-PACT Ig  1:25 
 
3.11 Confocal  Microscopy 
3.11.1 Immunofluorescence 
Following transfection (section 3.6.2) and one hour prior to fixing of cells, medium was 
aspirated from 8 well chamber slides and replaced with 500µL fresh RPMI medium
91 
containing 0.5µL (10mg/mL) Hoechst 33258 nuclear stain. Cells were then incubated in 
the dark at 37°C /5% CO2 for one hour to allow uptake of the Hoechst 33258 dye and 
staining of cell nuclei. Following this incubation, medium was removed and slides were 
gently washed 2X with 400µL PBS
72. PBS
72 was aspirated and cells were fixed by the 
addition of 400µL 4% formaldehyde
40 directly to the wells, cells were incubated for 15 
minutes at room temperature, then washed 3X with 400µL PBS
72 for 5 minutes at room 
temperature. Cells were permeabilised by the addition of 400µL 0.2% Triton X-100
146 
for 5 minutes at room temperature then washed 3X with 400µL PBS
72 for 5 minutes at 
room temperature. PBS
72 was aspirated, 400µL of confocal blocking buffer
12 was added 
and the cells were incubated for 30 minutes at room temperature then washed 3X 5 
minutes with 400µL PBS
72 at room temperature. Primary antibody (Table 3.7) was 
diluted in 1% BSA/PBS
9, 100µL was added drop-wise to each well and the chamber 
slides incubated at 4°C overnight in a humidifier tray shielded from light. The next 
morning, slides were washed 3X 5 minutes in PBS
72 and replaced in the humidifier tray. 
To detect primary antibody, secondary antibody (Table 3.7) was diluted in low light in 
1% BSA/PBS
9, 100µL was added drop-wise to each well and the chamber slides were 
incubated at room temperature for 1 hour. Wells were washed 3X 5 minutes in PBS
72 
then the chamber and gaskets were removed. Upon completion of staining, slides were 
mounted using ~15µL of low fade mounting media
60 and sealed around the edges of the 
cover slips with clear nail polish prior to viewing (section 3.11.2). Chapter Three ￿ Methods  
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Table 3.7 Immunofluorescence antibody dilutions 
Primary Antibody  Dilution  Secondary Antibody  Dilution 
Mouse anti-V5 Ig  1:500  Goat anti-mouse IgG Alexa Fluor 488  1:400 
Rabbit anti-Myc Ig  1:500  Goat anti-rabbit  IgG Alexa Fluor 546  1:400 
Goat anti-PACT Ig  1:1000  Donkey anti-goat  IgG Alexa Fluor 546  1:400 
 
3.11.2 Confocal  Microscopy 
The confocal scanning microscope creates an image by scanning a finely focused laser 
light across a sample and recording the light emitted from a scanned point using a light 
detector (photomultiplier tube). The recorded emissions are then digitised and displayed 
on a computer screen as a grey shaded image with 256 levels of grey.  In these studies 
the main advantage of using confocal microscopy over conventional fluorescence 
microscopy was that different proteins could be labelled with fluorochrome-antibody 
conjugates and imaged simultaneously. These images could be aligned, artificially 
coloured then merged to demonstrate the localisation and co-localisation of proteins 
within cells. 
 
Confocal microscopy was performed using a BioRad MCR 1000/1024 UV Laser 
Scanning Confocal Microscope equipped with Argon ion and Helium/Neon lasers. The 
250mW Argon UV laser, which excites light at a wavelength of 350nm, was used to 
detect the nuclei of cells which had been incubated with the Hoechst 33258 DNA stain. 
The 100mW Argon laser, which excites blue light at a wavelength of 488nm, and the 
Helium/Neon laser, which excites green light at wavelength of 543nm, were used to 
detect the localisation of cells incubated with the Alexa Fluor
 488 and Alexa Fluor
 
546 fluorochrome-antibody conjugates, respectively. A 40X Plan-Apo oil immersion 
lens with a numerical aperture of 1.3 was used for all images. 
 
To minimise cellular damage and photobleaching, the lasers were used at low power 
with a 1-3% intensity level for the Argon laser and 30-100% intensity level for the 
Helium/Neon, which has a much lower power output. To optimise the quality of the 
images collected, the level of signal amplification and the black level were adjusted and 
the images collected in normal scan rate using a Kalman collection filter set at 5 to 
average out noise. Images were viewed and artificially coloured using Confocal 
Assistant 4.02 (Todd Clark Brelje) software.  Chapter Three ￿ Methods  
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To determine protein localisation, images exhibiting fluorescence due to the Alexa 
Fluor
 546 fluorochrome-antibody conjugate were coloured red, whereas images 
exhibiting fluorescence due to the Alexa Fluor
 488 fluorochrome-antibody conjugate 
were coloured green. Co-localisation of proteins was determined from image overlays 
which produced a yellow colour where co-localisation had occurred. 
 
3.12  Luciferase Reporter Assays 
For luciferase reporter assays, cells were transfected in 96 well plates (section 3.6.2) 
with 1µg luciferase reporter plasmid (TK-Luc or NKX-TK-Luc; section 2.1.3) and 
combinations of NKX3-1-pcDNA3.1/V5-His-TOPO, FLJ22318-pcDNA3.1/V5-His-
TOPO and pCMV-Myc-FLJ22318 expression plasmids (sections 5.2.1.1; 5.2.1.4). To 
ensure DNA concentrations were equal in all wells transfected, lacZ-pcDNA3.1/V5-
His-TOPO plasmid (Figure 3.9) was added to give a final DNA concentration of 3µg 
per well. In addition, to control for variation in transfection efficiency, 10ng pRL-SV40-
Renilla plasmid (Figure 3.10) was included in all transfections. Twenty-four hours post 
transfection, luciferase activity was determined as follows: medium was aspirated from 
the wells and cells were rinsed with PBS
72 then lysed by the addition of 20µL of 1X 
Passive Lysis Buffer
71 (PLB) to each well. Plates were gently rocked for 15 minutes at 
room temperature to facilitate cell lysis. Firefly luciferase activity was assayed by 
dispensing 50µL of Luciferase buffer
61 into each well and the resulting luminescence 
read in a Wallac plate-reading luminometer. Renilla  luciferase activity was then 
assayed by dispensing 80µL of Stop & Glo
 Reagent
130 into each well and 
luminescence was again measured. 
 
3.13 Northern  Blotting 
3.13.1 RNA  Extraction 
To harvest cells, medium was aspirated from culture dishes and cells were lysed by the 
addition of 1mL Ultraspec￿ to each dish, the cells were scraped from the culture 
surface and transferred to pre-chilled 1.5mL microcentrifuge tubes and incubated on ice 
for 5 minutes.  Homogenates were diluted with 200µL chloroform with vigorous 
mixing, samples were incubated on ice for 5 minutes then centrifuged at 12000 x g for 
15 minutes at 4￿C and the upper aqueous phase (~600µL) transferred to clean 1.5mLChapter Three ￿ Methods  
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Figure 3.9 Map of the pcDNA3.1/V5-His-TOPO/lacZ vector which constitutively
expresses β -galactosidase from the CMV promoter when transfected into mammalian
cells. This plasmid was used to equalise DNA concentrations in luciferase assays
(http://www.clontech.com). 
Figure 3.10 Map of the pRL-SV40 vector. The pRL-SV40 vector produces
constitutive expression of Renilla luciferase in transfected mammalian cells from the
SV40 enhancer and early promoter elements and was used in luciferase assays as an
internal control to estimate and normalise results for variation in transfection
efficiency (http://www.promega.com). Chapter Three ￿ Methods  
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tubes. An equal volume of isopropanol was added and the samples were incubated on 
ice for 10 minutes followed by centrifugation at 12000 x g for 10 minutes at 4￿C and the 
supernatants discarded. RNA pellets were washed 2X with 1mL 70% ethanol
37, 
centrifuged at 7600 x g for 5 minutes at 4￿C, the ethanol decanted and the pellets air-
dried for 5-10 minutes.  Pellets were resuspended in 20-50￿L DEPC-H2O
16, vortexed 
briefly and stored at -80￿C. 
 
3.13.2  RNA Gel Electrophoresis 
For Northern blotting, 8µg of RNA was made to 2.3µL with DEPC-H2O
16, 7.7µL of 
RNA buffer
86 was added to each sample and samples were incubated at 65°C for 15 
minutes then placed on ice for 5 minutes. 1.5µL RNA loading dye
87 was added to each 
sample and samples were loaded in 1% MOPS/formaldehyde/agarose
70 gels. Following 
electrophoresis in 1X MOPS
68 buffer at 100V for approximately 2 hours, RNA bands 
were visualised under UV transillumination prior to northern transfer (section 3.13.3). 
 
3.13.3 Northern  Transfer 
To transfer RNA from gels to nylon membranes, northern gels were inverted onto two 
pieces of Whatman
 3MM filter paper that had been pre-soaked in 20X SSC-DEPC
128 
and placed over a plastic support to form a wick. Nylon membranes were cut to the size 
of the gel, equilibrated in DEPC-H2O
16 then 20X SSC-DEPC
128 and placed on top of the 
gel followed by another two pieces of Whatman
 3MM filter paper, also cut to the size 
of the gel and pre-soaked in 20X SSC-DEPC
128. A 10cm stack of paper towels, a 
perspex plate and a 500g weight were placed on top of the gel to assist capillary transfer 
and plastic wrap was placed around the base of the gel over the support to prevent 
wicking. Following overnight transfer of RNA at room temperature, nylon membranes 
were rinsed in 1X SSC-DEPC
126, UV crosslinked in a Stratagene 1800UV Crosslinker, 
placed in Whatman
 3MM filter paper, wrapped in aluminium foil and stored in the 
dark at room temperature. 
 
3.13.4  Labelling of DNA Probes 
Purified cDNA probes were labelled by random priming with α -[
32P]-dCTP using the 
Prime-A-Gene
 Labelling System (section 2.2). Twenty-five ng of DNA was made to 
30µL with ddH2O, then denatured at 95°C for 2 minutes and placed on ice. Two µL Chapter Three ￿ Methods  
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dNTPs
24, 2µL (10µg/µL) BSA, 10µL 5X Labelling Buffer, 5µL  α -[
32P]-dCTP 
(3000Ci/mmol) and 1µL DNA polymerase I Klenow fragment were added to each 
reaction and reactions were incubated at room temperature for 60 minutes. To stop the 
reaction, tubes were heated to 95°C for 2 minutes then 2µL 0.5M EDTA (pH 8.0)
34 was 
added to each tube to inactivate the DNA polymerase. Tubes were placed on ice until 
required.  
 
3.13.5 Northern  Hybridisation 
Nylon membranes were pre-hybridised in 8mL of preheated Rapid-hyb buffer for 1 
hour at 65°C with rotation in a Robbins hybridisation incubator. Following pre-
hybridisation, 50µL of labelled probe (section 3.13.4) was added and membranes were 
hybridised for 2 hours at 65°C with rotation. Membranes were then washed at 65°C 
with rotation for 20 minutes each in Wash buffer I
150 then Wash buffer II
151, and finally 
in Wash buffer III
152 for 15 minutes. All wash buffers were pre-heated to 65°C. 
Membranes were then wrapped in plastic film and exposed to X-Ray film for 24-72 
hours at -80°C. Following exposure, films were developed, scanned and images were 
stored in .TIF format.  
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Chapter Four ￿ Bioinformatic Analysis of FLJ22318 
4.1 Introduction 
FLJ22318 was originally identified through the National Institutes of Health, 
Mammalian Gene Collection (MGC) program, (Clone MGC2688, NCBI Accession 
BC00991; Strausberg et al., 2002). No phenotype has been reported for FLJ22318, 
however several features of this gene make it an appealing candidate for further study. 
 
The FLJ22318 gene is expressed at a very high level, 4 times the average gene (Thierry-
Mieg et al., 2005) and according to the National Center for Biotechnology Information 
(NCBI) UniGene database (Hs.519804) is found in cDNA libraries from a wide range 
of normal and malignant tissues in both the foetus and adult. In addition, the 5’-flanking 
region of the FLJ22318 locus and the region encompassing the first two exons of the 
FLJ22318 gene has a high percentage (24.7%) of a C (cytosine) base followed 
immediately by a G (guanine) base (CpG) which is relatively rare unless there is 
selective pressure to keep it as such for regulation of gene expression (Figure 4.1).  CpG 
islands are common near transcription start sites where they are present at significantly 
higher levels than is typical for the genome as a whole. Hypermethylation of CpG 
islands has been associated with transcriptional silencing, however it has been noted 
that CpG islands often surround the promoters of constitutively expressed 
(housekeeping) genes, particularly in vertebrates (Gardiner-Garden and Frommer, 
1987). As such, the latter function of the CpG island is most consistent with the high 
level and widespread detection of FLJ22318 expression in human cDNA libraries. 
 
FLJ22318 has an important cytogenetic location which is on the long arm of 
chromosome 5 at 5q35.3. This region frequently undergoes loss of heterozygosity 
(LOH) in both lung squamous cell carcinomas and lung adenocarcinomas (Mendes-da-
Silva et al., 2000) as well as in neuroblastomas (Mosse et al., 2005). Deletions, 
additions and translocations of 5q35 have also been reported in haematological 
malignancies, as well as ovarian and breast cancers (Mitelman et al., 2005; Mosse et al., 
2005) and recently this region has been linked to hereditary prostate cancer (Xu et al., 
2005a).  
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177490157 177490999 
    ∗  
 
cgaggccggtgcgcacctagcccagccactgcccctcacggcccccgcgccgccctcactgagcaggg
cgggcagcgctgtaagcgtaaccacttggggcttggggcttctgacccgggagtcgggtgctgggttg
agtgcgaggccgacgcctctgccgggtggggaacccgcccgccggcgaggagcggtcgcggccagggg
cttccgccgactgggaggcccggggccgggccggagggactcggaacctggaaacgaccaggcgcgac
ccccagaggactacaggcgcggcttttctggccgccgcccggttcccgcgggcgactccactcggcat
gcgcggcggggagcctcggcggtgaggcgcaaagccgcgggctcgtgggacggccacccctccgcaaa
accgccaatgggcgggcccgggccgccgatcgcccgccgcggcttccggttccgatgacagtggcgcc
gGAAGCCGGGGCCGGGGCTGCGGGGCGAGgtgagagcgggcgggcttgggagccggcaggtgcgggcc
gagggcgggcacagcggccggcggagctgaggcgcgcggcggggaaagctcggccggcctcccgggcc
ccagccttctccagaacccctgctacccacgactaagccccgaacaatctgcccttgggcttgttctc
ttcgcagTTGTCGGCCCTGGGCCGGGAGCTGGAGTCCCAGACTCATAGGTCCCGGCCCAGCCCCCGAA
GAGCCGCCTCAGCCGGGGGGAGTTGCTCGGACTCAAACGTCCAGTCCTCGTGCGACCGCGCTGGGTCG
GAAGTGAGCAGgtgcgcaccgggctcg 
Figure 4.1 CpG island surrounding the FLJ22318 transcription start site. Schematic
representation of the 843 base CpG rich (24.7%; green) region encompassing the 5’-
flanking region of the FLJ22318 locus and exons 1 and 2 (∗  blue) of the FLJ22318
gene (Adapted from http://genome.ucsc.edu/cgi-bin/hgTracks).   
∗Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
  98
At present the in vivo function of FLJ22318 has not been determined, however the 
presence of several interesting putative protein-protein interaction motifs, including a 
lissencephaly type-1- like homology motif (LisH), a C-terminal to LisH (CTLH) motif, 
and a CT11-RanBPM (CRA) domain suggest that the protein is involved in multiple 
cellular functions as these domains are found in proteins with diverse biological 
activities (Letunic et al., 2006). 
 
The LisH motif is a 33 amino acid motif composed of two α -helices that form a rare 
asymmetric homodimer that has a tightly packed hydrophobic core (Kim et al., 2004b; 
Figure 4.2). This motif is present in archaea, bacteria and eukaryotic proteins including 
human proteins (Letunic et al., 2006) and is based on the N-terminal sequence of the 
platelet-activating factor acetylhydrolase, isoform 1b, alpha subunit (PAFAH1B1; 
LIS1) protein which is involved in disorders of neural development (Emes and Ponting, 
2001).  
 
Mutations in the PAFAH1B1 gene which encodes the non-catalytic alpha subunit of the 
intracellular 1B isoform of acetylhydrolase result in lissencephaly associated with 
Miller-Dieker lissencephaly syndrome. In this syndrome, the neurons fail to migrate to 
the cortex during cerebral development resulting in disorganised cortical layers which 
cause severe mental retardation and early death (Hattori et al., 1993; Reiner et al., 
1993). Studies have shown that PAFAH1B1 is required for the movement of the 
dynein/dynactin complex along microtubules and it is also thought to regulate division 
of neuronal progenitor cells in the developing brain (Faulkner et al., 2000; Smith et al., 
2000). In addition, Caspi et al., (2000) found that PAFAH1B1 interacts with 
doublecortin (DCX) in the developing cortex to enhance tubulin polymerisation, 
suggesting that interaction of these proteins is required for correct microtubule function.  
Kitagawa et al., (2000) demonstrated that PAFAH1B1 bound to platelet-activating 
factor acetylhydrolase, isoform 1b, beta subunit (PAFAH1B2) and the mitotic spindle 
assembly protein nuclear distribution gene E homolog 1 (NDE1) in a competitive 
manner whilst Tarricone et al., (2004) showed that PAFAH1B1 competed for binding to 
PAFAH1B2 with NDE1-Like 1 (NDEL1). NDE1 has recently been reported to be 
critical for normal cortical development (Feng and Walsh, 2004), whilst NDEL1 is 
required for regulation of dynein activity (Shu et al., 2004). These data indicate that
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Figure 4.2 Schematic representation of the two α -helices that form the LisH motif.
Model shows the LisH motif from the platelet-activating factor acetylhydrolase, isoform 
Ib, alpha subunit (PAFAH1B1;LIS1) protein with the tightly packed hydrophobic core 
residues
iii  in black and the corresponding hydrophobic core residues for FLJ22318 in
red (Adapted from Kim et al., 2004).  
 
 
 
 
 
 
                                                 
iii A ￿ alanine, E ￿ glutamate, F ￿ phenylalanine, I ￿ isoleucine, L ￿ leucine, M ￿ methionine, 
    N ￿ asparagine, R ￿ arginine, V ￿ valine, Y ￿ tyrosine 
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PAFAH1B1 is required for microtubule organisation, nuclear translocation, and 
neuronal positioning. 
 
Homodimerisation of the N-terminal portion of PAFAH1B1 containing the LisH motif 
and a coiled-coil region is required for its biological activity. The mutant PAFAH1B1 
protein is no longer able to bind PAFAH1B2 and studies in mice lacking the LisH 
region of PAFAH1B1 show a lissencephaly phenotype (Cahana et al., 2001). More 
recently, the LisH motif has been shown to affect protein turnover and cellular 
localisation as mutations to the PAFAH1B1 LisH motif resulted in a significantly 
reduced protein half-life and localisation of PAFAH1B1 to actin filaments rather than 
the cytoplasm (Gerlitz et al., 2005). 
 
The LisH motif is also present in other proteins that are implicated in human neural 
developmental disorders including transducin β -like 1X (TBL1X) which is implicated 
in ocular albinism with late-onset sensorineural deafness and oral-facial-digital 
syndrome type I (OFD1) protein (Bassi et al., 1999; Ferrante et al., 2001). TBL1X and 
PAFAH1B1 contain WD40 repeat-containing β -propeller domains following the LisH 
motif whilst the OFD1 protein has several coiled-coil domains following the LisH 
motif. Other characterised human proteins containing a LisH motif include the ataxia-
telangiectasia locus  protein (NPAT) and RAN-binding protein  9 (RANBP9 ; Letunic et 
al., 2006).  
 
TBL1X is a nuclear protein involved in the recruitment of the ubiquitin/19S proteasome 
complex to nuclear receptor-regulated transcription units. It plays an essential role in 
transcriptional activation mediated by nuclear receptors and is an integral component of 
the nuclear receptor co-repressor 1-histone deactylase 3 (NCOR-HDAC3) complex 
(Perissi et al., 2004; Zhang et al., 2002). Interaction between TBL1X and NCOR occurs 
through the N-terminal domain of TBL1X encompassing the LisH motif, which is also 
required for TBL1X binding to histones H2B and H4 (Yoon et al., 2003). Characterised 
mutations within the LisH motif of TBL1X result in the protein no longer localising to 
the nucleus (Gerlitz et al., 2005). 
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OFD1 syndrome is an X-linked dominant male lethal disease that in females is 
characterised by malformations of the hands, face and skull, and mental retardation 
(Ferrante et al., 2001). OFD1 localises to the centriole of the cell and is a core 
component of the centrosome throughout the cell cycle where it is believed to be 
involved in the differentiation of metanephric precursor cells and microtubule 
organisation and assembly (Keller et al., 2005; Romio et al., 2004). It is widely 
expressed during development in the metanephros, brain, tongue, limbs and during 
mesenchymal-epithelial transition associated with nephrogenesis (Romio et al., 2004; 
Romio et al., 2003). Recent studies in OFD1 knock-out mice show failure of left-right 
axis specification in mutant male embryos in addition to impaired patterning of the 
neural tube and altered expression of the 5’ Hoxa and Hoxd genes in the limb buds 
(Ferrante et al., 2006). Mutations of the LisH motif in OFD1 result in aberrant OFD1 
protein localisation to the Golgi apparatus and in some cases the nucleus (Gerlitz et al., 
2005).  
 
The nuclear protein NPAT is a ubiquitously expressed housekeeping gene that promotes 
cell cycle progression through histone H4 gene regulation at the G1/S phase cell cycle 
transition (Imai et al., 1996; Ye et al., 2003). Apart from the LisH motif, NPAT has no 
other domains, but unlike PAFAH1B1, TBL1X and OFD1, point mutations in the LisH 
motif of NPAT do not affect its localisation to nuclear Cajal bodies but instead block 
histone H4 transcriptional activity (Wei et al., 2003). 
 
RANBP9 is a protein of 729 amino acids that is identical in sequence within the first 
500 amino acids of the human, mouse and hamster proteins and shares 96% sequence 
similarity overall between the human and mouse proteins (Nishitani et al., 2001). 
RANBP9 has 4 protein-protein interaction motifs including a splA RyR (SPRY) 
domain, originally identified in mammalian ryanodine receptor proteins (Ponting et al., 
1997) that is a protein-interacting module which recognises a specific individual partner 
protein based on protein conformation rather than a consensus sequence motif (Wei et 
al., 2003). Similar to FLJ22318, RANBP9 also contains a LisH motif, a CTLH domain 
and a C-terminal CRA domain (Menon et al., 2004).  
 
RANBP9 is a multi-functional protein that is found in both the cytoplasm and nucleus 
of the cell, and in association with the plasma membrane when phosphorylated (Denti et Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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al., 2004; Nishitani et al., 2001). It has been shown to activate the Ras/Erk signalling 
pathway by binding and up-regulating MET, a protein that is overexpressed in many 
human cancers leading to enhanced cell motility and tumour invasion (Wang et al., 
2002). In addition, RANBP9 has also been shown to bind and up-regulate both the 
androgen receptor (AR) and the glucocorticoid receptor (GR) in the presence of their 
ligands when transiently over expressed in prostate cancer cell lines (Rao et al., 2002). 
Conversely, RANBP9 binds and inhibits the co-activators, dual-specificity tyrosine 
phosphorylation-regulated kinases 1A (Dyrk1A) and Dyrk1B that are involved in 
epithelial cell migration (Zou et al., 2003) and increases the proapoptotic activity of p73 
by inhibiting its ubiquitination (Kramer et al., 2005). The binding of RANBP9 to MET, 
AR and GR was found to occur through the SPRY domain whereas the transcriptional 
inhibition of Dyrk1A and Dyrk1B required both the SPRY domain and the LisH motif 
(Zou et al., 2003).  
 
The CTLH domain is also predicted to be an α -helical domain that is found adjacent to 
the LisH motif in a number of proteins but is also found in some proteins in the absence 
of the LisH motif. This domain does not occur in archaea, bacteria or viruses and is 
found only in eukaryotes where the motif is present in all metazoans, indicating 
evolutionary conservation (Letunic et al., 2006).  The function of the CTLH domain has 
not yet been characterised. Of the 326 proteins listed in the simple modular architecture 
research tool (SMART) database (Schultz et al., 1998) that contain a CTLH domain, 
only one which contains just this domain has been characterised and this is the proposed 
FLJ22318 orthologue, RMD5 from S. cerevisiae. RMD5 functions as a negative 
regulator of gluconeogenesis and is required for the proteasome-dependent catabolite 
degradation of fructose-1,6-bisphosphatase (FBPase) where it is specifically required 
for the ubiquitination of FBPase (Regelmann et al., 2003).  Interestingly, yeast 
nutritional starvation induces sporulation and meiosis, and RMD5 has also been shown 
to be an IME1 inducible protein that is essential for sporulation and meiotic nuclear 
division (Enyenihi and Saunders, 2003).  Recently it has been shown that α -helical 
coiled-coil segments following the LisH motif are required for protein stability and that 
this region is necessary for an open or supercoiled conformation of the protein. It has 
been suggested that these coiled-coil segments in conjunction with LisH motifs have an Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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important biological activity and that the CTLH domain may have a similar function 
(Mateja et al., 2006).  
 
The CRA domain was initially identified in RANBP9 as a C-terminal protein-protein 
interaction domain required for binding to the fragile X mental retardation 1 protein 
(FMR1). Fragile X syndrome is characterised by moderate to severe mental retardation, 
macroorchidism, large ears, prominent jaw, and high-pitched jovial speech with mental 
retardation being the most common feature (Mandel and Biancalana, 2004). This 
syndrome is associated with mutations in the FMR1 gene with affected individuals 
having reduced FMR1 protein expression which has recently been shown to result in the 
early and abnormal differentiation of neuronal stem cells (Castren et al., 2005; Tassone 
and Hagerman, 2003). In unaffected individuals, neurons, dividing epithelial tissues and 
spermatogonia in adult testis show the highest levels of FMR1 expression while glial 
cells contain very low levels (Devys et al., 1993). Within the cell, FMR1 functions as a 
translational repressor RNA-binding protein that forms a messenger ribonucleoprotein 
complex that shuttles between the cytoplasm and nucleus of cells (Laggerbauer et al., 
2001; Tamanini et al., 1999). Binding of RANBP9 to FMR1 was shown to modulate 
FMR1 binding to RNA. As the CRA domain of RANBP9 was able to significantly 
decrease the binding of the MAP1B RNA, an RGG box-binding partner of FMR1, it 
would suggest that RANBP9 functions as an RGG box-binding protein through its CRA 
domain (Menon et al., 2004). 
 
The function of the hypothetical protein FLJ22318 is unknown and initial studies in this 
thesis sought to use bioinformatics analysis of its gene and protein sequences in order to 
characterise structural features of FLJ22318 that may be useful for investigating its 
biological activity. 
 
4.2 Results   
4.2.1  FLJ22318 Gene Structure 
The FLJ22318 gene as annotated in the NCBI Entrez Gene database (Gene ID 64777) 
spans 17.4 kilo base pairs (kb) of genomic DNA with an ORF encoded by 11 exons and 
10 introns. Examination of the FLJ22318 sequence demonstrates that all introns have 5’-
GT and 3’-AG splice donor and acceptor sites. Transcription of the FLJ22318 gene Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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produces a mRNA transcript of 1825bp comprising a 180bp 5’ untranslated region 
(UTR), 1182bp coding region and 464bp 3’ UTR and encodes a protein of 393 amino 
acids (Reference Sequence NP_073599). The start methionine of the 393 amino acid 
protein is within exon 3, with the stop codon in exon 11 (Figure 4.3). 
 
According to AceView however, alternative splicing of this gene can produce 16 
transcript variants (Figure 4.4) putatively encoding 14 different protein isoforms (Table 
4.1; Thierry-Mieg et al., 2005). The NCBI published sequence (Accession No. 
NM_022762), differs in transcript size to the AceView data, although variants b, c and d 
all encode a protein of 393aa with a molecular weight of 44.4kDa as nucleotide 
differences are confined to the UTRs and do not affect the translated amino acid 
composition. Transcript variants a, e, f, g, h, i, j, k, l, m and o all encode putative 
proteins that contain portions of the 393aa reference sequence, although transcript 
variants a, h, i and o also comprise additional amino acid sequences. Transcript variants 
n and p are proposed to encode proteins of 103 and 77aa that are completely different to 
the reference sequence. Interestingly, several of the proposed FLJ22318 isoforms may 
localise to the nucleus of the cell (Table 4.1) whilst the remainder are proposed to be 
cytoplasmic.  
 
4.2.1.1  Mammalian Gene Homologues of FLJ22318 
A search of the NCBI HomoloGene database (www.ncbi.nlm.nih.gov/entrez/query.fcgi?
db=homologene) revealed the presence of mammalian FLJ22318 gene homologues for 
the chimpanzee, mouse, rat and dog. Sequence alignment of the genes from these 
species against human FLJ22318 indicated that there is more than 80% nucleotide 
homology between these species within the coding exons. There is less homology 
evident within the 5’ and 3’-UTRs of the genes, although immediately prior to the 
translation start site and following the stop codon there are segments of  5-7 
homologous nucleotides that have been conserved and these may represent regulatory 
regions (Figure 4.5). 
 
Further evidence of a common ancestral gene comes from analysis of the genomic 
sequences for these 5 species based on a phylogenetic hidden Markov model 
(phastCons). The phastCons program computes conservation scores based on a type of 
probabilistic model that describes both the process of DNA substitution at each site in a 
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genome and the way this process changes from one site to the next (Siepel et al., 2005). 
Using this model it can be seen that there is conservation in the area immediately prior 
to the transcription start site (TSS) and within intronic regions of these genes, 
suggesting conservation of regulatory elements within these regions (Figure 4.6). In 
relation to the human gene, conserved regions can be observed in intron 2 prior to the 
translation start site as well as in introns 8, 9 and 10 and interestingly these conserved 
intronic regions correspond to the alternative splice variants as proposed in Figure 4.4. 
Furthermore, the alternative exon 1 proposed in splice variants e and j corresponds to 
conserved regions seen only in the human and chimpanzee genomes, suggesting that 
these transcripts may be specific for primates (Figure 4.6). 
 
Comparison of the chromosomal locations of human FLJ22318 with the homologous rat 
LOC497900 and mouse 0610039K22Rik genes demonstrates a high degree of 
chromosomal synteny including gene structure and transcript orientation (Figure 4.7). 
Both the rat and mouse genes are identical to one another in exon-intron structure and 
comprise 10 exons and 9 introns respectively. When compared to FLJ22318, the coding 
exons are completely conserved between all 3 genes and although mouse and rat exons 
1 and 10 differ in length to human exons 1-3 and exon 11, these exons are conserved in 
size relative to the transcription start site and stop codon (Table 4.2). In addition to 
homology within FLJ22318, the syntenic regions of human, mouse and rat 
chromosomes that encompass the FLJ22318 orthologues also include Nedd4 binding 
protein 3 (N4BP3) proximally and nucleolar protein family A member 2 (NOLA2) and 
heterogenous nuclear ribonucleoprotein A/B (HNRPAB) distally (Figure 4.7). 
 
4.2.1.2   Transcriptional Regulation of FLJ22318 Expression 
As the transcriptional regulation of FLJ22318 is undetermined, and based on the 
previous analysis of genomic sequence homology (Figure 4.6), a 1366bp segment 
comprising 1000 bases upstream of the transcription start site (TSS) and the CpG island 
were examined for potential cis-regulatory factor binding sites using the programme 
MatInspector V6.0 (http://www.genomatix.de/matinspector) which contains 431 
vertebrate matrices in 148 families and represents the largest publicly accessable library 
currently available (Cartharius et al., 2005). Forty three high quality (>0.90) potential 
transcription factor binding sites were identified, including 17 sites for genes belonging 
to the ANTP, PRD, TALE , SINE and POU homeobox classes. Of these 17 sites, 11Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
  113
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Comparison of genomic nucleotide conservation between mammalian
homologues of FLJ22318. As well as the high degree of sequence homology
observed within the exons, sequence homology can also be seen in genomic DNA
immediately prior to the transcription start site and in intron 2 prior to the translation
start site as well as in regions that correspond to alternative transcripts proposed for
this gene (see Figure 4.4; Adapted from http://genome.ucsc.edu/cgi-bin/hgTracks). 
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 Rat   Mouse  Human Rat   Human  Mouse
(A) (B) 
Figure 4.7 Analysis of the chromosomal localisation of FLJ22318 from the human, 
rat and mouse genomes. (A) Ideograms depicting the chromosomal localisation of
human FLJ22318 to chromosome 5q35.3 and the rat and mouse homologues to 
chromosomes 10q21 and 11B1.2. (B) Schematic representation of the high degree of 
synteny demonstrated between human chromosome 5q35.3 to rat chromosome 10q21
and mouse chromosome 11B1.2 including the structure and orientation of transcripts 
for FLJ22318, N4BP3, NOLA2 and HNRPAB (Adapted from
http://www.ncbi.nlm.nih.gov/mapview/maps.cgi).  Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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Human FLJ22318  Rat LOC497900  Mouse 0610039K22Rik 
Exon Length 
(bp) 
Coding 
exon 
(bp) 
Exon Length 
(bp) 
Coding 
exon 
(bp) 
Exon Length 
(bp) 
Coding 
exon 
(bp) 
1  28             
2 140  1  307    1  307   
3  151 139 2 186 139 2 186 139 
4  146 146 3 146 146 3 146 146 
5  141 141 4 141 141 4 141 141 
6  101 101 5 101 101 5 101 101 
7  167 167 6 167 167 6 167 167 
8  166 166 7 166 166 7 166 166 
9  103 103 8 103 103 8 103 103 
10  155 155 9 155 155 9 155 155 
11  509 64 10  473 64 10  473 64 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2 Comparison of gene structure between FLJ22318 and the rat and mouse
homologues demonstrates that the coding exons are completely conserved between
species. Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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were for the NK-related genes NKX2-1, NKX2-5, NKX3-2 and NKX5-1. Besides the 
potential homeobox gene binding sites that were identified, a number of potential 
binding sites were also identified for other transcriptional regulators involved in 
embryonic development and differentiation such as CP2, FOXN1, GATA1, MZF1, 
MYT1, TH1L and WT1 as well as 4 potential binding sites for the oncogenes N-Myc 
and MYB (Figure 4.8). 
 
A transcription factor binding site that occurs at a similar relative position in promoters 
from genes that presumably have the same function would suggest evolutionary 
conservation and provide additional evidence that the site may be functional (Cartharius 
et al., 2005). Therefore, the 1000 bases upstream of the TSS from the human and mouse 
FLJ22318 genes were compared identifying 9 binding sites (>0.83) that are common to 
both promoters including sites for CHREBP, HIC1, NKX5-1, SP1 and an additional 
MYB site that was not identified in the original promoter analysis (Figure 4.9).  
 
4.2.1.3   FLJ22318 Single Nucleotide Polymorphisms 
As there is a high degree of nucleotide sequence homology between mammalian 
FLJ22318 genes together with possible conservation of transcription factor binding sites 
within the promoter regions, a search of the dsSNP build 125 available from 
ftp.ncbi.nih.gov/snp was performed in order to identify sequence variants that may 
affect transcription or regulation of transcription of FLJ22318. This search revealed the 
presence of 44 single nucleotide polymorphisms (SNPs), five of which are located in 
the locus region within 2000 bases of the FLJ22318 gene. Of these five SNPs, four fall 
within potential NKX3-2 (-922), WT1 (-884), FOXN1 (-396) and TH1L (-203) 
transcription binding sites as identified by the MatInspector V 6.0 programme. 
Interestingly, the remaining 39 SNPs are all located within untranslated or intronic 
regions of the FLJ22318 gene with no SNPs having been identified within the coding 
region, suggesting that the invariant protein product from this gene has a function that is 
critical to the cell (Figure 4.10). 
 
4.2.2  FLJ22318 Protein Structure and Homology 
FLJ22318  transcribes a proposed protein comprised of 393 amino acids with a 
molecular weight of 44414 Daltons. Examination of this amino acid sequence identified 
three putative nuclear receptor boxes (NRBs) that are motifs found in nuclear proteins, 
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LisH CRA    NRB    NRB   NRB      CTLH
 FXXLL 
201-205 
LXXIL 
159-163
 LXXLL 
 29-33 
116-148 155-212 210-304
393 1 
Figure 4.10 Position of single nucleotide polymorphisms (SNPs) associated with the
FLJ22318 gene. Schematic representation showing that the SNPs associated with the 
FLJ22318 gene are located within the untranslated and intronic regions of the gene
together with 4 SNPs that are within 2000 bases of the transcription start site. 
Figure 4.11 Domain structure of the FLJ22318 protein. Examination of the
FLJ22318 amino acid sequence identified a lissencephaly type-1-like homology
motif (LisH), a C-terminal to LisH motif (CTLH), a CT11-RanBPM (CRA) domain
and three putative nuclear receptor boxes (NRB).  
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including nuclear receptor co-regulators (Huang et al., 1998; Li et al., 2001). A search 
of the simple modular architecture research tool (SMART) database (Schultz et al., 
1998) also revealed three conserved protein motifs/domains, a lissencephaly type-1- like 
homology motif (LisH; SMART accession number SM00667), a C-terminal to LisH  
motif (CTLH; SMART accession number SM00668), and a CT11-RanBPM domain 
(CRA; SMART accession number SM00757; Figure 4.11). The proposed NRBs 
comprise amino acids LXXLL, LXXIL and FXXLL
3 and encompass residues 29-33, 
159-163 and 201-205 respectively, with the LXXIL and FXXLL NRBs lying within the 
proposed CTLH motif. The LisH motif extends 33 residues from position 116 to 148, 
the CTLH motif 58 residues from position 155 to 212, and the CRA domain 95 residues 
from position 210 to 304.  
 
Currently the SMART non-redundant database contains 108 eukaryotic proteins or 
protein fragments displaying the same protein organisation as FLJ22318. Of these 
proteins, only two, glucose-induced degradation protein 8 (GID8) from yeast and 
macrophage erythroblast attacher (MAEA) protein from mouse and human have been 
characterised. MAEA is involved in erythroblast￿macrophage cell attachment, terminal 
maturation and enucleation of erythroid cells, erythroblast inhibition, apoptosis and in 
addition has recently been shown to contribute to nuclear architecture and cell division 
(Bala et al., 2006). Similarly, GID8 is also required for cell cycle progression where it 
interacts with the G1/S phase cell cycle regulator SWI4 to accelerate DNA replication 
(Pathak et al., 2004). In addition to its role in cell cycle progression, GID8 is also 
required for the ubiquitination and glucose-induced degradation of FBPase where it 
forms part of a large protein complex containing RMD5, the yeast orthologue of 
FLJ22318 (Regelmann et al., 2003). 
 
Although FLJ22318 is a proposed orthologue of RMD5 they do not share the same 
protein domain organisation as RMD5 contains only a CTLH motif. Therefore, a search 
of the InParanoid orthology database (http://inparanoid.cgb.ki.se) was performed in 
order to identify other mammalian orthologues of RMD5 to ascertain whether their 
domain organisation was similar to that of FLJ22318. This search resulted in the 
identification of 10 orthologous proteins which could be divided into two paralogous 
                                                 
3 F ￿ phenylanine, I ￿ isoleucine, L ￿ leucine, X ￿ any amino acid Chapter Four ￿ Bioinformatic Analysis of FLJ22318   
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groups with a representative from human, chimpanzee, dog, mouse and rat in each 
group, all of which comprised the same domain organisation to that of FLJ22318 (Table 
4.3). To determine the level of sequence conservation between FLJ22318 and the four 
other mammalian orthologues comprising this group, a multiple sequence alignment 
was performed using the CLUSTALW programme (Thompson et al., 1994). All 
proteins demonstrated an exceptionally high degree of sequence conservation (>97%) 
which was as expected as there is more than 80% nucleotide homology within the 
coding region of these genes (section 4.2.1.1; Figure 4.12). Moreover, this sequence 
conservation extended to the entire length of the protein and was not confined to the 
identified protein motifs/domains. These findings indicate that the N- and C-terminal 
regions of these proteins, which comprise approximately 100 amino acids each, are also 
necessary for biological function.  
 
The level of sequence conservation was also examined in the other orthologous group of 
RMD5 proteins (FLJ13910), and although sequence conservation was not as high 
within this group, as both the rat and chimpanzee proteins showed N-terminal 
diversification, the human, dog and mouse proteins displayed sequence conservation 
that also extended the entire length of the protein, providing further evidence that the N- 
and C-terminal regions of FLJ22318 are required for functionality (Table 4.3; Figure 
4.13A). Comparison of human FLJ22318 and FLJ13910 indicated 70% amino acid 
identity with only 9% of amino acids non-conserved (Figure 4.13B).  
 
4.3 Discussion 
FLJ22318 is a novel hypothetical protein that was identified as a potential NKX3-1 
interacting protein in prostate cancer cells. NKX3-1 binding proteins are poorly 
characterised in prostate cancer and regulation of NKX3-1 expression is not well 
understood, therefore characterisation of NKX3-1 binding proteins such as FLJ22318 is 
essential to our understanding of NKX3-1 regulation and function. As the in vivo 
function of FLJ22318 has not been determined, its activity in prostate cancer cells and 
the effects of its interaction with NKX3-1 are unknown. FLJ22318 has several features 
that make it an interesting gene and protein for further analysis including its 
chromosomal location and protein-protein interaction motifs which suggest involvement 
in multiple cellular functions.  Chapter Four ￿ Bioinformatic Analysis of FLJ22318   
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        Table 4.3 Proposed mammalian orthologues of S. cerevisiae RMD5 
 
 
 
 
FLJ22318 Orthologues 
Species  NCBI Protein Accession Number  Amino Acids 
H. sapiens  NP_073599  393 
P. troglodytes  XP_518140  393 
C. familiaris  XP_531873  393 
M. musculus  XP_079622  393 
R. norvegicus  XP_573086  393 
FLJ13910 Orthologues 
Species  NCBI Protein Accession Number  Amino Acids 
H. sapiens  NP_073617  391 
P. troglodytes  XP_525806  400 
C. familiaris  XP_532970  391 
M. musculus  XP_077250  391 
R. norvegicus  XP_232051  570  
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Comparison of human chromosomal region 5q35.3 with syntenic regions on mouse 
chromosome 11b1.3 and rat chromosome 10q22 indicate that the relative positions of 
FLJ22318 orthologues are identical. The regions of these chromosomes encompassing 
the FLJ22318 orthologues also show analogous gene organisation with regard to the 
adjacent genes N4BP3, NOLA2 and HNRPAB. Recently it has been shown that there is 
remarkable conservation in gene organisation between species and that while gene 
expression evolves very quickly, particularly in mammals, gene order is both 
evolutionarily very stable and in specific circumstances may be related to gene 
expression (Hillier et al., 2004; Khaitovich et al., 2004). 
 
Within this syntenic region, N4BP3 and HNRPAB are both transcribed in the same 
direction as FLJ22318 whereas the intervening gene NOLA2 is transcribed 
convergently to FLJ22318. Investigation of eukaryotic genomes has identified co-
evolution of gene expression when neighbouring genes are transcribed in the same or 
divergent directions but not when the genes are transcribed in convergent directions 
(SŁmon and Duret, 2006). In addition, N4BP3 and HNRPAB are positioned within 4.9 
and 56Kb respectively of FLJ22318 and co-expressed genes have been shown to cluster 
more closely than non co-expressed genes with the average distance between co-
expressed genes in humans being 284kb (median 89kb) compared to 617kb (median 
222kb) for neighbouring genes that are not co-expressed (SŁmon and Duret, 2006). 
These findings provide evidence for investigation of co-expression of FLJ22318 and its 
surrounding genes, N4BP3 and HNRPAB in human tissues. 
 
According to the AceView and NCBI UniGene databases, FLJ22318 is ubiquitously 
expressed, N4BP3 (Hs. 101761) is found in cDNA libraries and ESTs from a variety of 
tissues and is expressed more than would be expected for the average gene, whilst 
HNRPAB (Hs. 591731) is ubiquitously expressed at 8.7 times the average gene 
(Thierry-Mieg et al., 2005). Clusters of co-expressed genes in mammals are typically 
located within a gene dense region, are highly expressed and generally contains 2 or 3 
genes (Versteeg et al., 2003). Although FLJ22318, N4BP3 and HNRPAB are all highly 
expressed, the UniGene database does not contain cDNA libraries or ESTs from every 
human tissue at all stages of development therefore it is not known to what extent 
FLJ22318, N4BP3 and HNRPAB are expressed in the same tissues or at the same stages Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
  127
of development. Clusters of co-expressed genes are proposed to be maintained by 
selective pressure as greater than expected conservation of gene linkage is evident 
between species during evolution. Functional relationships of co-expressed genes have 
also been hypothesised although the extent of this is unknown (SŁmon and Duret, 
2006). As the biological activity of FLJ22318 has yet to be characterised, determination 
of FLJ22318 function and investigation of its distribution of expression and co-
expression with N4BP3 and/or HNRPAB will be required to characterise this cluster of 
highly expressed genes.  
 
Bioinformatic analysis of the promoter region of the FLJ22318 gene identified a 
putative CpG island of 843 bases surrounding the FLJ22318 transcription start site and 
the first two exons of the FLJ22318 gene. CpG islands are associated with the upstream 
region of many genes, generally cover all or part of the promoter and may extend into 
the first exon and beyond. All widely expressed (housekeeping) genes and up to 40% of 
tissue specific genes are associated with CpG islands, the majority of which are not 
methylated (Robinson et al., 2004). Hypermethylation of CpG islands is associated with 
both transcriptional silencing of gene expression such as tumour suppressor genes in 
cancer (Esteller, 2005) and constitutive gene expression.  The presence of FLJ22318 
mRNAs and ESTs in a wide range of different non-malignant and malignant tissues 
indicates widespread maintenance of expression of FLJ22318 and suggests that if 
hypermethylated, the FLJ22318 CpG island is not associated with transcriptional 
silencing. However, further investigation of the methylation status of the FLJ22318 
CpG island and its relationship to FLJ22318 expression will be required in order to 
determine the contribution of the CpG island to regulation of FLJ22318 mRNA 
transcription and steady-state levels.   
 
The cytogenetic location of FLJ22318 at 5q35.3 on chromosome 5 is important as 
chromosomal additions, deletions and translocations of the 5q35 region have been 
reported in a number of cancers including leukaemia, lymphoma, breast, ovarian and 
prostate cancer. Furthermore, deletions of 5q are the most frequent abnormality seen in 
breast cancers of BRCA1 mutation carriers (Johannsdottir et al., 2006). The 5q35.3 
cytogenetic location is also associated with hereditary prostate cancer and early age at 
onset of breast cancer, especially in women with BRCA1 and BRCA2 mutations 
(Johannsdottir et al., 2006; Xu et al., 2005b). These findings suggest that genes Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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affecting cancer progression, such as genes involved in cell cycle progression or DNA 
repair may be located within this region. Mapping studies within the 5q35.2-5q35.3 
region have shown that mutations and deletions at the NSD1 locus are responsible for 
Sotos syndrome, which is characterised by accelerated growth and macrocephaly 
(Douglas et al., 2003). However as patients with Sotos syndrome are also at an 
increased risk of developing cancer it indicates the presence of genes within the 5q35.2-
5q35.3 region that are required for growth regulation and whose deregulation may lead 
to uncontrolled cell cycle progression and cell transformation. Loss of heterozygosity at 
the NPM1 locus at 5q35.3 is associated with leukaemia and lymphoma but the genes 
within this region that are associated with breast and prostate cancer have not been 
mapped (Berger et al., 2006). None of the studies performed to date have included the 
FLJ22318 locus therefore it remains unknown whether loss or gain of FLJ22318 
expression could be involved in the cancers that are associated with this chromosomal 
region.  
 
The yeast orthologue of FLJ22318, RMD5, which contains only a CTLH motif is 
required for protein ubiquitination, degradation and cell division (Enyenihi and 
Saunders, 2003; Regelmann et al., 2003). Examination of the FLJ22318 amino acid 
sequence revealed that it contains LisH, CTLH and CRA domains, a domain structure 
that is present in 108 eukaryotic proteins of divergent genomes. Acquisition of the LisH 
and CRA domains suggests that human FLJ22318 has evolved different or additional 
functions in comparison to yeast RMD5. Of the proteins containing a similar domain 
composition to human FLJ22318, only MAEA and GID8 have been characterised and 
both are involved in cell cycle progression (Bala et al., 2006; Pathak et al., 2004). 
However, their interacting proteins or the domains contributing to these interactions 
have not been reported. Previous studies have shown that all of the characterised 29 
human proteins or protein fragments which contain a LisH motif either on its own or in 
combination with other domains, are involved in development, where they are also 
associated with the cell cycle (Schultz et al., 1998). In these proteins, the LisH motif has 
been shown to function as a protein-protein interaction domain, to affect protein 
stability and to direct protein localisation. The function of the CTLH domain has not 
been characterised whereas the CRA domain has also been described as a protein-
protein interaction domain that can modulate RNA binding. Analysis of the PAFAH1B1 
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α -helical secondary structure composed of several highly conserved elements and has 
resulted in the identification of regions that are required for protein function (Kim et al., 
2004b; Menon et al., 2004). Functional characterisation of FLJ22318 would also 
therefore investigate its secondary structure and the involvement of the LisH, CTLH 
and CRA domains in protein-protein interactions, protein localisation and the potential 
role of FLJ22318 in control of cell proliferation.  
 
Recently it has been suggested that the CTLH motif may be necessary for an open or 
closed protein conformation which may depend on protein binding. Within the CTLH 
motif of FLJ22318 there are two putative nuclear receptor boxes (NRB￿s), one of which 
(LXXIL) is located at the N-terminus whilst the other (FXXLL) is located at the C-
terminus of the CTLH domain. NRB￿s are short amino acid sequences which facilitate 
co-receptor binding to nuclear receptors. Nuclear receptors function as ligand-activated 
transcription factors where ligand binding to the receptor ligand binding domain causes 
a conformational change (Mangelsdorf and Evans, 1995). In the majority of nuclear 
receptors, co-regulator binding occurs through the activation function 2 (AF2) motif, an 
α -helical motif located in the C-terminus and also requires the NRB to adopt an α -
helical conformation (Durand et al., 1994). The putative LXXIL and FXXLL NRBs in 
FLJ22318 lie within the proposed α -helical CTLH motif and these motifs have been 
shown in previous studies to bind thyroid receptor (TR), retinoid X receptor (RXR) and 
retinoid acid receptor (RAR) in the presence of their ligands, thyroid hormone and 
retinoids. FLJ22318 also contains a third putative NRB LXXLL located at amino acids 
29-33 and previous studies have shown this motif can bind RAR in the absence of 
ligand and androgen receptor (AR) in the presence of ligand (Huang et al., 1998). The 
presence of these putative NRBs suggests that FLJ22318 may interact with members of 
the nuclear receptor superfamily and future studies would be necessary to determine 
whether FLJ22318 interacts with TR, RXR, RAR, AR or other nuclear receptors in the 
presence or absence of their respective ligands.  
 
Comparison of the 16 proposed FLJ22318 gene transcripts reveals that all but two of 
these transcripts encode proteins that comprise specific regions of the NCBI reference 
protein (NP_073599) with the remaining two transcripts, ￿n￿ and ￿p￿, proposed to 
encode completely different proteins. Transcript variants ￿k’ and ￿l￿ encode proteins Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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comprising the N-terminal region prior to the LisH motif, the LisH motif and distinct 
portions of the CTLH motif. Transcript variant ￿i￿ is similar to variant ￿l￿ except that 
this variant encodes an extra exon which introduces another putative LXXLL NRB. In 
contrast, transcript variant ￿j￿ encodes a protein comprising a truncated CTLH motif and 
CRA domain but is missing the LisH motif and highly conserved region prior to the 
LisH motif. Transcript variants ￿a￿, ￿e￿, ￿g￿ and ￿h￿ all encode proteins with intact LisH, 
CTLH and CRA domains, however variants ￿a￿ and ￿e￿ have different intron and exon 
structures prior to the LisH motif compared to the reference sequence, whilst variant ￿g￿ 
is truncated prior to the LisH motif and following the CRA domain. The three variants, 
￿b￿, ￿c￿ and ￿d￿ all encode proteins identical to the reference sequence but contain 
distinct 3‘ and 5‘ UTRs indicating that if expressed, these variants may be under 
differential transcriptional and/or translational regulation.  
 
The presence of ESTs in a wide range of normal and malignant tissues for the distinct 
variants ￿n￿ and ￿p￿ suggests expression of these transcripts as does the presence of 
ESTs for variant ￿i￿ which encodes an extra distinct exon. Of interest is that these ESTs 
are detected in embryonic stem cells and normal brain and uterine tissue indicating that 
specific FLJ22318 transcripts may be expressed in different tissue and at distinct stages 
of development. As transcript variants are also proposed which encode only the highly 
conserved N and C-terminal regions of FLJ22318 prior to the LisH motif and following 
the CRA domain, functional elements may reside within these regions. A number of 
these transcript variants are also proposed to encode proteins comprising combinations 
or part of the putative LisH, CTLH and CRA protein-protein interaction domains 
although expression of all of these variants cannot be distinguished using EST 
expression data.  
 
As the deduced subcellular location differs for proteins encoded by the proposed 
transcripts, it can be speculated that similar to other proteins including the previously 
described HNRPAB, FLJ22318 isoforms may perform different functions in distinct 
subcellular compartments. Northern blotting or library screening in future experiments 
will help to determine which FLJ22318 transcripts are expressed in specific tissues, 
however, generation of FLJ22318 antibodies will be required to examine expression of 
FLJ22318 isoforms in prostate, prostate cancer and in other tissues. This is further 
discussed in Chapter five.  Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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Bioinformatic analysis of the FLJ22318 promoter and CpG island identified several 
potential transcription factor binding sites for homeodomain proteins, which are 
important regulatory factors that are involved in diverse biological activities in 
embryonic and adult tissues including differentiation, proliferation and apoptosis 
(section 1.3.1). The majority of these proposed binding sites are for transcription factors 
that belong to the NK-related class of homeodomain proteins which generally have a 
tissue specific expression pattern. Previous studies have shown that the regulation of 
gene expression is governed by binding of different combinations of transcription 
factors in specific tissues and that subsets of binding sites may be relevant for specific 
tissues but not for others. Potential transcription factor binding sites in the mouse 
FLJ22318 promoter were also identified as identification of binding sites common to 
promoters in multiple species provides supporting evidence that these motifs may be 
functional. This analysis confirmed the presence of 9 potential binding sites for 
transcription factors that are common to both promoters. Of these 9 binding sites, the 
putative SP1 binding site is particularly interesting as constitutive expression of some 
genes has been shown to be dependent on SP1 binding (Zhang et al., 2006). In addition, 
as the yeast orthologue of FLJ22318, RMD5 is involved in the degradation of proteins 
involved in gluconeogenesis, the identification of the putative CHREBP binding site in 
the human FLJ22318 promoter region is of particular interest as CHREBP regulates 
gene transcription in a glucose dependent manner and previous studies have shown that 
RMD5 expression is repressed in response to glucose. Bioinformatic analysis of 
potential transcription factor binding sites in the FLJ22318 promoter has provided a 
starting point for investigating the regulation of FLJ22318 expression and suggests that 
FLJ22318 may have a constitutive basal level of expression that is modulated by 
binding of additional factors. Deletion analysis of the FLJ22318 promoter region to 
identify specific regions with promoter activity will be useful in determining the 
molecular mechanisms by which FLJ22318 expression is regulated.  
 
To date, no single nucleotide polymorphisms (SNPs) have been identified that are 
located within the coding exons of the FLJ22318 gene despite the identification of 44 
other SNPs that are located in the 5‘ and 3‘ untranslated and intronic regions of the 
gene. Polymorphisms associated with the promoters of genes can introduce new 
regulatory elements or disrupt existing transcription factor binding sites, allowing 
differential gene expression. In addition, intronic regions of genes can harbour Chapter Four ￿ Bioinformatic Analysis of FLJ22318  
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enhancers and therefore polymorphisms located in these regions can also regulate levels 
of expression (Tsukada et al., 2006). Analysis of all 44 SNPs across species to assess 
phylogenetic conservation, which may provide clues to their functional importance, 
identified just two SNPs where the reference nucleotide is conserved across a number of 
species. The most conserved SNP position, Rs11956603 in intron 5, was located in a 
DNA stretch completely conserved from human, chimpanzee, rhesus macaque and cow. 
In addition, single nucleotide conservation was also observed at this position from 
mouse, rat, rabbit and elephant. The second SNP position, Rs10036388 located in intron 
2, was located in a stretch of DNA that showed a high degree of conservation between 
human, chimpanzee, rhesus macaque, elephant and lesser hedgehog. Although the 
biological relevance of the SNPs in FLJ22318 are unknown, the regional conservation 
of these two sequences containing SNPs Rs11956603 and Rs10036388 warrants further 
study to determine whether these regions harbour regulatory elements that may be 
functionally important to FLJ22318 transcription. More importantly, the exceptionally 
high degree of sequence conservation seen within the coding exons across species 
coupled with the absence of known mutations within this region suggests that the 
protein encoded by this gene may be critical for cell survival and/or function.  
 
Since a significant conservation of nucleotide and amino acid sequences between 
human FLJ22318 and its orthologues in a diverse range of mammalian species provides 
strong evidence that FLJ22318 function is critical in the cell, the identification of 
protein-protein interaction domains in FLJ22318 that in other proteins are required for 
biological activity and which are associated with cell cycle regulation represents a 
significant finding. This may be especially relevant as the FLJ22318 gene maps to 
5q35.3, a region linked to hereditary prostate cancer that is thought to harbour genes 
whose deregulation leads to cell transformation and uncontrolled cell cycle progression. 
As such, characterisation of FLJ22318 and its interaction with NKX3-1 in prostate 
cancer cells will provide a better understanding of NKX3-1 function in human prostate 
cancers and the consequences of its loss in androgen dependent prostate cancers. 
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Chapter Five ￿ Characterisation of FLJ22318 Interaction 
with NKX3-1 
5.1 Introduction 
To determine how molecular pathways that operate within cells contribute to various 
biological functions, characterisation of protein-protein interactions is essential. Within 
the cell, proteins form rapid and transient complexes with other proteins and it is these 
complexes that control a large number of cellular processes such as proliferation, 
migration, basic or specialised metabolism and the activation and integration of 
signalling pathways. In addition, transient protein-protein interactions are involved in 
the assembly of transcriptional machinery at specific promoters, are required for protein 
transport and direct the formation and degradation of subcellular structures such as 
microtubules during the cell cycle (Phizicky and Fields, 1995). To understand the 
significance of protein-protein interactions within the cell, it is necessary to characterise 
the extent to which they occur and the functional consequences of the interactions. To 
elucidate the mechanisms involved in NKX3-1 regulation, this thesis investigated the 
interaction between NKX3-1 and FLJ22318. 
 
Protein-protein interactions can be studied using a variety of molecular based methods 
including yeast two-hybrid analysis, affinity chromatography and immunoprecipitation, 
each of which has particular advantages and disadvantages. Numerous eukaryotic 
transcription factors have DNA-binding and transcriptional activation domains that are 
distinct from one another and this is utilised in yeast two-hybrid analysis where protein 
interactions are examined by fusing one of the proteins to the DNA-binding domain of 
the yeast GAL4 transcription factor and the other to the GAL4 DNA-activation domain 
(Phizicky and Fields, 1995).  Plasmids encoding the two proteins are transfected into 
yeast and interactions detected by assaying for expression of a reporter gene construct 
containing a binding site for GAL4 (Fields and Song, 1989).  One advantage of using 
yeast two-hybrid analysis to confirm a protein-protein interaction is that this method is 
independent of endogenous protein expression and is often more sensitive than in vitro 
methods, making it better suited to detect weak and/or transient interactions (Gietz and 
Woods, 2002).  
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The yeast two-hybrid system however, is known to produce a significant number of 
false positive protein-protein interactions which are classified as being either technical 
or biological in origin (Vidalain et al., 2004). Technical false positives include those 
false positives which arise as a result of spontaneous mutations that occur in the BD-
fusion protein plasmid during the course of the library screen producing BD-fusion 
proteins which can auto-activate the reporter genes without interacting with an AD-
fusion protein (Walhout and Vidal, 1999). Another more common type of false positive 
is AD-fusion proteins that activate the reporter genes without interacting with the BD-
fusion protein (Vidalain et al., 2004). This type of false positive accounts for the high 
proportion of ribosomal subunits, heat shock proteins, proteasome subunits and 
cytoskeletal components that are commonly identified as interacting with numerous 
BD-fusion proteins in yeast two-hybrid library screens. The interactions are conjectured 
to occur as a result of the intrinsically sticky nature of these proteins, either because 
they have numerous binding partners or because of non specific coiled-coil domain 
interactions (Serebriiskii and Golemis, 2001).  
 
The other main category of false positives detected in yeast two-hybrid screens is the 
biological false positive. These false positives are protein-protein interactions that occur 
in yeast cells in comparison to the proteins￿ native environment where the two proteins 
may not be expressed in the same tissue or cellular compartment, or at the same time 
(Gietz et al., 1997). Extensive knowledge of the functions of the two interacting 
proteins, their subcellular localisation and identification of additional binding partners is 
required in order to confirm this type of false positive.  
 
Another commonly used method for detecting protein-protein interactions is the GST 
pull-down assay. This assay is based on the inducible, high-level expression of a protein 
in Escherichia coli that is fused with the Schistosoma japonicum GST tag at the amino 
terminus (Smith and Johnson, 1988). When expressed in E. coli, fusion proteins 
accumulate within the cytoplasm of the cell, can undergo dimerisation similar to that 
seen in nature and retain full enzymatic activity (Maru et al., 1996). The GST-fusion 
proteins can then be purified from the bacterial lysates by affinity chromatography using 
immobilised glutathione. The advantage of affinity chromatography to validate a 
protein-protein interaction is that this method is very sensitive and can detect 
interactions with a binding constant as weak as 10
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likely to be physiologically relevant (Formosa et al., 1991). In addition, this technique 
has a built-in specificity control as all proteins within a cell lysate are tested equally to 
see whether they interact with the GST-fusion protein (Phizicky and Fields, 1995). 
 
A major consideration when using GST pull-down assays is that the protein-protein 
interactions are detected in  vitro on the sepharose beads and therefore may not be 
functionally significant. In addition, cellular lysis leads to the disruption of subcellular 
structures thereby creating non physiological interactions amongst proteins that may 
normally reside in different cellular compartments (Monti et al., 2005).  
 
Co-immunoprecipitation is another well characterised method for detecting protein-
protein interactions whereby cell lysates are incubated with an antibody to the protein of 
interest, the antigen is precipitated then washed, and proteins bound to the antigen-
antibody complexes are eluted and analysed by western blotting (Phizicky and Fields, 
1995). Immunoprecipitating antibodies can be directed against the endogenous protein 
or alternatively, if antibodies to the protein of interest are not available, fusion proteins 
which carry an epitope for which antibodies are commercially available can be 
prepared. Once the fusion proteins have been constructed they can be utilised to test 
interactions with a number of different proteins. In addition, protein-protein interactions 
can be tested in the appropriate cell lines and the epitope tags are often small thereby 
minimising any effects they may have on protein function or localisation within the cell 
(Figeys, 2003). Nonetheless since transfection is required, examination of interacting 
proteins carrying epitopes can only be performed in cell lines and not in tissues (Droit et 
al., 2005).   
 
The biological activity of the fusion protein may also be affected by the amino acid 
composition of the epitope and its location at the N- or C-terminal of the protein   
(Bucher et al., 2002). More importantly, since the tagged protein will be overexpressed, 
it will not be present in the cell in the stoichiometric ratio necessary for optimum 
interactions to occur and as a consequence may compete with the endogenous non-
tagged protein in forming interactions with its partners (Droit et al., 2005). Another 
concern is that not all antibodies are suitable for immunoprecipitation, as these assays 
require antibodies with a high affinity for the correct antigen in order to avoid detecting 
non-specific protein interactions between closely related antigens (Monti et al., 2005). A Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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major advantage of immunoprecipitation assays, as with GST pull-down assays, is that 
these methods have negligible effects on the tertiary structure and therefore biological 
activity of the isolated proteins, which may be used subsequently in functional assays 
(Droit et al., 2005). Furthermore, all proteins within the cell are competing equally for 
binding indicating specificity when a protein-protein interaction occurs (Phizicky and 
Fields, 1995).  
 
Confirmation of a protein-protein interaction by several different techniques, combined 
with demonstration of co-localisation of the proteins within the cell would then provide 
strong supporting evidence of an interaction between NKX3-1 and FLJ22318 that is 
biologically significant in vivo.  
 
5.2 Results 
5.2.1  Construction of FLJ22318 Expression Vectors 
During this thesis, FLJ22318 cDNA corresponding to the coding region was ligated into 
the yeast expression vector pGBKT7 for yeast two-hybrid analyses (section 5.2.2), the 
pGEX2TK vector for GST pull-down assays (section 5.2.3) and the mammalian 
expression vectors, pcDNA3.1/V5-His-TOPO, pCMV-Myc, pCMV-HA and pEGFP-C2 
for studies of FLJ22318 protein expression, intracellular localisation and co-
immunoprecipitation assays (sections 5.2.4; 5.2.5 and 5.2.6). 
 
5.2.1.1  Construction of the FLJ22318-pcDNA3.1/V5-His-TOPO Vector 
5.2.1.1.1  PCR Optimisation with Taq Polymerase 
Full-length FLJ22318 was cloned into the mammalian expression plasmid, 
pcDNA3.1/V5-His-TOPO to allow it to be expressed with C-terminal V5 and His tags 
following transfection into mammalian cell lines. The 1179bp coding region of 
FLJ22318 was PCR amplified from LNCaP cDNA using FLJTOPO sense and 
FLJTOPO antisense primers using an initial annealing temperature of 55°C with 35 
cycles of PCR and increasing concentrations of MgCl2 (1-2mM). However, only two 
bands of approximately 200bp and 400bp were amplified at all MgCl2 concentrations 
tested (Figure 5.1A). When the annealing temperature was increased to 65°C to increase 
primer specificity and the number of cycles increased to 45, multiple bands were 
observed including a band at the correct molecular size of ~1200bp (Figure 5.1B). TheChapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.1 PCR amplification and ligation of FLJ22318 cDNA into pcDNA3.1/V5-
His-TOPO. (A) PCR amplification of full length FLJ22318 using FLJTOPO sense and
anti-sense primers and an initial annealing temperature of 55°C with 35 cycles
amplified two bands of ~200bp and ~400bp at all MgCl2 concentrations tested. (B)
When the annealing temperature was increased to 65°C with 45 cycles, multiple bands
were amplified including a band of the correct molecular size for FLJ22318 of
~1200bp. (C) Decreasing the number of PCR cycles to 40 resulted in amplification of
the target band of ~1200bp and two additional bands of ~200bp and ~650bp. (D) The
band corresponding to full-length FLJ22318 cDNA was excised and purified from the
gel, a 5µL aliquot was electrophoresed in a 2% agarose gel and the concentration
determined from the gel to be 10ng/µL. 
(A)   1  1.0mM MgCl2  (B)  1 1.5mM  MgCl2   
 2  1.5mM  MgCl2  2  -ve control (no cDNA)  
 3  2.0mM  MgCl2  3  1Kb Plus DNA Ladder 
  4  -ve control (no cDNA) 
 5  1Kb  Plus DNA Ladder  
 
(C)  1 1.5mM  MgCl2  (D)  1  Extracted and purified   
  2  -ve control (no cDNA)   FLJ22318 cDNA    
  3 1Kb  Plus DNA Ladder  2  1Kb Plus DNA Ladder 
   1        2    1     2     3     (C) 
 1200bp →  
primer →  
dimers 
   (D)
  1    2   3   1     2    3     4    5 
primer →
 dimers 
1200bp →  
  400bp →  
  200bp →  
   (B)    (A)  
  650bp →  
  200bp →  
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number of PCR cycles was then reduced to 40 to decrease the number of products 
amplified and this resulted in the amplification of a ~1200bp band and two additional 
bands of approximately 200bp and 650bp (Figure 5.1C). As the additional amplified 
products were significantly different in size to the target product, the target band was 
gel purified and 5µL visualised in a 2% agarose gel which indicated the presence of the 
desired ~1200bp product at an estimated concentration of 10ng/µL (sections 3.1.4; 
3.1.6; Figure 5.1D).              
 
5.2.1.1.2  Cloning of FLJ22318 into pcDNA3.1/V5-His-Topo 
Following purification, 40ng (4µL) of the FLJ22318 fragment was ligated into 1µL 
(10ng) of the pcDNA3.1/V5-His-TOPO cloning vector and 2µL of the ligation reaction 
was transformed into competent TOP10 E. coli bacteria (sections 3.2.4; 3.2.6). 
Transformants were selected on LB agar/ampicillin plates from which 10 colonies were 
picked into small-scale cultures, the plasmid DNA isolated (section 3.3.1), RNase 
treated, then digested using Hind III and Not  I and 5µL visualised in agarose gels 
(sections 3.1.4; 3.2.2). The presence of an insert of approximately 1200bp in clones A1 
to A7, A9 and A10 indicated that cloning of FLJ22318 into pcDNA3.1/V5-His-TOPO 
had been successful and glycerol stocks were prepared of these 9 clones (Figure 5.2).  
  
To confirm that the cloned insert was FLJ22318 as published by NCBI (Accession No. 
NM_022762), plasmid DNA isolated from clones A1 to A4 was purified and sequenced 
using the BGHREV primer then analysed using BLAST￿ (sections 3.1.5; 3.4). All 
sequences from clones A1 to A4 were found to encode ~600bp of the 1179bp ORF of 
FLJ22318 cloned in frame into pcDNA3.1/V5-His-TOPO, however only clones, A2 and 
A4, were found to encode the insert in the sense orientation and were sequenced further. 
To obtain the remaining 600bp of the ORF, the FLJREV and FLJREV2 antisense 
primers were used in additional sequencing reactions. Upon completion of sequencing, 
clone A2 was found to have a T > C mutation at position 586bp of the ORF which 
would encode a proline instead of leucine. Clone A4 however, contained the correct 
FLJ22318 sequence (Figure 5.3). Large-scale cultures of clone A4 were grown from the 
glycerol stock, the plasmid DNA was purified and used in subsequent experiments to 
characterise the expression and function of FLJ22318 (sections 3.1.5; 3.3.2).  
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Figure 5.2 Cloning of FLJ22318 into pcDNA3.1/V5-His-TOPO. 40ng of the
purified FLJ22318 fragment was ligated into the pcDNA3.1/V5-His-Topo cloning
vector and transformants selected on LB agar/ampicillin plates. Ten transformants
were picked and grown into small scale cultures and the plasmid DNA isolated then
digested using Hind III and Not I. Following digestion, a 5µL aliquot was visualised
in a 2% agarose gel indicating the presence of digested pcDNA3.1/V5-His-TOPO
(5437bp) and an insert of the correct molecular size of FLJ22318 (1265bp) in clones
A1 to A7, A9 and A10.  
  1-10  Clones A1-A10 digested with Hind III and Not I 
 11  1Kb  Plus DNA Ladder 
1    2    3    4     5    6    7    8    9   10   11      
   ~5437bp →  
   ~1265bp →   
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5.2.1.2  Construction of the pGEX2TK-FLJ22318 Vector 
5.2.1.2.1  PCR Optimisation with Taq Polymerase 
In order to clone FLJ22318 into the pGEX2TK cloning vector, full-length FLJ22318 
was amplified from the FLJ22318-pcDNA3.1/V5-His-TOPOA4 vector using 
FLJBamHI sense and FLJBamHI antisense primers (section 5.2.1.1.1). This PCR 
resulted in insertion of BamH I restriction sites at both ends of the coding region to 
enable ligation of FLJ22318 into BamH I digested pGEX2TK.  
 
PCR conditions were similar to those initially used for amplification of FLJ22318 
(section 5.2.1.1.1) however multiple bands were observed at all MgCl2 concentrations 
tested including a band at the correct molecular size of ~1200bp (Figure 5.4A). The 
number of PCR cycles was reduced to 30 to decrease the number of products amplified 
and this resulted in the amplification of a fragment of the correct molecular size 
(~1200bp) using a MgCl2  concentration of 1.0mM (Figure 5.4B). Following 
amplification, the FLJ22318 fragments were purified and the concentration determined 
from the gel to be 50ng/µL (section 3.1.5; results not shown).  
 
5.2.1.2.2  Preparation of pGEX2TK Vector 
To enable FLJ22318 to be ligated into pGEX2TK, the vector was linearised by 
digestion with BamH I (section 3.2.2). Following digestion, 20µL of linearised plasmid 
was treated with calf intestinal alkaline phosphatase (CIAP) to remove the 5’ phosphate 
groups from the DNA, preventing vector self re-ligation. Following CIAP treatment, the 
plasmid was purified, 5µL was electrophoresed in a 2% agarose gel and the 
concentration estimated to be 10ng/µL (section 3.1.5; Figure 5.5C).  
 
5.2.1.2.3  Cloning of FLJ22318 into pGEX2TK 
Fifty ng (1.0µL) of the FLJ22318 fragment was initially ligated into 2µL (50ng) of the 
pCR
2.1 plasmid and 2µL of the ligation reaction was transformed into competent 
DH5α  E. coli bacteria (sections 5.2.1.2.1; 3.2.4; 3.2.6). Transformants were selected on 
LB agar/ampicillin/X-Gal plates from which 23 white colonies were picked and grown 
in small-scale cultures (section 3.3.1). These colonies were screened by PCR for the 
presence of the FLJ22318 insert using the FLJBamHI sense and antisense primers 
(section 3.1.3; Figure 5.5A). Of the clones screened, plasmid DNA was isolated fromChapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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   (B)    (A)   1  2   3   4  5 
 ~1200bp →    ~1200bp →  
1  2   3  4   5
Figure 5.4 Optimisation of PCR conditions for FLJ22318 amplification using Taq
polymerase. (A) Amplification of FLJ22318 from the FLJ22318-pcDNA3.1/V5/His
TOPO vector with BamHI sense and anti-sense primers using an annealing
temperature of 65°C, 40 PCR cycles and varying concentrations of MgCl2 resulted in
multiple bands including a band of the correct molecular size of ~1200bp (B) To
decrease the products amplified the  number of PCR cycles was reduced to 30
resulting in amplification of a single product at the correct size for FLJ22318 using
1.0mM MgCl2.  
(A)  1  1.0mM MgCl2  (B)  1 1.0mM  MgCl2 
2 1.5mM  MgCl2  2 1.5mM  MgCl2 
3 2.0mM  MgCl2  3 2.0mM  MgCl2 
4  -ve control (no cDNA)  4  -ve control (no cDNA) 
 51 K b   P l u s  DNA Ladder 5 1Kb Plus DNA LadderChapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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 ~ 4969bp→
1   2    3          (C)   
←  ~1179bp 
  1   2        (B)   
        
      ←  ~1179bp  
         
     
      ← primer 
          dimers      
 1    2   3    4   5   6    7   8   9  10  11 12       (A)   
Figure 5.5 Construction of pGEX2TK-FLJ22318. To construct the pGEX2TK-
FLJ22318 vector, (A) 50ng of purified FLJ22318 amplified from pcDNA3.1/V5-His-
TOPO clone A4 with FLJBamHI sense and anti-sense primers was ligated into
pCR2.1
.
  pCR
2.1-FLJ22318 transformants were blue/white selected on LB
agar/ampicillin/X-Gal plates from which 23 colonies were grown in small-scale cultures
and PCR screened identifying FLJ22318 inserts in clones F13, F15, and F16. (B) A 5µL
aliquot of BamH  I digested and purified pCR2.1
-FLJ22318 clone F13 was
electrophoresed in a 2% agarose gel and its concentration was estimated from the gel to
be 50ng/µL.  (C) The pGEX2TK plasmid was BamH I digested, CIAP treated and
purified. 5µL of the prepared plasmid was electrophoresed in a 2% agarose gel and its
concentration was estimated from the gel to be 10ng/µL.  
(A) 1-10  pCR
2.1-FLJ22318 transformants F11-F20 
  11  -ve control (no cDNA) 
 12  1Kb  Plus DNA Ladder 
 
(B) 1  Purified  BamH I digested FLJ22318 fragment (50ng/µL) 
 2  1Kb  Plus DNA Ladder 
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clones F13, F15 and F16 which contained FLJ22318 inserts and glycerol stocks were 
prepared of these bacteria.  These 3 clones were BamH I digested from pCR
2.1 and an 
aliquot of the digest electrophoresed to confirm the presence of a ~1200bp fragment 
corresponding to FLJ22318 (results not shown). Multiple BamH I digests of the 
pCR2.1
2.1-FLJ22318F13 vector were performed (section 3.2.2), the digested plasmid 
was electrophoresed in a 2% agarose gel and the 1179bp fragment corresponding to 
FLJ22318 was gel extracted and purified (results not shown). Following purification, a 
5µL aliquot was visualised in a 2% agarose gel and its concentration determined from 
the gel to be ~50ng/µL (Figure 5.5B).  
 
Thity-five ng (0.7µL) of the FLJ22318 insert was ligated into 50ng (5.0µL) of the 
BamH I cut and CIAP treated pGEX2TK plasmid (section 5.2.1.2.2), and 2µL of the 
ligation reaction was transformed into competent DH5α  E. coli (sections 3.2.5; 3.2.6). 
Transformants were selected on LB/agar/ampicillin plates from which 13 were picked 
into small-scale cultures and PCR screened for the presence of a FLJ22318 insert using 
the pGEX sense and antisense primers (section 3.1.3; Figure 5.6A). Of the clones PCR 
screened, plasmid DNA was isolated from clones H3, H6, H7, H10 and H12 which 
contained FLJ22318 inserts and glycerol stocks were prepared of these bacterial clones. 
Following Rsa I digestion of plasmids isolated from these 5 clones, fragments of the 
expected sizes of approximately 845bp, 916bp, 1985bp and 2132bp, which indicated 
ligation of the FLJ22318 insert in the sense orientation, were seen in clones H7, H10 
and H12 (Figure 5.6B). Rsa I digestion of plasmid DNA isolated from clones H3 and 
H6 produced fragments of approximately 1455bp, 1985bp and 2132bp, which 
corresponded to the size of the pGEX2TK vector containing the FLJ22318 insert in the 
antisense orientation (Figure 5.6B).  
 
To verify that the cloned insert was FLJ22318, plasmid DNA isolated from clone H10 
was purified and sequenced using the pGEX sense primer then analysed using 
BLAST￿ (sections 3.1.5; 3.4). The sequence from clone H10 was found to encode 
~500bp of the 1179bp ORF of FLJ22318 cloned in frame into pGEX2TK in the sense 
orientation (results not shown). To obtain the remaining 679bp of the ORF, the FLJREV 
and pGEX antisense primers were used in additional sequencing reactions (results not 
shown). Upon completion of sequencing, clone H10 was found to contain the correctChapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.6 Screening of  pGEX2TK-FLJ22318 transformants. (A) PCR screen of
pGEX2TK-FLJ22318 transformants using pGEX sense and anti-sense primers
identified ligation of the 1179bp FLJ22318 insert in clones H3, H6, H7, H10 and H12.
(B) Rsa I digestion of plasmid DNA isolated from clones H3, H6, H7, H10 and H12
visualised in a 2% agarose gel. The presence of bands at 1455bp, 1985bp and 2132bp
indicated ligation of the FLJ22318 insert in the anti-sense orientation (clones H3 and
H6), while bands at 845bp, 916bp, 1985bp and 2132bp indicated that the FLJ22318
insert was in the sense orientation (clones H7, H10 and H12).  
(A) 1-13  Clones  E4-E9 
  14  -ve control (no cDNA) 
 15  1Kb  Plus DNA Ladder 
 
(B) 1-2 Rsa I digest of clones H3 and H6 
 3-5  Rsa I digest of clones H7, H10 and H12 respectively 
 6  1Kb Plus DNA Ladder
   (A)   1      2     3     4      5     6     7      8     9   10    11   12   13    14   15 
 
        
        ← 1200bp
 
        ← primer 
            dimers 
   (B)  
 ~2132bp 
 ~1985bp 
 ~1455bp 
1   2   3   4   5    6 
~916bp 
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FLJ22318 sequence and large-scale cultures of this clone were grown from the glycerol 
stock and the plasmid DNA isolated for use in GST pull-down assays (sections 3.2.7; 
3.3.2; 3.8).  
 
5.2.1.3  Construction of the pGBKT7-FLJ22318 Bait Vector 
5.2.1.3.1  PCR Optimisation with Pfu Polymerase  
Full-length FLJ22318 was amplified from the FLJ22318-pcDNA3.1/V5-His-TOPOA4 
vector using FLJSalI sense and FLJSalI antisense primers for cloning into the pGBKT7 
vector (section 5.2.1.1.1). This amplification would insert Sal I restriction sites at both 
ends of the coding region enabling ligation of FLJ22318 into Sal I digested pGBKT7. 
To eliminate mutations, the FLJ22318 fragment was amplified using Pfu polymerase as 
this enzyme, unlike Taq polymerase, has 3’ →  5’ exonuclease (proof-reading) activity. 
Amplified PCR fragments were then ligated into the pCR
2.1 cloning vector and sub-
cloned into pGBKT7.  
 
PCR conditions were similar to those used for Taq polymerase cloning of FLJ22318 
into pcDNA3.1/V5-His-TOPO (section 5.2.1.1.1), however the annealing time was 
reduced to 30 seconds and the extension time increased to 2.5 minutes according to the 
manufacturer’s recommendations. When 35 PCR cycles were used, no fragments were 
amplified using these conditions (results not shown). Therefore the annealing time was 
increased to 1 minute and the extension time increased to 3 minutes and using these 
cycling conditions a fragment of the correct molecular size (1179bp) was amplified 
(Figure 5.7A). Following PCR amplification, the reaction was incubated with Taq 
polymerase to add 3’ adenines to the FLJ22318 fragment, which is required for ligation 
into the pCR
2.1 plasmid (section 3.1.3). The amplified fragment was purified (section 
3.1.5), a 5µL aliquot of the purified fragment was electrophoresed in a 2% agarose gel 
and its concentration was estimated from the gel to be 50µg/µL (Figure 5.7B).  
 
5.2.1.3.2  Preparation of pGBKT7 Vector 
To enable FLJ22318 to be ligated into pGBKT7, the pGBKT7 cloning vector was 
linearised by digestion with Sal  I (section 3.2.2). Following digestion, 20µL of the 
linearised plasmid was treated with CIAP as previously described (section 3.2.3),
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  ~1200bp →  
 
 
 
     primer →  
     dimers
 
   (A)          1      2    3 
 
   (B)          1     2 
 
  ~1200bp →  
Figure 5.7 PCR Optimisation of FLJ22318 amplification using Pfu polymerase and 
FLJSalI sense and anti-sense primers. (A) Full length FLJ22318 was amplified from 
the FLJ22318-pcDNA3.1/V5/His TOPO vector using an annealing temperature of
65°C, annealing time of 1 minute, extension time of 3 minutes and 35 PCR cycles.
(B) 50µL of amplified FLJ22318 product was incubated with Taq polymerase to add 
3’ adenines to the FLJ22318 fragment for ligation into the pCR
2.1 vector then 
purified. 5µL of the purified PCR product was electrophoresed in a 2% agarose gel
and its concentration was estimated from the gel to be 50ng/µL. 
(A)  1  Pfu polymerase amplified FLJ22318 
2  -ve control (no cDNA) 
 3  1Kb  Plus DNA Ladder 
 
(B)  1  Purified FLJ22318 PCR fragment (50ng/µL) 
2 1Kb  Plus DNA Ladder Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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purified and 5µL was electrophoresed in a 2% agarose gel (section 3.1.5). The plasmid 
concentration was estimated from the gel to be 45ng/µL (Figure 5.8A).  
 
5.2.1.3.3  Cloning of FLJ22318 into pGBKT7 
Fifteen ng (0.3µL) of the FLJ22318 fragment was ligated into 1µL (50ng) of the 
pCR
2.1 plasmid and 2µL of the ligation reaction was transformed into competent 
TOP10 E. coli bacteria (sections 5.2.1.3.1; 3.2.4; 3.2.6). Transformants were selected on 
LB agar/ampicillin/X-Gal plates from which 10 white colonies were picked and grown 
in small-scale cultures then PCR screened for the presence of the FLJ22318 insert using 
the FLJSalI sense and FLJSalI antisense primers (sections 3.1.3; 3.3.1). Of the 10 clones 
PCR screened, plasmid DNA was isolated from clones C1, C6, C8 and C9 which 
contained FLJ22318 inserts and glycerol stocks of these bacteria were prepared (Figure 
5.8B).  The clones were Sal  I digested from pCR
2.1 and an aliquot of the digest 
electrophoresed to confirm the presence of a ~1200bp fragment corresponding to 
FLJ22318 (results not shown). In order to clone FLJ22318 into the pGBKT7 vector, 
multiple Sal I digests of the pCR2.12.1-FLJ22318C9 vector were performed and the 
digested plasmid was electrophoresed in a 2% agarose gel (section 3.2.2; results not 
shown). The 1179bp fragment corresponding to FLJ22318 was excised from the gel, 
purified and its concentration determined from the gel to be 30ng/µL (Figure 5.8C).  
 
Forty-eight ng (1.6µL) of the FLJ22318 insert was ligated into 100ng (2.2µL) of the Sal 
I cut and CIAP treated pGBKT7 (section 5.2.1.3.2; Figure 5.8A), and 6µL of the 
ligation reaction was transformed into competent DH5α  E. coli (section 3.2.5; 3.2.6). 
Transformants were selected on LB/agar/kanamycin plates producing 9 colonies of 
which 3 were picked into small-scale cultures and the plasmid DNA isolated (section 
3.3.1), RNase treated, then Hind III digested to screen for the presence of a FLJ22318 
insert (section 3.2.2). Following Hind III digestion of plasmids isolated from these 3 
clones, fragments of the expected sizes of approximately 1498bp, 2368bp and 4938bp, 
which corresponded to the size of the pGBKT7 vector containing FLJ22318 insert, were 
seen in clone E3 (Figure 5.9A). Hind III digestion of plasmid DNA isolated from clones 
E1 and E2 produced 3 fragments of approximately 868bp, 1498bp and 4938bp, which 
corresponded to the size of the pGBKT7 vector without insert (Figure 5.9A).  
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Figure 5.8 Construction of the pGBKT7-FLJ22318 bait vector.  To construct the 
pGBKT7-FLJ22318 vector, (A) the pGBKT7 plasmid was Sal  I  digested, CIAP 
treated and purified. 5µL of the prepared plasmid was electrophoresed in a 2%
agarose gel and its concentration was estimated from the gel to be 45ng/µL. (B) 10 
pCR
2.1-FLJ22318 transformants were picked and grown in small scale cultures and
1µL of the bacterial culture PCR amplified using FLJSalI sense and anti-sense primers 
identifying FLJ22318 inserts of ~1200bp in clones C1, C6, C8 and C9. (C) 80µL of 
Sal I digested pCR2.1
-FLJ22318 was electrophoresed in a 2% agarose gel and the
1179bp fragment corresponding to FLJ22318 excised and purified. 5µL of the purified 
plasmid was electrophoresed in a 2% agarose gel and its concentration was estimated
from the gel to be 30ng/µL.  
(A) 1  Purified  Sal I digested and CIAP treated pGBKT7 (45ng/µL) 
 2  1Kb  Plus DNA Ladder 
(B)  1-10 pCR
2.1-FLJ22318 transformants C1-C10 
11  -ve control (no cDNA) 
12 1Kb  Plus DNA Ladder   
(C) 1  Purified  Sal I digested FLJ22318 fragment (30ng/µL) 
   2  1Kb  Plus DNA Ladder
 ~7.3Kbp →
   1       2      (A)      1    2     3     4    5     6    7     8    9    10   11  12    (B)
←  1200bp
←  400bp 
←  primer 
     dimers
 ~1179bp →
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Figure 5.9 Screening of pGBKT7-FLJ22318 clones. (A) Undigested pGBKT7 (7.3kbp)
and HindIII digested clones E1, E2 and E3 were electrophoresed in a 2% agarose gel.
The presence of bands at 868bp, 1498bp and 4938bp indicated pGBKT7 vector without
insert (clones E1 and E2) whereas bands at 1498bp, 2368bp and 4938bp indicated
presence of a FLJ22318 insert in the pGBKT7 vector (clone E3). (B) To determine the
orientation of the FLJ22318 insert, clone E3 was digested with Pst  I and
electrophoresed in a 2% agarose gel. The presence of bands at 315bp and 8111bp
indicated ligation of the FLJ22318 insert in the anti-sense orientation. 
(A)  1  Undigested pGBKT7 control 
 2  HindIII digested clone E1 
 3  HindIII digested clone E2 
 4  HindIII digested clone E3 
 5  1Kb  Plus DNA Ladder 
 
(B)  1  Pst I digested clone E3   
 2  1Kb  Plus DNA Ladder 
   1        2 
 
8111bp →  
 
 
 
  315bp →
   (B)
 
  7.3kbp→  
 4938bp→  
 2638bp→  
 1498bp→  
 
   868bp→  
    1      2   3    4     5      (A) 
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Clone E3 containing the FLJ22318 insert was then digested with Pst I to determine the 
orientation of FLJ22318 in the pGBKT7 vector. Electrophoresis of the Pst I digested E3 
plasmid produced fragments of 315bp and 8111bp, which indicated that the insert was 
ligated in the antisense orientation (Figure 5.9B). The remaining 6 colonies were then 
picked into small-scale cultures and PCR screened for the presence of FLJ22318 using 
FLJSalI sense and antisense primers (section 3.3.1; 3.1.3). Of these clones, only clone 
E5 contained a FLJ22318 insert (Figure 5.10A). Plasmid DNA was isolated from this 
clone, RNase treated, and Pst I digested to determine the orientation of the FLJ22318 
insert. The presence of bands at 315bp, 827bp and 7341bp confirmed ligation of the 
FLJ22318 insert in the sense orientation (Figure 5.10B). 
 
To confirm the identity of this insert, clone E5 was purified (section 3.1.5), sequenced 
using the DNA-BD sense primer (section 3.4) and analysed using BLAST which 
confirmed 818bp of the ORF sequence of FLJ22318 that was in frame and contained no 
mutations (results not shown). To obtain the remaining 361bp of the ORF, the FLJ789 
sense primer was used in additional sequencing reactions (section 3.4). Upon 
completion of sequencing, it was confirmed that clone E5 contained the correct 
FLJ22318 sequence, therefore glycerol stocks were prepared of this clone (section 3.2.7; 
sequencing not shown). Large-scale cultures of clone E5 were grown from the glycerol 
stock to be used for small-scale yeast transformations (section 3.5.4).  
 
5.2.1.4  Construction of the pCMV-Myc-FLJ22318 Vector 
5.2.1.4.1  PCR Optimisation with Pfu Polymerase 
In order to clone FLJ22318 into the pCMV-Myc cloning vector, full-length FLJ22318 
was amplified from the FLJ22318-pcDNA3.1/V5-His-TOPOA4 cloning vector using 
pCMV sense and FLJSalI antisense primers (section 5.2.1.1.1. These primers inserted 
Sal I restriction sites at both ends of the coding region enabling ligation of FLJ22318 
into the (Sal I digested) pCMV-Myc mammalian expression plasmid, which encodes an 
N-terminal c-Myc epitope. Amplified PCR fragments were ligated into the pCR
2.1 
cloning vector prior to sub-cloning into pCMV-Myc. 
 
PCR conditions were optimised as previously described with a band of the correct 
molecular weight of ~1200bp amplified using a DNA extension time of 3 minutes, anChapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.10 Identification of pGBKT7 containing a FLJ22318 insert. (A)  Six 
pGBKT7-FLJ22318 transformed colonies were screened directly by PCR for the
presence of a FLJ22318 insert using 1µL of bacterial culture as target DNA. 
Amplification of a 1179bp product indicated that FLJ22318 had been ligated into
pGBKT7 (clone E5). (B) To determine the orientation of the FLJ22318 insert, clone
E5 was digested with Pst  I. The presence of bands at 315bp, 827bp and 7341bp
indicated ligation of the FLJ22318 insert in the sense orientation (clone E5), while 
bands at 315bp and 8111bp indicated that the FLJ22318 insert was in the anti-sense 
orientation (clone E3).  
(A) 1-6 Clones  E4-E9 
  7  Positive control (clone E3) 
  8  -ve control (no cDNA) 
 9  1Kb  Plus DNA Ladder 
 
(B) 1  Pst I digested clone E3 
  2  Pst I digested clone E5 
  3 1Kb  Plus DNA Ladder 
 1       2     3     4      5     6     7     8      9      
  1179bp →  
 
 
 
   primer 
   dimers →  
 (A) 
   7341bp→
 
     827bp→
     315bp→
12 3 (B) 
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annealing temperature of 65°C and 35 cycles of PCR (section 5.2.1.3.1; results not 
shown). Following amplification and incubation with Taq polymerase (section 3.1.3), 
the FLJ22318 fragments were purified (section 3.1.5), a 5µL aliquot was 
electrophoresed in a 2% agarose gel and the DNA concentration was determined from 
the gel to be 50ng/µL (results not shown).  
 
5.2.1.4.2  Preparation of the pCMV-Myc Vector 
To enable FLJ22318 to be ligated into pCMV-Myc, the pCMV-Myc cloning vector was 
linearised by digestion with SalI (section 3.2.2). Following digestion, 20µL of linearised 
plasmid was CIAP treated, purified and 5µL electrophoresed in a 2% agarose gel and 
the concentration estimated from the gel to be 10ng/µL (section 3.1.4; results not 
shown).  
 
5.2.1.4.3  Cloning of FLJ22318 into pCMV-Myc 
Following purification, 15ng (0.3µL) of the FLJ22318 fragment (section 5.2.1.4.1) was 
ligated into 1µL (50ng) of the pCR
2.1 cloning vector and 2µL of the ligation reaction 
was transformed into competent TOP10 E. coli bacteria (sections 3.2.4; 3.2.6). 
Transformants were selected on LB agar/ampicillin/X-Gal plates from which 20 white 
colonies were picked and grown in small-scale cultures then PCR screened for the 
presence of the FLJ22318 insert using the pCMV sense and FLJSalI antisense primers 
(sections 3.1.3; 3.3.1; Figure 5.11). Of the 20 colonies PCR screened, glycerol stocks 
were prepared for clones B13-B15 and B17-B19 which contained FLJ22318 inserts. 
Plasmid DNA was isolated from these 6 clones (section 3.3.1), RNase treated, multiple 
Sal I digests of clone B14 were electrophoresed in a 2% agarose gel and the 1179bp 
fragment representing FLJ22318 was gel extracted and purified (section 3.1.6). 
Following purification, a 5µL aliquot of the FLJ22318 fragment was visualised in a 2% 
agarose gel and its concentration determined from the gel to be 25ng/µL (section 3.1.4; 
results not shown).  
 
Forty ng (1.6µL) of the FLJ22318 insert was ligated into 50ng (5µL) of the Sal I cut and 
CIAP treated pCMV-Myc plasmid (section 5.2.1.4.2), and 2µL of the ligation reaction 
was transformed into competent TOP10 E. coli (sections 3.2.5; 3.2.6). Transformants 
were selected on LB/agar/ampicillin plates producing 40 colonies of which 30 wereChapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.11 PCR screen for FLJ22318 in pCR
2.1. Twenty pCR
2.1-FLJ22318 
transformants were picked and grown in small scale cultures. 1µL of each bacterial 
culture was PCR amplified using pCMV sense and FLJSalI antisense primers
identifying FLJ22318 inserts of 1179bp in clones B13, B14, B15, B17, B18 and B19. 
1-10 pCR
2.1-FLJ22318 transformants B11-B20 
13  -ve control (no cDNA) 
14 1Kb  Plus DNA Ladder 
← 1179bp 
← 200bp 
← primer 
    dimers 
   1      2     3     4      5      6     7      8     9     10    11    12 Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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picked into small-scale cultures and screened by PCR for the presence of the FLJ22318 
insert as previously described (section 3.1.3; Figure 5.12A). Of the 30 colonies 
screened, only 2 clones, D31 and D37, contained FLJ22318 inserts. Plasmid DNA was 
isolated from these 2 clones, RNase treated, then Pst I digested to confirm the presence 
and orientation of the FLJ22318 insert (sections 3.2.2; 3.3.1). Electrophoresis of the Pst 
I digested plasmids identified fragments of the expected sizes of approximately 315bp, 
918bp, 1071bp and 2665bp from clone D37, which corresponded to the size of the 
pCMV-Myc plasmid containing FLJ22318 insert in the sense orientation (Figure 
5.12B). Pst I digestion of plasmid DNA isolated from clone D31 produced 2 fragments 
of approximately 1126bp and 2665bp, which corresponded to the size of the pCMV-
Myc vector without insert (Figure 5.12B).  
 
To confirm the identity of this insert, clone D37 was purified and sequenced using the 
pCMV sense primer (sections 3.1.5; 3.4) then analysed using BLAST which 
confirmed the presence of 775bp of the ORF sequence of FLJ22318 inserted in frame 
into pCMV-Myc (results not shown). To obtain the remaining 404bp of the ORF, the 
FLJREV and FLJ789 sense primers were used in additional sequencing reactions 
(section 3.4). Results of sequencing indicated that the pCMV-Myc-FLJ22318 insert did 
not contain any mutations and glycerol stocks were prepared (section 3.2.7; sequencing 
results not shown). An aliquot of glycerol stock from clone D37 was grown in a large-
scale culture, the plasmid DNA isolated and the concentration determined 
spectrophotometrically to be 185ng/µL (sections 3.3.2; 3.3.3).  
 
5.2.1.5  Construction of the pCMV-HA-FLJ22318 Vector 
5.2.1.5.1  Preparation of the pCMV-HA Vector 
To enable FLJ22318 to be ligated into pCMV-HA, the pCMV-HA vector was prepared 
by digestion with Sal I and 20µL of the linearised plasmid was CIAP treated (section 
3.2.3). Following purification, a 5µL aliquot of the prepared vector was electrophoresed 
in a 2% agarose gel and the concentration estimated from the gel to be 10ng/µL (section 
3.1.4; results not shown).  
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Figure 5.12 Screening of pCMV-Myc-FLJ22318 clones. (A) Thirty pCMV-Myc-
FLJ22318 transformants were picked and grown in small scale cultures. 1µL of each 
bacterial culture was PCR amplified using pCMV sense and FLJSalI anti-sense 
primers, identifying FLJ22318 inserts of 1179bp in clones D31 and D37. (B) To 
determine the orientation of the insert, clones D31 and D37 were digested with Pst I. 
The presence of bands at 1126bp and 2665bp indicated pCMV-Myc vector without 
insert (clone D31), whereas bands at 918bp, 1071bp and 2665bp indicated the 
presence of the FLJ22318 insert in pCMV-Myc in the sense orientation (clone D37).  
 
(A)  1-10  pCMV-Myc-FLJ22318 transformants D31-D40 
  11  -ve control (no cDNA) 
 12  1Kb  Plus DNA Ladder 
 
(B) 1  Pst I digested clone D31 
 2  Pst I digested clone D37 
  3  Undigested pCMV-Myc-FLJ22318 control 
  4  Undigested pCMV-Myc-FLJ22318 control 
 5  1Kb  Plus DNA Ladder 
1     2     3    4     5     6    7     8     9   10   11  12 
← 1179bp
← primer 
    dimers 
(A)  
918bp 
2665bp →  
(B)      1    2     3    4     5 
1126bp   →  
1071bp
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5.2.1.5.2  Cloning of FLJ22318 into pCMV-HA 
In order to clone FLJ22318 into the pCMV-HA vector, multiple SalI digests of the 
pCR2.1
2.1-FLJ22318B14 vector were performed and the digested plasmid was 
electrophoresed in a 2% agarose gel (section 5.2.1.4.3; results not shown). The 1179bp 
fragment corresponding to FLJ22318 was excised from the gel, purified and its 
concentration determined from the gel to be 25ng/µL (results not shown). Fifteen ng 
(0.6µL) of the FLJ22318 insert was ligated into 100ng (5.0µL) of the Sal I cut and 
CIAP treated pCMV-HA vector (section 5.2.1.5.1), and 2µL of the ligation reaction 
transformed into competent DH5α  E. coli (sections 3.2.5; 3.2.6). Transformants were 
selected on LB/agar/ampicillin plates producing 29 colonies of which 13 were picked 
into small-scale cultures and screened by PCR for the presence of an FLJ22318 insert 
using the pCMV sense and FLJSalI antisense primers (section 5.2.1.4.3; Figure 5.13A). 
Following PCR screening, plasmid DNA was isolated from clone G7 (the only clone 
containing an insert) and Pst I digested (sections 3.3.1; 3.2.2) producing fragments of 
approximately 315bp, 909bp, 1071bp and 2665bp, which corresponded to the size of the 
pCMV-HA vector containing an FLJ22318 insert in the sense orientation (Figure 
5.13B).  
 
To confirm the identity of this insert, clone G7 was purified, sequenced using the 
pCMV sense primer (sections 3.1.5; 3.4) and analysed using BLAST which confirmed 
530bp of the ORF sequence of FLJ22318 that was in frame and contained no mutations 
(results not shown). To obtain the remaining 649bp of the ORF, the FLJ789S sense and 
FLJREV antisense primers were used in additional sequencing reactions (section 3.4). 
Upon completion of sequencing, it was confirmed that clone G7 contained the correct 
FLJ22318 sequence, therefore glycerol stocks of this clone were prepared, large-scale 
cultures were grown from the glycerol stock and the plasmid DNA isolated (sections 
3.2.7; 3.3.2). 
 
5.2.1.6  Construction of the pEGFP-C2-FLJ22318 Vector 
5.2.1.6.1  Preparation of pEGFP-C2 Vector 
To enable FLJ22318 to be ligated into the pEGFP-C2 vector, pEGFP-C2 was Sal I 
digested and CIAP treated and a 5µL aliquot was visualised in a 2% agarose gel where 
the concentration was estimated to be 10ng/µL (sections 3.2.2; 3.2.3; Figure 5.14A).  Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.13 Screening of pCMV-HA-FLJ22318 clones. To screen for the presence
of FLJ22318, 13 pCMV-HA-FLJ22318 transformants were picked and grown in
small scale cultures. 1µL of the bacterial culture was amplified by PCR using the
pCMV sense and FLJSalI anti-sense primers which identified an FLJ22318 insert in
clone G7. (B) Pst I digested clone G7 was electrophoresed in a 2% agarose gel. The
presence of bands at 315bp, 909bp, 1071bp and 2665bp indicated the presence of an
FLJ22318 insert in the pCMV-HA vector in the sense orientation. 
  
(A)  1-13  pCMV-HA-FLJ22318 transformants G1-G13 
  14  -ve control (no cDNA) 
 15  1Kb  Plus DNA Ladder 
 
(B)  1  Pst I digested clone G7   
 2  1Kb  Plus DNA Ladder 
 
  1     2     3    4      5      6     7     8     9    10    11   12   13   14    15 
  ← 1179bp
  ← primer
     dimers 
(A) 
(B)
  315bp →
2665bp →
  909bp →
1071bp →
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Figure 5.14 Construction of the pEGFP-C2-FLJ22318 vector. To construct the 
pEGFP-C2-FLJ22318 vector, (A) 1µg of the pEGFP-C2 plasmid was Sal I digested, 
CIAP treated and purified and 5µL of the prepared plasmid was electrophoresed in a
2% agarose gel. The concentration from the gel was estimated to be 10ng/µL. 20µL of 
Sal I digested pCR2.1
-FLJ22318 was electrophoresed in a 2% agarose gel and the
1179bp fragment corresponding to FLJ22318 excised and purified. 5µL of the purified 
plasmid was electrophoresed in a 2% agarose gel and its concentration was estimated
from the gel to be 5ng/µL. (B) Twenty pEGFP-C2-FLJ22318 transformed colonies 
were grown from bacterial culture and the plasmid DNA isolated then Sal I digested 
to screen for the presence of a FLJ22318 insert. A band of the expected size for
FLJ22318 (1179bp) indicated ligation of FLJ22318 into pEGFP-C2 clone I19. (C) To 
determine the orientation of the FLJ22318 insert, clone I19 was digested with Pst I. 
The presence of bands at 315bp and 5512bp indicated ligation of the FLJ22318 insert
in the sense orientation. 
(A)  1  Undigested pEGFP-C2 vector 
2 Purified  Sal I digested and CIAP treated pEGFP-C2 (10ng/µL) 
 3  Purified  Sal I digested FLJ22318 fragment (5ng/µL) 
 4  1Kb  Plus DNA Ladder 
B)  1-10  Clones I11-I20 
  11  Negative control (clone I10) 
  12  Positive control (pCMV-HA-FLJ22318) 
 13  1Kb  Plus DNA Ladder 
 
(C)  1  Pst I digested clone I19 
  2 1Kb  Plus DNA Ladder 
  5512bp →
  1     2     (C) 
    315bp →
  1     2   3     4 
←  1179bp 
4735bp →  
   1      2    3     4      5     6     7     8     9   10    11   12   13     (B) 
 ←  1179bp 
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5.2.1.6.2  Cloning of FLJ22318 into pEGFP-C2 
In order to clone FLJ22318 into pEGFP-C2, multiple Sal I digests of the pCR2.1
-
FLJ22318C8 vector were performed and the digested plasmid was electrophoresed in a 
2% agarose gel (section 5.2.1.3.3; results not shown). The 1179bp fragment 
corresponding to FLJ22318 was excised from the gel, purified and its concentration 
determined from the gel to be 5ng/µL (Figure 5.14A). Fifteen ng (3.0µL) of the 
FLJ22318 insert was ligated into 50ng (5.0µL) of the prepared pEGFP-C2 vector and 
5µL of the ligation reaction was transformed into competent DH5α  E. coli (sections 
5.2.1.6.1; 3.2.5; 3.2.6). Transformants were selected on LB/agar/kanamycin plates and 
20 colonies were picked and grown into small-scale cultures. Plasmid DNA was 
isolated from these cultures and Sal I digested to screen for the presence of an 
FLJ22318 insert (sections 3.2.2; 3.3.1). Of the 20 clones screened, only one clone, I19 
contained an insert of the correct size of ~1179bp (Figure 5.14B) and was further 
digested with Pst I to determine the orientation of FLJ22318 in the pEGFP-C2 vector. 
Electrophoresis of the Pst I digested I19 plasmid produced fragments of 315bp and 
5512bp, indicating that the insert was ligated in the sense orientation (Figure 5.14C).  
 
To confirm the identity of this insert, clone I19 was purified and sequenced using the 
EGFP 1266 sense primer and glycerol stocks were prepared (sections 3.1.5; 3.2.7; 3.4). 
Following sequencing, analysis using BLAST confirmed 893bp of the ORF sequence 
of FLJ22318 in frame with no mutations (results not shown). Therefore to obtain the 
remaining 286bp of the ORF, the FLJ789S sense primer was used in additional 
sequencing reactions (section 3.4). Upon completion of sequencing, it was confirmed 
that clone I19 contained the published FLJ22318 sequence, therefore large-scale 
cultures were grown from the glycerol stock and the plasmid DNA was isolated (section 
3.3.2; sequencing results not shown). 
 
5.2.2  Reverse Yeast Two-Hybrid Analysis 
In order to confirm the results of the original yeast two-hybrid analysis that identified an 
interaction between NKX3-1 and FLJ22318, yeast two-hybrid analysis was repeated 
with NKX3-1 and FLJ22318 ligated into plasmids in the reverse order to that used in 
the original screen. As such, interaction of FLJ22318 in the pGBKT7 plasmid (section  Characterisation of FLJ22318 Interaction with NKX3-1 
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5.2.1.3) and NKX3-1 in the pGADT7-Rec plasmid (available in the laboratory) was 
investigated in AH109 yeast. 
 
5.2.2.1  pGBKT7-FLJ22318 Protein Expression 
To verify FLJ22318 protein expression prior to the reverse yeast-two hybrid analysis, 
AH109 yeast cells were transformed with the pGBKT7-FLJ22318 construct using a 
small-scale yeast transformation which should result in expression of FLJ22318 as a 
fusion protein containing a c-Myc epitope tag (section 5.2.1.3; 3.5.4). Proteins were 
extracted 16 hours post transformation and analysed by anti-Myc western blotting 
(sections 3.7.1-3.7.4). Untransformed AH109 yeast cells did not exhibit 
immunoreactivity with the Myc epitope, while pGBKT7-FLJ22318 transformed AH109 
cells exhibited Myc immunoreactivity with a protein band of ~45.6kDa, the expected 
size for Myc-FLJ22318 protein (Figure 5.15). 
 
5.2.2.2  Transcriptional Activation of pGBKT7-FLJ22318 
Prior to using pGBKT7-FLJ22318 to confirm an interaction with NKX3-1 in a reverse 
yeast two-hybrid analysis, it was also necessary to confirm that the construct did not 
have autonomous reporter gene activity in AH109 yeast cells. AH109 can only grow on 
SD/-Trp agar plates if a functional TRP1 gene carried by pGBKT7-FLJ22318 is induced 
(positive transformation control) and should not grow on SD/-Ade/-His agar plates 
unless the ADE2 and HIS3 GAL4-responsive nutritional reporter genes carried by 
AH109 are activated (when the DNA-BD of the pGBKT7-FLJ22318 construct interacts 
with the AD of the pGADT7-Rec-NKX3-1 construct). Therefore to test the pGBKT7-
FLJ22318 DNA-BD fusion for intrinsic transcriptional activation, AH109 yeast cells 
were made competent and transformed with pGBKT7-FLJ22318 or pGBKT7 empty 
vector using a small-scale yeast transformation (sections 3.5.3; 3.5.4). As AH109 also 
carries the endogenous MEL1 reporter gene, whose gene product α -galactosidase is 
secreted into the culture medium where it catalyses the hydrolysis of X-α -Gal to yield a 
blue end product, transformants were selected on SD/-Trp, SD/-His/-Trp and SD/-Ade/-
Trp dropout media plates to which X-α -Gal was added (section 3.5.9). As MEL1 should 
not be expressed without activation by GAL4, growth of white colonies only on the 
SD/-Trp media plate (Figure 5.16) and no growth on the SD/-His/-Trp and SD/-Ade/-
Trp media plates (results not shown) confirmed that the pGBKT7-FLJ22318 bait protein   Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.16 AH109  S. cerevisiae yeast transformed with pGBKT7-FLJ22318. 
Transformants were able to grow as white colonies only on SD/-Trp/X-α -Gal 
indicating a successful transformation with no autonomous activation of the
endogenous yeast MEL1 reporter gene. 
   1        2
←
Figure 5.15 Expression of Myc-FLJ22318 in yeast. AH109 cells were transformed
with pGBKT7-FLJ22318, which should result in expression of Myc-tagged 
FLJ22318. Anti-Myc western blotting of proteins extracted from pGBKT7-FLJ22318 
transformed cells identified expression of a protein of the expected size of ~45.6kDa. 
1  Untransfected AH109  yeast cells (negative control) 
2  pGBKT7-FLJ22318 transformed AH109 yeast cells 
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was inactive and therefore suitable to use in a reverse yeast two-hybrid analysis. Similar 
results were obtained for AH109 cells transformed with pGBKT7 empty vector (results 
not shown). Following confirmation that the pGBKT7-FLJ22318 construct was 
inactive, glycerol stocks were prepared from a single white colony growing on the SD/-
Trp media plate (section 3.5.7; Figure 5.16).  
 
5.2.2.3  Toxicity of pGBKT7-FLJ22318 
In addition to confirming that the bait protein was inactive, it was also important to 
examine whether the pGBKT7-FLJ22318 plasmid was toxic to yeast cells. Therefore, 
pGBKT7-FLJ22318 transformed AH109 yeast cells were grown from frozen stocks for 
4 days at 30°C on SD/-Trp agar plates. From these cells a single large colony of 
approximately 2-3mm was cultured in SD/-Trp/Kan media (section 3.5.10) and the 
OD600 measured, an OD600 much less than 0.8 indicating the DNA-BD fusion may be 
toxic to the yeast cells. Following 20 hours of incubation, the OD600 of the pGBKT7-
FLJ22318 transformed yeast was 1.08, suggesting that expression of FLJ22318 did not 
impede yeast growth.   
 
5.2.2.4  Reverse Yeast Two-Hybrid Analysis 
In the original yeast two-hybrid screen (section 1.3.3.7), an interaction between full 
length FLJ22318 and NKX3-1 was demonstrated by growth of yeast that were shown to 
contain the pGADT7-Rec-FLJ22318 and pGBKT7-NKX3-1 plasmids. In order to 
confirm the interaction between the two proteins, full length FLJ22318 and NKX3-1 
were cloned into the pGBKT7 and pGADT7-Rec plasmids respectively, the reverse to 
that used in the original screen and used in a yeast two-hybrid assay. 
 
For this screen, pGBKT7-FLJ22318 (section 5.2.1.3), pGADT7-Rec-NKX3-1 (prepared 
previously in this laboratory) and competent AH109 yeast were used in a small scale 
yeast co-transformation (sections 3.5.3; 3.5.4). To confirm that the pGBKT7-FLJ22318 
and pGBKT7-FLJ22318/pGADT7-Rec-NKX3-1 plasmids had been successfully 
transformed, the transformation mixture was spread on SD/-Trp and SD/-Leu/-Trp 
Double Dropout (DDO) medium, whereas to select for co-transformants expressing 
interacting proteins the transformation mixture was spread on SD/-His/-Leu/-Trp Triple 
Dropout (TDO) and SD/-Ade/-His/-Leu/-Trp Quadruple Dropout (QDO) medium.  Characterisation of FLJ22318 Interaction with NKX3-1 
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Following 4 days of incubation at 30°C, growth of white colonies was observed on the 
SD/-Trp media plates for the pGBKT7-FLJ22318 plasmid, whereas no growth was 
observed on the pGBKT7-FLJ22318/pGADT7-Rec-NKX3-1 DDO, TDO and QDO 
media plates (results not shown). Therefore, although transformation of pGBKT7-
FLJ22318 had been successful, no growth on the DDO medium indicated that co-
transformation of pGBKT7-FLJ22318 and pGADT7-Rec-NKX3-1 had been 
unsuccessful or that FLJ22318 and NKX3-1 did not interact in this assay.  
 
As the pGBKT7-FLJ22318 construct was not toxic to yeast growth (section 5.2.2.3) it 
was decided to examine the interaction between FLJ22318 and NKX3-1 using 
sequential transformation of AH109 yeast. For the sequential transformation, 
AH109/pGBKT7-FLJ22318 yeast were made competent and a small scale 
transformation performed with the pGADT7-Rec-NKX3-1 construct (sections 5.2.2.4; 
3.5.3; 3.5.4). To select for transformation of the pGADT7-Rec-NKX3-1 plasmid, the 
transformation mixture was spread on DDO media plates, whereas to select for 
pGBKT7-FLJ22318/pGADT7-Rec-NKX3-1 transformants expressing interacting 
proteins the transformation mixture was spread on TDO and QDO medium. Following 4 
days of incubation at 30°C growth of colonies could be observed on the DDO media 
plates indicating that yeast colonies contained both the pGBKT7-FLJ22318 and 
pGADT7-Rec-NKX3-1 plasmids (Figure 5.17A). In addition, growth of colonies on the 
TDO media plates indicated the HIS3 gene had been activated showing an interaction 
had occurred between FLJ22318 and NKX3-1 (Figure 5.17B). The presence of colonies 
on the QDO media plate indicated the ADE2 gene had also been activated 
demonstrating a strong interaction between the two proteins (Figure 5.17C).  
 
Following 4 days of growth, single colonies from each of these plates were replica 
plated together with yeast cultures containing transformed pGADT7-Rec-FLJ22318, 
pGBKT7-NKX3-1 and co-transformed pGADT7-Rec-FLJ22318/pGBKT7-NKX3-1, 
from the original two-hybrid screen that were grown from frozen stocks, onto DDO, 
TDO and QDO medium to verify that correct phenotypes were maintained (Figure 
5.18).   
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Figure 5.18 Confirmation of an interaction between FLJ22318 and NKX3-1 in the 
original and reverse yeast-two hybrid screen. Yeast strain AH109 transformed with
pGBKT7-FLJ22318/pGADT7-NKX3-1 (4) and pGADT7-FLJ22318/pGBKT7-
NKX3-1 (5) were replica plated on (A) media lacking Leu and Trp (DDO), (B) on 
media lacking His, Leu and Trp (TDO) and (C) on media lacking Ade, His, Leu and 
Trp (QDO), demonstrating that correct phenotypes had been maintained. As negative
controls, untransformed AH109 yeast (1) and AH109 transformed with pGBKT7-
FLJ22318 (2) and pGADT7-NKX3-1 (3) constructs were also plated on media 
lacking Leu and Trp.  
 5
4
 (B) 
5
4 
(C)
5
4 2
3  (A)
1
Figure 5.17 Investigation of FLJ22318 interaction with NKX3-1 using (reverse) 
yeast two-hybrid analysis. (A) Growth of yeast colonies on media lacking Leu and
Trp (DDO) indicates the successful transformation of the pGADT7-Rec-NKX3-1 
construct into AH109/pGBKT7-FLJ22318 yeast whereas (B) growth of colonies on 
media lacking His, Leu and Trp (TDO) indicates activation of the HIS3 reporter 
gene  demonstrating an interaction between FLJ22318 and NKX3-1.  (C) The 
presence of colonies on media lacking Ade, His, Leu and Trp (QDO) demonstrates a
strong interaction between FLJ22318 and NKX3-1 as the ADE2 reporter gene has 
also been activated.  
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5.2.3  GST Pull-Down Analysis 
5.2.3.1  pGEX2TK-FLJ22318 Protein Expression 
In order to verify and optimise expression of glutathione S-transferase (GST)-FLJ22318 
fusion proteins in bacteria, screening of pGEX2TK-FLJ22318 recombinant clones was 
performed. For these expression studies, competent BL21 bacterial cells were 
transformed with the pGEX2TK-FLJ22318H10 construct and transformants were 
selected on LB/ agar/ampicillin plates (sections 3.2.5; 3.2.6; 5.2.1.2). The 4 colonies 
produced were individually picked into small-scale cultures together with 2 individual 
pGEX2TK transformed colonies (controls) that had been grown from glycerol stocks. 
Expression of GST and FLJ22318 as a C-terminal fusion to GST was induced by 
addition of isopropyl-β -D-thiogalactoside (IPTG) to the culture medium and the 
proteins were extracted 2 hours post IPTG induction (section 3.8.1). Extracted proteins 
were analysed by SDS-PAGE with Coomassie blue staining of protein gels (section 
3.8.2) revealing the presence of cellular proteins only in lane 2 (negative control, no 
IPTG induction), cellular proteins with a prominent protein band of approximately 
29kDa in lane 3 (positive control, GST alone), while proteins extracted from the 4 
pGEX2TK-FLJ22318 clones (lanes 4-7) exhibited cellular proteins with prominent 
protein bands of approximately 73kDa, the expected size for GST-FLJ22318 (Figure 
5.19A). As expression of the GST-FLJ22318 fusion protein was highest from clone 1, 
this clone was selected for further studies.  
 
5.2.3.2  Production and Purification of GST-FLJ22318 Fusion Protein 
Following GST-FLJ22318 fusion protein production, large scale production and 
purification of GST and GST-FLJ22318 fusion proteins was performed from 100mL 
bacterial cultures (section 3.8.3). Fusion proteins were purified from bacterial lysates 
using glutathione immobilised to sepharose and detected using SDS-PAGE with 
Coomassie blue staining of gels to verify size and purity of the proteins (section 3.8.2). 
Fusion protein concentration was estimated by comparing GST and GST-FLJ22318 
protein bands to a BSA protein standard (Figure 5.19B), with the concentration of GST 
protein estimated at 1.5µg/µL, whilst the concentration of GST-FLJ22318 protein was 
much lower than expected at 125ng/µL (Figure 5.19B). 
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      1      2     3      4     5      6    7   (A)
~29kDa →  
←  BSA protein 
     standard 
    1    2     3          4    5    6    7   (B)
~73kDa →   ~73kDa →  
~29kDa →  
Figure 5.19 GST-FLJ22318 pull-down Assay. (A) The presence of protein bands of 
~73kDa indicates expression of the GST-FLJ22318 fusion protein (Lanes 4-7) from 
IPTG induced pGEX2TK-FLJ22318H10. (B)  Purified GST-FLJ22318 protein of 
~73kDa with a protein concentration estimated from the gel to be 125ng/µL. (C) 
GST-FLJ22318 immobilised to glutathione was incubated with lysates from 
untransfected and from NKX3-1-pcDNA3.1/V5-His-TOPO transfected DU145 cells. 
The interaction between FLJ22318 and NKX3-1 was detected by anti V5 western 
blotting in protein precipitates incubated with GST-FLJ22318, but not in protein 
precipitates that had been incubated with GST alone. 
(A)  1 Benchmark  Prestained Protein Ladder 
2  No IPTG induction (negative control) 
3  IPTG induced GST expression (positive control; ~29kDa)  
4-7   IPTG induced GST-FLJ22318 expression (~73kDa) 
 
(B)  1 Benchmark  Prestained Protein Ladder 
  2  IPTG induced GST expression ~29kDa (positive control) 
  3  IPTG induced GST-FLJ22318 expression ~73kDa (125ng/µL) 
  4-7  BSA standard (0.5µg, 1.0µg, 2.0µg, 5.0µg)  
 
(C)  1,4 Whole  cell  lysates 
  2,5  GST protein precipitates 
  3,6  GST-FLJ22318 protein precipitates 
  
 WB: anti-V5
 (C)    1          2           3              4              5           6    
←  ~35kDa 
NKX3-1-pcDNA3.1/V5-His-TOPO 
transfected DU145 cells 
Untransfected
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5.2.3.3  GST Pull-Down Assay 
GST pull-down assays were performed using large scale preparations of the purified 
GST and GST-FLJ22318 fusion proteins (sections 5.2.3.2; 3.8.3). For these assays, 
DU145 prostate cancer cells, chosen as they do not express endogenous NKX3-1, were 
transiently transfected with NKX3-1-pcDNA3.1/V5-His-TOPO plasmids encoding 
NKX3-1 as a N-terminal fusion to a V5 epitope (sections 3.6.2; 5.2.1.1). Twenty-four 
hours post transfection, cells were lysed and 300µL aliquots of the lysate incubated with 
7.5µg GST alone or GST-FLJ22318 immobilised to glutathione. Following 18 hours of 
incubation, the protein complexes were precipitated and proteins separated by SDS-
PAGE then transferred onto nitrocellulose filters (sections 3.7.2; 3.7.3). To detect the 
interaction between FLJ22318 and NKX3-1, western blotting was performed using 
antibodies directed against the V5 epitope of the NKX3-1-pcDNA3.1/V5-His-TOPO 
fusion protein (section 3.7.4). In untransfected DU145 cells (controls), NKX3-1 was not 
detectable, whereas in NKX3-1-pcDNA3.1/V5-His-TOPO transfected cells NKX3-1 
could be detected in whole cell lysates and in protein precipitates incubated with GST-
FLJ22318, but not in protein precipitates that had been incubated with GST alone 
(Figure 5.19C). These results support the reverse yeast two-hybrid analysis results 
(section 5.2.2) and provide further evidence of an interaction between FLJ22318 and 
NKX3-1 in vitro. 
 
5.2.4  Co-immunoprecipitation of FLJ22318 and NKX3-1 
5.2.4.1  Co-immunoprecipitation of FLJ22318-pcDNA3.1/V5 and NKX3-1  
To verify FLJ22318-V5 protein expression prior to co-immunoprecipitation assays, 
DU145 prostate cancer cells were transiently transfected with the FLJ22318-
pcDNA3.1/V5-His-TOPO construct, the proteins extracted 24 hours post transfection 
and analysed by anti-V5 western blotting (sections 5.2.1.1; 3.6.2; 3.7.1-3.7.4). 
Untransfected DU145 cells did not exhibit immunoreactivity with the V5 epitope, while 
FLJ22318-pcDNA3.1/V5-His-TOPO transfected DU145 cells exhibited V5 
immunoreactivity with a protein band of 49.4kDa, the expected size for FLJ22318-V5 
protein (results not shown). 
 
As commercially available NKX3-1 antibodies are not precipitating antibodies, 
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FLJ22318-pcDNA3.1/V5-His-TOPO constructs were transiently transfected into 
LNCaP prostate cancer cells which express endogenous NKX3-1, and FLJ22318-V5 
complexes were immunoprecipitated using antibodies directed against the V5 epitope 
(sections 5.2.1.1; 3.10; Figure 5.20). Following immunoprecipitation however, the 
NKX3-1 antibody failed to detect endogenous NKX3-1 or NKX3-1 in controls (results 
not shown), suggesting that the NKX3-1 antibody available at the time was not sensitive 
enough for these experiments. 
  
5.2.4.2  Co-immunoprecipitation of pCMV-Myc-FLJ22318 and NKX3-1 
Co-immunoprecipitation assays were also carried out using Myc-tagged FLJ22318. For 
these experiments pCMV-Myc-FLJ22318 constructs were transiently transfected into 
LNCaP prostate cancer cells and western blotting was performed on extracted proteins 
using an anti c-Myc antibody, which confirmed expression of a Myc-FLJ22318 fusion 
protein of the correct size of 45.6kDa (sections 5.2.1.4.3; 3.7.1-.3.7.4; Figure 5.21). 
pCMV-Myc-FLJ22318 constructs were then transiently transfected into LNCaP cells 
together with NKX3-1-pcDNA3.1/V5-His-TOPO and NKX3-1-V5 complexes 
immunoprecipitated using antibodies directed against the V5 epitope as previously 
described (Figure 5.21B). Western blotting using a polyclonal anti-Myc antibody 
however, failed to detect FLJ22318 as part of a NKX3-1 complex or in controls, 
although when a monoclonal Myc antibody was used, FLJ22318 was detected in 
controls but not as part of a NKX3-1 complex (results not shown). As endogenous 
NKX3-1, which is present in LNCaP cells, was thought to be sequestering the 
transfected FLJ22318, the assays were repeated using the DU145 prostate cancer cell 
line, which has undetectable expression of endogenous NKX3-1 protein. 
 
For these assays, pCMV-Myc-FLJ22318 and NKX3-1-pcDNA3.1/V5-His-TOPO 
constructs were transiently transfected into the DU145 prostate cancer cell line and 
NKX3-1-V5 complexes were immunoprecipitated as previously described. However 
following immunoprecipitation, western blotting with monoclonal c-Myc antibodies 
detected non specific bands in both the untransfected DU145 cells (negative controls) 
and pCMV-Myc-FLJ22318 transfected cells suggesting that the c-Myc antibody was 
not specific enough for these experiments (section 3.7; Figure 5.21C).  
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Figure 5.20 Immunoprecipitation of FLJ22318-pcDNA3.1/V5-His-TOPO. Plasmids 
expressing FLJ22318-V5 were transiently transfected into LNCaP prostate cancer cells
and 24 hours post transfection proteins were immunoprecipitated with anti-V5 
antibodies. Protein complexes were collected with protein G sepharose and resolved by 
SDS-PAGE prior to western blotting with antibodies directed against the V5 epitope.
In transfected cells, FLJ22318 can be detected in the whole cell lysate and in protein
complexes immunoprecipitated with V5 antibody but not in protein complexes 
collected using protein G alone. In untransfected cells (controls) FLJ22318-V5 is not 
detectable. 
  1  Untransfected LNCaP cells ￿ whole cell lysate 
  2  Untransfected LNCaP cells ￿ protein G 
  3  Untransfected LNCaP cells ￿ protein G/anti-V5 antibody 
  4  FLJ22318-V5 transfected LNCaP cells ￿ whole cell lysate 
  5  FLJ22318-V5 transfected LNCaP cells ￿ protein G 
  6  FLJ22318-V5 transfected LNCaP cells ￿ protein G/anti-V5 antibody 
  1         2          3          4         5       6  
← IgG Heavy Chain ~50kDa
← IgG Light Chain ~25kDa
← Protein G ~30kDa
← FLJ22318-V5 ~49kDa  Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.21 Co-immunoprecipitation of NKX3-1-V5 and Myc-FLJ22318 (A) Anti-
Myc western blotting detected expression of Myc-FLJ22318 in pCMV-Myc-FLJ22318 
transfected LNCaP cells but not in untransfected cells. (B) LNCaP, and (C) DU145 
cells were transfected with either NKX3-1-pcDNA3.1/V5-His-TOPO or co-transfected 
with NKX3-1-pcDNA3.1/V5-His-TOPO and pCMV-Myc-FLJ22318. Proteins were 
harvested 24 hours post-transfection and immunoprecipitated with anti-V5 antibodies. 
(B) Anti-V5 western blotting indicated successful immunoprecipitation of NKX3-1-
V5 from LNCaP cells. (C) Anti-Myc western blotting did not identify co-
immunoprecipitation of Myc-FLJ22318 with NKX3-1-V5 but detected a nonspecific 
band of similar size to Myc-FLJ22318 in whole cell lysates.  
(A)  1  Untransfected LNCaP cells 
  2  pCMV-Myc-FLJ22318 transfected LNCaP cells 
 
(B,C)  1  NKX3-1-V5 transfected cells ￿ whole cell lysate 
  2  NKX3-1-V5 transfected cells ￿ protein G 
  3  NKX3-1-V5 transfected cells ￿ protein G/ anti-V5 
  4  NKX3-1-V5/Myc-FLJ22318 transfected cells ￿ whole cell lysate 
  5  NKX3-1-V5/Myc-FLJ22318 transfected cells ￿ protein G 
  6  NKX3-1-V5/Myc-FLJ22318 transfected cells ￿ protein G/anti-V5 
~45.6kDa →  
 (A)  1       2 
← IgG Heavy Chain ~50kDa
←  Myc-FLJ22318 45.6kDa  Non-specific band ~46kDa →  
1        2       3        4       5        6   (C) 
IP: anti-V5  WB: anti-Myc
← IgG Heavy Chain ~50kDa
← Protein G ~32kDa 
← NKX3-1-V5 ~35kDa 
 1      2      3     4       5     6    (B) 
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5.2.4.3  Co-immunoprecipitation of pCMV-HA-FLJ22318 and NKX3-1 
Due to difficulties with the immunoprecipitation experiments, LNCaP cells were 
transiently co-transfected with NKX3-1-pcDNA3.1/V5-His-TOPO and FLJ22318-
pCMV-HA constructs encoding V5-tagged NKX3-1 and HA-tagged FLJ22318 and 
protein complexes were immunoprecipitated using V5 antibodies (section 5.2.1.5.2). 
Proteins were separated by SDS-PAGE, and transferred to nitrocellulose membranes. 
Western blotting with HA antibodies detected FLJ22318 in whole cell lysates, however 
FLJ22318 could not be confirmed as part of immunoprecipitated NKX3-1 complexes as 
the IgG heavy chain of the immunoprecipitating antibodies was of a similar size to HA-
FLJ22318 (results not shown). 
 
5.2.4.4  Co-immunoprecipitation of pEGFP-C2-FLJ22318 and NKX3-1 
Prior to using the pEGFP-C2-FLJ22318 construct in immunoprecipitation assays, anti-
GFP western blotting of transiently transfected LNCaP cells was performed to confirm 
the expression of a GFP-FLJ22318 fusion protein of the expected size of approximately 
70kDa (sections 5.2.1.6.2; 3.6.2; 3.7.2-3.7.4; results not shown). Following verification 
of GFP-FLJ22318 protein expression, LNCaP cells were transiently co-transfected with 
NKX3-1-pcDNA3.1/V5-His-TOPO and pEGFP-C2-FLJ22318 vectors encoding 
NKX3-1-V5 and GFP-FLJ22318 fusion proteins and protein complexes were 
immunoprecipitated with V5 antibodies (or no antibody controls) 24 hours later. 
Western blotting using anti GFP antibodies detected FLJ22318 in whole cell lysates and 
in immunoprecipitated complexes with NKX3-1 but not in untransfected controls 
(section 3.7; Figure 5.22). These findings confirmed that FLJ22318 and NKX3-1 
interacted in vivo and supported the in vitro assay results. 
 
5.2.5 Characterisation  of  FLJ22318 Expression 
5.2.5.1  Preparation of cDNA Probes 
5.2.5.1.1  Preparation of the FLJ22318 cDNA Probe 
To prepare the FLJ22318 cDNA probe, 5µg of the pCMV-HA-FLJ22318 vector was 
digested using Sal I and Pst I and the digested plasmid electrophoresed in a 2% agarose 
gel (sections 5.2.1.5.2; 3.1.4; 3.2.2; results not shown). The 315bp fragment 
corresponding to the last 92bp of exon 3, exon 4 and the first 77bp of exon 5 of  Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.22 FLJ22318 interacts with NKX3-1 in vivo. Plasmids expressing GFP-
FLJ22318 and NKX3-1-V5 fusion proteins were transfected into LNCaP cells and
proteins immunoprecipitated with V5 antibodies. In the FLJ22318/NKX3-1 transfected
cells, western blotting using anti-V5 and anti-GFP antibodies detected both proteins in
the whole cell lysate and in protein complexes immunoprecipitated with V5 antibodies
but not in protein complexes precipitated using protein G alone. GFP-FLJ22318 and
NKX3-1-V5 were not detected in untransfected cells.  
  1  Untransfected cells ￿ LNCaP whole cell lysate 
  2  Untransfected cells ￿ Protein G  
  3  Untransfected cells ￿ Protein G/Anti-V5 
  4  FLJ22318-NKX3-1 transfected cells ￿ LNCaP whole cell lysate 
  5  FLJ22318-NKX3-1 transfected cells ￿ Protein G 
  6  FLJ22318-NKX3-1 transfected cells ￿ Protein G/Anti-V5 
 1      2       3       4        5         6 
FLJ22318 →  
 ~ 73kDa 
←  Anti-GFP  
←  Anti-V5  
IP: anti-V5
WB 
  NKX3-1 →  
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FLJ22318 was excised from the gel, purified and its concentration determined from the 
gel to be 10ng/µL (section; 3.1.6; Figure 5.23). 
 
5.2.5.1.2  Preparation of the GAPDH cDNA Probe 
To prepare the GAPDH cDNA probe, multiple Pst I digests of 1µg of the pHc-GAPDH 
vector were performed and the digested plasmid purified then digested with Xba I and 
electrophoresed in a 2% agarose gel (sections 2.1.3; 3.1.6; 3.2.2; results not shown). 
The 1283bp fragment corresponding to GAPDH was excised from the gel, purified and 
its concentration determined spectrophotometrically to be 21ng/µL (section 3.1.6). 
 
5.2.5.2  FLJ22318 Expression in Prostate and Breast Cancer Cells 
Expression of FLJ22318 mRNA was examined by Northern blotting in human LNCaP, 
DU145 and PC-3 prostate cancer cells, and MCF-7 breast cancer cells. Total cellular 
RNA was extracted from the cell lines, RNA concentration was determined 
spectrophotometrically and 10µg of each sample was separated in 1% 
MOPS/formaldehyde gels then transferred overnight onto nylon membranes (sections 
3.3.3; 3.6.1; 3.13.1-3.13.3).  
 
FLJ22318 mRNA levels were determined by Northern blotting with 
32P labelled 
FLJ22318 cDNA probes followed by exposure to autoradiographic film (sections 
5.2.5.1; 3.13.4-3.13.5). Unexpectedly, Northern blotting identified two transcripts of 
~1.8kbp and ~4kbp in all samples examined by plotting the mobility versus the log of 
the molecular weight in base pairs of the 18S and 28S rRNAs (Figure 5.24). The more 
abundant 1.8kbp transcript corresponds in size to the published RNA sequence that is 
proposed to encode a protein of 44.4kDa (NCBI Accession No. NP_073599). However, 
the FLJ22318 cDNA probe would have detected all but variant ￿m￿ of the alternative 
transcripts as proposed by AceView, therefore this transcript may represent variant ￿a￿, 
which also has a transcript size of approximately 1.8kbp (section 4.2.1; Table 4.1). The 
proposed protein encoded by this variant has a variant N-terminal to the published 
sequence that contains a clathrin box motif which is found on cargo adaptor proteins. 
The other transcript of ~4kbp detected by the FLJ22318 probe corresponds in size to 
transcript variant ￿d￿. This variant is also proposed to encode the 44.4kDa protein as Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.23 Construction of the cDNA probes. To construct the FLJ22318 cDNA
probe, 10µg the pCMV-HA-FLJ22318 vector was digested with Sal I and Pst I, and 
electrophoresed in a 2% agarose gel. The 315bp fragment corresponding to exons 3, 4
and 5 of FLJ22318 was excised, purified and 5µL electrophoresed in a 2% agarose gel. 
The concentration was estimated from the gel to be 10ng/µL.  
 1  Purified  Sal I/Pst I digested FLJ22318 cDNA probe (10ng/µL) 
 2  1Kb  Plus DNA Ladder 
     315bp →
12
Figure 5.24 Expression of FLJ22318 in prostate and breast cancer cell lines. To 
examine expression of FLJ22318,  (A)  10µg of total cellular RNA from LNCaP, 
DU145, and PC-3 prostate cancer cell lines and MCF-7 breast cancer cells was 
transferred onto nylon membranes. Northern blotting with 
32P labelled FLJ22318 
cDNA probes identified two FLJ22318 transcripts of approximately 4Kbp and 1.8Kbp 
in all cell lines tested. (B) Ethidium bromide stained RNA gel showing the 28S
(~5Kbp) rRNA. 
  1  LNCaP prostate cancer cell line 
  2  DU145 prostate cancer cell line 
  3  PC-3 prostate cancer cell line  
  4  MCF-7 breast cancer cell line 
~4Kbp →  
 ~1.8Kbp →
   1         2        3        4  (A)
    1         2        3        4  (B)
    ~5Kbp → Characterisation of FLJ22318 Interaction with NKX3-1 
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published by NCBI, and differs in transcript size to the published NCBI mRNA 
sequence (Accession No. NM_022762) only in its 3’ and 5’-UTRs.  
 
5.2.5.3  Androgen Regulation of FLJ22318 Expression  
To examine the regulation of FLJ22318 expression, mRNA levels of FLJ22318 were 
studied in LNCaP cells cultured in 5% CS-FCS medium containing 1 nM DHT for 0, 3, 
6, 12, 24, 48 and 72 hours (section 3.6.4). Following treatment, the FLJ22318 RNA was 
extracted and RNA concentration was determined spectrophotometrically as previously 
described (section 3.3.3). Ten µg of total cellular RNA from each sample was separated 
in 1% MOPS/formaldehyde gels and transferred overnight onto nylon membranes. 
FLJ22318 mRNA levels were determined by Northern blotting with 
32P labelled 
FLJ22318 cDNA probes and exposed to autoradiographic film (sections 5.2.5.1.1; 
3.13.4-3.13.5). Developed films were then analysed using Quantity One V4.5.2 
software. To determine FLJ22318 expression, membranes were re-probed with 
32P 
labelled GAPDH cDNA probes and for each sample, FLJ22318 expression determined 
as a proportion of GAPDH expression and represented as a proportion of FLJ22318 
mRNA levels detected in untreated controls (section 5.2.5.1.2).  
 
Following DHT treatment, FLJ22318 mRNA levels remained similar to that observed 
in the untreated cells at all time points tested suggesting that FLJ22318 expression is 
not regulated by androgens (Figure 5.25). 
 
5.2.6  Cellular Localisation and Co-localisation of FLJ22318 and NKX3-1 
To confirm that FLJ22318 and NKX3-1 are present within the same cellular 
compartment, DU145 and LNCaP cells were transiently transfected with 1µg of pCMV-
Myc-FLJ22318 and NKX3-1-pcDNA3.1/V5-His-TOPO vectors encoding Myc-
FLJ22318 and NKX3-1-V5 fusion proteins and the localisation and co-localisation of 
Myc-FLJ22318 and NKX3-1-V5 was determined by confocal microscopy using 
antibodies directed against the Myc and V5 epitopes (sections 5.2.1.4.3; 3.6.2; 3.11). 
Untransfected control cells displayed no immunoreactivity with the c-Myc or V5 
antibodies (results not shown).  
  Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.25 Androgen regulation of FLJ22318 mRNA in LNCaP cells. (A) LNCaP 
cells were cultured with 10
-8M DHT for 0-72 hours prior to RNA extraction and 
Northern blotting for FLJ22318 and GAPDH (loading control). (B) FLJ22318 mRNA 
levels were calculated as proportion of GAPDH mRNA and presented as mean ± SEM 
of FLJ22318 mRNA levels relative to time 0.  
(A)  DHT Treatment (hr) 
  Lane 1   0 
  Lane 2  3  
Lane 3  6 
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←  FLJ22318 ~ 4Kbp 
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In the DU145 prostate cancer cell line, FLJ22318 displayed a diffuse nuclear and 
perinuclear localisation. NKX3-1 was also localised to the perinuclear and nuclear 
regions of the cells but displayed a more punctate pattern of fluorescence compared to 
that of FLJ22318 (Figure 5.26). In the cells where NKX3-1 was predominantly 
localised to the perinuclear region of the cells with little nuclear localisation, very little 
co-localisation with FLJ22318 was observed (Figure 5.26A). However, in cells where 
NKX3-1 was localised in both the perinuclear and nuclear regions, more extensive co-
localisation of FLJ22318 and NKX3-1 was observed in these areas (Figure 5.26B) 
 
The finding that NKX3-1 localised to the perinuclear region of the cells was unexpected 
as previous studies have shown NKX3-1 to be a nuclear protein as would be expected 
for a transcription factor (Korkmaz et al., 2004). Previous studies were performed using 
the androgen responsive LNCaP cell line and as NKX3-1 expression has been shown to 
be altered or lost in advanced androgen independent prostate cancer and the DU145 cell 
line was derived from an androgen independent metastatic prostate cancer cell, it is 
possible that the cellular localisation of NKX3-1 in this cell line may be altered.  
 
Consequently, the localisation and co-localisation of FLJ22318 and NKX3-1 was re-
characterised in the LNCaP cell line as NKX3-1 is endogenously expressed in this cell 
line and as such other factors that may affect protein localisation would also be present. 
pCMV-Myc-FLJ22318 and NKX3-1-pcDNA3.1/V5-His-TOPO were transiently 
transfected into LNCaP cells and the cellular localisation determined by confocal 
microscopy using antibodies directed against the Myc or V5 epitopes as described 
previously (sections 5.2.1.4.3; 3.11).  Similar to results using the DU145 cell line, 
FLJ22318 showed a diffuse localisation throughout the perinuclear and nuclear region 
of the cells, however NKX3-1 showed a mainly perinuclear localisation with very little 
nuclear localisation or co-localisation with FLJ22318 (Figure 5.27A).  
 
As NKX3-1 is an androgen regulated gene and the LNCaP cell line is androgen 
responsive, confocal microscopy was also performed in LNCaP cells transfected as 
described above and treated with 1nM DHT. In DHT-treated cells, FLJ22318 displayed 
a similar perinuclear and nuclear localisation to that observed in untreated cultures. 
However, NKX3-1 was localised to both the perinuclear and nuclear regions of the Characterisation of FLJ22318 Interaction with NKX3-1 
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Figure 5.26 FLJ22318 and NKX3-1 localisation and co-localisation in DU145 
prostate cancer cells. DU145 cells were co-transfected with pCMV-Myc-FLJ22318 
and pcDNA3.1-NKX3-1-V5 vectors and incubated for 24 hours to allow expression
of recombinant proteins. (i) Cell nuclei were visualised using DAPI, and
immunostained with (ii), anti-Myc and (iii) and anti-V5 antibodies prior to confocal 
microscopy. Myc-FLJ22318 exhibited diffuse nuclear and perinuclear localisation
while NKX3-1-V5 exhibited either predominantly perinuclear (A iii) or both nuclear 
and perinuclear fluorescence (B iii). When images were overlayed, co-localisation 
(yellow) of FLJ22318 and NKX3-1 was detected in cells where localisation of 
NKX3-1 was both perinuclear and nuclear (A iv (arrow) and B iv) whereas in cells 
where localisation of NKX3-1 was predominantly perinuclear, very little co-
localisation of both proteins was observed (A iv *). Bar = 10µm. 
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Figure 5.27 FLJ22318 and NKX3-1 localisation and co-localisation in LNCaP 
prostate cancer cells. LNCaP cells were transfected with 1µg of pCMV-Myc-
FLJ22318 and pcDNA3.1-NKX3-1-V5 vectors and incubated for 24 hours in the 
absence (A) or presence (B) of 1nM DHT. Cell nuclei were visualised using (i)
DAPI and cells were immunostained with (ii) anti-Myc and (iii) anti-V5 prior to 
confocal microscopy. FLJ22318 exhibited diffuse nuclear and perinuclear 
localisation in untreated (A ii) and DHT-treated (B ii) cultures, while NKX3-1 
exhibited either (A iii) mainly perinuclear fluorescence in untreated cells or (B iii)
both nuclear and perinuclear fluorescence in the DHT-treated cells. When images 
were overlayed, (A iv) limited perinuclear co-localisation of Myc-FLJ22318 and 
NKX3-1-V5/His was detected in untreated cells. (B iv) In DHT treated cells, 
extensive nuclear and perinuclear co-localisation of Myc-FLJ22318 and NKX3-1-
V5/His was detected. Bar = 10µm. 
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DHT-treated LNCaP cells and extensive nuclear and perinuclear co-localisation of 
FLJ22318 and NKX3-1 was detected in these cultures (Figure 5.27B).  
 
5.2.7  Transcriptional Activity of FLJ22318 
The transcriptional activity of FLJ22318 and the regulation of NKX3-1 transcriptional 
activity by FLJ22318 were investigated in transiently transfected DU145 prostate 
cancer cells (section 3.6.2). Transcriptional activity was assessed by luciferase activity 
(section 3.12), induced from a herpes simplex virus thymidine kinase (TK) promoter 
upstream of a firefly luciferase gene (Luc). The DU145 cells were transfected with the 
reporter plasmids TK-Luc (control) or NKX-TK-Luc which contained three copies of a 
￿TCGATATTAAGTATAGGATTAAGTATAGGGATTAAGTAT￿ NKX3-1 response 
element (underlined) and various expression plasmids as listed in Figure 5.28. Cells 
were lysed 24 hours post-transfection and induced luciferase activity determined 
(section 3.12). An appropriate amount of pcDNA3.1/V5-His-TOPO/lacZ (Figure 3.9) 
was included in all transfections so that each well was transfected with an equal amount 
of DNA and the pRL/SV40 Renilla  plasmid (Figure 3.10) was also included in all 
transfections to control for variations in transfection efficiency. In addition, DU145 
cells were transiently transfected with either FLJ22318-pcDNA3.1/V5-His-TOPO or 
FLJ22318-pCMV-Myc to compare the effects on transcription of C-terminal V5 tagged 
FLJ22318 with N-terminal Myc tagged FLJ22318 protein. The data represents the 
average of two separate experiments normalised by Renilla luciferase activity.  
 
In both sets of experiments DU145 cells transfected with Renilla plasmid exhibited 
negligible background luciferase activity of 0.2% as did DU145 cells transfected with 
the TK-Luc luciferase reporter plasmid (2-3%), which represented the background 
activity of the TK promoter (Figure 5.28B,C). DU145 cells transfected with the NKX-
TK-Luc luciferase reporter plasmid exhibited a 32-fold and 49-fold increase in 
luciferase activity respectively when compared to controls (Figure 5.28B,C) which was 
then reduced by 83-88% when NKX-TK-Luc transfected DU145 cells were co-
transfected with NKX3-1-pcDNA3.1/V5-His-TOPO (Figure 5.28B,C). These results are 
in accordance with previous findings that NKX3-1 acts as a transcriptional repressor on 
this response element (Steadman et al., 2000). When compared to DU145 cells 
transfected with NKX-TK-Luc alone, cells co-transfected with NKX-TK-Luc and 
FLJ22318-pcDNA3.1/V5-His-TOPO, displayed a 44% reduction in luciferase activity  Characterisation of FLJ22318 Interaction with NKX3-1 
  185
(Figure 5.28B). Consistent with these results, DU145 cells co-transfected with NKX-
TK-Luc and pCMV-Myc-FLJ22318, displayed a 47% reduction in luciferase activity 
when compared to DU145 cells co-transfected with NKX-TK-Luc alone (Figure 
5.28C). These results suggest that FLJ22318 may have transcriptional repressor activity 
on this NKX3-1 response element. 
 
Compared to DU145 cells co-transfected with NKX-TK-Luc and NKX3-1-
pcDNA3.1/V5-His-TOPO, DU145 cells transfected with NKX-TK-Luc, NKX3-1-
pcDNA3.1/V5-His-TOPO and FLJ22318-pcDNA3.1/V5-His-TOPO exhibited a further 
42% decrease in luciferase activity (Figure 5.28B). Similarly, a further decrease in 
luciferase activity of 55% was observed in those cells transfected with NKX-TK-Luc, 
NKX3-1-pcDNA3.1/V5-His-TOPO and pCMV-Myc-FLJ22318 (Figure 5.28C).  These 
findings suggest that FLJ22318 may act as a transcriptional co-repressor with NKX3-1 
and indicate that neither the C-terminal V5 epitope of the FLJ22318-V5 fusion protein 
or the N-terminal Myc epitope of the FLJ22318-Myc fusion protein affected the 
transcriptional repressor or co-repressor activity of FLJ22318. 
 
5.2.8  Effect of FLJ22318 on NKX3-1 Protein Levels 
To assess whether the increase in NKX3-1 transcriptional repressor activity (section 
5.2.7) was a consequence of increased NKX3-1 protein levels following exogenous 
expression of FLJ22318, NKX3-1 protein levels were assessed by western blotting 
(section 3.7). For these experiments, LNCaP cells were transiently transfected with 
increasing amounts of vectors encoding FLJ22318-V5, GFP-FLJ22318 and HA-
FLJ22318 to compare the effects of C-terminal V5-tagged FLJ22318 or N-terminal 
GFP- and HA-tagged FLJ22318 on NKX3-1 protein levels (section 3.6.2; Figure 5.29). 
An appropriate amount of pcDNA3.1/V5-His-TOPO/lacZ (Figure 3.9) was included in 
all transfections so that each well was transfected with an equal amount of DNA. 
NKX3-1 proteins were detected using anti-NKX3-1 antibodies (section 2.1.6; Figure 
5.29A), and protein levels in samples standardised to β -actin. Results are presented as 
mean ± SEM of NKX3-1 protein levels relative to untransfected LNCaP cells. 
 
Following exogenous expression of FLJ22318 in LNCaP cells, NKX3-1 protein levels 
remained similar to that observed in the untransfected and solely pcDNA3.1/V5-His- 
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TOPO/lacZ transfected cells at all concentrations tested (Figure 5.29B). These results 
indicated that FLJ22318 does not regulate NKX3-1 protein levels in LNCaP prostate 
cancer cells.   
 
5.3 Discussion 
FLJ22318 was originally identified as a putative interacting partner of NKX3-1 by yeast 
two-hybrid analysis. To provide supporting evidence that the interaction between 
NKX3-1 and FLJ22318 was not a result of the intrinsic technical limitations of this 
method, full length FLJ22318 and NKX3-1 were cloned into yeast expression plasmids, 
the reverse to that used in the original screen and the yeast two-hybrid screen was 
repeated.  
 
In the initial reverse yeast two-hybrid screen, although transformation of FLJ22318 into 
yeast was successful, co-transformation of both FLJ22318 and NKX3-1 into the yeast 
cells was not. Therefore in the subsequent screen, FLJ22318 transformed yeast cells 
were used in a sequential transformation with NKX3-1 to confirm the interaction 
between FLJ22318 and NKX3-1. Co-transformation of FLJ22318 and NKX3-1 was 
unsuccessful most likely as the result of low transformation efficiency especially as 
efficiencies of transformations with single plasmids were lower than expected. The low 
transformation efficiencies may have resulted from suboptimal yeast competent cells, 
carrier DNA or plasmid DNA. The plasmid DNA was purified prior to transformation 
using the Wizard
  SV Gel and PCR Clean-Up System (section 2.2). However before 
transformation, additional ethanol precipitation of the plasmid DNA is recommended 
(Sambrook and Russell, 2001) therefore the low transformation efficiencies seen in 
these studies may have been due to residual guanidine isothiocyanate contamination of 
the plasmid DNA from the Wizard
  SV Gel and PCR Clean-Up System membrane 
binding solution. 
 
The interaction between NKX3-1 and FLJ22318 detected using GST pull-down and 
immunoprecipitation assays in these studies also proved to be technically difficult. This 
may have been due to an insufficient concentration of NKX3-1 and FLJ22318 able to be 
used to readily detect an interaction. The cellular concentration of an expressed protein 
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protein turnover and expression. For the GST-FLJ22318 pull-down assays, NKX3-1 
was exogenously expressed with a C-terminal V5 epitope in transiently transfected 
DU145 cells. Similarly for the immunoprecipitation assays, LNCaP prostate cancer 
cells were transiently transfected with plasmids encoding NKX-3-1/V5 and plasmids 
expressing FLJ22318 as a fusion protein with either a C-terminal V5 or N-terminal 
Myc, HA or GFP epitopes. Although it is possible that these epitopes may have 
interfered with the NKX3-1/FLJ22318 protein-protein interaction the epitopes have all 
been well characterised. Whereas one epitope may have caused a conformational 
change which inhibited or reduced protein binding it is less likely that all epitope tags at 
the C- and N-terminals used in these studies would have affected protein binding. It is 
possible however, that the level of protein expression affected the concentration of 
protein available for an interaction to occur. In transiently transfected cells, gene 
expression can be detected for between one and four days but expression is required for 
approximately one day following transfection before sufficient protein has accumulated 
in the cell to enable detection. As both NKX3-1 and FLJ22318 are predicted to be 
unstable in vivo (http://au.expasy.org/tools/protparam) and the mechanisms that regulate 
their turnover are unknown, it is possible that the rate of protein turnover exceeded the 
rate of protein synthesis leaving insufficient concentrations of one or both proteins for 
an interaction to be readily detected. A recent study in this laboratory has identified the 
half-life of endogenous NKX3-1 to be ~25 minutes (Thomas et al., 2006), however the 
half lives of exogenously expressed tagged NKX3-1 and FLJ22318 are unknown. 
 
The affinity of one protein for another can also be altered by the presence or absence of 
an effector molecule such as ATP. In addition, a change in physiological conditions 
such as temperature, pH or covalent modification including phosphorylation can all 
affect protein binding (Nooren and Thornton, 2003). In PAFAH1B1 the region 
containing the LisH motif followed by a coiled-coiled region switches between an open 
or closed conformation dependent on the salt concentration. In very low salt 
concentrations (<50mM NaCl) an open conformation is adopted whereas at 
concentrations above 50mM NaCl both open and closed conformations are found to be 
present (Mateja et al., 2006). Equilibrium between both conformations is reached at 
150mM NaCl with higher salt concentrations favouring a closed conformation. When 
the coiled-coiled region assumes the closed conformation a hydrophobic pocket in the 
LisH motif is obscured, which is proposed to have functional implications as this region Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1  
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is required for protein-protein interactions (Mateja et al., 2006). As CTLH motifs are 
proposed to have a similar function to coiled-coiled regions, FLJ22318 may also adopt 
an open or closed conformation that is dependent on the salt concentration. If this is the 
case, the salt concentrations of 150mM NaCl used in the immunoprecipitation assays in 
comparison to 50mM NaCl used in GST pull-down assays may have resulted in 
different proportions of alternative FLJ22318 conformations present in the two assays. 
As such, the salt concentrations used in GST pull-down and co-immunoprecipitation 
assays may account for the difficulties in detecting NKX3-1 and FLJ22318 interactions. 
 
Another possible explanation is that the interaction between NKX3-1 and FLJ22318 
may be weak and/or transient. Transient protein-protein interactions are regulated by 
physiological conditions that have the ability to change the affinity between partners 
thereby allowing for the effective control of dynamic protein complexes (Nooren and 
Thornton, 2003). In addition, protein-protein interactions can also be classified as 
obligate and non-obligate with obligate protein-protein complexes being formed by 
proteins that are not stable on their own in vivo. Proteins that are involved in strong 
obligate interactions are also generally expressed at the same time and are co-localised 
on synthesis (Nooren and Thornton, 2003). As co-localisation of NKX3-1 and 
FLJ22318 appears to be affected by androgens in LNCaP prostate cancer cells and both 
proteins are predicted to be unstable in vivo, NKX3-1 and FLJ22318 may be part of a 
weak obligate protein-protein complex. The exceptionally high degree of amino acid 
sequence conservation between mammalian FLJ22318 orthologues suggesting that 
FLJ22318 function is critical in the cell (section 4.2.2) is consistent with previous 
analyses which have indicated that complexes formed by obligate protein-protein 
interactions are also involved in essential functions in the cell.  
 
GST pull-down and co-immunoprecipitation assays were also limited by the ability to 
perform the techniques only in one direction. For GST pull-down assays, only GST-
FLJ22318 was able to be used to pull down NKX3-1/V5-His and for co-
immunoprecipitation assays, only NKX3-1/V5-His was able to be used to 
immunoprecipitate GFP-FLJ22318. Extensive previous studies in this laboratory have 
not been able to induce expression of GST-NKX3-1 in bacterial cells (Hooper & Bentel, 
unpublished). The reasons for this are unknown, however the use of rare codons by 
human NKX3-1, which would limit its expression in bacteria, and the reported Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1  
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(bacterial) transcription repressor activity of the C-terminal region of NKX3-1 cDNA 
may contribute to the inability to express GST-NKX3-1 in bacteria. The N-terminal 
region of NKX3-1 including the homeodomain has been able to be expressed in 
bacterial cells and it may be feasible in future studies to test this type of construct in 
GST pull-down assays with FLJ22318 (Steadman et al., 2000). 
 
Co-immunoprecipitation of FLJ22318 and NKX3-1 was also technically extremely 
difficult and several expression plasmids were tested before a suitable combination of 
NKX3-1-pcDNA3.1/V5-His and pEGFP-C2-FLJ22318 were identified. The anti-V5 
antibody used in these studies worked very well for immunoprecipitation and was 
eventually successful in co-precipitating NKX3-1/V5-His and GFP-FLJ22318. 
However, other technical difficulties including detection of nonspecific 
immunoreactivity from the anti-Myc antibodies, inefficient co-expression of 
combinations of tagged NKX3-1 and FLJ22318, interference by IgG heavy chain of 
detection of the similarly sized HA-tagged FLJ22318 as well as evidence from results 
obtained that NKX3-1 and FLJ22318 are not major binding partners of each other, each 
limited successful completion of the experiments. Future studies using NKX3-1 and 
FLJ22318 antibodies rather than antibodies to tagged exogenously expressed proteins 
will facilitate characterisation of additional NKX3-1 and FLJ22318 interacting proteins 
in in vitro and in vivo assays. 
 
Northern blotting of FLJ22318 mRNA extracted from human LNCaP, DU145 and PC-3 
prostate cancer cells, and MCF-7 breast cancer cells demonstrated that FLJ22318 is 
expressed in these cell lines with the detection of two transcripts of approximately 
1.8Kbp and 4Kbp. The 1.8Kbp transcript corresponds with theoretical data published by 
NCBI relating to the reference sequence as well as a proposed alternative transcript 
identified using AceView (section 4.2.1). As the expression of FLJ22318 has not been 
characterised previously, sequencing would be necessary to determine the identity of 
these transcripts. In addition, it remains unknown whether these transcripts are present 
in normal breast and prostate tissue as the tissue distribution of FLJ22318 mRNA in 
malignant compared to normal tissue has also not been reported. As antibodies to 
FLJ22318 are currently unavailable, translation of these transcripts into functional 
proteins and the molecular size(s) of the FLJ22318 proteins in relation to the proposed 
(hypothetical) proteins of 44.4 and 49.4kDa are also unknown. Due to the high amino Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1  
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acid conservation in mammalian FLJ22318 proteins, raising antibodies to human 
FLJ22318 may represent a challenge as it would be important to avoid self-recognition 
of the peptide by the host animal. To overcome cross species reactivity, antibodies are 
generally raised in the chicken for highly conserved mammalian proteins (Angeletti et 
al., 1997), however at present the chicken orthologue of FLJ22318 has not been 
identified so it is unknown how homologous these proteins may be. The chicken 
orthologue of human FLJ13910 has been identified and shares 95% homology with the 
human protein suggesting that chicken and human FLJ22318 may also share a high 
degree of amino acid conservation. In addition, care would need to be taken to ensure 
specificity to FLJ22318 as human FLJ22318 shares 70% amino acid identity with its 
(human) paralogue FLJ13910. 
 
As NKX3-1 expression is up-regulated by androgens and NKX3-1 and androgens have 
been shown to act synergistically to regulate gene expression in the prostate (Magee et 
al., 2003), regulation of FLJ22318 expression by androgens was investigated in this 
study. However, following treatment with the androgen DHT for up to 72 hours in 
LNCaP prostate cancer cells, FLJ22318 mRNA levels were found to be unaltered. 
Although these results would suggest that FLJ22318 expression is not androgen-
regulated in LNCaP prostate cancer cells, a recent study has shown that overexpression 
of NKX3-1 can down-regulate the expression of AR thereby modulating AR mediated 
signalling in the prostate (Lei et al., 2006). Since genes such as angiopoietin 2, have 
been identified that are regulated by androgens only in the absence of NKX3-1 
expression, it has been proposed that NKX3-1 may regulate expression of potential 
androgen target genes (Magee et al., 2003). Therefore, further studies will be necessary 
to determine whether FLJ22318 expression is modulated by androgens in prostate 
cancers that do not express high levels of NKX3-1. 
  
In this study, the cellular localisation of FLJ22318 and its co-localisation with NKX3-1 
was investigated by confocal microscopy. In DU145 and LNCaP prostate cancer cells, 
FLJ22318 was seen to have a diffuse localisation in both the perinuclear and nuclear 
regions of the cells and co-localised with NKX3-1 in these areas in both androgen 
treated LNCaP prostate cancer cells and in a proportion of untreated LNCaP and DU145 
prostate cancer cells.  As NKX3-1 is a homeodomain protein and as such a transcription 
factor that localises to the nucleus (Korkmaz et al., 2004) it was expected that for Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1  
  193
FLJ22318 to interact with NKX3-1, FLJ22318 would also be predominately localised to 
the nucleus. Although FLJ22318 does not contain a recognised nuclear localisation 
signal (NLS), at position 190 of the FLJ22318 amino acid sequence there is a putative 
casein kinase 2 (CK2) phosphorylation site. Previous studies have shown that proteins 
with a NLS can also contain putative CK2 sites at a distance of approximately 10-30 
amino acid residues from the NLS (Rihs et al., 1991). At position 195 of the FLJ22318 
amino acid sequence there is a stretch of positively charged amino acids (KXHRXH), 
reported to be a hallmark of NLS (Dingwall and Laskey, 1991) and although this stretch 
of amino acids is not continuous as is the case of the classical NLS it may nevertheless 
represent a novel NLS, which targets FLJ22318 to the nucleus. The transcription factor 
FOXO1 is one such protein that is targeted to the cell nucleus when a serine residue 
three amino acids from one of two non classical NLS is dephosphorylated (Zhao et al., 
2004).  
 
Although NKX3-1 was also seen to have a perinuclear and nuclear localisation, 
immunofluorescence was punctate in appearance suggesting the sequestering of NKX3-
1 within subcellular structures. Cytoplasmic accumulation of NKX3-1 has been 
observed in prostate cancers and the abnormal cellular localisation of NKX3-1 has been 
suggested as one of the mechanisms by which NKX3-1 is inactivated (Kim et al., 
2002b). Mechanisms that regulate the subcellular localisation and turnover of NKX3-1 
have not been defined. Of particular interest in this study is the previously unreported 
finding that androgens are required to facilitate accumulation of NKX3-1 in the nucleus 
in androgen responsive prostate cancer cells. This observation indicates that as well as 
regulating  NKX3-1 expression at the transcriptional level, androgens may also be 
involved in mediating NKX3-1 activation at the protein level. Previous studies have 
shown that androgens are required for the phosphorylation and subsequent nuclear 
translocation of other proteins such as Erk-1 (Peterziel et al., 1999), and homeodomain 
proteins are known to be posttranslationally modified by phosphorylation which in turn 
can affect their subcellular localisation and DNA binding affinity. The pancreatic 
duodenal homeobox-1 protein shuttles between the perinuclear and nuclear region of 
cells depending on its phosphorylation status whilst phosphorylation of the Drosophila 
homeobox protein engrailed has been shown to increase its DNA binding ability 
(Bourbon et al., 1995; Elrick and Docherty, 2001). Phosphorylation of NKX3-1 by 
protein kinase C (PKC) was also shown to affect NKX3-1 DNA binding affinity Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1  
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whereas phosphorylation by CK2 stabilised NKX3-1 protein levels protecting it from 
degradation via the ubiquitin-proteasomal pathway (Ju et al., 2006; Li et al., 2006b). At 
present, it is unknown whether phosphorylation by PKC or CK2 affects NKX3-1 
localisation, although previous studies have shown CK2 phosphorylation of testis 
specific protein, Y-linked (TSPY) is a prerequisite for its nuclear localisation whilst 
PKC phosphorylation of lim-kinase 2 (LIMK2) was shown to inhibit LIMK2 nuclear 
import (Goyal et al., 2006; Krick et al., 2006). As both PKC and CK2 activity are 
modulated by androgens (Maddali et al., 2005; Tawfic and Ahmed, 1994), future 
studies will be required to determine whether the androgen-mediated nuclear 
translocation of NKX3-1 observed in these studies is associated with NKX3-1 
phosphorylation. 
 
Results from this study indicate that FLJ22318 acts as a transcriptional repressor on the 
TAAGTA NKX3-1 consensus response element and in addition, FLJ22318 increases 
the transcriptional repressor function of NKX3-1 on this element. As FLJ22318 
exhibited significant repressor activity on the TAAGTA response element in the 
absence of NKX3-1, it is possible that FLJ22318 can bind DNA directly and this will 
need to be examined in future studies. In addition, it will be necessary to determine 
whether FLJ22318 exhibits transcriptional repressor activity and increases the 
transcriptional repressor activity of NKX3-1 in androgen responsive LNCaP cells and 
whether these effects are dependent or independent on the level of FLJ22318 
expression. Furthermore as the TAAGTA DNA-binding sequence has not been reported 
for any other NK class homeodomain protein and NKX3-1 expression is largely 
prostate specific, another possibility is that FLJ22318 may exhibit broad spectrum co-
repressor activity involving more than one transcription factor.  
 
As the NKX3-1 consensus response element used in this study was determined 
experimentally (target genes for NKX3-1 were unknown at the time) an examination of 
the DNA sequence comprising the NKE response element was undertaken to identify 
other potential transcription factor binding sites. Using the MatInspector V6.0 
programme this examination indicated the presence of putative ARID3A binding sites 
which partially overlap the NKX3-1 binding sites. ARID3A is a member of the ARID 
family of proteins which have various roles in embryonic development, cell cycle 
control and transcriptional regulation and is a homologue of the Drosophila ￿dead Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1  
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ringer￿ protein (Wilsker et al., 2002). During development, the sea urchin orthologue of 
￿dead ringer￿ SpDri regulates expression of the NK2 class homeodomain protein 
SpNK2.1 during gastrulation and human ARID3A is expressed in all tissues examined 
thus far, including prostate cDNA libraries (Ma et al., 2003; Takacs et al., 2004). 
Therefore ARID3A may bind to the NKE in the pT109-NKX-TK-Luc plasmid in 
DU145 cells which do not express endogenous NKX3-1 and potentially competes with 
NKX3-1 for binding to these sequences. A previous study has shown that ARID3A is 
necessary for E2F1 transcriptional activation in mouse fibroblasts and promotes G1/S 
transition through the cell cycle (Ma et al., 2003). ARID3A has also been shown to 
exhibit growth suppressive effects in the presence of p53 (Peeper et al., 2002). As p53 is 
non-functional in DU145 cells, ARID3A expression may be one possible explanation 
for the induced luciferase activity seen in this cell line upon transfection with the NKE 
reporter plasmid. To investigate this further, future studies could determine the identity 
of transcription factors that induce luciferase expression from the NKX-TK-Luc 
reporter vector in NKX3-1 expressing (LNCaP) and nonexpressing (DU145) cells and 
how FLJ22318 interacts with NKX3-1, other transcription factors and the NKE DNA 
sequences to repress transcription. It will also be necessary to repeat these studies using 
a biologically relevant NKX3-1 responsive promoter such as the SMGA or PSA 
promoters (section 1. 3.3.6) to more fully investigate FLJ22318 effects on NKX3-1 
mediated transcriptional regulation.   
 
Exogenous expression of FLJ22318 in this study was shown not to effect endogenous 
levels of NKX3-1 protein in LNCaP prostate cancer cells. This would indicate the 
increase in transcriptional repressor activity of NKX3-1 upon co-transfection of 
FLJ22318 was not as a result of an increase in NKX3-1 protein levels. However, the 
effect of FLJ22318 expression on NKX3-1 protein levels in normal prostate tissues is 
unknown and this would have to be investigated in future studies. 
 
To date, apart from FLJ22318, no other proteins containing LisH, CTLH and CRA 
domains are known to interact with homeodomain proteins, however NPAT which 
contains only a LisH domain is part of a large multi-protein complex containing the 
homeodomain protein OCT1 and OCA-S (Zheng et al., 2003), and mice lacking 
expression of Ofd1, which also contains only a LisH domain, have altered expression of 
Hoxa and Hoxd genes (Ferrante et al., 2006). Unlike FLJ22318, not all proteins Chapter Five ￿ Characterisation of FLJ22318 Interaction with NKX3-1  
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containing either LisH, CTLH, CRA or combinations of these domains localise to the 
cytoplasm and nucleus of cells, PAFAH1B is cytoplasmic whilst OFD1 localises to 
centrioles (Gerlitz et al., 2005; Keller et al., 2005). Intriguingly, RANBP9 which does 
contain all three domains also localises to both the cytoplasm and nucleus of cells and in 
addition associates with the plasma membrane once phosphorylated (Denti et al., 2004; 
Nishitani et al., 2001). Therefore it would be interesting to see in future studies whether 
FLJ22318 can be phosphorylated, especially as FLJ22318 contains a putative CK2 
phosphorylation site, and whether phosphorylation affects FLJ22318 cellular 
localisation. 
 
In summary, results from this chapter have demonstrated that FLJ22318 interacts with 
NKX3-1 both in vitro and in vivo and co-localises with NKX3-1 in the perinuclear and 
nuclear region of androgen dependent and androgen independent prostate cancer cells. 
In addition, FLJ22318 exhibited transcriptional repressor activity on an NKX3-1 
response element and increased NKX3-1 transcriptional repressor activity on this 
element.  As the yeast orthologue of FLJ22318, RMD5, is found in the cell as part of 
multi-protein complexes it is possible that FLJ22318 also exists within the cell as part 
of larger protein complexes. As such identification of other FLJ22318 binding proteins 
may indicate a biological function for FLJ22318 and help to clarify its interaction with 
NKX3-1 in prostate cancer cells.   
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Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
6.1 Introduction   
6.1.1  Isolation of FLJ22318 Binding Partners 
As discussed in chapter four, FLJ22318 is a ubiquitously expressed protein that is 
highly conserved in mammalian species, suggesting that it has important biological 
functions. In addition, FLJ22318 contains LisH, CTLH and CRA protein-protein 
binding motifs which are well conserved in higher eukaryotes. Although the overall 
function of proteins with this domain structure remains unknown, it is likely that a 
ubiquitously expressed protein that has multiple protein-protein interaction domains has 
numerous binding partners. It was shown in chapter five that FLJ22318 interacts with 
the homeodomain protein NKX3-1 and increases the transcriptional repressor activity of 
NKX3-1 on the NKX3-1 TAAGTA consensus binding sequence. Interestingly, 
FLJ22318 also showed transcriptional repressor activity on this sequence in the absence 
of NKX3-1 and as discussed in chapter five this may have been as a result of FLJ22318 
acting as part of a co-repressor complex in conjunction with other unidentified factors 
present in prostate cancer cells. In the cell, proteins may stably or rapidly and transiently 
associate with larger protein complexes and the biological function of a protein in a 
particular cell type may therefore be characterised following the identification of its 
interacting partners. As the cellular function of FLJ22318 is unknown and cannot be 
deduced from proteins with similar domain structures in human cells or in cells of other 
species, FLJ22318 binding proteins in LNCaP prostate cancer cells were isolated using 
a yeast two-hybrid screen. 
 
In recent years several strategies have been described to identify protein-protein 
interactions including protein mass spectrometry (MS) and yeast two-hybrid analysis. 
Other than its high cost, the main limitation of MS analysis of protein-protein 
interactions is that the protein complexes first need to be isolated. Using this approach a 
tagged bait protein and its interactors are selectively purified from a cell lysate and the 
isolated proteins digested into peptides using a protease such as trypsin. These peptide 
mixtures are then separated by two-dimensional gel analysis and analysed by MS, and 
the protein interactors identified by database searching (Droit et al., 2005). However 
many proteins will not be detected because they are too rare, large, small, acidic or 
alkaline to be studied by two-dimensional gel analysis (Mendelsohn and Brent, 1999). Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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Also, the biological activity of the fusion protein depends on the location and the amino 
acid composition of the tag. As the tagged protein is overexpressed, its stoichiometry is 
altered in comparison to that of its partners in the complex and it must compete for 
complex assembly with the non tagged version of the protein. Moreover, the increased 
level of expression of the bait protein may increase the occurrence of non-specific 
interactions. In addition, some interactions may be missed altogether as a result of the 
tag disturbing complex formation or transient and loosely associated proteins being 
washed off during purification. Use of this approach thereby predisposes to 
identification of protein complexes which are abundant within the cell and which form 
stable, high affinity interactions (Droit et al., 2005). 
 
Yeast two-hybrid analysis is a technique for identifying cDNAs that encode proteins 
which interact with a protein of known coding sequence. The system utilises the 
transcription of yeast reporter genes to detect protein-protein interactions and provides a 
sensitive method for detecting weak and transient protein interactions. As the assay is 
performed  in vivo, proteins are more likely to be in their native conformations, 
potentially increasing the accuracy of detection of bona fide binding partners of the 
protein of interest. 
 
The yeast two-hybrid method takes advantage of the domain structure of eukaryotic 
transcription factors which have functionally distinct DNA-binding (DNA-BD) and 
transcription activating domains (AD). Its principle was demonstrated by Fields and 
Song, (1989) who showed that yeast transcription could be used to identify protein-
protein interactions when one protein was fused to a DNA-BD and proteins encoded by 
the target or ￿prey￿ cDNA library were fused to an AD. Several yeast two-hybrid 
systems have since have been developed and consist of (i) yeast plasmids for expression 
of the known protein fused to a DNA-BD, (ii) yeast plasmids for expression of proteins 
encoded by cDNA fused to a transcription AD and (iii) yeast reporter genes that contain 
binding sites for the DNA-BD. These systems typically use the DNA-BD from either 
Gal4 or LexA acting upon a yeast promoter from either the GAL1 or CYC1 gene fused 
to lacZ. The lacZ gene encodes β -galactosidase, a secreted enzyme which cleaves the 
X-Gal substrate to form a blue product (Yocum et al., 1984). Yeast two-hybrid systems 
use additional reporter genes and a yeast strain which requires expression of these genes Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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to grow on specific media. To express the AD fused cDNA proteins, B42, an AD 
derived from bacteria, a very strong AD from the Herpes simplex virus protein VP16 or 
the strong AD from Gal4 can be used in conjunction with either a constitutive promoter, 
or a conditional promoter such as GAL1 which is induced by galactose (Yocum et al., 
1984). 
 
Although this system is a powerful method, it too has several limitations. In some cases, 
the DNA-BD or AD fusions themselves may obstruct the normal site of protein 
interaction, or impair protein folding resulting in the inability of the two proteins to 
interact (van Aelst et al., 1993). Also, it cannot detect interactions requiring three or 
more proteins or those depending on post-translational modifications such as 
glycosylation (Ito et al., 2002) and the detection of an interaction in the yeast two-
hybrid system does not necessarily mean that there is a corresponding interaction in the 
native environment of the proteins (Fields and Sternglanz, 1994). Some protein 
interactions may not be detectable in a GAL4 based two-hybrid system but may be 
detectable using a LexA based system (Mendelsohn and Brent, 1994) and finally, a 
significant number of interactions that are not of biological origin (false positives) can 
arise (Uetz, 2002). 
  
To isolate FLJ22318 binding partners in this study, the BD Matchmaker Library 
Construction and Screening Kit was used (Clontech). This system utilises four reporter 
genes to assay for protein-protein interactions which should significantly reduce the 
number of false positives that could arise using yeast two-hybrid systems.  
 
6.1.2  Yeast Two-Hybrid Analysis 
The BD Matchmaker Library Construction and Screening Kit is comprised of three 
components, (i) a plasmid for expression of the protein of interest, the ￿bait￿ protein, 
fused to a Gal4 DNA-BD, (ii) the AH109 yeast strain and (iii) a cDNA library. A Gal4 
based system was chosen in preference to a LexA system as LexA does not have a yeast 
nuclear localisation signal and although most LexA fusion proteins will enter the yeast 
nucleus this is not always the case. Also LexA requires a minimum level of expression 
before it will efficiently bind its BD sequence (Silver et al., 1986). On the other hand, 
the yeast GAL4 protein has an inherent nuclear localisation sequence (Fields and Song, Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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1989) that in this system is located at the amino terminus of the BD sequence. This 
DNA-BD sequence comprises the first 146 amino acids of the GAL4 protein and binds 
as a dimer to the galactose upstream activating sequence (UASG) located upstream of 
the yeast reporter genes (Bram and Kornberg, 1985). 
 
The yeast strain AH109 used in this study has four reporter genes ADE2, HIS3 and 
MEL1/lacZ. The ADE2 and HIS3 reporter genes are under the control of distinct GAL4 
UAS￿s enabling transcription of the ADE2 and HIS3 genes to be measured by the ability 
of the yeast to grow in the absence of adenine or histidine (James et al., 1996). The third 
reporter MEL1 is an endogenous GAL4 responsive gene (Liljestrom, 1985) whilst the 
lacZ reporter gene was introduced into the PJ69-2A yeast strain to create strain AH109 
and is also under the control of a distinct GAL4 UAS (Holtz and Zhu, 1995). MEL1 and 
lacZ encode α -galactosidase and β -galactosidase respectively.  α -galactosidase is a 
secreted enzyme which catalyses the hydrolysis of X-α -Gal yielding a blue end product 
and so providing an additional assay of activation by the ￿bait￿ and AD fused proteins 
that interact with it, together with some quantitative information about the strength of 
the interaction (Aho et al., 1997).  
 
The final component is a library plasmid which directs the expression of cDNA encoded 
proteins fused at their amino termini to a SV40 T-antigen nuclear localisation signal, a 
transcription AD comprised of amino acids 768-881 of the GAL4 protein and a 
haemagglutinin epitope tag.  The AD fused cDNA encoded protein is constitutively 
expressed in yeast at a high level from the ADH1 promoter (Chien et al., 1991).  
 
The BD Matchmaker yeast two-hybrid system is illustrated in Figure 6.1A. The 
constitutively expressed ￿bait￿ protein binds the GAL4 responsive UAS upstream of the 
reporter genes ADE2, HIS3, MEL1/lacZ but does not activate their transcription. When 
a (constitutively expressed) AD fused cDNA encoded protein interacts with the ￿bait￿, 
transcription of the reporter genes occurs enabling yeast cells containing the interacting 
proteins to grow on medium lacking adenine and histidine and to form blue colonies on 
X-α -Gal indicator plates. 
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Figure 6.1 The BD Matchmaker yeast two-hybrid system. (A)  A bait gene is
expressed as a fusion to the GAL4 DNA-BD while cDNA encoded proteins are
expressed as a fusion to the GAL4 AD. When bait and library fusion proteins interact
the DNA-BD and AD are brought into close proximity activating transcription of the
four reporter genes. (B) Reporter constructs in the AH109 yeast strain. Strain AH109
is a derivative of strain PJ69-2A and includes an introduced lacZ reporter, ADE2 and
HIS3 markers and the endogenous MEL1 gene. The HIS3, ADE2 and MEL1/lacZ
reporter genes are controlled by three distinct GAL4 responsive UAS and promoter
elements, namely GAL1, GAL2 and MEL1. 
(A) 
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6.1.3  The pGBKT7 GAL4 DNA-BD Expression Plasmid 
pGBKT7 is a multi-copy yeast plasmid containing a yeast 2 µ origin of replication and 
yeast selectable marker gene TRP1, as well as a GAL4 DNA-BD flanked by the yeast 
ADH1 promoter and transcription terminator. Bait proteins are constitutively expressed 
at high levels from this plasmid and can be introduced and maintained in a trp1
- yeast 
strain by selecting transformants on media lacking tryptophan. Moreover, yeast strains 
transformed with pGBKT7 have been shown to exhibit higher transformation 
efficiencies than strains transformed with other DNA-BD plasmids, which assists in the 
introduction of AD fusion libraries into yeast. The higher transformation efficiency also 
helps to maintain library complexity thereby increasing the possibility of detecting 
novel two-hybrid protein interactions (Louret et al., 1997).  
 
6.1.4  AH109 Yeast Strain 
The selection of cDNAs encoding interacting proteins depends on the yeast strain. 
AH109 are gal4
- and gal80
- to prevent interference of native regulatory proteins with 
the two-hybrid system and employs four reporter genes which are under the control of 
three distinct GAL4 UAS￿s and TATA boxes (Figure 6.1B). This greatly reduces the 
probability of false positives, as those false positives that interact directly with 
sequences flanking the GAL4 binding site and with transcription factors bound to 
specific TATA boxes are eliminated (James et al., 1996).  Furthermore, the stringency 
of screening can be varied by selecting for the ADE2 or HIS3 reporter genes or both, 
further reducing the incidence of false positives (James et al., 1996). In addition to the 
nutritional selection, the use of the MEL1 reporter provides further stringency to the 
system as false positives that may arise through activation of the ADE2 or HIS3 genes 
can be identified as they will fail to activate the MEL1 reporter. Also the MEL1 reporter 
provides a measure of the amount of transcription between a bait protein and a library 
protein allowing for the comparison of interaction strengths between the bait and 
different library proteins. Finally, in addition to the reporter genes, AH109 yeast carry 
mutations in the trp1 and leu2 marker genes allowing for selection of the plasmids used 
in the two-hybrid screen. The trp1 mutation is complemented by the TRP1 gene in the 
pGBKT7 bait expression vector whilst the leu2 mutation is complemented by the LEU2 
gene in the pGADT7Rec library expression plasmid (James et al., 1996). 
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6.1.5  Construction of the cDNA Library 
The cDNA library is constructed using BD SMART (Switching Mechanism at 5‘ end of 
RNA  Transcript) technology (Zhu et al., 2001). For first-strand cDNA synthesis, 
MMLV (Moloney Murine Leukaemia Virus) Reverse Transcriptase (RT) is used to 
transcribe poly A
+ RNA into DNA using a modified oligo(dT) primer, the BD 
Matchmaker CDS III Primer (Appendix 2). When MMLV RT reaches the 5‘ end of 
the mRNA, the enzyme￿s terminal transferase activity adds a few deoxycytidine (dC) 
nucleotides. The 3‘ end of the BD SMART III oligonucleotide (Appendix 2) anneals 
with this dC stretch forming an extended template. RT then switches templates and 
replicates the oligonucleotide, resulting in a single stranded (ss) cDNA containing the 
complete 5‘ end of the mRNA template as well as the sequence complementary to the 
BD SMART III oligonucleotide, the anchor. This anchor, together with the modified 
oligo(dT) then serve as priming sites for long distance (LD) PCR (Chenchik et al., 
1998), where only the ss cDNAs with a SMART anchor at their 5‘ ends are amplified, 
eliminating amplification of incomplete cDNA thereby generating a higher percentage 
of full-length double stranded (ds) cDNA (Figure 6.2).  
 
To produce the ds cDNA library, the ss cDNA is amplified by LD PCR using the BD 
Advantage 2 Polymerase Mix. This polymerase mix consists of a nuclease deficient N-
terminal deletion of Taq DNA polymerase, BD TITANIUM Taq DNA Polymerase, 
together with BD TaqStart Antibody which provides an automatic hot-start PCR 
(Kellogg et al., 1994). Proofreading polymerase is also included in the polymerase mix 
to increase the fidelity of amplified DNA (of up to 20Kb) (Barnes, 1994).  
 
6.1.6  pGADT7-Rec GAL4 AD Expression Plasmid and Library Screening 
The library plasmid used for the expression of the AD fused cDNA proteins is 
pGADT7-Rec (Figure 3.7). This plasmid is a high copy plasmid containing the LEU2 
marker and has been engineered with the BD SMART III and CDS III sequences (Zhu 
et al., 2001) to utilise the homologous recombination system in yeast (Figure 6.3A). 
With recombination mediated cloning the yeast are co-transformed with SmaI linearised 
pGADT7-Rec and the ds library cDNA, which then recombine in vivo to form a closed 
circular expression plasmid that expresses the cDNA insert as a GAL4 AD fusion 
protein that can be selected for by plating transformants on media lacking leucine.  Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
  204
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amplification by LD-PCR 
Template switching and 
extension by RT
5‘ Poly A 3‘ 
CDS III oligo(dT) primer
First strand synthesis 
coupled with dC tailing by RT 
5‘  Poly A  GGGG
CCCC
BD SMART III 
oligonucleotide 
5‘  Poly A  GGGG
CCCC
ds cDNA with BD SMART III
& CDS III anchors
Figure 6.2 cDNA library construction. An oligo(dT) CDS III primer is used for first-
strand synthesis from poly A
+ mRNA. When reverse transcriptase (RT) reaches the
5‘ end of the mRNA, the enzyme adds a few deoxycytidines (dC). The 3‘ end of the
SMART III oligonucleotide anneals with the dC stretch forming a template for RT.
The resultant single stranded cDNA is complementary to the mRNA template as well
as the CDS III and SMART III oligos that serve as priming sites for LD-PCR. LD-
PCRs result in double stranded cDNA products that have BD SMART III and CDS
III anchors enabling ligation into the pGADT7-Rec library expression vector. Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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Figure 6.3 Yeast two-hybrid library screen. (A) When co-transformed into yeast the
pGADT7-Rec plasmid is restored to its circular form by yeast enzymes using the
homologous sequences at the cDNA ends to produce a GAL4 AD fused with a
cDNA encoded protein expression plasmid. (B)  Double stranded cDNA, the
linearised GAL4 AD plasmid pGADT7-Rec and the GAL4 DNA-BD bait plasmid
pGBKT7 are co-transformed into the AH109 yeast reporter strain where the cDNA
recombines with homologous sequences in pGADT7-Rec. Transformants are then
screened for two-hybrid interactions by plating on selective medium lacking adenine,
histidine, leucine and tryptophan. 
(A) 
(B) 
Library plasmid and 
LNCaP cDNA  recombine 
in vivo 
ds LNCaP cDNA with BD 
SMART III & CDS III anchors
X X 
GAL4AD LEU
Amp
r 
pGADT7-Rec 
library plasmid
MCS 
Kan
r
TRP 
GAL4BD 
FLJ22318 
bait protein 
Plate transformed yeast 
onto selective media 
Co-transform yeast cells with 
cDNA, linearised library plasmid 
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To perform the library screen, the cDNA library is introduced into the AH109 yeast in a 
large co-transformation with the bait protein to obtain many transformed cells. Those 
cells that contain library plasmids encoding proteins that interact with the bait protein 
are then selected by plating on minimal media lacking adenine, histidine, leucine and 
tryptophan (Figure 6.3B). Plasmid DNA is isolated from these cells, the cDNA inserts 
PCR amplified, sequenced and the insert sequences identified using Basic Local 
Alignment Search Tool (BLAST) analysis (Altschul et al., 1990). 
 
6.2 Results 
6.2.1   Yeast Two-Hybrid Analysis (I) 
6.2.1.1   RNA Isolation and cDNA Synthesis 
In order to generate a LNCaP cDNA library, poly A
+ RNA was isolated from 2 x 10
8 
LNCaP prostate cancer cells using an Ambion Poly(A) Pure mRNA purification kit 
and 240ng poly A
+ RNA was used in first-strand cDNA synthesis using an oligo d(T) 
primer (sections 3.5.1.1-3.5.1.2).  Following first-strand synthesis, duplicate 2µL 
aliquots of the reaction were amplified by long distance-PCR using an annealing 
temperature of 68°C and 24 PCR cycles, however no product was amplified (section 
3.5.2.1; Figure 6.4A). This may have been due to PCR under cycling, therefore the 
number of PCR cycles was increased to 26 then 29 cycles, however no amplified 
products were detected (results not shown).  
 
Since parallel reactions using human placenta poly A
+ RNA (positive control) were 
performed, producing ds cDNA of the expected size of 0.2kb to 2kb, the failure of 
LNCaP ds cDNA amplification may have been due to a low yield of first-strand cDNA 
synthesis (Figure 6.4A). These results indicated that the LNCaP poly A
+ RNA may have 
partially degraded prior to first-strand synthesis, therefore, new poly A
+ RNA was 
isolated from another 2 x 10
8 freshly cultured LNCaP cells and 152ng was used for 
first-strand cDNA synthesis (sections 3.5.1.1; 3.5.1.2). Following first-strand synthesis, 
a 2µL aliquot of ss cDNA was PCR amplified as described above, and a 2µL aliquot of 
the cDNA￿s was electrophoresed in a 1% agarose gel, resulting in identification of 
LNCaP cDNA products of ~0.2kb to 2kb (Figure 6.4B). To select for cDNA￿s in excess 
of 200bp, the amplified LNCaP cDNA was purified through a CHROMA SPIN+TE-
400 column and 5µL of the purified cDNA￿s were electrophoresed in a 1% agarose gel Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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Figure 6.4 cDNA synthesis from LNCaP poly A
+ mRNA. (A) Initial PCR using an 
annealing temperature of 68°C and 24 PCR cycles failed to amplify LNCaP cDNA.
(B) Using freshly isolated LNCaP poly A
+ RNA a smear of cDNA 0.2kb to 2kb was 
observed. (C) Electrophoresis of the purified LNCaP cDNA in preparation for cloning 
into pGADT7-Rec confirmed presence of products of ~0.2-2.0Kb. 
(A)  1  Human placenta cDNA (positive control) 
  2  PCR amplified LNCaP cDNA 
3 1Kb  Plus DNA Ladder 
 
(B)  1  Human placenta cDNA (positive control) 
2  PCR amplified LNCaP cDNA 
3 1Kb  Plus DNA Ladder 
 
(C)  1  Purified LNCaP cDNA 
2 1Kb  Plus DNA Ladder   
 
 ← 2.0Kb 
(A)  1     2      3  
← 2.0Kb 
 
← 2.0Kb
(B)  1     2      3   (C)  1      2  
← 0.2Kb
← 0.2Kb 
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resulting in identification of LNCaP cDNA products of ~0.2kb to 2kb (section 3.5.2.2; 
Figure 6.4C). Following purification, the LNCaP cDNA was stored at -20°C. 
 
6.2.1.2  Yeast Two-Hybrid Analysis 
For the initial yeast two-hybrid screen, AH109/pGBKT7-FLJ22318 yeast were made 
competent and a library scale transformation performed (sections 3.5.3; 3.5.6). To select 
for interacting proteins the transformation mixture was spread on SD/-His/-Leu/-Trp 
Triple Dropout Medium (TDO) and SD/-Ade/-His/-Leu/-Trp/X-α -Gal Quadruple 
Dropout Medium (QDO). SD/-Leu and SD/-Leu/-Trp media plates were included as 
controls for transformation efficiency. Following 4 days of incubation at 30°C the 
number of colonies growing on the SD/-Leu medium was ~1.2 x 10
4 which represented 
the number of transformants/3µg pGADT7-Rec. This was well below the number of 
expected transformants of >1 x 10
6/3µg pGADT7-Rec.
 The 1.65 x 10
4 colonies growing 
on the SD/-Leu/-Trp medium were also below the expected >5 x 10
5 clones 
screened/library and there was no growth observed on the QDO media. However, small 
colonies could be seen on the TDO media and these plates were incubated a further 3 
days to confirm that the colonies were true Ade
+ as Ade
+ colonies are robust, can grow 
to >2mm in diameter and are white in colour, whereas Ade
- colonies never grow more 
than 1mm in diameter and turn red on adenine limited medium. 
 
Following a total of 7 days of incubation, 77 true Ade
+ colonies were observed on the 
TDO media. In addition, growth of these colonies on the TDO media indicated the HIS3 
and ADE2 genes had been activated suggesting an interaction between FLJ22318 and a 
protein in the LNCaP library in each transformant. The 77 colonies were replica plated 
onto the more stringent QDO media to eliminate the most common class of false 
positives and glycerol stocks were prepared (section 3.5.7). Of the 77 colonies, all grew 
on the QDO medium demonstrating that all 3 reporter genes ADE2, HIS3 and MEL1 
had been activated. Plasmid DNA was isolated from these colonies and the AD/library 
inserts were PCR amplified using the ADLD primers (sections 3.1.3; 3.5.8; Appendix 
2). Amplified products were then visualised in 1% agarose gels to screen for multiple 
AD/library plasmids or inserts and to determine insert sizes (Figure 6.5). 
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←  1Kbp 
←  2Kbp 
←  0.5Kbp 
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←  0.5Kbp
  (A)   (B)  1  2  3   4   5  6  7  8  +   -  M 
←  1Kbp 
←  2Kbp 
←  0.5Kbp 
←  1Kbp 
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  (E)   (F)
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Figure 6.5 PCR screen of AD/library inserts from pGADT7-Rec to ascertain insert size
and to check for multiple AD/library plasmids in colonies. Plasmid DNA was isolated
from individual colonies, PCR amplified using ADLD primers and the amplified products
electrophoresed in 1% agarose gels.  
(+)  AD-large T antigen (positive control) 
(− )  ddH2O (negative control) 
(M)  1Kb Plus DNA Ladder 
 
(A)  1-8  AD/library insert clones 1-8 
  
(B) 1-8 AD/library  insert  clones  9-16 
  
(C)  1-8  AD/library insert clones 17-24 
   
(D)  1-8  AD/library insert clones 25-32 
  
(E) 1-8 AD/library  insert  clones  33-40 
  
(F)  1-8  AD/library insert clones 41-48 
  
(G)  1-12  AD/library insert clones 50-55, 57-59, 61, 63-64 
  
(H)  1-12  AD/library insert clones 65-76 
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AD/library inserts 2, 3, 8, 9, 11, 13, 48, 53, 63 and 65 were selected for initial analysis 
as these represented larger products or products of a size that was common to multiple 
clones. The PCR products for these inserts were purified and sequenced using the 
ADLD sense primer (sections 3.1.5; 3.4), then analysed using BLAST. Of the 10 
sequences analysed (Table 6.1), 9 were found to encode for proteins that are commonly 
recorded as false positives in yeast two-hybrid screens whilst the remaining sequence 
was found to encode a portion of the 3‘ UTR of C6orf48, a protein of unknown 
function. Due to the high rate of detection of false positive clones and the initial poor 
growth of colonies in the yeast two-hybrid analysis it was decided to repeat the library 
screen. 
 
6.2.2  Yeast Two-Hybrid Analysis (II) 
6.2.2.1  RNA Isolation and cDNA Synthesis 
For the second yeast two-hybrid screen, poly A
+ RNA was isolated from 1.2 x 10
8 
freshly cultured LNCaP cells using a Ambion Poly(A) Pure mRNA purification kit 
and 312ng poly A
+ RNA was used in first-strand cDNA synthesis (sections 3.5.1.1- 
3.5.1.2). Following first-strand synthesis, 4 x 1µL aliquots of ss cDNA were LD-PCR 
amplified using an annealing temperature of 68°C and 20 PCR cycles resulting in 
LNCaP cDNA products of ~0.1kb to 2kb (section 3.5.2.1; results not shown). Amplified 
LNCaP cDNA was then purified through a CHROMA SPIN+TE-400 column and a 5µL 
aliquot visualised in a 1% agarose gel producing a smear of approximately 0.2kb to 2kb 
(section 3.5.2.2; Figure 6.6). The purified LNCaP cDNA was then stored at -20°C until 
the repeat yeast two-hybrid screen was performed. 
 
6.2.2.2  Yeast Two-Hybrid Analysis 
For the repeat yeast two-hybrid screen, AH109/pGBKT7-FLJ22318 yeast were made 
competent, a library scale transformation performed and interacting proteins selected as 
previously described (sections 6.2.1.2; 3.5.3; 3.5.6). Following 6 days of incubation at 
30°C, the number of transformants/3µg pGADT7-Rec was ~0.54 x 10
6 which was again 
below the number of expected transformants of >1 x 10
6/3µg pGADT7-Rec as was the 
total of 4.2 x 10
5 clones screened/library which was expected to be >5.0 x 10
5 clones 
screened/library. However, there was growth of 6 colonies on the QDO media and 
growth of 73 colonies on the TDO media, all of which were replica plated onto QDO 
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Figure 6.6 PCR amplification of LNCaP cDNA using poly A
+ RNA for the repeat yeast
two-hybrid screen. LNCaP cDNA was amplified using an annealing temperature of 68°C
and 20 PCR cycles then purified producing a product of approximately 0.2Kb to 2Kb.  
  1  Human placenta cDNA (positive control) 
  2  Purified LNCaP cDNA 
 3  1Kb  Plus DNA Ladder 
←  0.2Kb 
←  2.0Kb 
         1    2    3Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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media and incubated for a further 6 days. Following 6 days of incubation, Q6, T8, T13, 
T22 and T36 failed to re-grow and no further analysis was performed for these clones. 
Of the remaining 5 QDO and 69 TDO colonies, all re-grew on the QDO media and 
glycerol stocks of the yeast clones were prepared (section 3.5.7). Plasmid DNA was 
isolated from the 74 colonies and the AD/library inserts were PCR amplified as 
previously described (section 3.1.3; Figure 6.7). Insert sizes of less than 1000bp 
predominated with the majority of inserts ranging in size from 650bp to 950bp (Figure 
6.7). 
 
No further analysis was carried out for clones T18, T57 and T79 as they were found to 
contain multiple AD/library inserts. The PCR amplified AD/library inserts for the 
remaining clones were purified (section 3.1.5), sequenced using the ADLD sense primer 
(section 3.4) and analysed using BLAST. Of these 71 sequences, BLAST analysis 
identified 21 clones with inserts that had homology to either genomic DNA or in the 
case of 10 of these, homology to intronic regions of known genes. These inserts may 
represent false positives, as yet unidentified genes or alternatively spliced variants of 
known genes. Another 14 clones had inserts with homology to the 3‘UTR￿s of 10 
different proteins. This relatively high percentage (19%) may have been due to the use 
of an oligo(dT) primer when preparing the library cDNA instead of a random primer 
which would have resulted in a cDNA library with a greater representation of all 
portions of the gene, including amino-terminal and internal domains regardless of the 
mRNA secondary structure (Clontech, 2003). Analysis of the remaining 36 colonies 
identified inserts with homology to 33 different proteins with CKB, ATP5I and 
RPS15A each being identified twice. Four inserts (B2M, ATP5I, GEMIN7 and ARPC3) 
were found to contain complete ORF￿s with the remainder including between 10-91% 
of the ORF (Table 6.2).  
 
Of the 33 proteins identified, 5 were found to be ribosomal proteins which have been 
identified as common false positives in yeast two-hybrid analysis (Gietz et al., 1997). 
One protein, ATAD3B was found to be out of frame and was also considered to be a 
false positive and excluded from further analysis. Of the remaining, 6 proteins 
STOML2, Loc401396, YIPF3, RWDD2, THAP4 and GAGE4 had unknown functions, 
whilst the remaining 21 proteins could be organised into 6 functional groups using Gene  Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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← 1.0Kbp 
← 0.5Kbp 
← primer 
    dimers 
← 2.0Kbp
(H) 1  2   3   4  5   6  7  8  9 10   +
b -  M 
← 0.5Kbp 
← 2.0Kbp 
← 1.0Kbp 
← primer
    dimers 
 1   2    3   4    5   6    7   8    +
b  -   M  (G) 
← 1.0Kbp 
← 0.5Kbp 
← 2.0Kbp 
  1  2   3   4  5   6   7  8   9 10  +
b -   M  (I) 
← 2.0Kbp
← 0.5Kbp
← primer 
    dimers 
← 1.0Kbp 
(J) 1   2  3  4   5   6  7  8  9 10 11  +
b -  M 
← 2.0Kbp 
← 0.5Kbp
← primer
    dimers
← 1.0Kbp 
 1   2    3  4   5   6  7   8  9  10 11 12  +
b  -  M (K) Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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Figure 6.7 PCR screen of AD/library inserts from pGADT7-Rec. Plasmid DNA was
isolated from individual colonies, PCR amplified using ADLD primers and the amplified
products electrophoresed in 1% agarose gels to ascertain the insert size and to check for
multiple AD/library plasmids. pGADT7-Rec (200bp) or pGADT7-RecT containing an
AD-large T antigen fusion (2Kbp) were included as positive controls. (Q = clones isolated
on quadruple dropout medium, T = clones isolated on double dropout medium) 
(+
a)  AD-no insert (positive control)  
(+
b)  AD-large T antigen (positive control) 
(− )  ddH2O (negative control) 
(M)  1Kb Plus DNA Ladder 
 
(A)  1-5  AD/library insert clone Q1-Q5 
 
(B) 1-4 pGADT7-Rec  AD/library  insert  clone  T69-T72 
  
(C)  1-4  AD/library insert clone Q4, T35, T40, T54 
 
(D)  1-5  AD/library insert clone T11, T14, T25, T41, T68 
  
(E)  1-5  AD/library insert clone T45, T56, T59, T63, T76 
  
(F)  1-4  AD/library insert clone T10, T17, T33, T51 
  
(G)  1-8  AD/library insert clone T27, T32, T38, T47, T52-T53, T61, T67 
  
(H)  1-10  AD/library insert clone T7, T19, T12, T15, T29, T31, T34, T37, T60, T62 
  
(I)  1-10  AD/library insert clone T9, T16, T18, T20-T21, T23-T24, T26, T28, T30 
  
(J)  1-10  AD/library insert clone T39, T42-T44, T46, T48-T50, T52, T55, T57 
  
(K)  1-10  AD/library insert clone T58, T63-T66, T73-T79  
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Ontology (GO) terms assigned from the GO database (www.geneontology.org). These 
functional groups comprised 3 translational regulation and pre mRNA splicing proteins 
EEF1A1, MKNK2 and SNRPB, 3 cellular energy and transport proteins ATP5I, ETFA 
and IDH2, 2 cellular motility proteins ARPC3 and GEMIN7, 2 degradation proteins 
COPS4 and KLK3, 5 proteins involved in cellular metabolism CKB, ITPA, GAPDH, 
OAZ1 and ACLY and 6 transcriptional regulators B2M, MIF, RFXANK, NGFRAP1, 
NME2 and PRKRA. Of these proteins, a number have important functions involved in 
providing energy to the cell such as GAPDH which is an important enzyme in 
glycolysis, being the only oxidisable molecule in the glycolytic pathway. IDH2 and 
ACLY are both required for the tricarboxylic acid (TCA) cycle and ETFA is involved in 
electron transport. ITPA is involved in the metabolism of amino acids and OAZ1 the 
biosynthesis of polyamines and these are all cellular functions in which mitochondria 
have been shown to  play an important role (Becker et al., 1996). As IDH2 and ETFA 
are known mitochondrial proteins, a search of the mitochondrial proteome database 
(MITOP) which covers mitochondrial encoded proteins from Saccharomyces 
cerevisiae,  Mus musculus,  Caenorhabditis elegans,  Neurospora crassa and Homo 
sapiens (http://www.mips.biochem.mpg.de/proj/medgen/mitop) was undertaken to see 
whether any of the other proteins isolated in the in the yeast two-hybrid screen also had 
associations with mitochondria. 
 
Interestingly, this search identified 9 additional proteins as being associated with 
mitochondria. Of these, the nucleoside diphosphate kinase NME2 has been isolated 
from both human and mouse mitochondrial proteomes as has the glycolytic protein 
GAPDH and STOML2, one of the proteins of unknown function (Mootha et al., 2003; 
Taylor et al., 2003). Although GAPDH is regarded as a cytoplasmic glycolytic enzyme, 
the isolation of this protein from both mouse and human mitochondrial proteomes 
would suggest that this protein could be dual-targeted, reflecting its presence in multiple 
compartments. This is the case with Arabidopsis glycolytic enzymes which are found 
both in the cytoplasm and are functionally associated with the outer membrane of plant 
mitochondria (Giegĕ et al., 2003). A study showing that GAPDH may electrostatically 
associate with the mitochondrial outer membrane due its basic pI value lends support to 
this theory (Hartmann et al., 1993). Also, since glycolysis produces pyruvate which 
feeds into the TCA cycle in the mitochondrial matrix it would be biologically relevant 
for glycolytic enzymes to be in close proximity to the mitochondrion. Other proteins Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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that were isolated from mouse liver, brain, heart and kidney mitochondria were creatine 
kinase brain, ATP5I and OAZ1 (Mootha et al., 2003), and from human heart 
mitochondria the translation factor EEF1A1 (Taylor et al., 2003). In addition, OAZ1 has 
recently been shown to be involved in substrate delivery to the proteasome 
(Palanimurugan et al., 2004). Also of note, was the isolation from mouse mitochondria 
of subunits 2 and 6 of the COP9 signalosome, a multi-protein complex of the ubiquitin-
proteasome pathway that shares structural similarity with the 26S proteasome lid 
complex. Both of these sub units, COPS2 and COPS6 have been shown to interact with 
the COPS4 sub unit (Schwechheimer, 2004) although the functional significance of this 
has yet to be determined. Literature based searches of the remaining proteins revealed a 
mitochondrial association with 4 more proteins, RFXANK which is part of a complex 
containing the mitochondrial pro-apoptotic proteins caspase-9 and procaspase-3 
(Patriotis et al., 2001), NGFRAP1 which interacts with Smac, a protein released from 
the mitochondria during apoptosis and which promotes caspase activation (Yoon et al., 
2004), PRKRA which associates with replicating mitochondria (Kim et al., 2004a) and 
ARPC3 whose yeast orthologue arc18p associates with mitochondria in budding yeast  
(Fehrenbacher et al., 2005). Although the remaining 7 proteins along with FLJ22318 
were not identified as being associated with the mitochondria it has been estimated that 
there are 1500 human mitochondrial genes and proteins of which only 615 have been 
identified to date (Taylor et al., 2003). 
 
6.2.2.3  Yeast Two-Hybrid Analysis Controls 
Small scale yeast control co-transformation procedures were also performed in parallel 
to the library screens using pGADT7-RecT (Figure 6.8A), which encodes a fusion 
between the GAL4 AD and SV40 large T-antigen, and the positive control vector 
pGBKT7-53 which encodes a fusion between the GAL4 DNA-BD and murine p53 
(Figure 6.8C) and the negative control vector pGBKT7-Lam (Figure 6.8B). In the 
AH109 yeast, pGBKT7-53 interacts with SV40 large T-antigen whereas pGBKT7-Lam 
which encodes a fusion of the DNA-BD with human lamin C does not interact with 
either SV40 large T-antigen or most other proteins and therefore controls for false 
interactions between either the pGADT7-RecT control or an AD/library plasmid. For 
both the initial and repeat yeast two-hybrid screens, AH109 yeast cells were made 
competent and a small-scale yeast transformation performed (sections 3.5.3-3.5.4). To 
confirm that the pGBKT7-53/pGADT7-RecT and pGBKT7-Lam/pGADT7-RecTChapter Six ￿ Isolation of FLJ22318 Binding Partners 
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Figure 6.8 Vector maps of the Yeast-2 Hybrid control vectors (A) pGADT7-RecT is
a product of recombination that encodes a fusion of the SV40 large T antigen and the
GAL4 AD. (B) pGBKT7-lam is a negative control plasmid that encodes a fusion
protein of the human lamin C protein and the GAL DNA-BD.  Yeast co-transformed 
with pGADT7-RecT and pGBKT7-lam provide a measure of the background that is 
due to false positive two-hybrid interactions as Lamin C does not interact with most
proteins including pGADT7-RecT. (C) pGBKT7-53 is a positive control plasmid 
that encodes a fusion protein of the murine p53 protein and the GAL4 DNA-BD 
(www.clontech.com).  
(C)
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plasmids had been successfully transformed, the transformation mixture was spread on 
SD/-Leu/-Trp Double Dropout Medium (DDO), whereas to select for co-transformants 
expressing interacting proteins the transformation mixture was spread on QDO media 
plates. Following 6 days of incubation at 30°C, growth of white colonies were seen on 
the DDO media plates for both the pGBKT7-53/pGADT7-RecT and pGBKT7-
Lam/pGADT7-RecT plasmids, whereas growth of blue colonies was only observed on 
the pGBKT7-53/pGADT7-RecT QDO media plates (results not shown). This indicated 
that both the positive and negative control plasmids had been successfully transformed 
and that only the proteins encoded by the positive control plasmids pGBKT7-53 and 
pGADT7-RecT had interacted as expected.  
 
6.3 Discussion 
In this study a GAL4 based yeast two-hybrid system was used to identify proteins 
which interacted with the novel hypothetical protein FLJ22318. This in vivo method 
was chosen as it is often more sensitive and may therefore be more suited for detecting 
weak or transient and unstable interactions that may not be biochemically detectable, 
but which nonetheless are critical for the proper functioning of complex biological 
systems (Estojak et al., 1995). 
 
Lower than expected transformation efficiencies were seen in both the initial and repeat 
yeast two-hybrid screens and this may have occurred as a result of FLJ22318 interacting 
weakly or transiently with the other proteins. In these instances the time taken for the 
HIS3 reporter to be expressed as a result of a two-hybrid interaction and for the gene 
product to accumulate may not have allowed enough of the gene product to accumulate 
in the cells to permit survival of co-transformants plated directly onto TDO medium 
lacking His. Therefore, a HIS3 ￿jumpstart￿ may have resulted in a greater number of 
positive transformants. Plating the transformation mixture onto DDO and selecting for 
the FLJ22318 and the AD/library plasmids first may have been a better strategy as this 
would have allowed higher levels of the fusion protein and the HIS3 gene product to be 
expressed before replating on the TDO and QDO medium. Also the lower than expected 
transformation efficiencies may have been due to a recovery step performed in YPD 
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manufacturer on their website (www.clontech.com/clontech/techinfo/faqs/MMTechTip. 
shtml#GAL4) suggest elimination of this recovery step and plating of the 
transformation mixture on DDO medium to avoid loss of the DNA/bait vector in some 
of the cells which would reduce transformation efficiencies resulting in fewer colonies 
being isolated. 
 
Only 3 proteins were identified more than once as interacting with FLJ22318 and 
although a known partner, NKX3-1, was not identified, with a 2.5Kb 3’UTR, it is 
unlikely that generation of the LNCaP cDNA library using oligo dT primers would have 
resulted in amplification of the NKX3-1 coding region and therefore detection in this 
assay. Data from 64 successful yeast two-hybrid screens has shown that although 
partners were known for 30 bait proteins prior to screening, only 11 of the screens 
identified previously known partners whereas 19 yeast
  two-hybrid analyses identified only novel partners 
(www.fccc.edu/research/labs/golemis/InteractionTrap/InWork.html). A number of 
studies have also reported that interactions which were originally identified only once in 
a yeast two-hybrid screen were true interactors as confirmed by subsequent methods. A 
recent example is HOXB2 which was one of 10 individual clones isolated in a yeast 
two-hybrid screen as binding to the cell proliferation regulator p205 (Asefa et al., 2006). 
A relatively high number of the proteins identified in the present screen have 
associations with mitochondria, and mitochondria-associated proteins along with 
ribosomal proteins have been reported to occur as false positives in yeast two-hybrid 
screens, although with a lesser frequency. However, the interacting proteins identified in 
this study are also involved in cellular metabolism and energy production as well as 
protein ubiquitination, degradation and programmed cell death, pathways (and proteins) 
which can function both in association with and independently of the mitochondria 
(Kim and Dang, 2005; Yang and Yu, 2003). These results are consistent with the 
reported functions of proteins that have a similar domain structure to that of FLJ22318 
including the yeast homologue of FLJ22318, RMD5. 
 
Two of the proteins involved in cellular metabolism isolated in this study are the 
enzymes ACYL and IDH2, which are required for the oxidation of citrate in the 
tricarboxylic acid (TCA) cycle. As citrate metabolism in both normal prostate cells and 
prostate cancer cells differs from other cells, the isolation of these proteins maybe Chapter Six ￿ Isolation of FLJ22318 Binding Partners 
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significant. Normal prostate peripheral zone secretory epithelial cells produce an 
approximate 40 fold increase in citrate production compared to other cells in the body. 
However, the majority of this citrate is not oxidised and instead is secreted from the 
cells (Costello et al., 2005). In addition, unlike other cells, the high levels of citrate 
would be expected to inhibit glycolysis through the regulation of phosphofructokinase 
(PFK) however this is not the case and prostate cells exhibit a high level of aerobic 
glycolysis, suggesting that the regulation of PFK in these cells and its effect on 
glycolysis are unique (Costello and Franklin, 1997). The accelerated utilisation of 
glucose in these cells also results in the synthesis of citrate through the production of 
acetyl-coA. The high level of aerobic glycolysis combined with a truncated TCA cycle 
should result in a ~65% decrease in ATP production in these cells. However, prostate 
cells exhibit the same levels of ATP as other cells suggesting the existence of 
alternative metabolic pathways (Costello and Franklin, 1997). At present, these 
pathways and the proteins involved remain unknown. In addition to the high levels of 
citrate seen in prostate cells, zinc levels are also high and in these cells prevents the 
oxidation of citrate by inhibiting aconitase. Furthermore, the cellular accumulation of 
zinc has been shown to inhibit cellular proliferation by apoptosis through a zinc-
mitochondrial interaction, which has only been documented in citrate producing 
prostate cells and does not occur elsewhere in the body (Costello et al., 2005).  
 
In contrast to normal cells, malignant prostate cells exhibit a decrease in aerobic 
glycolysis, have low levels of citrate and transform from citrate producing to citrate 
oxidising cells with a fully functional TCA cycle (Costello and Franklin, 1997). This is 
in contrast to other mammalian cancer cells which generally transform from energy-
efficient, citrate oxidising cells to energy-inefficient citrate producing cells with a 
truncated TCA cycle, and in these cells the citrate is then transported to the cytoplasm 
for metabolism to acetyl-coA for lipogenesis, a process essential for cancer cell 
proliferation (Costello and Franklin, 1997). In addition to the low levels of citrate seen 
in malignant prostate cells, the level of zinc also falls, which in turn has been shown to 
inhibit apoptosis (Costello et al., 2005). 
 
As malignant prostate cells exhibit a decrease in aerobic glycolysis, the isolation of 
GAPDH in conjunction with ACLY and IDH2 suggest that FLJ22318 is involved in the 
regulation of cellular metabolism. On the other hand, GAPDH has recently been shownChapter Six ￿ Isolation of FLJ22318 Binding Partners 
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 to function as part of a co-activator complex responsible for the S-phase dependent 
trans-activation of the histone H2B gene where it was proposed that GAPDH integrated 
energy metabolism with cell cycle regulation (Zheng et al., 2003). The role of GAPDH 
in regulating cellular proliferation has been suggested by several other studies, which 
reported it to be a target for an anti-proliferative bacterial agent, anti-cancer nucleoside 
analogues and when over-expressed in COS-7 cells, GAPDH has also been shown to 
induce apoptosis (Kim and Dang, 2005).  
 
Integration between cellular metabolism and cellular proliferation is also well-
characterised and is supported in this study by the isolation of proteins involved in both 
pathways. One of these proteins, ETFA is involved in generating mitochondrial 
membrane potential and disruptions to this mitochondrial membrane potential can result 
in the induction of programmed cell death through the release of pro-apoptotic proteins 
into the cytoplasm (Bras et al., 2005).  Therefore the isolation of RFXANK and 
NGFRAP1, which have been shown to interact with these pro-apoptotic proteins 
(Patriotis et al., 2001; Yoon et al., 2004), maybe significant as may the isolation of 
PRKRA which has also been implicated in apoptotic cell death (Gupta and Patel, 2002).  
 
It is now understood that programmed cell death pathways, classified as type I 
(apoptosis), type II (autophagic) or type III (necrosis-like) are most likely all linked 
through shared signalling pathways, with the mitochondria having a major role in 
integrating these cell death signals (Bras et al., 2005). At present however, there is little 
information on the proteins or pathways involved in the communication of mitochondria 
with the cytoplasm and nucleus. 
 
As cancer develops when molecular pathways that control cellular proliferation and/or 
programmed cell death are deregulated, with a reduction in autophagic activity and 
resistance to apoptosis being common occurrences, the identification of proteins 
involved in these processes is of particular importance, especially as it is the acquisition 
of apoptosis resistance that leads to treatment resistance seen in advanced prostate 
cancer. In androgen responsive prostate cancer cells, androgens down regulate the 
expression of the pro-apoptotic protein Bax whilst the increased expression of the anti-
apoptotic protein Bcl-2 is linked to the survival of prostate cancer cells following 
androgen ablation therapy (McKenzie and Kyprianou, 2006). Both Bax and Bcl-2 haveChapter Six ￿ Isolation of FLJ22318 Binding Partners 
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 been identified as targets for ubiquitination and it is now known that the ubiquitination 
and proteasomal degradation pathway regulates numerous apoptosis associated proteins, 
a process that can contribute to the apoptosis resistance seen in cancer (Zhang et al., 
2004). 
 
For protein degradation to occur, activated ubiquitin is transferred to a target protein by 
a ubiquitin E3 ligase which can function as a single protein or as part of a multi-protein 
complex (Lee and Peter, 2003). Currently there are 2 known types of E3 ligases defined 
as either ￿homologous to E6-AP carboxyl terminus￿ (HECT) or ￿really interesting new 
gene￿ (RING) domains of which the RING domain family comprise the majority. 
However, of the ~200 RING domain family proteins in mammalian cells the majority 
remain uncharacterised (Yang and Yu, 2003). Once ubiquitinated, the target protein is 
degraded by the proteasome and although the mechanism of target protein delivery to 
the proteasome remains unknown, it is thought to require chaperone molecules which 
facilitate proteasome degradation (Yang and Yu, 2003). 
 
As well as degradation by the proteasome, the regulation of cullin containing ubiquitin 
E3 ligases has recently been attributed to the COP9 signalosome. Cullin proteins act as 
scaffold proteins for E3 ligases and in this degradation pathway deneddylation of cullins 
is required for protein degradation to occur (Richardson and Zundel, 2005). As several 
of these cullin-mediated E3 ligases are implicated in cell cycle control and apoptosis 
(Willems et al., 2004) the identification of a component of the COP9 signalosome 
together with potential components of the 26S proteasome lends support to FLJ22318 
being involved in ubiquitin mediated protein degradation.  
 
Further support that FLJ22318 functions as a component of ubiquitin mediated protein 
degradation is provided by the S. cerevisiae protein RMD5. FLJ22318 is 1 of 2 
orthologues of RMD5 and as such may be predicted to have a similar function. In yeast, 
RMD5 has been shown to be part of a large protein complex with a molecular mass of 
at least 600kDa. This complex consists of 8 proteins, 7 of which are required for the 
catabolite degradation of fructose-1,6-bisphosphatase (FBPase). Within this complex, 
RMD5 was specifically required for the ubiquitination of  FBPase and is required for 
the proteasome dependent degradation of FBPase  (Regelmann et al., 2003). More 
importantly as FBPase is degraded when the cell switches from anaerobic respiration toChapter Six ￿ Isolation of FLJ22318 Binding Partners 
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 aerobic respiration, if FLJ22318 has a similar role in mammalian cells, results from this 
study may provide a link between glycolytic PFK and gluconeogenic FBPase regulation 
in prostate cancer cells. Finally, other proteins containing a LisH domain, such as 
TBL1X, have been shown to recruit the ubiquitin-proteasome complex to nuclear 
receptor-regulated transcription factors. Therefore FLJ22318 may have a role in 
recruiting the ubiquitin-proteasome complex to transcription factors including NKX3-1 
which is positively regulated by androgen receptor and whose degradation has recently 
been shown to be mediated by the ubiquitin-proteasome pathway (Lei et al., 2006). 
 
As the yeast two-hybrid screen identified 6 candidate FLJ22318 interacting proteins that 
can act as transcriptional regulators, and FLJ22318 exhibited transcriptional regulatory 
activity on an NKX3-1 responsive element in the absence and presence of NKX3-1, it 
was decided to further investigate one of these proteins. The 6 transcriptional regulators 
isolated in the yeast two-hybrid screen were B2M, MIF, RFXANK, NGFRAP1, NME2 
and PRKRA (Table 6.2). As PRKRA is a multifunctional protein with widespread 
expression and is involved in apoptosis and cellular proliferation, the interaction 
between PRKRA and FLJ22318 was examined in several preliminary studies carried 
out at the end of this thesis project.  
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Chapter Seven ￿ Analysis of PRKRA: A Candidate FLJ22318 
Binding Partner 
 
7.1 Introduction 
Protein kinase, interferon-inducible double stranded RNA dependent activator 
(PRKRA; PACT) was one of six transcriptional regulators isolated as a putative 
FLJ22318 binding partner using yeast two-hybrid analysis. Several features of PRKRA 
make it an interesting candidate for further study. PRKRA comprises 313 amino acids 
and contains three proposed protein-protein interaction domains, the first two resemble 
dsRNA binding motifs (dsRBM) whilst the 3
rd domain comprising 66 amino acids 
remains largely uncharacterised (Li et al., 2006a). The PRKRA protein fragment 
isolated in this study encoded the C-terminal 175 amino acids which encompasses 73% 
of the 2
nd dsRBM and the entire 3
rd protein-protein interaction domain. Like NKX3-1, 
PRKRA is also involved in regulating cellular proliferation and apoptosis and to date is 
the only known protein activator of eukaryotic translation initiation factor 2-alpha 
kinase 2 (EIF2AK2; PKR; Li et al., 2006a).  Activation of EIF2AK2 requires the 3
rd 
domain of PRKRA which upon binding to the kinase domain of EIF2AK2 causes a 
change from a closed/inactive to an open/active conformation. Binding of either of the 
remaining domains to EIF2AK2 was also required in addition to the 3
rd domain 
although the function of these domains was not clear (Li et al., 2006a). 
 
EIF2AK2 is a ribosomal protein which is activated by phosphorylation, it is thought 
after release from the ribosome, and is involved in regulating a variety of cellular 
functions including host anti-viral defences, differentiation, cellular proliferation and 
apoptosis (Ruvolo et al., 2001). PRKRA has been shown to activate EIF2AK2 in the 
absence of dsRNA produced by viral infection and in uninfected cells activates 
EIF2AK2 in response to a number of cell stresses including serum starvation, growth 
factor withdrawal or ceramide treatment (Ruvolo et al., 2001; Yang et al., 2003).  
 
Studies using RAX, the mouse homologue of PRKRA, indicated that under cellular 
stress PRKRA is phosphorylated which precedes EIF2AK2 activation and induction of 
apoptosis (Ito et al., 1999). In the presence of growth factors such as IL3 however, the 
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unphosphorylated and expression of both PRKRA and EIF2AK2 is very low (Ito et al., 
1999). These findings are in agreement with other studies which show that PRKRA is 
expressed at very high levels in mouse epithelial cells of the colon as they exit the cell 
cycle and enter the apoptotic pathway. Expression of phosphorylated PRKRA was 
found to coincide with differentiating cells and was increased as cells moved towards 
the luminal surface and underwent apoptosis (Gupta and Patel, 2002). Exogenous 
expression of unphosphorylated PRKRA in proliferating cells was also found to be 
insufficient to activate EIF2AK2 and induce apoptosis (Ito et al., 1999). More recently, 
expression of an inactive unphosphorylated PRKRA mutant was shown to increase cell 
growth and promote cellular transformation (Bennett et al., 2006).  
 
PRKRA has also been shown to enhance SV40 T-Ag dependent DNA replication, 
independent of EIF2AK2 binding, as well as enhancing Newcastle Disease Virus 
(NDV) activation (Iwamura et al., 2001; Yang et al., 2003). Expression of NDV 
together with PRKRA resulted in increased activation of the IFN-β  gene enhancer, 
which was mediated by NF-κ B activation and required binding of PRKRA to dsRNA 
although it is unknown which domain(s) of PRKRA were involved in this interaction 
(Iwamura et al., 2001). PRKRA was not shown to bind SV40 directly but was believed 
to regulate the interaction of AP1 with the SV40 enhancer (Yang et al., 2003). Due to 
the similarities between viral and mammalian DNA replication it was thought that 
PRKRA may also be involved in regulating mammalian DNA replication. 
 
PRKRA is associated with pre-micro RNA (miRNA) processing and is required for the 
accumulation of mature miRNAs (Lee et al., 2006). miRNAs are small RNAs that 
function in a variety of regulatory pathways including induction of mRNA degradation 
and translational repression which is commonly referred to as RNA silencing 
(Baulcombe, 2005). miRNA are transcribed from endogenous genes and then 
transported to the cytoplasm for processing into mature miRNAs by Dicer (Hutvagner 
et al., 2001; Kim, 2005; Lund et al., 2004). These small RNAs are then assembled into 
the RNA-induced silencing complex (RISC) by a variety of factors including Dicer, 
hAgo2 and TRBP. TRBP has a similar domain structure to PRKRA and binds to 
EIF2AK2 through its 3
rd domain, however, unlike PRKRA, TRBP has been shown to 
inhibit EIF2AK2 activation (Lee et al., 2006). PRKRA is also associated with RISC Chapter Seven ￿ Analysis of PRKRA: A Candidate FLJ22318 Binding Partner 
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where it is thought to contribute to the stabilisation of Dicer (Lee et al., 2006). 
Interestingly PRKRA binding to Dicer also required the 3
rd domain of PRKRA, 
although this domain was not required for PRKRA binding to hAgo2. As both TRBP 
and PRKRA are required for binding and inactivation/activation of EIF2AK2 it was 
thought that crosstalk may exist between the EIF2AK2 pathway and the RNA silencing 
pathway (Lee et al., 2006). As PRKRA promotes growth or induces apoptosis in other 
tissues/cells dependent on its phosphorylation status, the nature of FLJ22318 interaction 
with PRKRA will provide additional information regarding the function of FLJ22318 in 
prostate cancer cells. 
 
7.2 Results 
7.2.1  PRKRA Protein Expression in LNCaP Prostate Cancer Cells 
To investigate endogenous PRKRA expression in LNCaP prostate cancer cells, proteins 
were extracted from LNCaP cells, resolved by polyacrylamide gel electrophoresis then 
transferred to nitrocellulose membranes (sections 3.7.1-3.7.3). Following transfer, 
immunoreactive bands were detected by western blotting using rabbit or goat polyclonal 
anti-human PACT (PRKRA) antibodies of various concentrations (section 3.7.4). 
Benchmark pre-stained protein markers were run concurrently and used to generate 
standard curves. Molecular weight was plotted against mobility, from which the 
molecular weights of immunoreactive bands were determined. 
 
Use of the goat anti-PRKRA antibody at 1:200 and 1:500 dilutions in western blotting 
produced immunoreactive bands of ~34kDa with a less intense band detected at ~68kDa 
(Figure 7.1A,B). This (commercial) antibody also produced a very high background on 
the filters. Western blots using the rabbit anti-PRKRA antibody at 1:200 and 1:500 
dilutions also detected protein bands of ~34kDa and ~68kDa at a concentration of 1:200 
and 1:500 as well as two additional bands of ~41kDa and ~115kDa (Figure 7.1C,D). 
Based on these results, additional western blotting experiments utilised the rabbit anti-
PRKRA antibody while immunocytochemical analyses utilised the goat anti-PRKRA 
antibody as the antibody has been used previously for this application (Chen et al., 
2006).   
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Figure 7.1  Western blot analysis of representative LNCaP prostate cancer cell
lysates with anti-PRKRA antibodies to detect expression of endogenous PRKRA.
(A,B) Goat anti-PRKRA antibodies detected protein bands of ~34kDa, the predicted 
molecular weight of PRKRA, and another band of ~68kDa.  (C,D) Rabbit anti-
PRKRA antibodies also detected immunoreactive bands of ~34kDa and ~68kDa as
well as two additional bands of ~41kDa and ~115kDa. (A,C antibody dilution =
1:200; B,D antibody dilution = 1:500)  
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7.2.2  Cellular Localisation and Co-Localisation of PRKRA and FLJ22318 
As the cellular localisation of PRKRA has not been reported previously in prostate 
cancer cell lines, immunocytochemistry was performed in initial studies using 
antibodies directed against endogenously expressed PRKRA protein in LNCaP prostate 
cancer cells to optimise experimental conditions and to determine PRKRA cellular 
localisation (section 3.9.2). Control cells (no primary antibody) displayed background 
immunoreactivity (Figure 7.2A) whereas LNCaP cells immunostained with goat anti-
PRKRA antibodies displayed immunoreactivity at all antibody concentrations tested 
(Figures 7.2B-D).  
 
These results demonstrated that PRKRA was distributed throughout the cytoplasm of 
the cell, which is consistent with previous studies using HeLa human cervical 
carcinoma and HT1080 human fibrosarcoma cell lines that reported PRKRA to be a 
mostly cytoplasmic protein (Iwamura et al., 2001; Peters et al., 2001). In a proportion of 
cells, increased perinuclear accumulation of PRKRA was also detected in addition to 
the PRKRA cytoplasmic staining (Figure 7.2C). To further investigate PRKRA cellular 
localisation and its co-localisation with FLJ22318, confocal microscopy was undertaken 
using a 1:1000 dilution of the goat anti-PRKRA antibody.  
 
For the confocal microscopy studies, LNCaP cells were transiently transfected with 1µg 
of FLJ22318-pcDNA3.1/V5-His-TOPO vector (section 5.2.1.1.3) encoding FLJ22318-
V5 fusion proteins and the localisation and co-localisation of PRKRA and FLJ22318-
V5 were determined by confocal microscopy using antibodies directed against 
endogenous PRKRA and the V5 epitopes of the  FLJ22318-V5 fusion proteins (sections 
3.6.2; 3.11). As the LNCaP cell line is androgen responsive, confocal microscopy was 
also performed in transfected LNCaP cells that had been treated with 1nM DHT to 
determine whether androgens affected the cellular distribution of PRKRA or its co-
localisation with FLJ22318.  
 
Control cells (no primary antibody) displayed no immunoreactivity (data not shown). In 
the untreated and DHT treated cells FLJ22318 was distributed throughout the 
perinuclear and nuclear region of most cells consistent with previous results (section 
5.2.6; Figure 7.3A). In a proportion of cells, FLJ22318 was localised to the cytoplasmChapter Seven ￿ Analysis of PRKRA: A Candidate FLJ22318 Binding Partner 
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(B) (A) 
Figure 7.2 Localisation of PRKRA in LNCaP prostate cancer cells. (A) LNCaP cells 
treated with no primary antibody (negative control) exhibited background
immunoreactivity whereas cells treated with goat anti-PRKRA antibody at 
concentrations of 1:750 (B) 1:1000 (C) and 1:1500 (D) demonstrated cytoplasmic (• ) 
and perinuclear (♦ ) immunoreactivity. (Bar = 10µm). 
♦
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Figure 7.3 Cellular localisation of FLJ22318 and PRKRA in LNCaP prostate cancer
cells. LNCaP cells either untreated (i) or treated with 1nM DHT (ii) were transfected
with 1µg of pcDNA3.1-FLJ22318-V5 vectors and incubated for 24 hours to allow
expression of recombinant proteins. Cell nuclei were stained with DAPI (blue), anti-
V5  (red)  and anti-PRKRA (green)  antibodies then examined using confocal
microscopy. FLJ22318 exhibited a mainly nuclear and perinuclear localisation
although in a few cells FLJ22318 is localised to the cytoplasm (• ) and in these cells
very little FLJ22318 nuclear localisation is evident (A i; A ii). PRKRA exhibited a
predominantly cytoplasmic fluorescence (B i; B ii). (Bar =10µm). 
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(A)  i ii 
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and perinuclear regions of the cell with very little nuclear localisation evident and was 
punctate in appearance (Figures 7.3A; 7.4A).  Comparable to the immunocytochemistry 
results, PRKRA localised within the cytoplasm in both the untreated and DHT treated 
cells, however the immunoreactivity was punctate, rather than diffuse in appearance 
(Figures 7.3B; 7.4B). Results from these studies indicated that the localisation of both 
PRKRA and FLJ22318 was not altered in DHT-treated LNCaP cells. 
 
Extensive co-localisation of FLJ22318 and PRKRA was observed in those cells where 
FLJ22318 was localised to the cytoplasm and the perinuclear regions of the cell and in 
these cells co-localisation of FLJ22318 and PRKRA appeared to be predominantly 
cytoplasmic (Figure 7.4). To further investigate the localisation and co-localisation of 
FLJ22318 and PRKRA, a more detailed examination of a single cell was undertaken. 
For these studies, images of FLJ22318-V5 and PRKRA were taken at 1µM intervals 
through the cell and combined to produce a 3-D image. From the data collected, it was 
evident that FLJ22318-V5 and PRKRA are distributed throughout the cytoplasm and 
have a punctate pattern of fluorescence (Figure 7.5A, B). A proportion of FLJ22318 and 
PRKRA co-localise, predominantly in the perinuclear region of the cell in what appears 
to be discrete vesicles (Figure 7.5C). Data obtained from overlaying images in which 
the cell nuclei were coloured red determined that co-localisation of FLJ22318 and 
PRKRA does not occur in the nucleus (results not shown).  
 
7.2.3  GST Pull-Down Analysis 
Interaction between FLJ22318 and PRKRA was also investigated by GST pull-down 
assays using purified GST-FLJ22318 fusion proteins (section 3.8.3). Large scale 
production and purification of GST and GST-FLJ22318 fusion proteins was performed 
from 100mL bacterial cultures (section 3.8.3) and the proteins were purified from 
bacterial lysates using glutathione immobilised to sepharose. SDS-PAGE with 
Coomassie blue staining of gels was carried out to verify size and purity of the proteins 
(section 3.8.2) and fusion protein concentration was estimated by comparing GST and 
GST-FLJ22318 protein bands to BSA protein standards (Figure 7.6A). The 
concentration of GST protein was estimated to be 750ng/µL, whilst the concentration of 
GST-FLJ22318 protein was much lower at 150ng/µL (Figure 7.6A). 
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Figure 7.4 Co-localisation of FLJ22318 and PRKRA in LNCaP prostate cancer
cells. LNCaP cells either untreated (i) or treated with 1nM DHT (ii) were transfected
with 1µg of pcDNA3.1-FLJ22318-V5 vector and the co-localisation of FLJ22318
and PRKRA was detected by confocal microscopy using antibodies directed against
the V5 epitope (red) and endogenous PRKRA protein (green). FLJ22318 (A i; A ii)
and PRKRA (B i; B ii) displayed a cytoplasmic and perinuclear localisation, and
when the images were overlayed (C i; C ii), co-localisation (yellow) of FLJ22318
and PRKRA was predominantly cytoplasmic. (Bar =10µm). 
ii  i (C) 
i (A) 
i (B) ii 
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Figure 7.5 Analysis of FLJ22318 and PRKRA co-localisation in LNCaP prostate 
cancer cells. LNCaP cells were transfected with 1µg of pcDNA3.1-FLJ22318-V5 
vectors and incubated for 24 hours to allow expression of recombinant proteins. Cell 
nuclei were stained with DAPI (blue), anti-V5 (A, red) and anti-PRKRA (B, green)
antibodies, then examined using confocal microscopy. FLJ22318 and PRKRA
exhibited a cytoplasmic fluorescence that was punctate in appearance (A; B). When 
images were overlayed, co-localisation (yellow) of FLJ22318 and PRKRA was seen 
within discrete vesicles in the perinuclear region of the cell (C). (Bar =10µm). Chapter Seven ￿ Analysis of PRKRA: A Candidate FLJ22318 Binding Partner 
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Figure 7.6 GST-FLJ22318 pull-down assay. (A) Electrophoresis of purified GST-
FLJ22318 protein (~73kDa) and GST (~29kDa). Protein concentrations were
estimated in comparison to the BSA standards to be 150ng/µL (GST-FLJ22318) and
750ng/µL (GST). (B) GST-FLJ22318 immobilised to glutathione was incubated with
lysates from LNCaP cells which express endogenous PRKRA. The interaction
between FLJ22318 and PRKRA was detected by anti PRKRA western blotting in
protein precipitates incubated with GST-FLJ22318, but not in protein precipitates
that had been incubated with GST alone. 
(A)  1 Benchmark  Prestained Protein Ladder 
  2-5  BSA standard (0.5µg, 1.0µg, 2.0µg, 5.0µg) 
  6   IPTG induced GST-FLJ22318 expression ~73kDa (150ng/µL) 
  7  IPTG induced GST expression ~29kDa (positive control) 
 
(B)  1 Whole  cell  lysates 
  2  GST protein precipitates 
  3  GST-FLJ22318 protein precipitates 
 
←  ~29kDa  
BSA protein standard →   ←  ~73kDa 
 1       2      3      4       5      6       7  (A) 
WB anti-PRKRA  
←  PRKRA ~34kDa
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For the GST pull-down assays, 300µL aliquots of LNCaP prostate cancer cell lysates, 
chosen as LNCaP cells express endogenous PRKRA (section 7.2.1), were incubated 
with 15µg GST alone or GST-FLJ22318 immobilised to glutathione and protein 
complexes were precipitated following 18 hours of incubation (section 3.8.4). Proteins 
were separated by SDS-PAGE then transferred onto nitrocellulose filters and the 
interaction between FLJ22318 and PRKRA detected by western blotting using 
antibodies directed against PRKRA (section 3.7.4). PRKRA (34kDa) was detected in 
whole cell lysates and in protein precipitates incubated with GST-FLJ22318 (Figure 
7.6B), but was not detected in precipitates that had been incubated with GST alone 
(Figure 7.6B).  These findings supported an interaction between FLJ22318 and PRKRA 
although the weak intensity of the precipitated PRKRA protein band suggested that the 
interaction between FLJ22318 and PRKRA was of low affinity, that PRKRA was not a 
major FLJ22318 binding partner or that the experimental conditions required further 
optimisation.  
 
7.2.4  Co-immunoprecipitation of FLJ22318-pcDNA3.1/V5 and PRKRA 
To investigate the in vivo interaction of FLJ22318-V5 and PRKRA, FLJ22318-
pcDNA3.1/V5-His-TOPO constructs were transiently transfected into LNCaP prostate 
cancer cells which express endogenous PRKRA and FLJ22318-V5 complexes were 
immunoprecipitated 24 hours later using V5 antibodies and protein G  (sections 
5.2.1.1.3; 3.10). Following immunoprecipitation western blotting with PRKRA 
antibodies detected PRKRA in whole cell lysates, however PRKRA could not be 
confirmed as part of immunoprecipitated FLJ22318 complexes as protein G was of a 
similar size to PRKRA (results not shown). Therefore FLJ22318-pcDNA3.1/V5-His-
TOPO constructs were transiently transfected into LNCaP cells and FLJ22318-V5 
complexes were immunoprecipitated 24 hours later using V5 antibodies and protein A. 
Western blotting using V5 antibodies indicated very weak affinity for the FLJ22318-V5 
complexes for protein A (results not shown), which is consistent with the 
manufacturer￿s datasheets indicating that protein A binding to mouse antibodies is less 
than its binding to rabbit antibodies.  
 
Due to difficulties performing the experiments using the V5 antibody, FLJ22318-
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complexes were immunoprecipitated 24 hours later using rabbit anti-PRKRA 
antibodies. Following immunoprecipitation, western blotting using rabbit anti-PRKRA 
antibodies was performed, which detected PRKRA in whole cell lysates and in the lane 
containing immunoprecipitated proteins but not in control lysates ￿immunoprecipitated￿ 
without antibody (section 3.7; Figure 7.7A).  
 
Western blotting using anti V5 antibodies detected FLJ22318-V5 in whole cell lysates 
and in complexes immunoprecipitated with anti-PRKRA antibodies, findings which 
support an in vivo interaction between FLJ22318-V5 and PRKRA (section 3.7; Figure 
7.7B,C). However, nonspecific bands were also detected in control lanes of the the V5 
western blots which were of similar size to FLJ22318-V5 (~49-50kDa). While the 
bands can be distinguished on western blots, the quality of the results is insufficient to 
provide definitive evidence of PRKRA-FLJ22318-V5 co-immunoprecipitation. Further 
experiments using different PRKRA antibodies and alternatively tagged FLJ22318, or 
ideally, antibodies to endogenous FLJ22318 will be required to confirm these results.  
 
7.3 Discussion 
Of the six cDNA￿s classified as transcriptional regulators isolated in the yeast two-
hybrid screen as interacting with FLJ22318, PRKRA is unique in that it can bind 
dsRNA and is the only known protein activator of EIF2AK2, a serine/threonine kinase 
that is induced by interferons (IFN) or viral infection. PRKRA activation of EIF2AK2 
in vivo results in activation of the apoptotic pathway. 
 
In this study, antibodies to detect the expression of endogenous PRKRA protein in 
LNCaP prostate cancer cells reacted with distinct protein bands of approximately 
34kDa, 41kDa, 68kDa and 115kDa. Only one protein of 34kDa is published in the 
National Center for Biotechnology Information (NCBI) database (Accession
NP003681). According to AceView (www.ncbi.nlm.nih.gov/IEBResearch/Acembly/av)
however the PRKRA gene may produce 10 different protein isoforms by alternative 
splicing. Of these, isoform ￿a￿ has a predicted molecular weight of ~42kDa whereas 
isoform ￿b￿ has a predicted molecular weight of ~39kDa. As PRKRA expression is 
unknown in prostate cancer cells it is possible that the ~41kDa band observed in this
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Figure 7.7 Co-immunoprecipitation of FLJ22318-V5 and PRKRA. FLJ22318-V5
expression plasmids were transfected into LNCaP cells and cellular proteins were
immunoprecipitated with PRKRA antibodies using protein A sepharose. (A, B) In
the FLJ22318-V5 transfected cells, western blotting using anti-PRKRA and anti-
V5 antibodies detected PRKRA and FLJ22318 in the whole cell lysates and in
protein complexes immunoprecipitated with PRKRA antibody but not in protein
complexes precipitated using protein A sepharose alone. (C) FLJ22318-V5 was
not detected in untransfected (control) cells. (A,B Lane 1 ￿ film has been exposed
for a longer period of time compared to Lanes 2 and 3). 
  1  LNCaP whole cell lysate 
  2  IP: No antibody/Protein A 
 3  IP:  Anti-PRKRA/Protein  A 
IP: Anti-PRKRA 
←  FLJ22318-V5 ~49.4kDa
(B) 
          
          WB anti-V5 
    1                          2                           3 
(A) 
←  PRKRA ~34kDa 
WB 
anti-PRKRA 
    1                          2                           3 
(C) 
←  Nonspecific band ~50kDa 
      
          WB anti-V5 
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study represents one of the protein isoforms as predicted by AceView and the higher 
molecular weight bands may be multimers (dimers or trimers) of one of these isoforms. 
 
Comparison of the two predicted PRKRA mRNA￿s indicates that they encode proteins 
with an additional N-terminal exon to that of the reference protein 
(www.ncbi.nlm.nih.gov/IEB Research/Acembly/av.). Isoform ￿a￿ is predicted to localise 
to mitochondria and isoform ￿b￿ to the nucleus, suggesting that PRKRA isoforms if 
present may function in distinct subcellular compartments. The punctate appearance of 
PRKRA detected using confocal microscopy is consistent with a mitochondrial 
localisation, however further confocal microscopy studies using mitochondrial markers 
such as MitoTracker
  (Molecular Probes) would be required to determine whether 
PRKRA (or FLJ22318) co-localise with the mitochondria. In the case of isoform ￿a￿, the 
additional exon introduces several new putative phosphorylation sites including two for 
AKT (http://elm.eu.org).  
 
Reports of PRKRA ESTs in both normal and malignant tissues suggests expression of 
these transcripts, however the presence of alternative transcripts and potentially variant 
proteins have not been explored. Further investigation of PRKRA expression, including 
expression of tissue- or disease-specific isoforms will be required to determine whether 
the higher molecular weight proteins detected by western blotting of LNCaP cell lysates 
represent PRKRA isoforms. Use of PRKRA monoclonal antibodies rather than the 
polyclonal antisera used in the present study may also clarify results. Results using the 
commercially available goat anti-PRKRA antibodies have been reported in the literature 
for immunoblotting and immunohistochemistry studies however the immunoblot data 
was not shown (Chen et al., 2006). It is also noted that most in vitro studies of PRKRA 
have used transfected tagged PRKRA cDNA￿s with detection of the protein products 
performed using anti-tag antibodies (Lee et al., 2006; Ruvolo et al., 2001)  
 
Existence of PRKRA dimers has not been reported previously, however previous 
studies have shown that the 3
rd protein-protein interaction domain of PRKRA is able to 
oligomerise in vitro (Hitti et al., 2004). Whether PRKRA forms dimers or complexes 
with other proteins resistant to the weakly denaturing conditions used in the present 
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PRKRA, Xlrbpa, predominantly forms dimers in vitro and is thought to exist as a 
dimer/multimer  in vivo (Hitti et al., 2004), it is feasible that the multiple 
immunoreactive bands detected by western blotting represent PRKRA dimers or 
PRKRA-containing complexes. 
   
In this study localisation of PRKRA and co-localisation of PRKRA with FLJ22318 was 
predominantly cytoplasmic. This finding is consistent with previous studies that have 
reported the cellular localisation of PRKRA to be predominantly cytoplasmic, however 
in those studies endogenous and transfected PRKRA displayed a diffuse 
immunofluorescence throughout the cytoplasm (Iwamura et al., 2001; Lee et al., 2006). 
In the present study, PRKRA immunoreactivity appeared diffuse using 
immunocytochemical staining with DAB detection and had a punctate appearance using 
confocal microscopy in cells that were untransfected or co-transfected to express 
FLJ22318-V5. As previous studies have all used immunofluorescence and not confocal 
microscopy, it is feasible that differences in the appearance of cytoplasmic PRKRA 
staining were due in part to the increased resolution afforded by 3-D confocal 
microscopy imaging.  
 
In virally infected cells treatment with TNF-α , which is known to induce 
phosphorylation and subsequent activation of PRKRA, was shown to induce 
cytoplasmic aggregation of PRKRA, in that case with viral replication complexes 
(Iwamura et al., 2001). It is possible that inactive PRKRA exhibits a predominantly 
diffuse cytoplasmic localisation whereas activated PRKRA localises to discrete vesicles 
within the cytoplasm. Serum deprivation is known to activate PRKRA (Bennett et al., 
2006) and the cells used for confocal microscopic analysis in this study were cultured in 
steroid-depleted media, which is growth inhibitory, prior to DHT treatments. Therefore 
the punctate immunofluorescence pattern observed for PRKRA may be associated with 
its activation due to the cell culture conditions. In future studies comparison of the 
cytoplasmic distribution of PRKRA in cells growing under normal culture conditions 
and under growth-restricting culture conditions will be useful in elucidating PRKRA 
localisation and co-localisation with FLJ22318.  
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As PRKRA was initially isolated as an interacting partner of FLJ22318 by yeast two-
hybrid analyses, GST pull-down and immunoprecipitation assays were performed to 
provide supporting evidence of an interaction between PRKRA and FLJ22318 in vitro 
and  in vivo. Although there were technical problems associated with both of these 
assays, PRKRA was identified in GST pull-down assays using GST-FLJ22318, 
supporting yeast two-hybrid analysis results that had indicated interaction of FLJ22318 
and PRKRA. In addition, preliminary co-immunoprecipitation studies indicate that 
FLJ22318 and PRKRA interact in vivo.  
 
Technical difficulties associated with the GST pull-down and co-immunoprecipitation 
assays involved both the antibodies and interference by protein A and protein G which 
dissociated from the sepharose bead during the immunoprecipitation procedure. 
Although recommended by the manufacturer for use in western blotting, the 
commercially prepared goat anti-PRKRA antibody used in this study was not sensitive 
enough to detect endogenous PRKRA and in addition produced very high levels of 
background. Interference due to the similar size of protein A and protein G bands with 
bands of interest also hindered interpretation of results and several alternative strategies 
could be used in future experiments to improve the GST pull-down and co-
immunoprecipitation experiments. For GST pull-down assays these include alteration of 
buffer salt concentrations and/or pH to facilitate FLJ22318-PRKRA interactions, 
transfection of LNCaP cells to overexpress PRKRA to increase detection of complexes 
and development of GST-PRKRA so that the assays could also be carried out in reverse. 
For co-immunoprecipitation assays, transfection of cells to overexpress PRKRA would 
also potentially increase the amount of FLJ22318-PRKRA complexes able to be formed 
and therefore immunoprecipitated. The use of PRKRA monoclonal antibodies may also 
facilitate detection of proteins and use of different tagged proteins whose molecular 
weights do not coincide with that of protein A/G bands would also assist in completion 
of experiments confirming the interaction of FLJ22318 and PRKRA.  
 
As PRKRA expression has been reported to be low in proliferating cells in other tissues 
(Gupta and Patel, 2002), the interaction between FLJ22318 and PRKRA may also have 
been difficult to detect due to low expression of PRKRA in LNCaP cells. In addition as 
previous studies have reported PRKRA to be unphosphorylated and inactive in 
proliferating cells unless cellular stress occurs (Bennett et al., 2006; Peters et al., 2006), Chapter Seven ￿ Analysis of PRKRA: A Candidate FLJ22318 Binding Partner 
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it is feasible that FLJ22318 and PRKRA are minor binding partners when PRKRA is in 
either an active or an inactive form. Treatment of cells with ethanol was recently shown 
to enhance co-immunoprecipitation of the phosphorylated mouse homologue of 
PRKRA, RAX with EIF2AK2 although an unphosphorylatable PRKRA mutant was still 
able to co-immunoprecipitate EIF2AK2 but at a greatly reduced concentration (Chen et 
al., 2006). Although extensive co-localisation was observed in this study in cells that 
had been growth-restricted as part of DHT treatment protocols future studies are needed 
to determine whether co-immunoprecipitation of PRKRA and FLJ22318 is altered 
depending on the phosphorylation status of PRKRA, treatment of the cells with various 
stress inducing or growth factors and the phosphorylation or activation status of 
PRKRA.  
 
Phosphorylation of specific residues within the 3
rd protein-protein interaction domain of 
PRKRA has recently been shown to be required for PRKRA activation, binding to 
EIF2AK2 and initiation of apoptosis (Peters et al., 2006). As the protein fragment 
isolated in the yeast two-hybrid screen encompassed this domain, a series of GAL4-
PRKRA and GAL4-FLJ22318 deletion mutants could also be created in future studies 
and screened by yeast two-hybrid analysis to determine the protein-protein interaction 
domains of PRKRA and FLJ22318. Finally, co-immunoprecipitation and kinase assays 
would determine the affect of FLJ22318 interaction with PRKRA on PRKRA function, 
including binding to and activation of EIF2AK2 and regulation of miRNA processing.  
 
In summary, the data presented in this chapter provides preliminary evidence of an in 
vitro and in vivo interaction between FLJ22318 and PRKRA supporting results from the 
yeast two-hybrid analysis. Future studies continuing characterisation of the interaction 
between FLJ22318 and PRKRA as well as interactions and functional consequences of 
the interactions between FLJ22318 and other candidate binding partners identified in 
the yeast two-hybrid analysis will help to determine the biological activity of FLJ22318. 
These results will be critical in describing the role of FLJ22318 in malignant cells, 
especially those with abnormalities in the 5q35 locus harbouring the FLJ22318 gene. 
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Chapter Eight ￿ General Discussion 
 
8.1 Discussion 
FLJ22318 is a novel hypothetical protein that was identified by yeast two-hybrid 
analysis to interact with the prostatic homeodomain protein, NKX3-1. An androgen-
regulated gene, NKX3-1 is expressed in secretory epithelial cells of the adult prostate 
where it is involved in maintaining the differentiated state of the prostatic epithelium 
(Bhatia-Gaur et al., 1999). Expression of NKX3-1 is reduced or lost in prostate tumours, 
leading to its classification as a prostate-specific tumour suppressor (Bowen et al., 
2000). As a homeodomain protein NKX3-1 is a transcriptional regulator, acting in 
multiprotein complexes to regulate transcription of its target genes. In this thesis, the 
structure and biological activity of the candidate NKX3-1 interactor, FLJ22318 was 
investigated. 
 
Yeast two-hybrid analysis performed to isolate NKX3-1 binding proteins had identified 
cDNA￿s encoding a variety of characterised and uncharacterised (hypothetical) proteins. 
As NKX3-1 is a homeodomain protein and therefore active in the nucleus where it 
functions as a transcription factor (Abdulkadir, 2005), it would be expected that NKX3-
1 binding proteins would include proteins regulating intracellular transport including 
nuclear import and export proteins, factors involved in modification (eg 
phosphorylation) of target proteins and transcriptional co-regulators including 
coactivators, corepressors and scaffolding proteins that may anchor NKX3-1 in 
complexes, including transcriptional regulatory complexes. Although an 
uncharacterised protein, the isolation of FLJ22318 in multiple clones from the yeast 
two-hybrid screen and its unusual domain structure indicated it to be a novel and 
potentially interesting modifier of NKX3-1 activity. 
 
Bioinformatic analysis suggested that the FLJ22318 protein contains three strong 
protein-protein interaction domains, a Lissencephaly type-1-like homology (LisH), a C-
terminal to LisH (CTLH) and a CT11-RanBPM (CRA) domain (http://smart.embl-
heidelberg.de/), motifs which are found in a diverse range of proteins, several of which 
function as transcriptional co-regulators or are involved in cell cycle progression. 
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characterised in a variety of proteins, the number of proteins with similar domain 
composition and organisation to FLJ22318 is limited.  
 
Currently there are seven human proteins with this domain composition including 
FLJ22318 and its orthologue FLJ13910. The remaining five proteins are C20orf11, 
MAEA isoform 1, MAEA isoform 2, RANBP9 and RANBP10. Interestingly, all seven 
of these proteins have the same domain organisation, an N-terminal LisH motif 
followed by the CTLH domain and then the C-terminal CRA domain, although both 
RANBP9 and RANBP10 also contain an additional SPRY domain N-terminal to the 
LisH domain. These findings suggest that the domain organisation as well as the 
domain composition of this group of proteins may be functionally significant. At 
present however, studies of proteins with this domain organisation are limited to 
RANBP9, containing the additional SPRY domain, and MAEA and although MAEA is 
involved in erythroid cell differentiation, apoptosis and contributes to cell division it is 
unknown which domain(s) are associated with or contribute to a particular function 
(Bala et al., 2006; Hanspal et al., 1998; Soni et al., 2006). RANBP9 is also associated 
with apoptosis and has been shown to function as a transcriptional coactivator or 
corepressor. The SPRY domain in combination with the LisH domain was required for 
RANBP9 corepressor activity whereas the C-terminal region of RANBP9 encompassing 
the CTLH and CRA domains was found to be necessary for its coactivator activity 
(Poirier et al., 2006; Zou et al., 2003).  
 
In this study FLJ22318 was shown to exhibit transcriptional repressor activity on an 
NKX3-1 response element although the regions of FLJ22318 involved in this activity 
were not determined. Of interest was the finding that FLJ22318 exhibited repressor 
activity on the NKE in both the absence and presence of NKX3-1. The functioning of 
this response element is unusual as luciferase activity is induced from the element in the 
absence of NKX3-1 by as yet unidentified transcription factors (Steadman et al., 2000), 
with overexpression of NKX3-1 repressing the induced luciferase activity. FLJ22318 
does not contain recognised DNA binding domains and it is likely that its repressor 
activity is mediated by binding to transcription factors or transcriptional regulatory 
complexes including those involving NKX3-1. The repressor activity of FLJ22318 on 
the NKE in the absence of NKX3-1 indicated that FLJ22318 can target transcription 
factors other than NKX3-1, a finding consistent with the widespread expression of Chapter Eight ￿ General Discussion 
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FLJ22318 in all tissues of the body in comparison to the prostate restricted expression 
of NKX3-1 (Bieberich et al., 1996). While the SPRY and LisH domains of RANBP9 
have been shown to be required for its corepressor activity (Zou et al., 2003), FLJ22318 
does not contain a SPRY domain and the function of the highly conserved N-terminal of 
FLJ22318 has not been investigated previously. As such, the contribution of the 
domains identified in FLJ22318 to its function as a corepressor will need to be 
addressed in future studies. 
 
The LisH and/or CTLH domains can be found in >40 human proteins which have a 
diverse range of functions, however the CRA domain is found in only nine proteins 
(http://smart.embl-heidelberg.de/). Interestingly, these are the seven previously 
mentioned proteins plus two additional hypothetical proteins FLJ43512 and FLJ46442 
where the CRA domain is located at the N-terminal and is the only recognised domain 
within the predicted coding regions of these genes. The CRA domain has been 
described as a protein-protein interaction domain that can inhibit RNA binding (Menon 
et al., 2004). In RANBP9, the CRA domain is required for its interaction with FMR1 
and was shown to inhibit FMR1 binding to RNA although RANBP9 did not bind RNA 
directly (Menon et al., 2004). As inhibition of RNA binding was more specific for 
RNAs that bound to RGG boxes of RNA binding proteins it was thought the CRA 
domain may interact with RGG boxes thereby directly competing for binding with 
RNAs (Menon et al., 2004).  
 
This study has shown that FLJ22318 localises to the nucleus and perinucleus of DU145 
cells and in addition, localises to the cytoplasm as well as the perinuclear and nuclear 
regions of LNCaP cells. MAEA and RANBP9 are widely distributed throughout the cell 
localising to the plasma membrane, cytoplasm, perinucleus and nucleus of cells (Bala et 
al., 2006; Hanspal et al., 1998; Kramer et al., 2005; Rao et al., 2002; Wang et al., 2002). 
As such, it has been suggested that these proteins have specific and distinct functions in 
the nucleus as compared to the cytoplasm. Cytoplasmic MAEA is required for the 
attachment of erythroblasts to macrophages and in the absence of attachment, apoptosis 
of erythroblasts occurs suggesting that MAEA is an inhibitor of apoptosis (Hanspal et 
al., 1998). In the nucleus, MAEA functions in cell division and has a recognised nuclear 
localisation signal (NLS) although it is unknown whether this signal actually mediates 
import of MAEA into the nucleus (Bala et al., 2006). A function for cytoplasmic Chapter Eight ￿ General Discussion 
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RANBP9 has not been elucidated, however it has been reported that a decrease in 
cytoplasmic RANBP9 coincides with an increase in nuclear RANBP9, following 
RANBP9 interaction with p73 (Kramer et al., 2005). In the presence of their respective 
ligands nuclear RANBP9 has been shown to activate glucocorticoid receptor, androgen 
receptor and thyroid receptor enhancing their transcriptional activation (Poirier et al., 
2006; Rao et al., 2002).  
 
A NLS has not been reported for RANBP9 however, RANBP9 was originally isolated 
as a binding partner of Ran which is involved in the nucleocytoplasmic transport of 
proteins through the nuclear pore complex (NPC) (Nakamura et al., 1998). Like 
RANBP9, FLJ22318 does not contain a recognised NLS however FLJ22318 does 
contain a putative non classical NLS and nuclear export signal (NES) that fits the 
consensus sequence that is commonly bound by the export receptor CRM1 and is found 
in other proteins that depend on the Ran GTP/GDP axis (Heger et al., 2001; Pemberton 
and Paschal, 2005). The presence of two mRNA transcripts identified in these studies 
suggests that more than one isoform of FLJ22318 may be present in prostate and breast 
cancer cells, possibly with different cellular localisations. Although additional studies 
will be necessary to investigate this, the use of C-terminal V5 and N-terminal Myc 
tagged fusion proteins and the detection by western blotting of only a single protein of 
the predicted size encoded by these expression plasmids provides evidence that the 
cellular distribution of FLJ22318 observed in this study relates to the same protein. 
Therefore it appears that FLJ22318 is localised and may also shuttle between the 
cytoplasm and nucleus of the cell although whether FLJ22318 has specific and distinct 
functions in the nucleus and in the cytoplasm will require further investigation. Recent 
reports have provided strong evidence that the shuttling of proteins between the nucleus 
and cytoplasm plays a key role in regulating the cell cycle, proliferation and apoptosis 
and as such, intracellular localisation and movement of FLJ22318 will be important to 
address in future studies (Fahrenkrog, 2006; Wang and Hung, 2005). 
 
A number of homeodomain proteins including the paired-like homeodomain proteins 
Vsx1 and Chx10 are known to actively shuttle between the cytoplasm and nucleus 
(Knauer et al., 2005). Nuclear export of Vsx1 and Cx10 is mediated by CRM1 and 
facilitates their degradation via the ubiquitin/proteasome pathway whereas preventing 
the nuclear export of both proteins was shown to increase protein stability and increase Chapter Eight ￿ General Discussion 
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their transcriptional activation activity (Knauer et al., 2005). Although not yet explored, 
modulation of the nuclear import/export of NKX3-1 may be an important regulatory 
mechanism governing NKX3-1 function as a transcriptional repressor, in particular in 
the presence of androgens. As FLJ22318 was detected in both the nucleus and 
cytoplasm in this study, one possible explanation for the observed nuclear localisation 
and co-localisation of FLJ22318 with NKX3-1 is that their repressor activities are 
mediated in part, by nucleocytoplasmic shuttling (ie. their localisation). It is feasible 
that in the nucleus FLJ22318 either binds DNA directly or more likely interacts with 
regulatory complexes which bind DNA. This may account for the increase in NKX3-1 
transcriptional repressor activity that was seen in these studies upon co-transfection of 
FLJ22318. As the nuclear export of proteins has been shown to promote their 
degradation via the ubiquitin/proteasome pathway (Xu and Massague, 2004), it will also 
be interesting in future studies to investigate whether the cytoplasmic localisation of 
NKX3-1 observed in these studies represents newly synthesised NKX3-1 being retained 
in the cytoplasm or is due to the increased nuclear export of NKX3-1. 
 
During 2006, FLJ22318 and its orthologue FLJ13910 were renamed by the HUGO 
Gene Nomenclature Committee. FLJ13910 was renamed ￿required for meiotic nuclear 
division 5 homologue A (S. cerevisiae) (RMND5A)￿ whilst FLJ22318 was renamed 
RMND5B. A comparison of FLJ22318 and FLJ13910 with the yeast protein RMD5 
revealed 21.8% sequence homology between FLJ22318 and RMD5 and 23.2% 
sequence homology between FLJ13910 and RMD5. In addition, RMD5 was found to 
contain only a CTLH motif as compared to FLJ22318 and FLJ13910 which contain 
LisH, CTLH and CRA domains. It has been predicted that during vertebrate evolution 
whole genome duplication events occurred twice which have been followed by loss of 
some of the duplicated genes in particular in frog, chicken and fish genomes, with 
comparatively fewer duplicate genes lost in mammalian genomes (Blomme et al., 
2006).  This finding may account for the observation that to date RMND5A (FLJ13910) 
and RMND5B (FLJ22318) paralogues only appear in mammalian genomes. Following 
gene duplication, one gene may retain the ancestral function, in this case that of RMD5, 
and the second duplicated gene can diverge in sequence and function. Alternatively, 
mutations may occur in both duplicated genes resulting in either the retention of 
different aspects of the original function or the evolution of new functions or expression 
patterns (Hancock, 2005). It would appear from sequence comparisons between Chapter Eight ￿ General Discussion 
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FLJ22318 and FLJ13910 and their domain organisation that both paralogues have 
diverged markedly in sequence and therefore have probably acquired additional 
functions in comparison to the ancestral RMD5 gene. 
 
Bioinformatic analysis in this study has identified an exceptionally high degree of 
sequence conservation between FLJ22318 protein homologues in mammalian species 
(>97%) with significant but lesser homology between FLJ22318 and its orthologue 
FLJ13910 (>70%), suggesting microfunctionalisation. The lack of reported sequence 
variations (polymorphisms) within the FLJ22318 protein coding region provides strong 
evidence that FLJ22318 is essential and/or critical to cell function or survival. Although 
the determination of FLJ22318 transcriptional repressor activity and intracellular 
localisation, along with the isolation and preliminary categorisation of candidate 
FLJ22318 interacting factors have provided a basic characterisation of FLJ22318 and a 
foundation for future research, the function of FLJ22318 remains enigmatic. 
 
8.2 Future  Directions 
  This thesis has generated important information that has begun to characterise the 
structure of the FLJ22318 gene and protein, the interaction between FLJ22318 and 
NKX3-1 and the potential biological functions of FLJ22318 in eukaryotic cells. 
 
Initial bioinformatic analysis of the amino acid sequence of FLJ22318 indicated the 
presence of LisH and CTLH motifs which are proposed to form α -helices in other 
proteins including PAFAH1B1. Further analyses using programmes such as PSA 
(http://bmerc-www.bu.edu/psa/request.htm) would be required to indicate whether the 
proposed LisH and CTLH motifs in FLJ22318 are able to adopt an α -helical 
conformation, which has been shown for other proteins containing these motifs to direct 
cellular localisation and biological activity. Crystallography studies could also be used 
to determine full-length FLJ22318 structure in vitro and in particular whether FLJ22318 
can adopt an open and closed conformation as is the case with the PAFAH1B1 protein 
which has a LisH motif followed by a coiled-coiled region. As 11 of the 14 deduced 
FLJ22318 isoforms are proposed to encode proteins that are truncated within the highly 
conserved N-terminal (CTLH domain) and C-terminal (CRA domain), similar studies 
could also be used to determine whether these alternative FLJ22318 proteins form α -Chapter Eight ￿ General Discussion 
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helices in vitro. Crystallography could also provide additional information regarding the 
putative nuclear receptor boxes of FLJ22318 as previous  crystal structure studies have 
indicated that nuclear receptor binding occurs as a result of these motifs adopting an  α -
helical conformation. 
 
Several readily available bioinformatic programmes were used in this thesis to identify 
and confirm the presence of protein motifs and to examine FLJ22318 homologues in 
other species. Use of additional and more comprehensive programmes including PSI-
BLAST and PHI-BLAST could be used in additional studies to identify other protein-
protein interaction domains and to more fully characterise the motifs identified in the 
present work. These programmes may be particularly useful in identifying proteins that 
are distantly related to FLJ22318 and could provide additional information regarding 
FLJ22318 function or cellular localisation.  
 
In this study, FLJ22318 was shown to interact with NKX3-1 although this proved very 
difficult due in part to technical limitations associated with the lack of FLJ22318 
antibodies available at the time that the experiments were performed. In addition, it 
appeared that FLJ22318 and NKX3-1 were not major binding partners of each other, a 
finding consistent with bioinformatic evidence of multiple protein-protein interaction 
domains in FLJ22318. As discussed in Chapter 5, development of FLJ22318 antibodies 
that can be used for western blotting, immunoprecipitation and immunohistochemistry 
will be essential for future functional and translational studies. FLJ22318 has not been 
characterised previously therefore it is unknown which domain(s) of FLJ22318 directly 
interact with NKX3-1. Future studies using GAL4-FLJ22318 deletion mutants, in 
particular, constructs with deletions of the LisH, CTLH and CRA domains could be 
employed in yeast two-hybrid analyses with NKX3-1 to identify FLJ22318 interaction 
domains. A similar series of deletion mutants could also be constructed to identify the 
regions of NKX3-1 that are required for binding to FLJ22318. The use of FLJ22318 
deletion constructs in mammalian expression vectors may also assist in determining 
which regions of FLJ22318 direct its cellular location and are required for FLJ22318 
transcriptional repressor activity. 
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Preliminary studies performed in this thesis identified transcriptional repressor activity 
of FLJ22318 on an NKX3-1 response element in both the absence and presence of 
NKX3-1. At present it is unknown whether FLJ22318 can bind DNA directly or 
whether it forms complexes either with NKX3-1 or with other as yet unidentified 
transcription factors that are able to bind DNA. Electromobility shift assays (EMSAs) 
and supershift assays could be used to determine whether FLJ22318 is present in protein 
complexes bound to the target DNA sequence (NKE). Until FLJ22318 antibodies are 
generated, these experiments would have to be carried out by transfection of cells to 
overexpress tagged FLJ22318 protein, with antibodies to the tag (eg. V5, GFP) used in 
supershift assays. Technical difficulties with such experiments would include 
competition between transfected and endogenous FLJ22318 for inclusion in the DNA-
binding complexes and the potential for the tagged FLJ22318 to destabilise the protein 
complexes (due to the tag). FLJ22318-deletion constructs could then be used to assess 
the formation of DNA binding complexes in similar EMSAs. To isolate other proteins 
in DNA binding complexes (in the presence and absence of NKX3-1), antibodies to 
FLJ22318 could be used to precipitate the complexes followed by mass 
spectrophotometry to identify the bound proteins. 
 
Northern blotting in this study identified two FLJ22318 transcripts in LNCaP, DU145 
and PC-3 prostate cancer cell lines. Bioinformatic analysis suggests that these 
transcripts correspond to the reference sequence as published by NCBI and alternative 
proposed transcripts ￿a￿ and ￿d￿. To confirm the identity of these mRNA￿s further 
studies would require sequencing of the transcripts from cDNA libraries of the cell 
lines. Following their identification, it would then be possible to screen other cell lines 
and human tissue specimens (including non-malignant and malignant prostate) using 
more routine methods such as RT-PCR or real-time RT-PCR to determine both the 
presence and the levels of FLJ22318 transcripts. Real-time RT-PCR would also identify 
whether the relative levels of FLJ22318 transcripts are altered between normal and 
malignant prostate, during progression of prostate cancers to androgen independence or 
in prostate cancer metastases. In situ hybridisation using probes specific for the 
identified transcripts would determine the cellular distribution of these transcripts in 
normal and malignant prostate and in particular prostate tumours that have progressed 
from androgen dependence to androgen independence. Transcript variant ￿d￿ is 
proposed to encode the same protein as the reference sequence transcript with the Chapter Eight ￿ General Discussion 
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difference in size due to alternative 5‘ and 3‘-UTR sequences.  It is possible that these 
transcripts are differentially regulated and further bioinformatic analyses of these 
regions in comparison to the UTRs of the reference sequence transcript may suggest 
regulatory elements specific to each transcript that could then be functionally tested in 
cell culture studies. 
 
Following the development of antibodies to FLJ22318, western blotting could be 
performed to investigate FLJ22318 proteins expressed in prostate cancer and other cell 
lines as well as in normal and malignant prostate tissues. The presence of alternative 
FLJ22318 protein isoforms indicates the potential for differential function and/or 
cellular localisation of the proteins, especially if one of the isoforms includes a clathrin 
box. It may be necessary to develop further FLJ22318 antibodies that are specific for 
the different isoforms and use these to compare the localisation of the isoforms using 
confocal microscopy. Availability of isoform-specific FLJ22318 antibodies would also 
permit identification of which isoforms(s) were able to interact with NKX3-1 and 
whether they exhibited transcriptional repressor activity (in the absence or presence of 
NKX3-1).  
 
Bioinformatic analysis indicated that the FLJ22318 promoter contains a putative CpG 
island. As CpG islands can be associated with either transcriptional silencing or 
constitutive expression (housekeeping genes), the function, if any, of this sequence and 
its methylation status cannot be deduced. Bisulphite genomic sequencing and 
methylation-specific PCR targeted to the area surrounding the transcription start site and 
encompassing the proposed CpG island could be used to determine the methylation 
status of this region in cell lines and potentially in human tissues. As FLJ22318 
expression has been noted in cDNA libraries from both normal and malignant tissues, 
the methylation status of the FLJ22318 promoter would need to be established for both 
normal and malignant tissues. If the FLJ22318 promoter is hypermethylated, changes in 
FLJ22318 mRNA levels in cell lines following treatment with a DNA demethylating 
agent such as 5-aza-2‘-deoxycytidine could be carried out to investigate the functional 
consequences of methylation of the CpG island and would provide a useful adjunct to 
other promoter analyses (discussed in Chapter 4).  
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Two proteins containing only LisH, CTLH and CRA domains, MAEA and GID8, have 
been characterised to date, both of which are involved in cell cycle progression, 
however proteins with a wide variety of functions contain individual or two of these 
domains. Studies performed in this thesis have not identified the cellular function(s) of 
FLJ22318 and further experiments will be required to characterise the biological 
activity of this ubiquitously expressed gene. These could include siRNA knock-down of 
identified FLJ22318 transcripts both individually and in combination, with real-time 
RT-PCR enabling identification of the reduction in FLJ22318 mRNA.  
 
Following FLJ22318 knockdown, changes in cell morphology including cytoskeletal 
and nuclear features could be examined using light, confocal and electron microscopy. 
Cell proliferation could be examined in both monolayer cultures and by anchorage 
independent growth and cell cycle distribution and progression could be examined using 
propidium iodide staining and flow cytometry. The effects of FLJ22318 knockdown on 
NKX3-1 levels and transcriptional repressor activity could also be investigated to 
determine whether FLJ22318 is required, either directly or indirectly, for NKX3-1 
function. 
 
The yeast two-hybrid analysis carried out during this thesis to identify FLJ22318 
interacting proteins, resulted in the isolation of a number of candidate proteins and 
protein fragments. Although these candidate proteins could be divided into several 
functional groups, which will assist in the characterisation of the biological activity of 
FLJ22318, it will be essential in future studies to confirm the interaction of key 
proteins. These studies would involve techniques used in this thesis including reverse 
yeast two-hybrid analyses, GST pull-down and co-immunoprecipitation assays, 
evidence of co-localisation of FLJ22318 and candidate interacting proteins by confocal 
microscopy and determination of the effects of FLJ22318 overexpression (by 
transfection) or knockdown on the cellular levels, localisation and function of the 
interacting protein(s).  
 
Finally, as disruption of 5q35.3 including the FLJ22318 gene locus is associated with 
prostate, breast and other cancer types, generation of FLJ22318 knockout mice may also 
assist in the elucidation of both the normal cellular function of FLJ22318 as well as its 
role in carcinogenesis. Due to the ubiquitous expression of FLJ22318 and its reported Chapter Eight ￿ General Discussion 
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detection in cDNA libraries derived from early embryonic tissues, it is acknowledged 
that  FLJ22318 knockout may be embryonic lethal. As such targeted FLJ22318 
knockout could be used (eg. to prostate tissues) for these studies. 
 
8.3 Concluding  Remarks 
Data presented in this thesis has demonstrated that the FLJ22318 gene and protein are 
highly conserved in mammalian species and contain a unique domain composition that 
is shared by only six other known proteins in the human genome. FLJ22318 was shown 
to interact with NKX3-1 in prostate cancer cells and exhibited transcriptional repressor 
function on an NKX3-1 responsive element in the presence and absence of NKX3-1, 
results that are consistent with the reported widespread expression of FLJ22318 and 
which are suggestive of FLJ22318 interaction with transcriptional regulators other than 
NKX3-1. With further functional studies, the normal biological activity of FLJ22318 
will be determined, leading to identification of alterations in its function and expression 
that contribute to prostate carcinogenesis and to development of other tumour types.  
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Appendix 1 ￿ Buffers and Solutions 
 
1. 30% Acrylamide 
 
58g Acrylamide 
2g N,N’-Methylene-Bis-
 Acrylamide 
Reagents were dissolved in 200mL 
ddH2O and stored at 4°C. 
 
2. 1/2% Agarose/TAE Gels 
 
1-2g Agarose 
100mL 1X  TAE
134 
5µL Ethidium  Bromide
39 
Agarose was dissolved in 1X TAE by 
heating in a microwave and ethidium 
bromide was added to give a final 
concentration of 0.5µg/mL. 
 
3. 0.2% Adenine 
 
200mg Adenine 
100mL ddH2O 
Reagents were combined, autoclaved 
and stored at 4°C. 
 
4. 100mM Adenosine 5’ Triphosphate 
 
1g ATP 
18mL ddH2O 
Reagents were combined and stored in 
1mL aliquots at -20°C. 
 
5. 5M Ammonium Acetate 
 
Supplied with the Poly (A) Pure 
mRNA Purification Kit. 
 
6. 10% Ammonium Persulphate 
 
100mg Ammonium  Persulphate 
1mL ddH2O 
Ammonium persulphate was dissolved 
in ddH2O and stored at 4°C. Solution 
was made fresh for each polyacrylamide 
gel. 
 
 
7. 100mg/mL Ampicillin 
 
100mg  Ampicillin Powder   
1mL ddH2O 
Ampicillin powder was dissolved in 
ddH2O and stored at -20°C. 
 
8. Binding Buffer 
 
Supplied with the Poly (A) Pure 
mRNA Purification Kit 
 
9. 1% BSA/PBS 
 
10mg  BSA fraction V  
1mL   PBS
72 
Reagents were combined on day of use 
and stored at 4°C. 
 
10. 1M Calcium Chloride 
 
27g   Calcium  Chloride 
100mL ddH2O 
Reagents were combined and the 
solution sterilised by passing through a 
0.2￿m filter then stored at -20°C in 5mL 
aliquots. 
 
11. 100mM Co-Enzyme A 
 
100mg   Co-Enzyme A Lithium salt 
1.3mL ddH2O 
Reagents were combined and the 
solution stored in 25µL aliquots at -20°C 
shielded from light. 
 
12. Confocal Blocking Buffer 
 
5mL   Horse serum 
500mg BSA  fraction  V 
10mg Sodium  Azide 
45mL PBS
72 
Reagents were combined and the 
solution stored at 4°C shielded from 
light. 
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13. Coomassie Blue Staining Solution 
 
1g  Coomassie Brilliant Blue 
450mL Methanol 
450mL ddH2O 
100mL  Glacial Acetic Acid 
Coomassie brilliant blue was dissolved 
in methanol and the ddH2O added. The 
glacial acetic acid was then added in a 
fume hood and the solution stored at 
room temperature. 
 
14. Coomassie De-Stain Solution 
 
450mL   ddH2O 
450mL   Methanol 
100mL   Glacial Acetic Acid 
Methanol was combined with the ddH2O 
and the glacial acetic acid was added in 
a fume hood. The solution was stored at 
room temperature. 
 
15. DAB Staining Reagent 
DAB staining reagent was prepared by 
adding 20µL of DAB reagent (DAKO) 
to 1mL of solvent immediately prior to 
use. 
 
16. DEPC-Treated H2O 
 
1L ddH2O    
1mL Diethylpyrocarbonate  (DEPC) 
DEPC was added to ddH2O in a fume 
hood, mixed and left at room 
temperature overnight to dissolve. 
Solution was then autoclaved and stored 
at room temperature. 
 
17. 10
-2M DHT 
 
2.904mg   DHT 
1mL     Absolute Ethanol 
Reagents were combined and the 
solution was stored at -20°C shielded 
from light. 
 
 
 
 
 
18. 10
-4M DHT 
 
10µL     10
-2M DHT
17 
990µL   Absolute  Ethanol 
Reagents were combined and the 
solution was stored at -20°C shielded 
from light. 
 
19. 10
-6M DHT 
 
10µL     10
-4M DHT
18 
990µL   Absolute  Ethanol 
Reagents were combined and the 
solution was stored at -20°C shielded 
from light. 
 
20.  Dilution Buffer 
 
Supplied with the Poly (A) Pure mRNA 
Purification Kit (10mM Tris pH 7.5, 1mM 
EDTA). 
 
21. 100mM D-Luciferin  
 
25mg  D-Luciferin Potassium Salt    
785µL ddH2O 
Reagents were combined and the 
solution stored in 50µL aliquots at -20°C 
shielded from light. 
 
22. 6X DNA Loading Dye 
 
10mg Xylene  Cyanol 
10mg Bromophenol  Blue 
7g Sucrose 
2mL 0.5M  EDTA
34 
8mL ddH2O
 
Reagents were combined and stored at 
room temperature. 
 
23. 25mM dNTP (PCR) 
 
25µL 100mM  dATP 
25µL 100mM  dCTP 
25µL 100mM  dGTP 
25µL 100mM  dTTP 
dNTPs were combined and stored at  
-20°C. 
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24. dNTP (Random Priming) 
 
1µL 1.5mM  dATP 
1µL 1.5mM  dGTP 
1µL 1.5mM  dTTP 
dNTPs were combined immediately 
before use and stored on ice. 
 
25. 1M DTT 
 
5.0g   Dithiothreitol 
32mL ddH2O 
DTT powder was dissolved in ddH2O, 
filter sterilised by passing through a 
0.2￿m filter and stored in 1mL aliquots 
at -20°C. 
 
26. E1 Cell Suspension Buffer 
 
Supplied with the Concert￿ High Purity 
Plasmid Maxiprep Purification System 
(50mM Tris-HCl pH8.0, 10mM EDTA). 
RNaseA (also supplied with Concert￿ 
High Purity Plasmid Purification 
System) was added according to the 
manufacturer￿s specifications prior to 
use and the solution was stored at 4°C. 
 
27. E2 Cell Lysis Solution 
 
Supplied with the Concert￿ High Purity 
Plasmid Maxiprep Purification System 
(200mM NaOH, 1% SDS v/v) 
 
28. E3 Neutralisation Buffer 
 
Supplied with the Concert￿ High Purity 
Plasmid Maxiprep Purification System 
(3.1M potassium acetate pH4.5) 
 
29. E4 Equilibration Buffer 
 
Supplied with the Concert￿ High Purity 
Plasmid Maxiprep Purification System 
(600mM NaCl, 100mM sodium acetate 
pH 5.5, 0.15% Triton
ﬁX-100 v/v). 
 
 
 
 
30. E5 Wash Buffer 
 
Supplied  with the Concert￿ High 
Purity Plasmid Maxiprep Purification 
System (800mM NaCl, 100mM sodium 
acetate pH5.5). 
 
31. E6 Elution Buffer 
 
Supplied with the Concert￿ High Purity 
Plasmid Maxiprep Purification System 
(1.25mM NaCl, 100mM Tris-HCl 
pH8.5). 
 
32. ECL Detection Reagent 
 
Supplied with ECL Western Blotting 
Detection Reagents (Amersham 
Pharmacia Biotech, Australia). ECL 
detection reagent was prepared by 
adding equal volumes of Solution 1 and 
Solution 2 immediately prior to use. 
 
33. ECL Plus Detection Reagent 
 
Supplied with ECL Western Blotting 
Detection Reagents (Amersham 
Pharmacia Biotech, Australia). ECL Plus 
detection reagent was prepared by 
adding Solutions A and B in a ratio of 
40:1 immediately prior to use. 
 
34. 0.5M EDTA pH 8.0  
 
186.12g  EDTA 
20g  Sodium Hydroxide Pellets 
EDTA was dissolved in 500mL ddH2O, 
pH adjusted to 8.0 with sodium 
hydroxide pellets, the volume adjusted 
to 1L with ddH2O and the solution 
autoclaved and stored at room 
temperature.  
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35. 0.5M EDTA pH 8.0 (DEPC) 
 
186.12g  EDTA 
20g  Sodium Hydroxide Pellets 
EDTA was dissolved in 500mL ddH2O, 
pH adjusted to 8.0 with sodium 
hydroxide pellets, the volume adjusted 
to 1L with ddH2O and 1mL of DEPC 
was added in a fume hood. The solution 
was mixed and left overnight, then 
autoclaved and stored at room 
temperature.  
 
36. Elution Buffer 
 
Supplied with the Poly (A) Pure mRNA 
Purification Kit (10mM Tris pH 7.5, 1mM 
EDTA). 
 
37. 70% (v/v) Ethanol 
 
70mL Ethanol  (absolute) 
30mL ddH2O 
Reagents were combined and stored at 
room temperature. 
 
38. 95% (v/v) Ethanol 
 
95mL Ethanol  (absolute) 
5mL ddH2O 
Reagents were combined and stored at 
room temperature. 
 
39. 10mg/mL Ethidium Bromide 
 
10mg Ethidium  Bromide 
1mL ddH2O 
Ethidium bromide was dissolved in 1mL 
of ddH2O and stored in the dark at room 
temperature. 
 
40. 4% Formaldehyde 
 
200µL Formaldehyde 
1800µL PBS
72 
Reagents were combined in a fume-hood 
on day of use and stored at room 
temperature shielded from light. 
 
 
41. 40% Glucose 
 
40g Glucose 
100mL ddH2O 
Glucose was dissolved in ddH2O and the 
solution filter sterilised and stored at 4°C. 
 
42. 50% Glutathione Sepharose 4B 
 
133µL  75% Sepharose/10mL Sonicate 
Sepharose slurry was settled by 
centrifugation at 500 x g for 5 minutes, 
the supernatant was removed, the 
sepharose washed 3X using 1mL cold 
(4￿C) PBS with centrifugation at 500 x g 
for 5 minutes, and the supernatant 
removed. Sepharose was resuspended in 
100￿L of cold (4￿C) PBS
 to yield a 50% 
slurry. Glutathione Sepharose was 
prepared fresh immediately prior to use. 
 
43. 50% Glycerol 
 
5mL       Glycerol 
5mL   ddH2O  
ddH2O was added to glycerol and the 
reagents were thoroughly mixed. 
 
44. 80% Glycerol 
 
8mL       Glycerol 
2mL   ddH2O  
ddH2O was added to glycerol and the 
reagents were thoroughly mixed. 
 
45. Glycerol Buffer 
 
6mL   1M Calcium Chloride
10 
1mL   1M PIPES
78 pH 7.0 
15mL    Glycerol 
100mL    ddH2O 
Reagents were combined and the 
solution was sterilised by passing 
through a 0.2￿m filter then stored at 
4°C. 
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46. Herring Testes Carrier DNA 
 
Supplied with the Yeastmaker￿ Yeast 
Transformation System 2. Prior to use, 
~15µL of herring DNA was incubated at 
100°C for 5 minutes then immediately 
chilled on ice twice. 
 
47. 100mM IPTG 
 
500mg IPTG  Powder 
20mL ddH2O 
IPTG powder was dissolved in ddH2O, 
filter sterilised by passing through a 
0.2￿m filter then stored in 1mL aliquots 
at -20°C. 
 
48. 100mg/mL Kanamycin 
 
100mg Kanamycin  powder 
1mL ddH2O 
Kanamycin powder was dissolved in 
ddH2O and stored at -20°C. 
 
49. LB Agar 
 
5g Tryptone 
2.5g Yeast  Extract 
5g Sodium  Chloride 
7.5g Agar  Bacteriological 
Reagents were dissolved in 400mL 
ddH2O, the pH adjusted to 7.0 and the 
volume adjusted to 500mL with ddH2O.  
Agar was added and the solution 
autoclaved then stored at room 
temperature.  
 
50. LB Agar/Ampicillin  
 
500mL LB  Agar
49 
500µL Ampicillin
7 
Prior to use, LB agar was melted, 
allowed to cool to approximately 60°C 
and ampicillin added to a final 
concentration of 100µg/mL. LB 
agar/ampicillin was then poured into 
petri dishes and allowed to set. 
 
 
 
51. LB Agar/Ampicillin/X-Gal Plates 
 
15mL LB  Agar/Ampicillin
50 
LB agar/ampicillin plates were prepared 
as usual and allowed to set. 40µL of X-
Gal (50mg/mL) was spread over the top. 
 
52. LB Agar/Kanamycin  
 
500mL LB  Agar
49 
500µL Kanamycin
48 
Prior to use, LB agar was melted, 
allowed to cool to approximately 60°C 
and kanamycin added to give a final 
concentration of 100µg/mL. LB 
agar/kanamycin was then poured into 
petri dishes and allowed to set. 
 
53. LB Broth 
 
10g Tryptone 
5g Yeast  Extract 
10g Sodium  Chloride 
Reagents were dissolved in 900mL of 
ddH2O, pH was adjusted to 7.0 and the 
volume was adjusted to 1L with ddH2O.  
The solution was then autoclaved and 
stored at room temperature.  
 
54. LB Broth/Ampicillin 
 
One  µL of 100mg/mL ampicillin
7 was 
added per 1mL of LB Broth
53 to give a 
final concentration of 100µg/mL 
ampicillin. 
 
55. LB Broth/Kanamycin 
 
One µL of 100mg/mL kanamycin
48 was 
added per 2mL of LB Broth to give a 
final concentration of 50µg/mL 
kanamycin. 
 
56. 10% LB/Glycerol 
 
9mL LB  Broth
53 
1mL Glycerol 
Glycerol was added to LB broth and 
reagents thoroughly mixed. 
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57.10X L-Histidine HCl Monohydrate 
 
20mg  L-Histidine HCl Monohydrate 
100mL ddH2O 
Reagents were combined and the 
solution autoclaved and stored at 4°C. 
 
58. 10X L-Leucine 
 
100mg L-Leucine 
100mL ddH2O 
Reagents were combined and the 
solution autoclaved and stored at 4°C. 
 
59. 10X (1M) Lithium Acetate 
 
51g LiAc 
Lithium acetate was dissolved in 450mL 
ddH2O, the pH adjusted to 7.5 using 
dilute acetic acid and the volume 
adjusted to 500mL. The solution was 
then autoclaved and stored at room 
temperature. 
 
60. Low-Fade Mounting Media 
 
5mL   Tris-Phosphate Buffer
145 
75mL ddH2O 
2 drops  1% Phenol Red
77 
20g   Polyvinyl  Alcohol 
30mL Glycerol 
100mg Chlorobutanol 
Tris-phosphate buffer, ddH2O and 
phenol red were combined. The 
polyvinyl alcohol was added and the 
solution incubated at 60°C for 2-3 hours 
with occasional swirling until dissolved. 
The glycerol and chlorobutanol were 
added and the pH adjusted to below 8.2 
with Tris-phosphate as necessary. The 
solution was stored in aliquots at -20° 
with the working aliquot stored at 4°C. 
 
 
 
 
 
 
 
61. Luciferase Buffer 
 
250µL  1M Tris HCl
144 pH 7.8 
150µL 0.5M  MgSO4
65 
165µL 1M  DTT
25 
1µL 0.5M  EDTA
34 
12.5µL 100mM  Co-Enzyme  A
11 
25µL 100mM  D-Luciferin
21 
25µL 100mM  ATP
4 
250µL  10% Triton X-100
147 
4.2mL ddH2O 
Reagents were combined immediately 
prior to use and shielded from light. 
 
62. Lysis Solution 
 
Supplied with the Poly (A) Pure 
mRNA Purification Kit 
 
63. Lysozyme 10mg/mL 
 
100mg Lysozyme 
2mL  1M Tris HCl
144 pH 8.0 
8mL ddH2O 
Reagents were combined and the 
solution filter sterilised by passing 
through a 0.2￿m filter. Lysozyme was 
then stored in 1mL aliquots at -20°C. 
 
64. 1M Magnesium Chloride 
 
203.3g        MgCl3.6H2O 
Magnesium chloride was dissolved in 
800mL ddH2O and the volume adjusted 
to 1L. The solution was then autoclaved 
and stored at room temperature. 
 
65. 0.5M Magnesium Sulphate 
 
12g        MgSO4.7H2O 
Magnesium sulphate was dissolved in 
80mL ddH2O and the volume adjusted to 
100mL. The solution was then 
autoclaved and stored at room 
temperature. 
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66. Membrane Binding Solution 
 
Supplied with the Wizard
  SV Gel and 
PCR Clean-Up System (4.5M guanidine 
isothiocyanate, 0.5M potassium acetate 
pH 5.0). 
 
67. Membrane Wash Solution 
 
Supplied with the Wizard
  SV Gel and 
PCR Clean-Up System (10mM 
potassium acetate pH 5.0, 80% ethanol, 
16.7µM EDTA pH 8.0). 
 
68. 1X MOPS Buffer 
 
100mL  10X MOPS Buffer
69 
900mL DEPC-Treated  H2O
16 
Reagents were combined immediately 
prior to use. 
 
69. 10X MOPS Buffer 
 
41.2g MOPS 
40mL  0.5M EDTA pH 8.0 (DEPC)
35 
6.56g Sodium  Acetate 
1mL DEPC 
MOPS and sodium acetate were 
dissolved in 800mL of ddH2O and the 
pH was adjusted to 7.0 using 10M 
sodium hydroxide. 0.5M EDTA pH 8.0 
was added and the volume adjusted to 
1L with ddH2O. 1mL of DEPC was 
added and the solution was mixed and 
left overnight. 10X MOPS buffer was 
then autoclaved and stored in the dark at 
room temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
70. MOPS/Formaldehyde Gel 
 
1g Agarose 
72mL DEPC-Treated  H2O
16 
10mL  10X MOPS Buffer
69 
18mL Formaldehyde 
Agarose was dissolved in DEPC-treated 
H2O by heating in a microwave. 10X 
MOPS buffer was next added followed 
by formaldehyde in a fume hood. The 
gel was poured into a casting tray and 
allowed to set in a fume hood covered 
with plastic film. 
 
71. 5X Passive Lysis Buffer (PLB) 
 
(Supplied with Dual-Luciferase
ﬁ 
Reporter Assay). Solution was diluted to 
1X with ddH2O immediately prior to 
use. 
 
72. PBS (Phosphate Buffered Saline) 
8g         Sodium Chloride 
0.2g       Potassium Chloride 
1.44g     Disodium Hydrogen 
 Orthophosphate 
0.44g     Potassium Dihydrogen  
   Orthophosphate 
Reagents were dissolved in 800mL of 
ddH2O, pH was adjusted to 7.2 then the 
volume was adjusted to 1L with ddH2O. 
The solution was autoclaved and stored 
at room temperature. 
 
73. 5X PCR Buffer 
 
5mL  Taq  10X PCR Buffer minus 
MgCl2 (Supplied with Taq DNA 
polymerase) 
200µL 25mM dNTP
23 
4.8mL ddH2O 
Reagents were combined and stored at  
-20°C. 
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74. 10X PCR Buffer with MgSO4 
 
Supplied with Pfu  DNA Polymerase 
(200mM Tris-HCl pH8.8, 100mM KCl, 
100mM (NH4)2SO4, 20mM MgSO4, 
1mg/mL nuclease-free BSA, 1% Triton
ﬁ 
X-100) 
 
75. 50% PEG 3550 
 
250g   PEG-3350 
PEG-3350 was dissolved in 500mL 
ddH2O and the solution stored at room 
temperature. 
 
76. PEG/LiAc/TE 
 
800µL 50%  PEG-3350
75 
100µL  10X 1 M LiAc
59 
100µL 10X  TE
141 
Reagents were combined immediately 
prior to use. 
 
77. 1% Phenol Red 
 
10mg      Phenol Red Sodium Salt 
1mL     ddH2O 
Reagents were combined and stored at 
room temperature. 
 
78.  1M PIPES 
 
30.43g   PIPES 
100mL  ddH2O 
Reagents were dissolved in 80mL of 
ddH2O, the pH adjusted to 7.0 and the 
volume made to 100mL with ddH2O. 
The solution was sterilised by passing 
through a 0.2￿m filter then stored at 
room temperature. 
 
 
 
 
 
 
 
 
 
 
79. 1Kb Plus  Mol. Weight Marker 
 
250µL  1Kb Plus Mol.Weight Marker 
833.3µL 6X DNA Loading Dye
22 
Molecular weight marker was combined 
with freshly prepared DNA loading dye 
and the volume adjusted to 5mL with 
freshly prepared storage buffer
132. 
Solution was dispensed into 1mL 
aliquots and stored at -20°C. 
 
80. 200mM PMSF 
 
348.4mg PMSF 
10mL Isopropanol 
PMSF was dissolved in isopropanol in a 
fume hood and the solution stored at 
room temperature. 
 
81. 12% Polyacrylamide Separating Gel 
 
6ml       30%  Acrylamide
1 
5.03mL  ddH2O         
3.75mL  1M Tris HCl
144 pH 8.8
 
75µL      20% SDS
110 
75µL      10% APS
6 
7.5µL     TEMED 
Tris HCl, acrylamide, SDS and ddH2O 
were combined and mixed by inversion. 
APS and TEMED were added, the 
solution was mixed then immediately 
pipetted into the gel casting apparatus. 
 
82. 6% Polyacrylamide Stacking Gel 
 
2ml   30% Acrylamide
1 
6.65mL  ddH2O 
1.25mL   1M Tris HCl
144 pH 8.8
 
50µL      20% SDS
110 
50µL      10% APS
6 
10µL      TEMED 
Tris HCl, acrylamide, SDS and ddH2O, 
were combined and mixed by inversion. 
APS and TEMED were added.  The 
solution was mixed then immediately 
pipetted into the gel casting apparatus. 
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83. 5M Potassium Acetate 
 
24.5g Potassium  Acetate 
50mL ddH2O 
Potassium acetate was dissolved in 
50mL of ddH2O, and the solution was 
autoclaved and stored at room 
temperature. 
 
84. 50% Protein A/G Sepharose 
 
100µL Sepharose Slurry/mL Cell Lysate 
Sepharose slurry was centrifuged at 
4000rpm for 30 seconds and the 
supernatant removed. The sepharose was 
then washed 3X with 400￿L cold (4￿C) 
PBS followed by centrifugation at 
4000rpm for 30 seconds and the 
supernatant removed.
  Sepharose was 
resuspended in an equal volume of cold 
(4￿C) PBS
 to yield a 50% slurry. Protein 
A and Protein G were prepared fresh 
immediately prior to use. 
 
85. RIPA Buffer 
 
1.6mL ddH2O 
625µL  1% Sodium Deoxycholate
 
125µL 1M  Tris-HCl
144 pH 7.4
 
93.8µL  4M Sodium Chloride
115 
25µL NP-40 
12.5µL   200mM Na3VO4
121 
12.5µL 200mM  PMSF
80 
5µL 0.5M  EDTA
34 
5µL  0.5M Sodium Fluoride
119 
 …     Mini-protease inhibitor tablet 
The mini-protease inhibitor tablet was 
dissolved in ddH2O, then Tris HCl, 
NaCl, NP-40, Na-deoxycholate, EDTA, 
NaF,  Na3VO4  were  added, and the 
solution stored at 4°C for up to 5 days. 
Immediately before use, PMSF was 
added. 
 
 
 
 
 
 
86. RNA Denaturing Buffer 
 
1µL 10X  MOPS
69 
1.75µL  Formaldehyde 
5µL   Formamide 
Reagents were combined then added to 
RNA samples. 
 
87. RNA Loading Dye 
 
5mL Glycerol 
10µL     1M EDTA pH 8.0 (DEPC)
35 
25mg   Bromophenol  Blue 
Reagents were combined, dispensed into 
500µL aliquots and stored at ￿20°C. 
Prior to use, 0.5µL of ethidium bromide
 
was added to 1µL of RNA loading dye 
for each RNA sample. 
 
88. 10mg/mL RNaseA 
 
100mg   RNaseA 
100µL   1M  Tris-HCl
144 pH 7.5
 
37.5µL   4M Sodium Chloride
115 
Reagents were combined and the 
volume adjusted to 10mL with ddH2O, 
heated to 100°C for 15 minutes then 
cooled slowly to room temperature. 
Solution was then dispensed into 1mL 
aliquots and stored at -20°C. 
 
89. RPMI 1640 Medium 
 
1 sachet    RPMI 1640 with L-Glutamine 
1L   Baxter  H2O 
2g   Sodium  Bicarbonate 
RPMI 1640 powder was dissolved in 
Baxter H2O, sodium bicarbonate was 
added, and the medium was filtered 
using a 0.2µm filter into sterilised 
bottles then stored at 4°C. 
 
90. RPMI/5% CS-F￿tal Calf Serum 
 
475m  RPMI 1640 Medium
89  
25ml Charcoal  Stripped-FCS 
Reagents were combined and stored at 
4°C. 
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91. RPMI/10% F￿tal Calf Serum  
 
900ml  RPMI 1640 Medium
89  
100ml  F￿tal Calf Serum (FCS) 
Reagents were combined and stored at 
4°C. 
 
92. RPMI/10% F￿tal Calf Serum/PS 
 
900ml  RPMI 1640 Medium
89 
100ml  F￿tal Calf Serum 
1000U Penicillin  (100U/mL) 
1mg Streptomycin  (100µg/mL) 
Reagents were combined and stored at 
4°C. 
 
93. 2X Sample Buffer (SDS-PAGE) 
 
2.5mL   1M  Tris-HCl
144 pH 6.8
 
1mL   Glycerol 
400µL   20%  SDS
110 
200µL   β -Mercaptoethanol 
0.6mg   Bromophenol  Blue 
Reagents were combined and the 
volume adjusted to 10mL with ddH2O. 
The solution was dispensed into 1mL 
aliquots and stored at -20°C. 
 
94. 10X Sample Buffer (SDS-PAGE) 
 
12.5mL  Glycerol 
2.5mL  1M Tris HCl
144 pH 6.8
 
2.5mL 20%  SDS
110 
2.5mL  β -Mercaptoethanol 
0.25g Bromophenol  Blue 
Reagents were combined and the 
volume adjusted to 25mL with ddH2O. 
The solution was dispensed into 1mL 
aliquots and stored at -20°C. 
 
 
 
 
 
 
 
 
 
 
 
95. SD/- Ade/-His/-Leu/-Trp Medium 
 
300mg    -Ade/-His/-Leu/-Trp Dropout 
3.35g  Yeast Nitrogen Base 
25mL    40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 475mL 
ddH2O and the pH adjusted to 5.8. The 
solution was then autoclaved, allowed to 
cool to ~55°C, the glucose added and the 
solution stored at room temperature. 
 
96. SD/-Ade/-His/-Leu/-Trp Agar 
 
150mg -Ade/-His/-Leu/-Trp  Dropout 
1.675g   Yeast Nitrogen Base 
5g Agar  Bacteriological 
12.5mL  40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 237.5mL 
ddH2O and the pH adjusted to 5.8. Agar 
was then added and the solution 
autoclaved then allowed to cool to 
~55°C. Glucose was added and 25mL 
per plate poured into petri dishes and 
allowed to set. Plates were stored 
inverted at 4°C.  
 
97. SD/-Ade/-His/-Leu/-Trp-X-α -Gal 
Agar 
  
SD/-Ade/-His/-Leu/-Trp Agar Plates
96 
X-α -Gal
157 
Prior to use, 100µL of X-α -Gal per plate 
was spread and plates were allowed to 
dry for 15 minutes at 30°C prior to use. 
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98. SD/-Ade/-Trp-X-α -Gal Agar  
 
150mg -Ade/-His/-Leu/-Trp  Dropout 
1.675g  Yeast Nitrogen Base 
25mL  10X L-Histidine HCl 
 Monohydrate
57 
25mL 10X  L-Leucine
58 
5g   Agar Bacteriological 
12.5mL   40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 187.5mL 
ddH2O, the histidine and leucine were 
added and the pH adjusted to 5.8. Agar 
was added and the solution autoclaved 
then allowed to cool to ~55°C. Glucose 
was added and 25mL per plate poured 
into petri dishes and allowed to set. Prior 
to use, 100µL of X-α -Gal was spread 
and the plates dried for 15 minutes at 
30°C. 
 
99. SD/-His/-Leu/-Trp Agar  
 
155mg -His/-Leu/-Trp  Dropout 
1.675g  Yeast Nitrogen Base 
5g Agar  Bacteriological 
12.5mL  40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 237.5mL 
ddH2O and the pH adjusted to 5.8. Agar 
was added and the solution was 
autoclaved then allowed to cool to 
~55°C. Glucose was added and 25mL 
per plate poured into petri dishes and 
allowed to set. Plates were stored 
inverted at 4°C.  
 
100. SD/-His/-Leu/-Trp-X-α -Gal Agar 
 
SD/-His/-Leu/-Trp Agar Plates
99 
X-α -Gal
157 
Prior to use, 100µL of X-α -Gal per plate 
was spread and plates were dried for 15 
minutes at 30°C prior to use. 
 
 
 
 
 
101. SD/-His/-Trp-X-α -Gal Agar  
 
155mg -His/-Leu/-Trp  Dropout 
25mL 10X  L-Leucine
58 
1.675g  Yeast Nitrogen Base 
5g Agar  Bacteriological 
12.5mL  40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 212.5mL 
ddH2O, the leucine added and the pH 
adjusted to 5.8. Agar was added and the 
solution was autoclaved then allowed to 
cool to ~55°C. Glucose was added and 
25mL per plate poured into petri dishes 
and allowed to set. Prior to use, 100µL 
of X-α -Gal was spread and the plates 
were dried for 15 minutes at 30°C. 
 
102. SD/-Leu Agar  
 
172.5mg -Leu Dropout 
1.675g  Yeast Nitrogen Base 
5g Agar  Bacteriological 
12.5mL  40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 237.5mL 
ddH2O and the pH adjusted to 5.8. Agar 
was added and the solution was 
autoclaved then allowed to cool to 
~55°C. Glucose was added and 25mL 
per plate poured into petri dishes and 
allowed to set. Plates were stored 
inverted at 4°C. 
 
103. SD/-Leu Medium 
 
172.5mg -Leu Dropout 
1.675g  Yeast Nitrogen Base 
12.5mL   40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 237.5mL 
ddH2O and the pH adjusted to 5.8. The 
solution was then autoclaved, allowed to 
cool to ~55°C and the glucose added. 
Medium was stored at room 
temperature.  
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104. SD/-Leu/-Trp Agar  
 
160mg -Leu/-Trp  Dropout 
1.675g  Yeast Nitrogen Base 
5g   Agar  Bacteriological 
12.5mL   40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 237.5mL 
ddH2O and the pH adjusted to 5.8. Agar 
was added and the solution was 
autoclaved then allowed to cool to 
~55°C. Glucose was added and 25mL 
per plate poured into petri dishes and 
allowed to set. Plates were stored 
inverted at 4°C.  
 
105.  SD/-Leu/-Trp Medium 
 
160mg -Leu/-Trp  Dropout 
1.675g  Yeast Nitrogen Base 
12.5mL   40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 237.5mL 
ddH2O and the pH adjusted to 5.8. The 
solution was then autoclaved, allowed to 
cool to ~55°C and the glucose added. 
Medium was stored at room 
temperature.  
 
106. SD/-Trp Agar  
 
185mg    -Trp Dropout 
1.675g  Yeast Nitrogen Base 
5g   Agar 
12.5mL   40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 237.5mL 
ddH2O and the pH adjusted to 5.8. Agar 
was added and the solution autoclaved 
then allowed to cool to ~55°C. Glucose 
was added and 25mL per plate poured 
into petri dishes and allowed to set. 
Plates were stored inverted at 4°C.  
 
 
 
 
 
 
 
107. SD/-Trp Medium 
 
185mg    -Trp Dropout 
1.675g  Yeast Nitrogen Base 
12.5mL   40% Glucose
41 
Yeast nitrogen base and dropout 
supplement were dissolved in 237.5mL 
ddH2O and the pH adjusted to 5.8. The 
solution was then autoclaved, allowed to 
cool to ~55°C and the glucose added. 
Medium was stored at room 
temperature.  
 
108. SD/-Trp/Kan Medium 
 
Ten µL of 100mg/mL kanamycin
48 was 
added per 50mL of SD/-Trp Medium
107 
to give a final concentration of 20µg/mL 
kanamycin. 
 
109. SD/-Trp-X-α -Gal Agar  
 
SD/-Trp Agar Plates
106 
X-α -Gal
157 
Prior to use, 100µL of X-α -Gal per plate 
was spread and plates were allowed to 
dry for 15 minutes at 30°C 
 
110. 20% SDS 
 
10g SDS 
50mL ddH2O    
SDS was dissolved in ddH2O in a fume 
hood and the solution stored at room 
temperature. 
 
111. 2M Sodium Acetate (pH 4.0) 
 
32.8g Sodium  Acetate 
200mL DEPC-ddH2O
16 
Sodium acetate was dissolved in 160mL 
of ddH2O and the pH adjusted to 4.0 
with glacial acetic acid. The volume was 
adjusted to 200mL with DEPC-ddH2O, 
the solution autoclaved and stored at 
room temperature.  
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112. 3M Sodium Acetate (pH 4.6) 
 
49.2g Sodium  Acetate 
200mL ddH2O 
Sodium acetate was dissolved in 160mL 
of ddH2O and the pH was adjusted to 4.6 
with glacial acetic acid. The volume was 
adjusted to 200mL with ddH2O, and the 
solution was autoclaved and stored at 
room temperature.  
 
113. 10mM Sodium Acetate (pH 5.2) 
 
82mg Sodium  Acetate 
100mL ddH2O 
Sodium acetate was dissolved in 90mL 
of ddH2O and the pH was adjusted to 5.2 
with glacial acetic acid. The volume was 
adjusted to 100mL with ddH2O, and the 
solution was autoclaved and stored at 
room temperature.  
 
114. 0.9% Sodium Chloride 
 
0.9g   Sodium  Chloride 
100mL ddH2O 
Sodium chloride was dissolved in 
ddH2O, the solution autoclaved then 
stored at room temperature. 
 
115. 4M Sodium Chloride 
 
117.2g   Sodium Chloride 
500mL ddH2O 
Sodium chloride was dissolved in 
ddH2O, the solution autoclaved then 
stored at room temperature. 
 
116. 5M Sodium Chloride 
 
Supplied with the Poly (A) Pure 
mRNA Purification Kit. 
 
 
 
 
 
 
 
 
117. 1% Sodium Deoxycholate 
 
1g   Sodium  Deoxycholate 
100mL  ddH2O 
Sodium deoxycholate was dissolved in 
ddH2O and the solution was autoclaved 
and stored in the dark at room 
temperature. 
 
118. 1M Sodium Dihydrogen 
Orthophosphate 
 
15.62g   Sodium Dihydrogen     
   Orthophosphate 
100mL    ddH2O 
Sodium dihydrogen orthophosphate was 
dissolved in ddH2O and the solution 
autoclaved and stored at room 
temperature. 
 
119. 0.5M Sodium Fluoride 
 
2.1g Sodium  Fluoride 
100mL ddH2O 
Sodium fluoride was dissolved in ddH2O 
in a fume hood, the solution autoclaved 
then stored at room temperature. 
 
120.  10M Sodium Hydroxide 
 
20g  Sodium Hydroxide Pellets 
50mL ddH2O 
Sodium hydroxide was dissolved in 
ddH2O then stored at room temperature. 
 
121. 200mM Sodium Orthovanadate 
 
3.7g Sodium  Orthovanadate 
10mL ddH2O 
Reagents were combined and the pH 
adjusted to 10.0 with HCl. Solution was 
heated at 95°C until colourless (~10 
minutes) then pH re-adjusted to 10.0. 
This procedure was repeated until 
solution remained colourless at pH10.0. 
Solution was then stored in 1mL aliquots 
at -20°C. 
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122. Solution I 
 
0.9g Glucose 
2.5mL  1M Tris HCL
144 pH 8.8
 
2mL 0.5M  EDTA
34 pH 8.0
 
Reagents were combined, made up to 
100mL with ddH2O, autoclaved and 
stored at 4°C. 
 
123. Solution II 
 
1.86mL  ddH2O 
100µL 20%  SDS
110 
40µL  10M Sodium Hydroxide
120 
Sodium hydroxide and SDS were added 
to ddH2O and mixed by inversion. 
Solution II was made fresh immediately 
prior to use. 
 
124. Solution III 
 
60mL 5M  Potassium  Acetate
83 
11.5mL  Glacial Acetic Acid 
28.5mL  ddH2O 
Reagents were combined, autoclaved 
then stored at 4°C. 
 
125. Sonication Buffer 
 
25mL  1M Tris HCl
144 pH 8.0
 
5mL   5M Sodium Chloride
116 
1mL   0.5M EDTA
34 
469mL ddH2O 
Reagents were combined, autoclaved 
then stored at room temperature. 
 
126. 1X SSC-DEPC 
 
50mL 20X  SSC-DEPC
128 
950mL DEPC-Treated  ddH2O
16 
Reagents were combined immediately 
prior to use. 
 
 
 
 
 
 
 
 
127. 20X SSC 
 
175.3g Sodium  Chloride 
88.2g Sodium  Citrate 
Sodium chloride and sodium citrate 
were dissolved in 900mL ddH2O, pH 
adjusted to 7.0 and the volume was 
adjusted to 1L with ddH2O. The solution 
was then autoclaved and stored at room 
temperature. 
 
128. 20X SSC-DEPC 
 
1L 20X  SSC
127 
1mL DEPC 
One mL of DEPC was added to 20X 
SSC, the solution was mixed, left 
overnight then autoclaved and stored at 
room temperature. 
 
129. 1X Stop & Glo
ﬁBuffer 
 
(Supplied with Dual-Luciferase
ﬁ 
Reporter Assay). Buffer was stored at -
20°C in the dark. 
 
130. 1X Stop & Glo
ﬁ Reagent 
 
20µL of 50X Stop & Glo
ﬁ Substrate
 was 
added to 1mL of 1X Stop & Glo
ﬁBuffer 
immediately prior to use. 
 
131. 50X Stop & Glo
ﬁ Substrate 
 
(Supplied with Dual-Luciferase
ﬁ 
Reporter Assay). Stop & Glo
ﬁ Substrate 
was dissolved in Stop & Glo
ﬁ Substrate 
solvent, vortexed for 10 seconds and 
stored at -80°C in the dark. 
 
132. Storage Buffer 
 
50µL  1M Tris HCl
144 pH 7.5
 
10µL 0.5M  EDTA
34 pH 8.0
 
62.5µL  4M Sodium Chloride
115 
Reagents were combined and the 
volume made up to 5mL with ddH2O. 
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133. 20% Sucrose 
 
20g Sucrose 
100mL ddH2O 
Sucrose was dissolved in 25mL ddH2O 
and made up to 100mL then stored at 
room temperature. 
 
134.  1X TAE (Tris Acetate EDTA)  
 
100mL  50X TAE
135 
4.9L ddH2O
 
Solutions were combined and stored at 
room temperature. 
 
135. 50X TAE (Tris Acetate EDTA) 
 
242g Tris  Base 
57.1mL  Glacial Acetic Acid 
100mL   0.5M EDTA
34 pH 8.0
 
Tris base was dissolved in ddH2O, 
glacial acetic acid and EDTA were 
added and the volume was adjusted to 
1L with ddH2O. The solution was then 
autoclaved and stored at room 
temperature.  
 
136. TBS (Tris Buffered Saline) 
 
50mL  1M Tris HCl
144 pH 7.4
 
37.5mL  4M Sodium Chloride
115 
Reagents were combined, the volume 
was adjusted to 1L with ddH2O and 
stored at room temperature. 
 
137. TBS-3% Blotto 
 
10mL TBS
136 
0.3g Skim  Milk  Powder 
Milk powder was dissolved in TBS
 on 
the day of use. 
 
138. TBST (TBS Tween) 
 
500mL TBS
136 
1mL Tween  20 
Reagents were combined, mixed by 
inversion and stored at room 
temperature. 
 
139. TBST-1% Blotto 
 
30mL TBST
138 
0.3g Skim  Milk  Powder 
Milk powder was dissolved in TBST
 on 
the day of use. 
 
140. TE Buffer 
 
Supplied with the Concert￿ High Purity 
Plasmid Purification System (10mM 
Tris-HCl pH 8.0, 0.1mM EDTA). 
 
141. 10X TE Buffer 
 
6.05g    Tris Base 
10mL 0.5M  EDTA
34 
Tris base was dissolved in 450mL 
ddH2O, the EDTA added and the pH 
adjusted to 7.5 using concentrated HCl. 
The volume was adjusted to 500mL with 
ddH2O and the solution autoclaved and 
stored at room temperature. 
   
142. 1X TE 
 
1mL   10X TE Buffer
141 
9mL    ddH2O 
Reagents were combined immediately 
prior to use. 
 
143. 1X TE/LiAc 
 
1mL  10X TE Buffer
141 
1mL 10X  LiAc
59 
8mL   ddH2O 
Reagents were combined immediately 
prior to use. 
 
144. 1M Tris HCl (pH 6.8, 7.4, 7.5, 7.6, 
8.0, 8.8) 
 
121.1g Tris  Base 
1L ddH2O 
Tris base was dissolved in 800mL of 
ddH2O, the pH was adjusted with 
concentrated HCl and the volume was 
adjusted to 1L with ddH2O. The solution 
was then autoclaved and stored at room 
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145.  Tris-Phosphate Buffer 
 
50mL   1M Tris HCl
144 
1M Sodium dihydrogen orthophosphate
118 was 
added dropwise to Tris until a pH of 9.0 was 
obtained. 
 
146. 0.2% Triton X-100 
 
100µL  10% Triton X-100
147 
4.9mL PBS
72 
Reagents were combined immediately 
prior to use. 
 
147. 10% Triton X-100 
 
5mL Triton X-100 
45mL PBS
72 
Reagents were combined and the 
solution stored at room temperature 
shielded from light. 
 
148. Transformation Solution (BL21) 
 
1.0g   Tryptone 
0.5g   Yeast  Extract 
0.5g   Sodium  Chloride 
10.0g PEG-3350 
5.0mL DMSO 
5.0mL 1M  Magnesium  Chloride
64 
Reagents were dissolved in 70mL 
ddH2O, the pH adjusted to 6.5 and the 
volume made up to 100mL. The solution 
was then sterilised by passing through a 
0.2￿m filter and stored at 4°C for up to 6 
months. 
 
149. Wash Buffer 
 
Supplied with the Poly (A) Pure 
mRNA Purification Kit 
 
150. Wash Buffer I 
 
5mL 20X  SSC
127 
250µL 20%  SDS
110 
44.75mL  ddH2O 
Reagents were combined and the 
solution was made fresh prior to use. 
 
151. Wash Buffer II 
 
2.5mL 20X  SSC
127 
250µL 20%  SDS
110 
47.25mL  ddH2O 
Reagents were combined and the 
solution was made fresh prior to use. 
 
152. Wash Buffer III 
 
250µL 20X  SSC
127 
250µL 20%  SDS
110 
49.5mL  ddH2O 
Reagents were combined and the 
solution was made fresh prior to use. 
 
 153. Western Lysis  Buffer 
 
1.25mL 1M Tris HCL
144 pH 6.8
 
12.5mL  20% Sucrose
133 
2.5mL 20%  SDS
110 
1.25mL  β -Mercaptoethanol 
7.5mL ddH2O 
Reagents were combined and stored in 
the dark at room temperature for up to 
one week. 
 
154. 1X Western Running Buffer 
 
180mL  5X Western Running Buffer
155 
720mL ddH2O 
Reagents were combined and the 
solution made fresh prior to use. 
 
155. 5X Western Running Buffer 
 
15g Tris  Base 
72g Glycine 
5g SDS 
1L ddH2O 
Reagents were dissolved in ddH2O and 
stored at room temperature. 
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156. Western Transfer Buffer 
 
3.03g Tris  Base 
14.4g Glycine 
800mL  ddH2O 
200mL  Methanol 
Tris base and glycine were dissolved in 
600mL ddH2O, methanol was added and 
the solution was made up to 1L with 
ddH2O then stored at ￿20°C for at least 
three hours prior to transfer. The 
solution was made fresh on the day of 
use. 
 
157. X-α -Gal/DMF 
 
25mg X-α -Gal 
6.25mL  Dimethyl Formamide  
Reagents were combined and stored in 
the dark at -20°C. 
 
158. Yeast Lysis Buffer 
 
0.5mL  1M Tris HCL
144 pH 8.0
 
2.5mL 20%  SDS
110 
1.0mL Triton  X-100 
100µL 0.5M  EDTA
34 pH8.0
 
290mg Sodium  Chloride 
Reagents were combined, the solution 
made up to 50mL with ddH2O and 
stored at room temperature. 
 
159. YPDA Agar  
 
10g Peptone 
5g Yeast  Extract 
7.5mL    0.2% Adenine
3 
25mL     40% Glucose
41 
10g Agar 
Peptone and yeast were dissolved in 
400mL ddH2O, the pH adjusted to 6.5 
and ddH2O added to 475mL. The agar 
was added and the solution autoclaved 
then allowed to cool to ~55°C. The 
glucose and adenine were added and the 
YPDA agar stored at room temperature. 
Prior to use, agar was melted in a 
microwave and 15mL per plate was 
poured into 10cm petri dishes and 
allowed to set. 
160. YPDA Medium 
 
10g Peptone 
5g Yeast  Extract 
7.5mL 0.2%  Adenine
3 
25mL 40%  Glucose
41 
Peptone and yeast were dissolved in 
400mL ddH2O, the pH adjusted to 6.5 
and ddH2O added to 467.5mL. The 
solution was then autoclaved, allowed to 
cool to ~55°C, the adenine and glucose 
added and the solution stored at room 
temperature. 
 
161. YPD Plus Liquid Medium 
 
Supplied with the Yeastmaker￿ Yeast 
Transformation System 2.  
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Appendix 2 ￿ Primers 
 
 
PCR Primers Nucleotide  Sequence 
  
ADLD Sense 
5’CTATTCGATGAAGATACCCCACCAAACCC
3’ 
ADLD Antisense 
5’AATCGTAGATACTGAAAAACCCCGCAAGTTCAC
3’ 
  
BAC Sense 
5’AGAAGGATTCCTATGTGGGCGACGA
3’ 
BAC Antisense 
5’CGAGTACATCACGATGCCAGTGGTA
3’ 
 
 
CDS III Oligo d(T) 
5’ ATTCTAGAGGCCGAGGCGGCCGACATG-d(T)30VN-
3’vii4 
 
 
FLJBamHI Sense 
5’ATGGGATCCATGGAGCAGTGT
3’ 
FLJBamHI Antisense 
5’ATGGGATCCTCAGAATATGATGCG
3’ 
 
 
pCMV Sense 
5’ATGGTCGACTATGGAGCAGTGTGCG
3’ 
 
 
FLJSalI Sense 
5’ATGGTCGACTTATGGAGCAGTGTGCG
3’ 
FLJSalI Antisense 
5’ATGGTCGACTCAGAATATGATGCGTTT
3’ 
  
FLJTOPO Sense 
5’ATTATGGAGCAGTGTGCGTGCGTG
3’ 
FLJTOPO Antisense 
5’GAATATGATGCGTTTCCCATCTGC
3’ 
  
5’ PCR Sense 
5’ TTCCACCCAAGCAGTGGTATCAACGCAGAGTGG
3’ 
3’ PCR Anti-Sense 
5’ GTATCGATGCCCACCCTCTAGAGGCCGAGGCGGCCGACA
3’ 
  
pGEX Sense 
5’GGGCTGGCAAGCCACGTTTGGTG
3’ 
pGEX Antisense 
5’CCGGGAGCTGCATGTGTCAGAGG
3’ 
 
 
SMART III  Oligo 
5’AAGCAGTGGTATCAACGCAGAGTGGCCATTATGGCCGGG
3’ 
 
 
Sequencing Primers Nucleotide  Sequence 
  
BGHREV Antisense 
5’TAGAAGGCACAGTCGAGG
3’ 
DNA-BD Sense 
5’TCATCGGAAGAGAGTAG
3’ 
EGFP1266 Sense 
5’CATGGTCCTGCTGGAGTTCGTG
3’ 
FLJ789 Sense 
5’ATCTGTGAGACCTTTACCCGG
3’ 
FLJREV Antisense 
5’AAAGCTGACGCTAAGGGGGGA
3’ 
FLJREV2 Antisense 
5’CTGGAAGTGCCGAGCATAGCT
3’ 
pCMV Sense 
5’GATCCGGTACTAGAGGAACTGAAAAAC
3’ 
pGBREV Antisense 
5’GAAATTCGCCCGGAATTAGCT
3’ 
 
 
 
 
 
                                                 
viii N = A, G, C, or T; V = A, G, or C. 